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Synthesis of aza-Spirocyclic Dienones and Their Application Toward 
Natural Product Synthesis 
and 
Synthesis and Evaluation of Anticancer Tetracyclic Indole Containing 
Compounds 
 
William Laurence Montgomery, Ph. D. 
The University of Texas at Austin, 2016 
 
Supervisor:  Stephen F. Martin 
 
A novel route to access the aza-spirocyclic cross-conjugated dienone motif was 
developed utilizing an intramolecular phenolic C-alkylation and Suzuki coupling to form 
the key quaternary carbon center. A chemoselective addition of crotyl silane to the aza-
spirocyclic dienone motif was developed in an effort to synthesize the spiro-
bicyclononane core of (±)-aspernomine and (±)-sespenine. 
The structure-activity-relationship of anticancer tetracyclic indole containing 
compounds was developed via the synthesis and biological evaluation of 48 novel 
derivatives. Additionally, tool compounds containing a biotin and photoaffinity 
crosslinker were synthesized for use in future target identification studies.  
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Chapter 1: Base Catalyzed Phenolic C-Alkylation as a Alternative to 
Oxidative Phenolic Coupling 
1.1 THE SPIROCYCLIC DIENONE MOTIF AND ITS UTILITY IN ALKALOID SYNTHESIS 
1.1.1 The Spirocyclic Dienone Motif in Alkaloid Biosynthesis 
The spirocyclic dienone is a common structural motif found in a large number of 
natural products and biosynthetic intermediates. In Figure 1.1, examples of alkaloids that 
contain the spirocyclic dienone motif as a biosynthetic intermediates are shown; the C-C 
bonds that originate from the dienone motif are highlighted in red. 
Figure 1.1. Representative Examples of Alkaloids with Spirocyclic Dienones as a 
Biosynthetic Intermediate 
 
It has been shown that nature synthesizes the cross-conjugated dienone motif via 
oxidation by cytochrome P450 to form radical cations and then recombination of the 
radicals produces new C-C bonds. When phenolic radical cations cyclize to form new C-






























methylnorbelladiene (1.6), the radicals can combine in a para-ortho (1.7), para-para 
(1.8), or ortho-para (1.9) fashion to afford the skeletal frameworks of lycorine (1.10), 
crinine (1.5), and galanthamine (1.1), respectively (Scheme 1.1).1  


















































1.1.2 Alkaloid Synthesis Via Biomimetic Spirocyclic Dienone Formation 
Although nature performs the oxidative phenolic coupling enzymatically with 
high efficiency, efforts to replicate this transformation in the laboratory have proven 
problematic. In the case of galanthamine (1.2), issues pertaining to product stability, poor 
regiocontrol, and over oxidation have plagued attempts at biomimetic syntheses.2-14  
1.1.2.1 Biomimetic Synthesis of (±)-Galanthamine by Barton et al 
In the first total synthesis of (±)-galanthamine (1.2), the key biomimetic dienone 
intermediate 1.12 was formed in 0.3% yield upon exposing phenol 1.11 to MnO2 (Scheme 
1.2). The authors found that polymerization of 1.11 was the major product, yet trace 
amount of (±)-narwedine (1.13) could be isolated, and subsequent reduction of 1.13 with 
lithium aluminum hydride afforded (±)-galanthamine (1.2) in 60% yield.13  
































1.1.2.2 Biomimetic Syntheses of Galanthamine by Node et al 
In the most recent biomimetic synthesis of (–)-galanthamine (1.2), the key 
oxidative coupling of phenol 1.14 to afford 1.15 proceeded in 85% yield.3 To achieve the 
desired regioisomer in high yield, several protecting and blocking groups were required 
(Scheme 1.3). As a result, six addition chemical transformations were needed to convert 
dienone 1.16 to (±)-narwedine (1.13). Since (±)-narwedine (1.13) is known to undergo 
dynamic chiral resolution when recrystallization is seeded with (–)-narwedine,15 a formal 
synthesis of (–)-galanthamine was completed.  
Scheme 1.3: The Most Recently Published Biomimetic Synthesis of (–)-Galanthamine 
 
1.1.2.3 Biomimetic Synthesis of Salutaridine 
A biomimetic synthesis of (±)-salutaridine (1.3) has been published as well. 

































1. Tf2O, pyr 99%
2. Pd(OAc)2, PPh3, NEt3
    HCO2H, 97%
3. ethylene glycol
    PPTS, 92%
4. LiAlH4
5. HCl 83% (two steps)
TFE = trifluoroethanol; PIFA = (Bis(trifluoroacetoxy)iodo)benzene; 
PPTS = pyridinium p-toluenesulfonate
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also suffered from poor yields of the key oxidative coupling step.16 Exposure of N-
protected reticuline 1.17 to periodobenzene diacetate (PIDA) afforded dienone 1.18 in 
only 22% yield (Scheme 1.4).16 The major by-product was tetracycle 1.19, which was 
isolated in 18% yield and arose due to lack of regiocontrol in the oxidative coupling step.  
Scheme 1.4: Biomimetic Synthesis of Salutaridine 
 
1.1.3 The aza- Spirocyclic Dienone Motif in Alkaloid Synthesis 
Similar to the phenol derived spirocyclic dienones, the aniline derived systems are 
found in various natural products, and this privileged structural motif has found utility as 
an intermediate in the synthesis of other compounds. The aza-spirocyclic dienone moiety 
is a structural motif found in the discorhabdin family of natural products (1.20-22) 
(Figure 1.2, aza-spirocyclic dienone shown in red). These alkaloids were isolated from 
sea sponges located off the coast of New Zealand and were found to be cytotoxic at very 
low concentrations (ED50 < 100 ng/mL).17 As a result, these compounds have garnered 
significant interest from the greater synthetic community because of their unique 































Figure 1.2. The Cytotoxic Sponge Metabolites of the Discorhabdin Family 
 
The aza-spirocyclic dienone moiety has also found utility as an intermediate in 
the synthesis of natural products and natural product-like compounds. For example, the 
natural product-like compound aza-galanthamine (1.25) was synthesized from the aza-
spirocyclic dienone 1.23 (Scheme 1.5). Galanthamine (1.2) and the aza-derivative 1.25 
were both under investigation as a potential therapeutic for Alzheimer’s disease through 
its role as a selective acetylcholinestease inhibitor.18  
Scheme 1.5. Synthesis of aza-Galanthamine 
 
In 2007, Guillou et al demonstrated that aza-spirocyclic dienone (1.26) can be an 
intermediate in the synthesis of Büchi’s ketone (1.29) (Scheme 1.6), which is an 
intermediate in the synthesis of the indole alkaloid vindorosine (1.30)19 and contains the 
carbon substructure of several Aspidosperma alkaloids (Figure 1.3).20 The conversion of 
dienone 1.26 to indoline 1.28 was believed to occur via nucleophilic attack of an amine to 














































addition to afford indoline 1.28. Compound 1.28 was converted in five additional steps to 
Büchi’s ketone (1.29). 
Scheme 1.6. Synthesis of Büchi’s Ketone (1.29) from aza-Spirocyclic Dienone 1.26 
 















































































As an expansion of the double Michael addition rearrangement developed to form 
the indoline skeleton (Scheme 1.6), an enantioselective variant was reported by Fan et al 
that utilizes the chiral thiourea catalyst 1.37 (Scheme 1.7).21 The authors found that 
dienone 1.26 can be converted to indolines 1.35 and 1.36 in 51% yield (94% ee) and 45% 
yield (90% ee), respectively. The transformation was found to tolerate a wide variety of 
arene substitution patterns on both the aniline and benzylamine moieties as well as a 
variety of carbamates on the aniline nitrogen atom. 
Scheme 1.7. Enantioselective Synthesis of Indolines from aza-Spirocyclic Dienones 
 
With enantiopure indoline 1.36 in hand, the authors were able to rapidly 
synthesize the indole alkaloids (+)-limaspermidine (1.44) and (+)-deethyllbophyllidine 

































Scheme 1.8. Synthesis of Indole Alkaloids (+)-Limaspermidine (1.44) and (+)-
Deethyllbophyllidine (1.41) 
 
Given the application of aza-spirocyclic dienones in the synthesis of indole 


































































and efficiently synthesize these structural motifs would be beneficial to the greater 
synthetic community.  
1.1.4 Synthesis of aza-Spirocyclic Dienones 
There are several known methodologies for the synthesis of aza-spirocyclic 
dienones, and the majority of these rely on oxidative conditions. As such, they suffer 
from many of the same issues that plagued the oxidative phenolic couplings discussed 
earlier (Scheme 1.2, Scheme 1.3, and Scheme 1.4). 
1.1.4.1 Hypervalent Iodide Based Methods 
The earliest example of an oxidative coupling of a phenol to an aniline-like 
system is shown in Scheme 1.9. In a model study towards the synthesis of the 
discorhabdin alkaloids, Kita et al found that the aza-spirocyclic dienones 1.47-54 could 
be formed from a variety of trimethylsilyl protected phenols in 42-86% yields using the 
hypervalent iodide reagent PIFA.22,23 Unfortunately, the yields of the transformation were 
highly substrate dependent: for example, the deactivated dibrominated arene 1.46 
afforded dienone 1.48 in significantly poorer yield (42%) than the conversion of non-








Scheme 1.9. Model Studies Towards the Synthesis of Discorhabdin Alkaloids 
 
Using the methodology established on their model system, Kita et al completed 
the syntheses of both discorhabdin C (1.22) and discorhabdin A (1.20).24,25 In both cases, 
the key spirocyclic dienone moiety was formed in modest yield using his oxidative 





































































1.47: X = H  (86%)
1.48: X = Br (42%)
1.45: X = H
1.46:  X = Br
PIFA
TFE, rt
PIFA = periodobenzene bis(trifluoroacetate); TFE = trifluoroethanol
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Figure 1.4. Key Oxidative Coupling in the Synthesis of Discorhabdin A and C 
 
Hypervalent iodide reagents have also been developed to synthesize aza-
spirocyclic dienones that do not have the indolo-iminoquinone core of the discorhabdin 
alkaloids. Using oxidative conditions analogous to those used by Kita et al the 
discorhabdin syntheses, Doris et al found that spirocyclic 1.60 was obtained in 60% yield 
from anilide 1.59 (Scheme 1.10).26 The authors propose that the hypervalent iodide 
oxidant creates intermediate arenium 1.61, which undergoes electrophilic aromatic 
substitution with anilide 1.59. However, the authors reported only one example, and no 
investigation into the scope of the transformation was performed. Several years later, Yu 
et al extended the substrate scope slightly, demonstrating that the reaction tolerated 









1.56a: R = COCF3 (58%)








1.55a: R = COCF3




























PIFA = periodobenzene bis(trifluoroacetate); TFE = trifluoroethanol;
TEOC = 2-(trimethylsilyl)ethoxycarbonyl
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Scheme 1.10. Initial Report By Doris et al Utilizing Hypervalent Iodide 
 
Scheme 1.11. Substitution on Aniline Reduces Yields of Oxidative Coupling 
 
In an attempt to form dienone 1.23 via an oxidative coupling, Guillou et al found 
that oxidation of the ortho-methoxy anilide 1.66 did not afford any of the desired dienone 
1.23. Instead, they identified compounds 1.67 and 1.68 as the major products in 10% and 
15% yield, respectively (Scheme 1.12).28,29 This observation illustrated the sensitivity of 




























1.64: R= 4-EtO (42%)











PIFA = periodobenzene bis(trifluoroacetate); TFE = trifluoroethanol
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Scheme 1.12. Attempted Synthesis of Dienone 1.23 by Guillou et al 
 
1.1.4.2 Radical Based Methods 
Other oxidative conditions have been developed in order to overcome some of the 
limitations of hypervalent iodine reagents. For example, homolytic cleavage of a C-I 
bond has been used to synthesize aza-spirocyclic dienones analogous to 1.60 (Scheme 
1.10). Curran et al found that iodoanilide 1.69 could be converted to dienone 1.72 in 
moderate yields using triethylborane/O2 as a radical initiator in conjunction with TTMS 
(tris(trimethylsilyl)silane) (Table 1.1).30 Although the yields were comparable to the 
methods utilizing hypervalent iodide, this strategy provided a broader substrate scope 
than previous methods. Specifically, the previously inaccessible ortho-methoxy derivate 
1.23 was formed in 40% yield, culminating in the formal synthesis of aza-galanthamine 
































PIFA = periodobenzene bis(trifluoroacetate); TFE = trifluoroethanol
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Table 1.1. Synthesis of spiro-Cyclohexyldienone Via an Oxidative Radical Process by 
Curran et al 
 
Following the initial efforts by Curran et al, Lanza et al reported a similar 
approach utilizing an aryl azide in lieu of a trityl or silyl protected phenol (Table 1.2).31,32 
The authors reported comparable yields over two steps to that of the Curran group (55-
68% vs 40-65%), but they claimed their method was superior because the starting 
materials were more readily accessible (Table 1.1). The Lanza group also observed a 
competing reaction pathway in which the benzylic position of the aryl azide was 

































































TTMS = Tris(trimethylsilyl)silane; Tr = triphenylmethyl
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the authors reported that Boc protected anilide 1.73e did not react under the reaction 
conditions, and they provided no explanation for the observed lack of reactivity. 
Table 1.2. Synthesis of spiro-Cyclohexyldienone Via an Oxidative Radical Proccess 
from Aryl Azides 
 




















































































































In 2013, Chuang et al accessed aza-spirocyclic dienones via an oxidative 
methodology in which the order of bond formation is reversed relative to the Curran and 
Lanza strategy.33 In the Chuang et al paper, an α-allylsulfonyl amide was treated with 
sodium p-toluenesulfonate and manganese (III) acetate to generate a carbon centered 
radical that then adds ipso to the biaryl affording the desired dienone 1.81 in good yields 
(72-94%) (Table 1.3). Although this strategy provided that best yields to date, there were 
some regioselectivity issues as 1.82 was produced in yields as high as 14%. These 
reactions also required a large amount of manganese (III) acetate (2.5 eq) to proceed, 
which can complicate purification. 
Table 1.3. Dienone Synthesis Via an Oxidative Radical Proccess Initiated by 
Allylsulfonyl Degradation 
 
1.1.4.3 Other Oxidative Approaches 
There are two additional oxidative approaches to the aza-spirocyclic dienone core 


















































































centered radicals to perform the requisite cyclization. Yamamura et al explored an 
approach using constant current electrolysis to synthesize the dienone core of the natural 
product discorhabdin C (1.22).34,35 Unfortunately, this electrochemical approach afforded 
the aza-spirocyclic dienone in only 24% yield (Scheme 1.14). In addition, the dienone 
produced (1.22) was shown to decompose under the reaction conditions, affording phenol 
1.84 in 6% yield.  
Scheme 1.14. Alternative Oxidative Approach to Discorhabdin C using Constant Current 
Electrolysis 
 
In 1999, Heathcock et al published a biomimetic route to discorhabdin C in which 
he proposed that phenolate 1.86 is in equilibrium with aminohydroquinone 1.87 (Scheme 
1.15). Indeed, the authors found that phenol 1.85 proceeded to dienone 1.88 in high 
yields under slightly basic and mild oxidizing conditions.36 Although this transformation 
proceeded quite readily, this approach would not be generalizable to scaffolds that do not 
contain the quinone moiety because the mild oxidant does not oxidize the phenol directly. 
Rather, the CuCl2/O2 system oxidizes aminohydroquinone 1.87 that is formed upon 1,4-
addition of the phenolate. Thus, this cyclization reaction would find little utility outside 































Scheme 1.15. Proposed Biomimetic Synthesis of the Discorhabdin Alkaloids 
 
1.1.4.4 Non-oxidative Approaches 
So far, the cyclization strategies shown rely on oxidation of a phenol or 
aminohydroquinone to form the desired aza-spirocyclic dienone moiety. However, there 
are two published strategies to aza-spirocyclic dienones that do not involve oxidation. In 
2007, Guillou et al utilized an intramolecular Heck reaction followed by selenium 
dioxide oxidation to form aza-spirocyclic dienones (Table 1.4).20 Although this approach 
was applied to a variety of substituted anilido arenes (Table 1.4, 1.89a-e), the protracted 













































Table 1.4. Guillou et al Synthesis of spiro-Cyclohexyldienones Via an Intramolecular 
Heck Reaction 
 
In 1989, Knölker et al showed that iron tricarbonyl arenium complex 1.92 reacted 
with anilines 1.93 to synthesize the complexed diene 1.94 (Table 1.5).37 Unfortunately, 
the de-complexed compounds 1.95 were very unstable, and diene 1.95e rapidly 





















































































aHeck reaction with ligand. bHeck reaction without ligand. cYield over four steps.
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Table 1.5. Knölker et al Synthesis of spiro-Cyclohexyldienes Via Iron Tricarbonyl 
Dearomatization 
 
Scheme 1.16. Rearrangement of Diene 1.95e to Indoline 1.96 
 
In analogy to their previous work, Knölker et al showed that iron tricarbonyl 
arenium complex 1.97 reacts with indoline 1.98 to access the carbon skeleton of the 
discorhabdin alkaloids (Scheme 1.17). However, this reaction proceeded with very poor 







































































Scheme 1.17. Alternative Oxidative Approach to the Discorhabdin Alkaloids using η4-
Tricarbonyliron 
 
1.2 MAGNUS APPROACH TO ALKALOID SYNTHESIS 
1.2.1 Bond Formation Strategy 
Given the ubiquitous nature of the spirocyclic cross-conjugated dienone moiety as 
an intermediate in the biosynthesis of numerous alkaloids, the Magnus lab sought to 
exploit that structural motif in the synthesis of (±)-codeine and (-)-galanthamine.39 In 
view of the aforementioned limited success by numerous groups to form dienones via 
biomimetic oxidative methods, Magnus hypothesized that those natural products could be 
synthesized utilizing a phenolic C-alkylation in lieu of an oxidative coupling. This 
strategy would allow reversal of the order of bond formation and avoid the poor reaction 
profiles associated with oxidative couplings, while still utilizing biosynthetically relevant 





































Figure 1.5. General Example of Phenolic C-Alkylation in Lieu of Oxidative Coupling 
 
1.2.2 The Phenolic C-Alkylation Reaction 
1.2.2.1 Discovery of the Phenolic C-Alkylation 
The base induced phenolic C-alkylation was first discovered by Winstein and 
Baird in 1957.40 In their seminal work, phenol 1.101 formed spiro-cyclohexyldienone 
1.103 upon deprotonation with potassium tert-butoxide in anhydrous tert-butyl alcohol 
(Scheme 1.18). They noticed that the product contained a carbonyl group via IR and 
verified the spirocyclic structural assignment via rearrangement of dienone 1.103 to 
phenol 1.104 under acidic conditions. After preliminary mechanistic studies, Winstein 
and Baird further determined that the cyclization occurred via Ar1 participation of 















Scheme 1.18. First Example of Base Catalyzed Phenolic C-Alkylation 
 
After the initial discovery in 1957, Mandell expanded the methodology to include 
alkylation at the ortho position of a phenol during efforts towards the synthesis of 
santonin-like compounds.42 Mandell found that phenol 1.105 afforded exclusively the 
ortho alkylated product 1.106 after treatment with base, whereas the disubstituted phenol 
1.107 afforded a mixture (2:1) of dienones 1.108 and 1.109 (Scheme 1.19). 
Scheme 1.19. First Examples of ortho-Phenolic c-Alkylation 
 
1.2.2.2 Early Use of the Phenolic C-Alkylation in Natural Product Synthesis 
In 1963, this methodology proved valuable in the context of natural product total 
synthesis as a means of generating quaternary carbon centers. Of particular note, 
Masamune utilized an intramolecular phenolic C-alkylation to synthesize the bicyclo-
[3.2.1]octane moiety found in a variety of diterpene natural products.43 The work 
culminated in back-to-back publications of four articles detailing the syntheses of atisine 



























intermediate synthesized by Masamune was utilized by Marshall in the total synthesis of 
hinesol.48 
Scheme 1.20. Masamune Synthesis of Kaurene, Garryine, and Atisine 
 
Since the publication of Masamune’s work, the base induced phenolic C-
alkylation has been utilitized in the synthesis of terpenes, steroids, and other unique 
spirocyclic structural motifs.49 Given that a wide variety of alkaloid natural products 
contain a central quaternary carbon center (Figure 1.6), the Magnus lab found it 
surprising that this C-C bond forming reaction had not been extensively utilized for the 






























kaurene (1.113) garryine (1.114) atisine (1.115)
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Figure 1.6. Mapping of the Dienone from Masamune’s Intermediate Onto a Diverse Set 
of Alkaloids 
 
Before the Magnus lab investigated the utility of the phenolic C-alkylation 
reaction in 2008, there was only one relevant example of an alkaloid synthesized via a 
base-induced intramolecular phenolic C-alkylation to afford a spirocyclic cross-
conjugated dienone.50 In 1990, Kublak et al published a study towards the synthesis of 
discorhabdin C (1.22). The authors sought to synthesize the unique aza-spirocyclic core 
via a phenolic C-alkylation, but they found that mesylate 1.116 afforded dienone 1.48 in 
only 33% yield (Scheme 1.21). To further investigate why the reaction proceeded poorly, 
the authors synthesized model system 1.117; they discovered that the poor yield in the 
conversion of 1.117 to 1.47 was due to aziridine 1.118 formation being faster than 
phenolic C-alkylation. In addition, they found that upon resubjecting aziridine 1.118 to 


































σ* orbital of the aziridine C-N bond could not align with the π system of the phenol, 
resulting in this unproductive byproduct. 
Scheme 1.21.  Synthesis of the Aza-Spirobicyclic Core of Discorhabdin C Via an 
Intramolecular Base-Catalyzed Phenolic C-Alkylation 
 
1.2.3 Successful Application of the Phenolic C-Alkylation to Alkaloid Synthesis 
1.2.3.1 Synthesis of Galanthamine and Codeine 
The Magnus lab hypothesized that an approach employing a phenolic C-
















































aziridines. In the syntheses of (-)-galanthamine (1.2) and (±)-codeine (1.123) in 2009, the 
spirocyclic dienone 1.122 served as a divergent intermediate for both natural products 
(Scheme 1.22).39 By first forming the biaryl bond via a Suzuki reaction followed by 
phenolic C-alkylation, the order of bond formation for the central quaternary carbon was 
reversed from the biomimetic process (Scheme 1.1), and the key dienone intermediate 
1.122 was formed in 95% yield from biaryl 1.121. This approach proved to be a dramatic 
improvement over previous syntheses, affording (–)-galanthamine and (±)-codeine in 


















Scheme 1.22. Sythesis of (±)-Codeine and (-)-Galanthamine Via Phenolic C-Alkylation 
 
1.2.3.2 Synthesis of Dihydrosalutaridine 
After initial success of the phenolic C-alkylation strategy, the Magnus group 
sought to apply their C-C bond forming strategy to the syntheses of other natural 
products. The phenolic C-alkylation reaction was next used to synthesize 8,14-
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87% yield.51 In addition to rapidly synthesizing 1.127, this sequence also expanded the 
phenolic C-alkylation strategy to include the preparation of differentially substituted 
dienones (Scheme 1.23). This synthesis was a dramatic improvement from the previous 
biomimetic synthesis of the closely related alkaloid salutaridine (1.3), which afforded the 
key spirocyclic cross-conjugated dienone 1.18 in only 22% yield (Scheme 1.4).16 
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1.2.3.3 Synthesis of Cepharatine A 
Although there is no biomimetic synthesis for the hasubanan alkaloid cepharatine 
A (1.4), it is believed that the compound arises in nature from sinoacutine (1.129), which 
is synthesized via an oxidative phenolic coupling of (S)-reticulin (1.128) (Scheme 1.24).52  
Scheme 1.24. Putative Biosynthesis of Cepharatine A 
 
Employing the phenolic alkylation strategy once again, the Magnus lab 
synthesized tetracyclic dienone 1.134 in one step from biaryl 1.132 via a phenolic 
alkylation-annulation cascade. The tetracyclic dienone 1.134 was further elaborated into 
cephartine A (1.4), affording the natural product in seven steps and 16% overall yield 
(Scheme 1.25).53 This synthesis was an improvement over the previous work done by 


























Scheme 1.25. Phenolic C-Alkylation-Annulation Used in the Synthesis of Cepharatine A 
 
1.2.3.4 Synthesis of Homoaporphine and Aporphine Alkaloids 
The Magnus lab has also applied the phenolic C-alkylation strategy to the 
synthesis of proaporphine and homoproaporphine-type alkaloids.55 In this work, the 
biaryl 1.135 was used as a common divergent intermediate to access 
tetrahydroisoquinoline moities 1.136 and 1.138. It was then shown that mesylate 1.136 
afforded dienone 1.137 in 81% yield upon exposure to CsF at elevated temperatures. 
Under analogous conditions, dienone 1.139 was synthesized in high yields from biaryl 






















    K3PO4, Me2CO
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EVE = Ethylvinyl ether; DIPEA = diisopropylethyl amine
SPhos = 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl
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proaporphine alkaloid stepharine (1.1) and a general scaffold for homoproaporphine-type 
alkaloids (1.139), respectively (Scheme 1.26). 
Scheme 1.26. Phenolic Alkylation Strategy for the Synthesis of Proaporphine and 
Homoproaporphine Alkaloids 
 
Curiously, the choice in protecting groups for the homoproaporphine systems was 
paramount to the success of the transformation. When a carbamate protecting group was 
used instead of a sulfonamide for tetrahydroisoquinoline 1.140, the nucleophilic oxygen 
of the carbamate displaced the leaving group affording the cyclic carbamate 1.141, 
which, upon work up, hydrolyzed to primary alcohol 1.142 (Scheme 1.27).56 This 







































Scheme 1.27. Cyclic Carbamate Formation Occur faster that Phenolic C-Alkylation 
 
1.2.3.5 Attempted Synthesis of Crinine 
The phenolic C-alkylation strategy has also been applied to the Amarylidaceae 
alkaloid family in an attempt to prepare crinine (1.5), but the cyclization did not proceed 
as intended. Instead of providing the desired 7-membered ring, products resulting from 
dimerization (1.145) or elimination to the N-tosyl enamine (1.144) were observed (Figure 
1.7).57 Although the inability to affect formation of dienone 1.143 was disheartening, the 
data point was still valuable in establishing the scope and limitation of the strategy 
because there is a large entropic penalty in the transition state for the formation of seven-
membered rings. Thus, if the transition state is too high in energy, the cyclization will not 


























Figure 1.7. Failed Application of Phenolic C-Alkylation to the Synthesis of Crinine 
 
 
1.2.3.6 Attempted Synthesis of Fargenone Alkaloids 
Others outside the Magnus lab have also applied the phenolic alkylation strategy 
to natural product synthesis. For example, Denton et al utilized the phenolic alkylation 
approach in an attempts to prepare the tricyclic core of the fargenone and fargenin family 
of natural products, represented by 1.146 and 1.147 (Figure 1.8).58 The authors speculated 
that hemiacetal 1.151 would be in equilibrium with aldehyde 1.153, and aldehyde 1.153 
would react chemoselectively with methyl phosphonium ylide to form alkene 1.148. 
Unfortunately, no chemoselectively was observed. Instead, the double adduct 1.154 was 


















































1.148, they were able to prepare the spirocyclic cross-conjugated dienone 1.150 in 99% 
yield from biaryl 1.149 (Scheme 1.28).  
Figure 1.8. Natural Products Fargenone A, Fargenin, and a Common Structural Motif 
 
Scheme 1.28. Phenolic Alkylation Strategy Used in Studies Towards the 

















































The spirocyclic dienone structural motif is a privileged intermediate that is 
embedded into the carbon framework of numerous alkaloids (Figure 1.1). Prior to the 
work done in the Magnus lab, the most efficient way to form these motifs involved using 
a biomimetic oxidative coupling that often suffered from low yields and poor 
regiocontrol (Schemes 1.2-4). To overcome these issues, the Magnus lab proposed a 
different strategy in which the key quaternary carbon is synthesized via a Suzuki 
coupling followed by an intramolecular phenolic C-alkylation (Figure 1.5), and through 
this bond forming strategy, numerous natural products have been synthesized in high 
yields (Schemes 1.22-26). 
Similarly, the aza-spirocyclic dienone is a structural motif found in numerous 
natural products (Figure 1.2), and it has been used as an intermediate in the synthesis of 
natural products and natural product-like compounds (Schemes 1.22-26). The current 
generalizable strategies for synthesizing aza-spirocyclic dienones are shown in Figure 
1.9, and each of these approaches have various shortcomings that limit the utility of each 
method. The approach that utilizes the hypervalent iodide reagent PIFA (Figure 1.9a) 
benefits from the anilide system being very simple and easy to prepare, but yields of the 
transformation are poor (40-60%) and the substrate scope is very limited (Schemes 1.10-
12). The radical based approaches using triethylborane (Figure 1.9b) have a broader 
substrate scope than the hypervalent iodide method, but the yields (40-60%) are also poor 
(Tables 1.1 and 1.2). The radical based approach using Mn(OAc)3 (Figure 1.9c) showed 
the best yields (70-96%), but the approach encountered regioselectivity issues when 
substitution was placed on the phenol moiety (Table 1.3). The approach employing a 
Heck reaction (Figure 1.9d) was able to synthesize the aza-spirocyclic dienone moiety, 
but the overall yield was poor due to the protracted synthesis (Table 1.4). Lastly, the 
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approach that utilizes the iron arenium complex (Figure 1.9e) has nominal utility due to 
poor regioselectivity and product instability (Table 1.5, Scheme 1.16, and Scheme 1.17). 
Figure 1.9. Summary of Known Methods 
 
Because of the glaring deficiencies with the current ways to synthesize the aza-
spirocyclic dienone structural motif, a new method that is high yielding and function 
group tolerant would be extremely valuable to the synthetic community. We propose that 
the Magnus strategy for spirocyclic dienone synthesis could be expanded to aniline based 
systems, and this approach would be higher yielding and more functional group tolerant 
than the current methods that are known (Figure 1.10). Additionally, we believe that the 
Magnus approach could be expanded to include dienones arising from an ortho-phenolic 










































































































Chapter 2: Synthesis and Utilization of aza-Spirocyclic Dienones 
2.1 SYNTHESIS OF AZA-SPIROCYCLIC DIENONES VIA AN INTRAMOLECULAR PHENOLIC 
C-ALKYLATION 
2.1.1 Introduction 
The aza-spirocyclic dienone moiety (Figure 2.1, outlined in read) is a structural 
motif present in the in the discorhabdin family of indole alkaloids. Additionally, the aza-
spirocyclic structural moiety has been used as divergent intermediate to access a variety 
of natural products and natural product-like compounds (Figure 2.1).20,21,30 































































Various strategies have been developed to synthesize the aza-spirocyclic dienone 
motif, and the current approaches have obvious deficiencies, such as low yields and poor 
scope, that limit their utility and generalizability (Figure 1.9). We hypothesized that the 
Suzuki coupling/phenolic C-alkylation strategy developed in the Magnus lab would be 
able to synthesize aza-spirocyclic dienones in high yields. In addition, we sought to 
explore whether structures arising from ortho- as well as para-phenolic C-alkylation 
could be synthesized in order to access novel chemical structures (Figure 2.2).  
Figure 2.2. Proposed Synthesis of spiro-Cyclohexyldienone Via an Intramolecular 
Phenolic C-Alkylation 
 
2.1.2 para-Phenolic C-Alkylation of Aniline Derived Systems 
2.1.2.1 First Generation Model System for para-Phenolic C-Alkylation 
To determine the viability of the para-phenolic C-alkylation strategy for the 
synthesis of aza-spirocyclic dienones, we initially employed the simple model system 2.2 































acylation of biaryl 2.4, which in turn could be synthesized via a Suzuki cross coupling 
reaction from known boronic acid 2.6 and commercially available 2-bromoaniline (2.5).  
Scheme 2.1. Retrosynthetic Analysis for Initial Biaryl Model System 
 
The metal/ligand complex Pd(dppf)Cl2 readily catalyzed the coupling of boroxine 
1.120 and 2-bromoaniline (2.5) to afford biaryl 2.4 in 90% yield (Scheme 2.2). During 
the course of optimizing the reaction, it was determined that transient oxygen in the 
reaction flask would react with and degrade the boronic acid generated in situ, resulting 
in highly variable reaction profiles (50-90% yield). Thus, rigorous degassing of the 
dioxane/water mixture and addition of the oxygen scavenger BHT (2,6-di-tert-butyl-4-
methylphenol) were key to obtaining consistently high yields of biaryl 2.4. Acylation of 
2.4 with bromoacetylchloride afforded amide 2.7 in 38% yield. Upon subjecting amide 
2.7 to the conditions previously optimized by Magnus et al39, none of the desired dienone 
2.2 was observed. Instead, a mixture of products were obtained, none of which showed 

























were observed. These results were in alignment with a previous observation in which 2.8 
failed to provide dienone 2.9 (Scheme 2.3).59 It is hypothesized that the amide resonance 
rigidified the system by restricting rotation around C-N bond, thus preventing the 
requisite orbital overlap between the σ*C-Br and π system required for the reaction to 
proceed as desired. 
Scheme 2.2. Synthesis of Initial Model System 
 























































2.1.2.2 Second Generation Model System for para-Phenolic C-Alkylation 
The model system was then revised to increase the flexibility in the tether to 
address the proposed issues pertaining to transition state orbital overlap. We envisioned 
that optimum orbital overlap could be achieved by utilizing the alpha halo hemiaminal 
ether 2.11 instead of the alpha halo amide 2.7 (Scheme 2.4).  
Scheme 2.4. Retrosynthetic Analysis for Revised Biaryl Model System 
 
Before commencing with the synthesis of derivatives of 2.10, we were aware of 
several potential issues that needed to be addressed in the model system: 1) hemiaminal 
ether moieties are known to readily ionize under mild acidic and thermal conditions; and 
2) if the nitrogen atom of 2.11 is sufficiently nucleophilic, aziridine formation may occur 
rapidly and compete with dienone formation. Through previous work, we knew that high 
temperatures (130 ºC, DMF) were needed to induce dienone formation59 and that dienone 
formation does not occur faster that aziridine formation if R = H.50 We hypothesized that 
an inductively withdrawing group appended to the nitrogen atom might mitigate those 
issues, as long as the protecting group does not allow for additional reaction pathways. 
Given that amides and carbamates can anchimerically displace alkyl halides, we 
determined that R = amide or R = carbamate were poor choices. Thus, we decided that R 



















The synthesis of the second generation system commenced with the 
quantitative protection of biaryl 2.4 with p-TsCl to afford 2.12. The protected biaryl was 
next alkylated with in situ brominated ethyl vinyl ether (2.15) to quantitatively afford the 
hemiaminal ether 2.13. Upon subjecting hemiaminal ether 2.13 to the conditions 
developed by Magnus et al,39 the desired dienone 2.14 was obtained in 96% yield 
(Scheme 2.5). The structure of dienone 2.14 was unambiguously determined by x-ray 
crystallography (Figure 2.3).  









































Figure 2.3. Crystal Structure of 2.14 
 
2.1.2.3 Exploration of Reaction Scope for para-Phenolic C-Alkylation 
We next sought to explore the scope of the cyclization by exploring other 
sulfonamide protecting groups. The para-nitrobenzenesulfonyl (nosyl) and 
methanesulfonyl (mesyl) protecting group were appended to biaryl 2.4 to afford 2.16 and 
2.17 in 68% and 69% yields, respectively (Scheme 2.6).  
Scheme 2.6. Synthesis of Nosyl and Mesyl Protected Anilines 
 
Using our established alkylation conditions, the two sulfonamide protected 
hemiaminal ethers 2.18 and 2.19 were formed in 87% and 74% yields, respectively 
(Scheme 2.7). Subjecting compounds 2.18 and 2.19 to CsF/DMF 130 ºC afforded 


















p-NsCl = para-nitrobenzenesulfonyl chloride; MsCl = methanesulfonyl chloride
 47 
Scheme 2.7. Synthesis of Dienones with Varying Sulfonamide Protecting Groups 
 
While we were pleased that the mesyl stubstituted system gave comparable yields 
to the tosyl substituted system, we were surprised that the nosyl system gave such poor 
results. Upon LCMS analysis of the crude reaction mixture, masses corresponding to loss 
of SO2 were observed. It is known that under basic conditions at elevated temperatures a 
para-nitrobenzenesulfonamide can undergo intramolecular nucleophilic aromatic 
substitution and decompose to afford the corresponding aniline and an equivalent of 
SO2.60-64 For example, Barber reported one of the earliest known examples in which nosyl 
protected amidine 2.22 could be converted to 2.23 in basic glycerol at 200 ºC in 95% 
yield (Scheme 2.8).60 Thus, we hypothesized that dienone 2.21 was not stable to the 
reaction conditions (CsF, 130 ºC DMF), and the poor yield (34%) was due to 
decomposition of the product. Once the system loses SO2, the inductively stabilizing 
effects of the sulfonamide are lost, resulting in further degradation of the system. A 
proposed mechanism for loss of SO2 is shown in Scheme 2.9. To test the hypothesis that 
the product was not stable to the reaction conditions, a small amount of dienone 2.21 was 
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EVE = ethylvinyl ether
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Scheme 2.8. SO2 Expulsion from Amidine 2.22 
 
Scheme 2.9. Proposed Mechanism for Thermal Decomposition of 2.21. 
 
After probing the sensitivity of the reaction to differing sulfonamides, the ability 
of the system to tolerate substitution on the aniline and phenol moieties was investigated. 
Starting from the readily available bromoanilines 2.26-d, the corresponding biaryls 2.27-e 













































Table 2.1. Synthesis of Substituted Biaryls from Corresponding Anilines 
 
Because some of the desired bromoanilines were not readily accessible, 
bromonitrobenzene derivatives 2.28a and 2.28b were used to synthesize biaryls 2.29a 
and 2.29b in 66% and 82% yield, respectively (Table 2.2). During the conversion of 
2.28a to 2.29a, the corresponding unprotected phenol 2.29c was isolated in 15% yield. 
The phenol was subsequently reprotected affording biaryl 2.29a in quantitative yield. The 
nitroarenes 2.29a and 2.29b were reduced to the corresponding anilines 2.30a and 2.30b 











































2.26 1.120: R3 = H
















Table 2.2. Synthesis of Substituted Biaryls from Corresponding Nitrobenzenes 
 
The substituted biaryl aniline moieties 2.27a-e and 2.30a,b were converted the the 
tosyl protected hemiaminal ethers 2.31a-g in high yields over two steps (Table 2.3) with 
p-TsCl/pyridine then EVE/Br2/i-Pr2NEt. 











































aThe free phenol (2.29c) was isolated in 15% yield and subsequently quantitatively reprotected
























































































































EVE = ethylvinyl ether
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With hemiaminal ethers 2.32a-g in hand, the desired dienones 2.33a-g were 
formed in 89-99% yields upon exposure to CsF at 130 ºC, with the exception of 
hemiaminal ether 2.33f, which failed to provide dienone 2.33f (Table 2.4). For dienone 
2.33g, a separable mixture (5:4) of diastereomers was observed, and the relative 
stereochemistry of the major product was determined via X-ray crystallography. 
Table 2.4. Synthesis of Differentially Substituted Dienones 2.33 
 


































































a5:4 mixture of diastereomers
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We hypothesized that the failure of 2.32f to form dienone 2.33 was due to an 
adverse steric interaction in the transition state between the sulfonamide protecting group 
and the ortho-methoxy substituent of the aniline ring (Scheme 2.10). In order for the 
alkyl bromide to align with the developing negative charge on the phenol, the 
sulfonamide must eclipse the ortho-methoxy substituent, thus increasing the energy of the 
transition state. All attempts to run the reaction at higher temperatures (CsF/refluxing 
NMP) afforded only the deprotected phenol 2.34 and unidentified decomposition 
products. 
Scheme 2.10. The ortho-Methoxy Substituted System Failed to Form the Desired 
Dienone 
 
2.1.2.4 Synthesis of Naphthol Derived Dienones 
To further investigate the scope of the reaction, derivatives containing a naphthol 
ring were explored. Beginning with the known silyl protected bromonaphthol 2.36, the 
boronic acid was formed in 66% yield via metal-halogen exchange followed by reaction 
with triisopropyl borate (Scheme 2.11). A Suzuki coupling of 2.37 with 2-bromoaniline 



























compound was highly unstable and decomposed readily under ambient conditions. 
Fortunately, the sulfonamide protected biaryl 2.39 was stable to ambient conditions. 
Because the biaryl was unstable, the reaction mixture was worked up, and the crude 
material was used in the next step. By doing so, the protected biaryl 2.38 was isolated in 
24% yield over two steps. Alkylation of 2.38 with Br2/EVE afforded hemiaminal ether 
2.39 in 81% yield. Subjecting 2.39 to CsF at 130 ºC gave dienone 2.40 in 84% yield as an 
inseparable mixture (4:1) of diastereomers (Scheme 2.11).  
Scheme 2.11. Synthesis of Naphthol Derived Dienone 2.40 
 
Encouraged by the preparation of 1-naphthol derivative 2.40, efforts were 
undertaken to perform a para-phenolic C-alkylation on a 2-naphthol derivative to 
synthesize the extended dienone 2.44. A Suzuki coupling of 2-bromoaniline (2.5) with 
the boronic acid 2.41, followed by sulfonamide formation provided protected biaryl 2.42 
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    dioxane/water, 100 ºC
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BHT = 2,6-di-tert-butyl-4-methylphenol; dppf = 1,1-Bis(diphenylphosphino)ferrocene
EVE = ethylvinyl ether
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the standard alkylation conditions (Br2/EVE/i-Pr2NEt). Unfortunately, all attempts to 
induce cyclization to dienone 2.44 with CsF in DMF at 130 ºC afforded an intractable 
mixture. Lower reaction temperatures resulted in exclusively desilylated starting material, 
and increased reaction temperatures afforded no observable dienone by LCMS or crude 
1H-NMR analysis. We speculate that the reaction does not proceed as desired because the 
formation of the requisite anionic intermediate would require completely breaking the 
aromaticity of the naphthol ring, thus forming a very high-energy transition state.  
Scheme 2.12. Attempted Formation of Extended Dienone 2.44 
 
2.1.3 Attempted ortho- Phenolic C-Alkylation of Aniline Derived Systems 
To test whether dienone 2.45 could be synthesized via an ortho-phenol C-
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BHT = 2,6-di-tert-butyl-4-methylphenol; dppf = 1,1-Bis(diphenylphosphino)ferrocene
EVE = ethylvinyl ether
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system used for the para-phenolic C-alkylation, we believed that commercially available 
2-bromonitrobenzene (2.49) and 2-hydroxyphenyl boronic acid (2.48) would be suitable 
starting material.   
Scheme 2.13. Retrosynthetic Analysis for 2.45 
 
The synthesis of the 2.45 commenced with a Suzuki coupling between 
commercially available 2-bromonitrobenzene (2.49) and 2-hydroxyphenyl boronic acid 
(2.48) (Scheme 2.14). The previously optimized conditions used to form biaryl 2.4 
(Pd(dppf)Cl2/K2CO3) did not work well for this system. Indeed, only ~50% conversion of 
starting material was observed after 24 h. Fortunately, switching the base from K2CO3 to 
Cs2CO3 shortened the reaction time to 6 h and provided the desired biaryl 2.50 in 99% 
yield. The phenol moiety was then protected as the TBS ether to give 2.51 in 96% yield, 
which was reduced by catalytic hydrogenation to provide 2.47 in 97% yield. Subsequent 
sulfonylation of 2.47 afforded sulfonamide 2.52 in 95% yield. The sulfonamide 2.52 was 





















Scheme 2.14. Synthesis of Model System for Attempted ortho-ortho Phenolic c-
Alkylation 
 
Unfortunately, treatment of 2.53 with CsF at 130 ºC failed to afford any of the 
desired C-alkylated product 2.54 (Scheme 2.15). Instead, the O-alkylated system 2.56 
was isolated in quantitative yield. We hypothesized that the ortho-alkylation would 
require higher energy than the para-alkylation, but higher temperatures (CsF/NMP 
reflux) or classical alkylation conditions (t-BuOK/t-BuOH) on the phenol failed to 
provide any of the desired product, as determined by LCMS or NMR analysis of the 










































EVE = ethylvinyl ether; DCE = 1,2-dichloroethane; dppf = 1,1-Bis(diphenylphosphino)ferrocene
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Scheme 2.15. Attempted ortho-Phenolic C-Alkylation 
 
While attempts were being made to promote ortho-phenolic C-alkylation of an 
aniline derived system, a colleague, Timothy Hodges, was exploring a similar strategy 
with a phenol derived model system, and his results were in alignment with mine; none of 
the desired ortho-phenolic C-alkylation was observed (Scheme 2.16).57  

















































2.2. CHEMOSELECTIVE ADDITION OF OXYGEN NUCLEOPHILES TO N-TOSYL 
HEMIAMINAL ETHERS IN THE PRESENCE OF A DIENONE 
2.2.1 Introduction 
To probe the utility of the aza-spirocyclic dienones for the synthesis of natural 
product and natural product-like compounds, we sought to determine whether the 
hemiaminal ether moiety of 2.14 could be chemoselectively functionalized in the 
presence of the dienone moiety. It is well known that cross-conjugated dienones will 
rearrange to the phenol under acidic coniditions.65-68 Indeed, Doris et al reported that 
dienone 1.60 underwent a dienone-phenol rearrangement to give 2.61 under acidic 
conditions (Scheme 2.17).26 
Scheme 2.17. Known Rearrangements of Dienone 1.60 
 
However, we hypothesized that under mild Lewis or Brønsted acidic conditions 
hemiaminal ether ionization (Scheme 2.18: 2.14 to 2.65) would occur more rapidly than 
dienone phenol rearrangement (Scheme 2.18: 2.14 to 2.63 and 2.64). If the selective 
ionization occurred, we further hypothesized that the N-tosyliminium species 2.65 would 
be a more reactive electrophile than the dienone. Thus, we believed various nucleophiles 
would add chemoselectively into the transiently formed N-tosyliminium ion to synthesize 
















Scheme 2.18. Potential Reaction Pathways for Dienone 2.14 
 
2.2.2 Addition of Peroxyacids to N-Tosyl Hemiaminal Ethers in the Presence of a 
Dienone 
Acetals and iminiums are known to undergo oxidation with meta-
chloroperoxyacetic acid (m-CPBA) to the corresponding lactols and amides.69,70 For 
example, Wasserman et al reported that azetidine carboxylic acid 2.67 could be 
decarboxylated with oxalyl chloride to form an iminium salt, which readily underwent 
oxidation to the corresponding β-lactam in high yields (Figure 2.5: 2.67 to 2.68).69 Grieco 
et al later reported in 1978 that cyclic acetal 2.69 could be efficiently oxidized to lactone 















































Figure 2.5. Precedent for the conversion of Hemiaminal Ether 2.14 to Amide 2.73 
 
To test the hypothesis that a nucleophile could add chemoselectively to the 
transiently formed N-tosyliminium ion 2.65, we sought to oxidize the hemiaminal ether 
moiety of 2.14 to the corresponding anilide 2.73 (Scheme 2.19). Employing the Lewis 
acidic conditions published by Grieco et al, we found that hemiaminal ether 2.14 
underwent facile oxidation to the corresponding anilide 2.73 in 55% yield (Scheme 
2.19).70 Mechanistically, we envision that BF3•Et2O ionized 2.14 to generate N-tosyl 
iminium ion 2.65, and m-CPBA (2.71) added into 2.65 to form the peroxyaminal 2.72. 
Intermediate 2.72 likely undergoes intramolecular deprotonation to afford anilide 2.73 

























Scheme 2.19. Proposed Mechanism for Formation of Amide 2.73 
 
2.2.3 Solvolysis of N-Tosyl Hemiaminal Ethers in the Presence of a Dienone 
After determining that hemiaminal ether 2.14 could be selectively functionalized 
under Lewis acidic conditions, several Brønsted acids were screened for their ability to 
evoke solvolysis of 2.14 with methanol. As expected, mineral acids (H2SO4) and p-
toluenesulphonic acid caused rapid degradation of the dienone to phenolic products, 
whereas acetic acid returned starting material, even at elevated temperatures. However, 











































Scheme 2.20. Solvolysis of Hemiaminal Ether with Methanol 
 
The solvolysis of dienone 2.14 with water was investigated next. In the synthesis 
of (–)-galanthamine by Magnus et al, dienone 2.75 rearranged under aqueous acidic 
conditions to give lactol 2.76.39 It was hypothesized that 2.14 would rearrange and 
hydrate to give a similar lactol. 
Scheme 2.21. Rearrangement Observed in the Magnus Synthesis of (–)-Galanthamine39 
 
Dienone 2.14 was subjected to similar conditions to those used by Magnus et al, 
and lactol 2.81 was synthesized in 84% yield (Scheme 2.22). The structure of 2.81 was 
verified via x-ray crystallography (Figure 2.6). Mechanistically, it is believed that 
hemiaminal 2.77 is formed first, which would be in equilibrium with aldehyde 2.78. 
Compound 2.78 could then undergo an intramolecular conjugate addition to give enone 
2.79 that could hydrate to 2.80 and combine with the aldehyde moiety to form 2.81. We 
speculate that this rearrangement may prove valuable for the synthesis of indole alkaloids 






























Scheme 2.22. Proposed Mechanism for Hydrolysis and Rearrangement of Dienone 2.14 
 






































2.3 STUDIES TOWARDS THE SYNTHESIS OF THE SPIRO-BICYCLONONANE CORE OF 
ASPERNOMINE AND SESPENINE 
2.3.1 Introduction 
The indolosesquiterpenes sespenine (2.82) and aspernomine (2.83) are secondary 
metabolites that contain a unique spiro-bicyclononane core (Figure 2.7). Aspernomine 
was first isolated by Staub et al in 1992 from the sclerotia of the fungus Aspergillus 
nomius and was found to be cytotoxic against human cancer cell lines and a potent 
antiinsectan.71 The related natural product sespenine was first isolated by Ding et al in 
2011 from a bacterial culture broth of Streptomyces sp. HKI0595, an endophyte of the 
widespread mangrove tree Kandelia candel. Sespenine also exhibited potent anti-
insectant properties, but it elicited no cytotoxicity in several human cancer cells lines.72  
Figure 2.7. The Indolosesquiterpenes Aspernomine (2.82) and Sespenine (2.83) 
 
2.3.2 Biosynthesis and Previous Synthetic Efforts Towards the spiro-Bicyclononane 
Core 
2.3.2.1 Proposed Biosynthesis of spiro-Bicyclononane Core 
It has been proposed that the spiro-bicyclononane cores of aspernomine and 
sespenine arise biosynthetically via an oxidative rearrangement of the structurally related 
indolosesquiterpenes indosespine (2.84) and nominine (2.86), which were isolated in 
small quantities from the same fungal and bacterial extracts as aspernomine (2.82) and 














Figure 2.8. Proposed Biosynthesis of Sespenine and Aspernomine  
 
The proposed biosynthesis is supported by both experimental observations and 
computational studies. In 2003, Liu et al observed an unanticipated rearrangement during 
their synthetic studies towards an unrelated indole alkaloid.73 They found that 
hydroxyindole 2.88 rearranged to give a mixture (1:2) of 2.89 and compound 2.90 
(Scheme 2.23). Through extensive 2D-NMR analysis, it was determined that the structure 











































Thus, the authors proposed that a 3-hydroxyindole intermediate is involved in the 
biosynthesis of the indolosesquiterpenes.  
Scheme 2.23. Unexpected Rearrangement Observed of 3-Hydroxyindole Species 2.88 
 
Mechanistically, it is believed that this transformation proceeds via a boat 
conformation in which the alkene of 2.92 aligns with the iminium to form a 2º 
carbocation 2.93 that is stabilized by the proximal aniline moiety, subsequently forming 
arenium 2.94. The arenium ion is then quenched via the formation of ketone 2.95 
(Scheme 2.24). This mechanism for oxidative rearrangement is supported by quantum 
chemical calculation in which Tantillo et al suggests that the pathway involves a 























Scheme 2.24. Proposed Mechanism of Oxidative Rearrangement 
 
2.3.2.2 Bioinspired Total Synthesis of Sespenine 
When our investigations of these natural products began in 2012, there were no 
published syntheses of either aspernomine or sespenine. However, in 2014, Sun et al 
published the first total synthesis of sespenine in which they performed a bioinspired 
oxidative carbocation rearrangement to form the spiro-bicyclononane core of 2.83 in a 
manner analogous to the proposed biosynthetic rearrangement (Scheme 2.24, 2.91 to 
2.96).75 As of this writing, the related natural product aspernomine has not been 
synthesized. 
Sun’s total synthesis of sespenine started with the known alkene 2.97, which was 
converted to propargyl alcohol 2.98 in seven steps (Scheme 2.25). Compound 2.98 
underwent a radical cyclization using [Cp2TiCl2] and Mn0 to afford decalin system 2.99. 
Subsequent oxidation and alcohol protection afforded enone 2.100 in 62% yield over 
three steps. A conjugate addition of indole to 2.100 under mild conditions provided 2.101 
in 89% yield. Olefination of 2.101 using TiCl4/Nysted reagent (Scheme 2.25, 2.103) 























Scheme 2.25. Synthesis of Precursor to Oxidative Rearrangement 
 
With 2.102 in hand, a large number of oxidants were screened with the intention 
of optimizing the formation of 2.105. However, 2.105 was isolated only in 0-21% yield, 
and in several instances the over oxidized product 2.106 (0-16% yield) was isolated 
(Scheme 2.26). The authors speculated that the 3-hydroxyindole intermediate 2.104 that 
forms upon initial oxidation of the indole moiety was highly unstable and readily 
underwent undesired reaction pathways such as over oxidation and rearrangement to 
compounds other than the desired product 2.105. Thus, they proposed that the conversion 
of 2.102 to 2.105 would proceed more efficiently if the 3-hydroxyindole intermediate 






















































Scheme 2.26. Attempted Oxidative Rearrangement 
 
To stabilize the 3-hydroxyindole intermediate 2.104, Sun and coworkers utilized 
indole 2-methyl ester 2.107 in lieu of indole. Using slightly modified conditions, 
Bi(OTf)3 catalzyed the 1,4-addition of 2.107 to afford 2.108 in 71% yield. Subsequent 
olefination of 2.108 with Nysted reagent provided olefin 2.109 in 78% yield (Scheme 
2.27). 


























































Subjecting the modified system to oxidation with oxone/acetone provided the 3-
hydroxyindole species as a stable mixture of diastereomers that readily converged to the 
desired spiro-bicyclonone system 2.110 present in the natural product in 58% yield over 
two steps (Scheme 2.28). A Krapcho-demethoxycarbonylation of 2.110 followed by 
saponification of the ester and acetyl moieties afforded that natural product sespenine 
(2.83) in high yields.   
Scheme 2.28. Successful Oxidative Rearrangement and Completion of the Natural 
Product 
 
In summary, sespenine (2.83) was formed in 21 steps from commercially 
available material. Employing a radical cyclization, the authors formed the decalin 
system, and a bioinspired oxidative carbocation rearrangement synthesized the spiro-
bicyclononane core. Due to the spiro-bicyclononane core being formed last, this 
synthesis could not be used to access the related natural product aspernomine. Thus, we 
propose that a synthetic strategy in which the spiro-bicyclonone core is formed first 























1. NaCl, 140 ºC, 87%
2. LiOH, 50 ºC, 92%
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2.3.3 Synthetic Efforts Towards the Synthesis of Aspernomine and Sespenine 
2.3.3.1 Retrosynthetic Analysis of the spiro-Bicyclononane Core 
In our analysis of the synthetic challenges posed by sespenine (2.83) and 
aspernomine (2.82), we hypothesized that the tetracyclic compound 2.111 could serve as 
a divergent intermediate (Scheme 2.29). We envisioned that 2.111 could arise from an 
intramolecular conjugate addition of ketone 2.112, which could be synthesized from 
dienone 2.14 via addition of an acyl anion (2.113) equivalent to an N-tosyliminium ion 
that would be formed in situ.  










































2.3.3.2 Initial Strategy for Addition of Acyl Anion Equivalent 
Our strategy to form ketone 2.112 involved nucleophilic addition of a two-carbon 
unit to the iminium ion generated from dienone 2.14, which could be either oxidized (in 
the case of an alkene) or hydrated (in the case of an alkyne) to afford the desired ketone 
(Scheme 2.30).  
Scheme 2.30. Initial Strategy for Installation of Acyl Anion Equivalent 
 
Initial attempts to form the desired alkyne adduct with lithium and sodium 
acetylides resulted in exclusively 1,2-addition to the enone (Table 2.5, entries 1 and 2). In 
order for a chemoselective addition to the acetal to occur, we envisioned that the carbon 
nucleophile must be mild enough to not react with the dienone, yet reactive enough to 
add into the N-tosyl iminium ion. It was then determined that less reactive metal species 
were needed because we wanted the nucleophile to react exclusively with the transiently 
formed iminium ion. Subsequent attempts using a zinc acetylide, formed either 
stoichiometrically with n-BuLi and ZnCl2, or catalytically with ZnOTf2 and (i-Pr)2NEt, 






















Table 2.5. Li, Na, and Zn Acetylide Addition to Dienone 2.14 
 
Thinking that an even milder metal acetylide species might be needed, copper 
acetylides were explored. It was found that the copper acetylide species formed with 
CuBr and i-Pr2NEt did not react with dienone 2.14 at room temperature; however, upon 
heating the reaction 1,4-addition (2.114) was observed (Table 2.6, entries 1 and 2). This 
result was particularly disheartening given a report by Zhang et al in which a copper 
acetylide added to hemiaminal ether 2.115 (Figure 2.9).76 In a different report, Watson et 
al found that copper acetylides can add enantioselectively to isochroman acetals (2.117) 
when Lewis acid co-catalysts were employed (Figure 2.9).77 Unfortunately, only 1,4-
addition was observed when the Lewis acids BF3•OEt2 and TMS-OTf were used as co-






















































Table 2.6. Cu Acetylide Addition to Dienone 2.14 
 
Figure 2.9. Copper Acetylide Addition to Hemiaminal Ethers and Acetals 
 
 
At this juncture, we reasoned that blocking the reactivity of the dienone via a 
Luche reduction might allow for nucleophilic addition to the hemiaminal ether. Using 
CeCl3•7H2O/NaBH4/MeOH, dienone 2.14 was reduced to alcohol 2.120 in 91% yield.78 
The double allylic alcohol 2.120 was subsequently protected as the silyl ether to afford 



































0 ºC → rt












































Scheme 2.31. Synthesis of Protected Allylic Alcohol 2.121 
 
Unfortunately, it was found that 2.121 was much less stable than dienone 2.14 and 
rapidly ionized under Lewis acidic conditions. When 2.121 was subjected to identical 
conditions used previous CuBr/i-Pr2NEt/TMS-OTf or CuBr/i-Pr2NEt/BF3•OEt2, 2.121 
rapidly degraded to 2.122. Because 2.121 showed poor stability, it was determined that 
this approach should not be pursued further.  
Scheme 2.32. Protected Allylic Alcohol Undergoes Rapid Degradation 
 
While efforts were being undertaken to add metal acetylides into hemiaminal 
ether 2.14, we were concurrently investigating vinyl nucleophiles as an alternative. The 
addition of vinylsilanes to iminiums and other highly reactive electrophiles is well 
precedented (Figure 2.10).79-81 For example, as an intermediate in the synthesis of (±)-
quadrone, Burke et al formed cyclopentenone 2.125 via an intramolecular vinylsilane 
addition (Figure 2.10, entry 1).82 Evans et al have also reported an enantioselective 






































entry 2),31 and in a report by Hioki et al, they perform an intramolecular vinylsilane 
addition to a hemiaminal ether using TiCl4 as a Lewis acid catalyst (Scheme 2.10, entry 
3). 
Figure 2.10. Examples of Inter- and Intramolecular Vinylsilane Additions 
 
Several attempts to convert 2.14 to the vinyl adduct were unsuccessful (Table 
2.7). For example, when vinyltrimethylsilane was combined with dienone 2.14 in the 
presence of BF3•OEt2, degradation of starting material to 2.132 and 2.133 was observed 
(Table 2.7, entry 1). The same results were obtained when the vinylsilane reagent was 
used as the solvent for the reaction (Table 2.7, entry 2). When trifluoroacetic acid was 
used in lieu of BF3•OEt2, starting material was recovered due to the Brønsted acid 
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Table 2.7. Attempted Addition of Vinyltrimethylsilane 
 
 The Petasis borono-Mannich reaction is a well-studied multicomponent reaction 
in which an aldehyde, amine, and boronic acid combine to form highly substituted amine 
(Scheme 2.33).83  
Scheme 2.33. General Mechanism for Petasis Borono-Mannich Reaction 
 
We envisioned that a boronic acid or ester might ionize the hemiaminal ether 2.14 
to form the N-tosyliminium ion, which would in turn react with the boronate to form the 
desired adduct. Unfortunately, vinyl boroxine and vinyl potassium trifuoroborate did not 


































































2.8). After these results, it was hypothesized that the boronic esters used (vinyl 
boroxine/pyridine complex and vinyl potassium trifluoroborate) were not Lewis acidic 
enough to ionize the hemiaminal ether.  
Table 2.8. Failed Attempts to Form Alkene Adduct 2.142 
 
There have been numerous reports of reactions of boronic acids with acetals.83 
Although in some cases, additional Lewis acids are required to activate the system to 



















































Figure 2.11. Vinyl Borate Addition to Acetals 
 
When 2.14 was combined with vinyl potassium trifluoroborate and BF3•OEt2, 
none of the desired alkene adduct was obtained (Scheme 2.34). Instead, products 
resulting from dienone-phenol rearrangement were observed. These experiments suggest 
vinyl boronic acid addition is slower that dienone-phenol rearrangement. Given that none 
of the desired product was observed for any of these transformations, we began to pursue 
other strategies for forming C-C bonds. 














































2.3.3.3 Revised Strategy for Addition of Acyl Anion Equivalent 
At this juncture, we then envisioned that the addition of a three carbon crotyl 
group to hemiaminal ether 2.14 could give terminal alkene (2.147), which could be 
converted to ketone 2.112 via successive oxidative cleavages (Scheme 2.35).  
Scheme 2.35. Revised Strategy for Installation of Acyl Anion Equivalent 
 
There are numerous examples in the literature for the addition of an allylsilane to 
an imine or an N-tosyl hemiaminal ether (Figure 2.12).86-91 In a report by Somfai et al, it 
was found that TMS allylsilane added readily and efficiently to hemiaminal ether 2.148 
in the presence of several different Lewis acid catalysts (Figure 2.12, entry 1).86 This 
transformation was later employed by Zhou et al in the synthesis of (+)-
desoxoprosophylline88 and by Haroutounian et al in their approach to the synthesis of 
alkaloid lipids (Figure 2.12, entry 2).87 The bicyclic hemiaminal ether 2.152 was also 
shown to react stereospecifically with TMS allylsilane under strong Lewis acidic 
conditions (Figure 2.12, entry 3). More recently, the oxa-bridged piperidine system 2.154 
was combined with TMS allylsilane in a stereospecific manner to afford highly 
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Figure 2.12. Precedent for Addition of Allyltrimethylsilane to Cyclic N-Tosyl 
Hemiaminal Ether 
 
The synthesis of the crotylsilane began via palladium catalyzed hydrosilation of 
butadiene (2.156) with trichlorosilane to afford (Z)-trichlorocrotyl silane (2.157) in 67% 
yield. Trichlorosilane 2.157 was subsequently converted to (Z)-triethylcrotylsilane 2.158 
in 85% yield on multigram scale by reacting with ethylmagnesium bromide (Scheme 
2.36).92 The (Z)-isomer was chosen because the materials used to make it were readily 
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Scheme 2.36. Synthesis of (Z)-Crotylsilane 2.158 
 
With crotylsilane 2.158 in hand, reaction conditions for addition to hemiaminal 
ether 2.14 were screened. In analogy with the prior art (Figure 2.12), titanium 
tetrachloride, trifluoroacetic acid, and boron trifluoride etherate were evaluated for their 
ability to induce addition of crotylsilane to 2.14 (Table 2.9). Even at reduced 
temperatures (–78 ºC), rapid and complete degradation of the starting material was 
observed when TiCl4 was used as a Lewis acid. The Brønsted acid TFA did afford the 
desired crotyl adduct 2.147, but only as the minor product. The major product 2.159 arose 
from elimination to the N-tosylenamine (Table 2.9, entry 2). The Lewis acid BF3•OEt2 
gave the best results, and although no elimination product was observed, starting material 
was not completely consumed (Table 2.9, entry 3). In fact, the reaction gave rather 
inconsistent results, with yields ranging from 30-89%. We hypothesized that the 
presumptive N-tosyliminium ion was highly destabilized; thus a more polar solvent 
would stabilize the transiently formed N-tosyl iminium ion and accelerate the rate of the 
reaction. In the event, switching the solvent from dichloromethane to acetonitrile 
improved the transformation dramatically. The product distribution for the transformation 
employing TFA switched from 1:4 to 1:1 in favor of crotyl adduct 2.147 (Table 2.9, entry 
4). When BF3•OEt2 was used at room temperature, complete conversion of starting 
material was observed, and 2.147 was isolated in 83% yield (Table 2.9, entry 5). Upon 
further experimentation, we found that reducing the reaction temperature to 0 ºC afforded 














in acetonitrile, temperatures colder than 0 ºC were not explored. Finally, the optimized 
conditions were determined to be two equivalents BF3•OEt2 and two equivalents of 
triethylcrotylsilane 2.158. The reaction proceeded quantitatively on a 100 mg scale and 
gave comparable yields on a gram scale (97%) (Table 2.9, entries 7 and 8). 
Table 2.9. Optimization of Crotylsilane Addition 
 
2.3.3.4 Bis Oxidative Cleavage of Terminal Olefin 
Having developed a methodology that produces large amounts of terminal alkene 
2.147, we examined the to oxidative cleavage of the terminal olefin to give 2.162 under 
Johnson-Lemieux oxidative cleavage conditions. Alkene 2.147 was thus converted to 
aldehyde 2.162 in 62% yield (Table 2.10, entry 1). Reducing the number of equivalents 
of NaIO4 (10 eq to 5 eq) made no significant change to the reaction profile (Table 2.10, 
































































2.147 : 2.159 (1:4)
2.147














1 Reaction run on 100 mg scale
2 Reaction run on 1 gram scale
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dramatically for the conversion of 2.160 to 2.161 by suppressing over-oxidation and 
buffering the pH of the reaction media (Scheme 2.37).93 
Scheme 2.37. 2,6-Lutidine as an Additive for a Johnson-Lemieux Oxidation 
 
Subjecting alkene 2.147 to the modified conditions of Jin et al resulted in a 
significant improvement in yield of 2.162 (Table 2.10, entry 3 and 4).  
Table 2.10. Optimization of Johnson-Lemieux Oxidation 
 
Curiously, during the course of synthesizing appreciable amounts of 2.162, 
varying quantities of phenol 2.164 were isolated from the reaction mixture. We 
hypothesized that this by-product was observed as a result of Johnson-Lemieux oxidation 
of enamine 2.159 to dialdehyde 2.163, which under the aqueous reaction conditions could 





















































it is possible that enamine 2.159 could arise via gamma deprotonation and retro-aldol of 
aldehyde 2.162, resubjecting 2.162 to the reaction conditions resulted in no degradation.  
Scheme 2.38. Rationalization for the Observation of Phenol 2.164 
 
The formation of silyl enol ether 2.165 proved to be a troublesome 
transformation. Initial attempts using TBS-Cl with imidazole as the base provided the 
desired enol ether in 30-50% yields (Table 2.11, entry 1). However, the reaction was 
quite sluggish and required heating to 50 ºC to consume all of the starting material. In 
addition to silyl enol ether 2.165, the crude reaction mixture contained compounds that 
were bearing a phenol group, likely arising from acid catalyzed dienone-phenol 
rearrangment. When the more reactive TBS-OTf was used, the reaction went to 
completion at room temperature and afforded 2.165 in 63% yield (Table 2.11, entry 2). 
Unfortunately, attempts to optimize the reaction further were not successful. The stronger 
base DBU gave no product and caused rapid dimerization of the aldehyde. (Table 2.11, 
entry 3). We hypothesized that the imidazolium triflate formed when imidazole combines 
with TBS-OTf was causing starting material degradation, yet switching to N-
methylimidazole resulted in no improvement in yield (Table 2.11, entry 4). Switching the 
base to 2,6-lutidine resulted in worse yields (30-40%) (Table 2.11, entry 5). Curiously, 
2.166, which arises from the intramolecular Michael addition, was isolated in 10-20% 

















acidity of the conjugate acid of 2,6-lutidine, which would in turn activate the dienone 
moiety to nucleophilic attack. Attempts were also made to form the silyl enol ether under 
strong base condition; however, none of the desired product was observed. Instead, the 
gamma elimination/retroaldol product 2.159 was observed. Although further optimization 
is needed, we decided to investigate the feasibility of subsequent oxidative cleavage steps 
before continuing with these synthetic efforts.  
Table 2.11. Attempts to Optimize the Formation of Silyl Enol Ether 2.165 
 
Johnson-Lemieux oxidation of silyl enol ether 2.165 proceeded readily to ketone 
2.112. Using conditions similar to those used for terminal alkene 2.147, 2.112 was 





































































Scheme 2.39. Johnson-Lemieux Oxidation of Silyl Enol Ether 2.165 
 
2.3.3.5 Attempted Intramolecular Michael Addition to Synthesize spiro-Bicyclononane 
Core 
We had initially hypothesized that the intramolecular conjugate addition would 
proceed readily if the kinetic enolate 2.166 could be formed (Scheme 2.40). To test that 
hypothesis, we screened several bulky strong bases to see if the less substituted enolate 
could be formed quantitatively.  
Scheme 2.40. Proposed Route to Tetracycle 2.111 
 
Unfortunately, all attempts to stoichiometrically form the kinetic enolate failed 
(Scheme 2.41). Instead, elimination of the sulfonamide and isomerization to enamine 
2.167 was observed. Attempts to trap the kinetic enolate via addition of TBS-Cl failed as 





































Scheme 2.41. Attempts to Stoichiometrically Form the Kinetic Enol Ether 
 
It has also been shown that kinetic enolates can form in high yields under general 
base conditions (Scheme 2.42).94 For example, Pecunioso et al demonstrated that ketone 
2.168 could be converted to silyl enol ether 2.169 in high yields using TMS-OTf and 
triethylamine.94  
Scheme 2.42. Alternative Method to Form Kinetic Enolates 
 
Unfortunately, all attempts to form 2.111 under general base conditions were 
unsuccessful. Using the conditions published by Pecunioso et al did not afford any of the 
desired enol ether. Instead, a complex mixture of products was formed that, upon 
quenching with tetrabutylammonium fluoride, funneled to compound 2.170. Quenching 
the reaction at –78 ºC did not effect the product distribution. We then speculated that a 
bulkier base might lead to deprotonation at the less hindered position to form the desired 















KHMDS, THF, –78 ºC
LDA, TBS-Cl, THF, –78 ºC
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Scheme 2.43. Failed Attempts to Form Kinetic Enolate Under General Base Conditions 
 
Given that all attempts to induce intramolecular conjugate addition were 
unsuccessful coupled with the untimely retirement of Phil Magnus (advisor while this 
work was undertaken), these synthetic efforts were abandoned.  
2.4 SUMMARY 
In this investigation into the phenolic C-alkylation of aniline based systems, it 
was found that the readily synthesized scaffold 2.171 forms dienones of the form 2.172 in 
high yields (84-99%) and was tolerant of substitution on both arene rings (Table 2.12). 
Due to the high yields and broad substrate scope, this approach compares very favorably 
to the other methods enumerated in Chapter 1. As of this moment, this strategy is also the 
only published methodology that can synthesize derivatives with a methyl substituent 





















NEt3, TMS-OTf, CH2Cl2 0 ºC → rt 
DTBMP, TMS-OTf, CH2Cl2 0 ºC → rt 
DTBMP, TBS-OTf, CH2Cl2 0 ºC → rt
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Table 2.12. Summary of Results for para-Phenolic C-Alkylation of Aniline Derived 
spiro-Cyclohexyldienones 
  
Studies were also undertaken to synthesize the spiro-bicyclic nonane core of 
aspernomine (2.82) and sespenine (2.83). A sequence was developed in which ketone 
2.112 was synthesized in 8 steps and 34% yield from known materials (Scheme 2.44). 
The key transformation in this sequence is a chemoselective addition of crotylsilane to 
2.14. Efforts to elaborate 2.112 into 2.111 have been unsuccessful, primarily due to the 
inability to form the less substituted enolate or enol ether. Moving forward, future studies 
should be focused towards forming the less substituted enol ether. One may be able to 
preferentially form the desired enolate via pre-installing a halogen alpha to the ketone 
that could be reduced in a Reformansky reaction. Additionally, one may consider 
removing the sulfonamide protecting group and attempting the intramolecular conjugate 






























































































Scheme 2.44. Summary of Synthetic Efforts Towards the spiro-Bicyclic Nonane Core of 



























































































4 eq NaIO4, 2,6-lutidine
5% K2OsO4•2H2O
dioxane : H2O (4:1)
81%
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Chapter 3: Previous Synthesis of Actinophyllic Acid and Previous 
Evaluation of Diverted Intermediates for Anticancer Activity 
Portions of this chapter are reproduced with permission from Knezevic, C. E. 
“Development of Poly(ADP-Ribose) Glycohydrolase Inhibitors and Tetracyclic Indoles 
as Anticancer Compounds.” Ph. D. dissertation, University of Illinois at Urbana-
Champaign, 2013.95 Parkinson, E. I. “Deoxynyboquinones as NQO1-Targeted Anticancer 
Compounds and Deoxynybomycins as Potent and Selective Antibiotics.” Ph.D. 
dissertation, University of Illinois at Urbana-Champaign, 2015.96 
 
3.1 NATURAL PRODUCTS AND THEIR DERIVATIVES AS SOURCES OF NEW 
CHEMOTHERAPEUTICS 
3.1.1 Introduction 
In 2015, the American Cancer Society estimated over 1,650,000 individuals were 
diagnosed with cancer in the United States and nearly 590,000 deaths were attributed to 
the disease. There are an estimated 14.5 million Americans living with a history of cancer 
(either currently or previously diagnosed), and the direct medical costs for treatment and 
care are estimated to be roughly 88.7 billion dollars.97 Although the five year survival rate 
for cancer has risen dramatically from 49% (for years 1975-1977) to 68% (for years 
2004-2010), the disease is far from eradicated, and newer, better treatments are needed.97   
3.1.2 Natural Products as a Source for New Therapeutics 
 Over the last 76 years, natural products have been a source of new and potent 
anti-cancer therapeutics. From 1940 to 2010, 140 anti-cancer agents have been approved 
by the FDA. Of these 140 approved agents, 126 are small molecules, and 67% of the 
small molecules are natural in origin, meaning they are either natural products or are a 
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semi-synthetic analog.98 Indeed, over one third of the anti-cancer agents named to the 
World Health Organization’s list of essential medications required for basic healthcare 
are natural product derived.99 For example, one of the most studied classes of anticancer 
natural products are the taxanes (Figure 3.1, representative examples 3.1 and 3.2). The 
natural product paclitaxel (3.1) and the semi-synthetic taxane docetaxel (3.2) are frontline 
chemotherapeutics and are listed on the WHO List of Essential Medicines.99 
Figure 3.1. The Natural Product Paclitaxel and Derivative Docetaxel 
 
3.1.3 Diverted Total Synthesis as a Strategy for Drug Discovery 
In recent years, the strategy of evaluating analogs of intermediates and their 
analogs encountered during the course of total synthesis has become an effective 
approach to access unique natural product derivatives. Researchers are often more 
interested in natural product analogs than the natural products themselves because the 
analogs may have unique activity,100 higher potency,101 or better pharmacokinetic 
properties.102 The strategy of diverted total synthesis (DTS) was first coined by 
Danishefsky et al during his work on the natural product migrastatin.101 In DTS, 
advanced intermediates are diverted to create unique analogs that would not be otherwise 
accessible through biosynthetic or semi-synthetic means (Figure 3.2). Additionally, the 
analogs synthesized via DTS may provide valuable insight into which structural elements 























Figure 3.2. Graphic Depiction of Diverted Total Synthesis101 
 
In the synthesis of (+)-migrastatin (3.4), Danishefsky et al found that the 
structurally simpler analogs 3.5 and 3.6 were 103 times more potent against 4T1 cell in a 
cellular migration assay (Scheme 3.1).101 Using a DTS approach, advanced intermediate 
3.3 was converted to the more potent derivatives 3.5 and 3.6 in three steps, whereas the 
natural product (+)-migrastatin (3.4) required 14 additional transformations. Since the 
initial publication of the (+)-migrastatin analogs, the pharmacophore was minimized 
further, and these simplified derivatives are under pre-clinical investigation for their 
ability to suppress lung and breast cancer metastases.103 This example demonstrates the 
powerful results a DTS approach can provide. The more potent intermediates 3.5 and 3.6 
would not have be accessible by any other means than laboratory synthesis, be they 
























Scheme 3.1. Synthesis of (+)-Migrastatin and Analogs by Danishefsky et al101 
 
Indeed, the concept of DTS has found application outside of the Danishefsky 
research group. The amphidinolide,104 latrunculin,105 gambierol,106 mycolactone,107 
ainsliatrimer,108 hyperlactone,109 and many other  classes110 of natural products have been 
subjects of DTS studies that have shed insight into what structural motifs lead to 
biological activity. Hence, total synthesis of biologically relevant natural products has 






























3.2 ISOLATION AND PRIOR SYNTHESIS OF ACTINOPHYLLIC ACID 
3.2.1 Isolation and Initial Biological Evaluation of Actinophyllic Acid 
The indole alkaloid actinophyllic acid (3.7) was first isolated by Carroll et al in 
2005 from the aqueous leaf extracts of Alstonia actinophylla, a plant native to 
Queensland, Australia via bioassay-guided fractionation (Figure 3.3).111 The authors 
claimed that the natural product exhibited potent inhibitory activity against 
carboxypeptidase U (CPU) (IC50= 0.84 µM), which is an endogenous inhibitor of 
fibrinolysis.111 The compound was also of interest to the synthetic community because it 
contained a unique hexacyclic indole core. 
Figure 3.3. The Indole Alkaloid Actinophyllic Acid 
 
3.2.1.1 Carboxypeptidase U and Its Role Fibrinolysis 
Fibrinolysis is a biological process in which fibrin is degraded to prevent the 
clogging of blood vessels. Fibrin is a globular protein in the clotting response that 
polymerizes and combines with platelets to repair damaged blood vessels.112 
Biochemically, fibrinolysis occurs when fibrin forms a ternary complex with the proteins 
plasminogen and tissue-type plasminogen activator (tPA).113 Once the complex is formed, 
inactive plasminogen is cleaved to the active serine protease plasmin, which in turn 
degrades fibrin. Carboxypeptidase U does not exist is its active form. Instead, it exists as 
the inactive zymogen pro-CPU that is cleaved to its active form (CPU) by the enzymes 










cleaves the C-terminal arginine and lysine residues of fibrin. The C-terminal arginine and 
lysine residues are necessary for fibrin to form the ternary complex with plasminogen and 
tPA.113 Thus, CPU inhibits fibrinolysis by preventing the formation of the ternary 
complex, resulting in no plasmin formation (Figure 3.4). 
Figure 3.4. Graphical Depiction of Fibrinolysis Signalling Pathways 
 
3.2.1.2 Implications of CPU in Cancer 
In addition to the role CPU plays in fibrinolysis, the protein has been shown to be 
upregulated in the plasma samples of lung cancer patients.116 Specifically, individuals 
with small cell carcinoma of the lung (SCCL) possess plasma levels of CPU greater than 
ten times that of a healthy control.116 The reason for the upregulation of CPU is unknown; 




















it is not known whether the upregulation of CPU is a direct result of translation from the 
cancerous cells or a phenotypic response of the body to the cancer.116 
The plasminogen/plasmin system, which is regulated by CPU, is involved in 
processes that mediate tumor growth, including cell proliferation and angiogenesis.117 
Angiogenesis, the process by which new blood vessels are formed, relies heavily on 
coagulation and fibrinolysis to facilitate the rapid and continuous rearrangement of the 
extracellular matrix (ECM) that is required during cancer proliferation.118,119 Therefore, 
we speculated that CPU would promote the constant remodeling of the ECM that is 
required for angiogenesis and sustained tumor formation. We further speculated that an 
inhibitor of CPU, such as actinophyllic acid (3.7), would inhibit tumor growth and 
prevent tumor metastases. To evaluate this hypothesis, the Martin lab and Hergenrother 
lab at the University of Illinois at Urbana-Champaign collaborated to synthesize and 
evaluate the anticancer properties of actinophyllic acid (3.7). 
3.2.2 Martin Synthesis of Actinophyllic Acid 
Through the efforts of Dr. Brett Granger and Dr. Ivan Jewitt, the Martin lab 
completed the synthesis of (±)-actinophyllic acid (3.7) in 2013.100 Retrosynthetically, the 
Martin lab envisioned that actinophyllic acid (3.7) could arise from deprotection and 
oxidation of pentacycle 3.3, which in turn could be synthesized from tetracycle 3.9 via an 
intramolecular alkylation (Figure 3.2). The key step in this synthesis was a proposed 
formal [4+3] cascade between vinylogous amide enol ether 3.10 and indolo-acetate 3.11 




Scheme 3.2. Retrosynthetic Analysis of (±)-Actinophyllic Acid (3.7)  
 
Before the proposed cascade could be evaluated, the individual components 3.10 
and 3.11 were synthesized (Schemes 3.3, 3.4, and 3.5). The vinylogous amide 3.13 was 
formed in 71% yield from N-vinylpyridone (3.12) via a Norrish type 1 rearrangement. 
Subsequent protection of the amide nitrogen atom as the allyl carbamate followed by silyl 
enol ether formation afforded the π-nucleophile 3.10 in 77% over two steps (Scheme 
3.3).100  
Scheme 3.3. Synthesis of π-Nucleophile 3.10 
 
Ketone 3.17 was synthesized in three steps from glycerol (3.14) by per-
benzylation with benzyl bromide to give compound 3.15 in 63% yield. The protected 
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MeOH
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2. NaHMDS, TIPS-Cl 
    THF, –78 ºC
    77% (2 Steps)
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3.16 in 91% yield. Subsequent Swern oxidation of alcohol 3.16 gave ketone 3.17 in 93% 
yield (Scheme 3.4).100  
Scheme 3.4. Synthesis of Ketone 3.17 
 
The indolo-acetate 3.11 was synthesized from indole (3.18) via a one-pot 
multistep protocol (Scheme 3.5). First, indole (3.18) was deprotonated with n-BuLi to 
give the lithium anion that was then combined with dry CO2 gas to give the lithium 
carboxylate salt. The carboxylate salt then underwent a directed deprotonation at the 2-
postion with tert-BuLi to give dianion 3.19. Dianion 3.19 was then added via cannula to a 
solution of ketone 3.17 to give the corresponding alcohol. Acetic anhydride was then 
added, and the reaction mixture was allowed to warm to room temperature. This one-pot, 
five-step protocol afforded indolo-acetate 3.11 in 85% yield.100  
Scheme 3.5. One Pot Synthesis of Indolo-Acetate 3.11 
 
Having completed the synthesis of compounds 3.10 and 3.11, it was found that, 
after much optimization, the cascade progressed as intended to form tetracycle 3.23 in 
high yield (Scheme 3.6).100 It is believed that the reaction proceeded via ionization of 




































    85%
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nucleophile 3.10 in an SN1 manner to afford N-acyl iminium 3.21. Iminium 3.21 then 
would react in an intramolecular fashion to give compound 3.22, which would rapidly 
deprotonate and rearomatize the indole moiety. The reaction was quenched with 
tetrabutylammonium fluoride at –78 ºC to give ketone 3.23 in 92% yield. It was observed 
that the choice of base was vital to the success of this transformation. If 2,6-lutidine was 
used instead of 2,6-di-tert-butylpyridine, the reaction did not initiate and starting material 
was recovered.120,121 The lack of reactivity was attributed to TMS-OTf forming a Lewis 
acid/Lewis base pair with 2,6-lutidine, thus attenuating its reactivity. Although a step-
wise reaction is shown in Scheme 3.6, there is a distinct possibility the that reaction 
proceeds through a concerted [4+3] reaction pathway, further mechanistic studies would 
be needed to determine which pathway is preferred.  
Scheme 3.6. Successful Formation of the Tetracyclic Core of Actinophyllic Acid 
 
Dr. Brett Granger completed the synthesis of actinophyllic acid in six additional 
steps (Scheme 3.7). Beginning with the tetracycle 3.23, the nitrogen atom was protected 








































Pd2dba3/DPPB and the allyl cation scavenger N,N-dimethylbarbituric acid to afford the 2º 
amine 3.24 in 76% overall yield. Reductive amination of compound 3.24 with 
chloroacetaldehyde and NaBH(OAc)3, followed immediately by intramolecular 
alkylation afforded pentacycle 3.25 in 83% yield. The Boc group of 3.25 was removed 
using hydrochloric acid in methanol then the O-Bn groups were removed in the same pot 
via hydrogenolysis to give primary alcohol 3.26 in 86% yield. Oxidation of 3.26 to the 
natural product 3.7 proved unexpectedly troublesome. A three-step protocol was used in 
which the alcohol was first oxidized to the aldehyde with excess IBX, N-
hydroxysuccinimide was added to form the hydroxysuccinimide ester, and then 
saponification of the ester afforded (±)-actinophyllic acid (3.7) in 31% yield. In 
summary, the natural product (±)-actinophyllic acid (3.7) was prepared in 12 steps and 
7% overall yield from readily available, known compounds.100,122  
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3.3 DISCOVERY OF A LEAD COMPOUND  
Having completed the synthesis of (±)-actinophyllic acid (3.7), we next sought to 
test our hypothesis that actinophyllic acid (3.7) might inhibit cancer cell growth through 
its CPU activity by evaluating the anticancer properties in a cell death assay. Recalling 
the work pioneered by Danishefsky et al on diverted total synthesis (Figure 3.2 and 
Scheme 3.1), we became curious as to whether the less structurally complex 
intermediates, specifically 3.23, displayed any anticancer activity. We were particularly 
interested in compound 3.23, or a derivative thereof, because its unique carbon 
framework was not readily accessible by other means. Additionally, 3.23 could be 
synthesized on multi-gram scale in 40% yield from commercially available materials, 
making the material readily accessible for biological evaluation.  
3.3.1 Discovery of Cytotoxic Properties 
Upon completion of the total synthesis, (±)-actinophyllic acid (3.7) and select 
derivatives prepared by Dr. Brett Granger and Bruce Hua (Figures 3.6 and 3.7) were 
tested by the Hergenrother lab against several cancer cell lines. Initially, each compound 
was screened against the triple-negative breast cancer cell line Hs578t at 100 µM, and the 
viability of the cells was determined using the dye alamar blue. In the presence of healthy 
cells with properly functioning mitochondria, the active ingredient of alamar blue, 
resazurin (3.27), is reduced to the highly florescent blue chromophore resorufin (3.28) 
(Figure 3.5).123 Since florescence is a function of cell viability, the percent cell viability 
can be determined by the relative UV absorption of cells dosed with a compound to a 




Figure 3.5. The Cell Viability Probe Alamar Blue 
 








































































































Figure 3.7. Compounds That Showed Cytotoxicity 
 
The initial experiments, performed by Dr. Claire Knezevic and Dr. Betsy 
Parkinson, indicated that actinophyllic acid (SFM1267, 3.7), actinophyllic acid methyl 
ester (SFM1268, 3.37), and a number of other intermediates were not active against 
cancer cells (Figure 3.6, Figure 3.8); however, multiple compounds derived from the 
tetracyclic cascade product 3.23 were efficacious and demonstrated anticancer activity at 
high concentrations (Figure 3.7, Figure 3.8). The compounds that showed positive results 
in the initial cytotoxicity screen were further evaluated, and their IC50 values were 
determined (Table 3.1). Of the active compounds, it was found that the IC50 values ranged 
from 63.0 to 6.6 µM. The most potent compound, SFM1257 (3.43), was further evaluated 
against a diverse panel of cancer cell lines, and SFM1257 (3.43) was found to exhibit 



























































Figure 3.8. Initial Screen For Cytotoxicity95 
 
Table 3.1. Further Evaluation of Cytotoxic Compounds95,96 
A) B) Cell Line Cancer Cell Type IC50 (µM)* 
 
Compound Hs578t IC50 (µM)*  Hs578t triple-negative breast 6.6 ± 0.7 
 SFM1227 63 ± 16.0  BT549 triple-negative breast 8.0 ± 0.6 
 SFM1239 14.9 ± 4.8  MDA-MB-231 triple-negative breast 3.4 ± 0.02 
 SFM1243 20.4 ± 3.6  4T1 murine breast 6.1 ± 1.5 
 SFM1245 13.2 ± 1.3  T47D ER+ breast 10 ± 2.3 
 SFM1256 12.6 ± 2.5  MCF-7 ER+ breast 4.3 ± 0.4 
 SFM1257 6.6 ± 0.7  U937 lymphoma 3.3 ± 0.2 
 SFM1258 15.5 ± 2.8  HeLa cervical 9.7 
 SFM1269 11.2 ± 1.9  U87 brain 4.8 ± 0.5 
    A549 lung 6.8 ± 1.3 
    MIA-PaCa-2 pancreatic 4.3 ± 0.2 
A) IC50 values for active compounds B) Evaluation of SFM1257 (3.43) against a panel of cell lines. *N= 3, s.e.m. where error is 
indicated. No error implies N= 1. 
3.3.2 Analysis of Dose-Response-Curves  
3.3.2.1 The Importance of IC50, Emax, and Hill Slope 
The ultimate goal during the preclinical assessment of a drug candidate is to find a 
small molecule that will have the highest probability of providing positive clinical 
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remain at the site for a sufficient duration, and not be overly toxic. A major assumption in 
much of academia and pharmaceutical drug development is that a compound possessing 
high potency in cells (low IC50) has a higher likelihood to be efficacious in human 
patients.124 The logic is that high potency implies lower therapeutic doses will be 
required, and lower therapeutic doses will, in turn, lead to less off-target toxicity or 
accumulated deleterious metabolites. Unfortunately, these common assumptions about 
cancer therapeutics are not supported by preclinical and clinical data.124-127 In a retro-
analysis of FDA approved chemotherapy drugs against the NCI-60 panel of cancer cell 
lines, it was determined that high potency (nanomolar IC50 values) bore little relevance to 
clinical efficacy, and most major classes of cytotoxic chemotherapeutics lacked 
nanomolar potency in cells.126 However, there are other metrics determined from a dose-
response curve that may help predict the effectiveness of a compound for the treatment of 
cancer. Specifically, those metrics are the Hill slope (HS) (Figure 3.9, purple line) and 
Emax (Figure 3.9, green line). 
Figure 3.9. Example Dose Response Curve 
 
The HS is defined as the slope of the dose response curve at the point of 
inflection.128 Qualitatively, the HS is a quantification of how quickly a compound 
approaches the maximum response (Emax). In the context of a cell death assay, the 
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theoretical Emax is 100, meaning 100% percent cell death. The percent cell death at a 
given concentration can be determined mathematically from the equation shown in 
Figure 3.10.129 For example, a compound with Emax= 100, IC50= 1 µM, and HS= 1 would 
require a concentration of 19 µM to achieve 95% cell death. If Emax= 100, IC50= 1 µM, 
but HS= 2, a concentration of only ~3.5 µM is needed to achieve 95% cell death. In the 
case of a potential anticancer compound, the desired therapeutic outcome is 100% cancer 
cell death. Therefore, one is lead to conclude that compounds that display larger HS 
values may have a higher probability to show positive therapeutic outcomes. 
Figure 3.10. Equation Used to Calculate Percent Cell Death129 
 
Indeed, studies have shown a positive correlation between clinical efficacy of 
drugs and HS. For BCR-ABL inhibitors used in the treatment of myeloid leukemia, 
Druker et al found that there was a strong correlation between clinical response and HS 
for various cell lines containing point mutations in the BCR-ABL kinase domain.130 
Inhibitors that displayed lower HS values were associated with poorer clinic responses, 
and inhibitors with higher HS values were associated with better clinical outcomes.130 
The authors noted that a mutation that led to a worse IC50 but maintained a high HS could 
be treated clinically by simply increasing the dose. A similar observation was reported by 
Siliciano et al for HIV-targeted retrovirals. The authors noted that genetic mutations in 
the drug target modulated the IC50 and HS of an inhibitor, and if a mutation causes a 
slight change in IC50 but a dramatic change in HS, the efficacy of a drug at concentrations 
= Emax +








above the IC50 is dramatically reduced.131 Thus, chemotherapeutic kinase inhibitors and 
HIV retroviral inhibitors both benefit clinically from steeper Hill slopes. 
In a recent report by Sorger et al, the authors analyzed 64 cancer drugs over 53 
breast cancer cell lines and found that HS values varied by drug class and did not 
correlate to IC50.129 For example, mTOR inhibitors were found to have an average HS of 
0.41, and it was determined that the major driver of the shallow dose-response curve was 
the high degree of cell-to-cell variability within a cellular population that contributes to a 
non-uniform response to the cytotoxins.129 Even at high doses well above the IC50 value, 
wide variations in response to the mTOR inhibitors were observed. This fact is 
particularly troublesome because partial or fractional killing leads to selection bias and 
the development of resistance.129 On the other hand, proteosome and HSP90 (heat shock 
protein 90) inhibitors showed the highest average HS values (~2). Through meta-
analysis, the authors showed that compounds with a similar mode-of-action displayed 
comparable HS values.129 
Since HS strongly correlates with mode-of-action, a HS greater than one could 
imply that a compound impacts a single biological target that in turn modulates multiple 
biological processes or that a compound impacts multiple biological targets 
(polypharmacology). Although polypharmacology is typically associated with non-
specific toxicity, a recent report found that approved drugs have on average six biological 
targets,132 and other reports have found that complex, multigenic diseases like cancer may 
benefit from polypharmacology as an alternative to complex therapeutic approaches.133-135 
Thus, the HS exhibited by a compound in a cell death assay is more accurately viewed as 
an innate characteristic rather than a parameter that is capable of being optimized.  
The Emax is another often overlooked metric that quantifies the percentage of cells 
remaining after the dose-response-curve reaches a plateau. This parameter is key for 
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determining how effective a compound is at killing cells at high concentrations. Sorger et 
al demonstrated that compounds that display a high Emax across several cancer cell lines 
did not develop resistant upon regrowth and retained the same overall levels of sensitivity 
to the cytotoxins.129 As a result, compounds that display a high Emax across multiple cell 
lines have a lower risk of developing resistance. 
3.3.2.2 Actinophyllic Acid Intermediates Show Consistently Steep Hill Slopes and High 
Emax  
Upon screening SFM1257 (3.43), it became evident to Dr. Claire Knezevic and 
Dr. Betsy Parkinson that this novel compound killed cancer cells with uniformly steep 
Hill slopes and Emax either at or approaching the theoretical maximum (100% cell death) 
(Table 3.2).  As compared to the FDA approved frontline anticancer drugs doxorubicin, 
5-flurouracil, and cisplatin, SFM1257 (3.43) showed significantly higher average HS 
values over the cancer cell lines tested (Figure 3.11).96 Additionally, SFM1257 (3.43) 
showed consistently higher average Emax values than all three of the other compounds 
tested (Figure 3.11).96 The IC50 values for the compounds varied rather dramatically; 
doxorubicin was the most potent with low nanomolar values, but the values for SFM1257 
(3.43), 5-fluorouracil, and cisplatin were comparable over the cell lines examined. Given 
that a steep Hill slope and high value for Emax is shown to correlates well with positive 
clinical outcomes and IC50 does not, they decided to continue pursuing investigations into 






Table 3.2. IC50, Hill slope, and Emax Values For SFM1257 Versus FDA Approved 
Anticancer Drugs96 
Figure 3.11. Average Emax and Hill Slope Values of SFM1257, Doxorubicin, 5-
Fluorouracil, and Cisplatin Over All Cell Lines96 
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3.3.3 Actinophyllic Acid Intermediates Induce Rapid Cell Death 
During the course of evaluating SFM1257 (3.43) and other derivatives, Dr. Claire 
Knezevic and Dr. Betsy Parkinson observed that the rate of cell death was very rapid, and 
incubation times past 12 h did not increase the amount of observed cell death.95 Thus, 
they sought to compare the rate of SFM1257 (3.43) induced cell death to that of known 
cytotoxins. The rate of cell death was determined via incubation of U937 lymphoma cell 
with 10 µM cytotoxin (20 µM for thapsigargin) and evaluation of their viability by flow 
cytometry at set time points. They found that SFM1257 (3.43) elicited >95% cell death in 
only six hours. (Figure 3.12).95 The FDA approved anti-cancer agents mitomycin C (3.46) 
(purple line), paclitaxel (3.1) (dark green line), and doxorubicin (3.48) (pink line) as well 
as the catalytic ROS generator DNQ (3.50) (blue line) all killed cancer cells slower than 
SFM1257 (3.43) (light green line).95,136 Interestingly, mitomycin C (3.46), doxorubicin 
(3.48), and DNQ (3.50) elicit cell death via damage to the cellular DNA, indicating that 











Figure 3.12. Relative Rate of SFM1257 (3.43) Induced Cell Death Versus Other Known 
Cytotoxins95 
 
In other experiments, SFM1257 (3.43) was found to work with speeds 
comparable to thapsigargin (3.47), velcade (3.45), staurosporine (3.49), and 1541b (3.51). 
The tool compound thapsigargin (3.46) is a SERCA (sarco/endoplasmic reticulum Ca2+-
ATPase) that induces a build up of cytosolic calcium, which in turn triggers apoptotsis 
and other cell death pathways.137 Velcade (bortezomib) (3.45) is a potent proteosome 
inhibitor FDA approved for the treatment of relapsed multiple myleoma and mantle cell 
lymphoma.138 The indole alkaloid staurosporine (3.49) is a nonspecific pan-kinase 
inhibitor known as the gold-standard for rapid induction of cell death.139 The cytotoxin 
1541b (3.51) is a procaspase-3 activator, which is the final ‘executioner’ caspase in the 
apoptotic signaling pathway.140 These four compounds have little in common with 
regards to mode-of-action or structure, so no real mechanistic insights could be garnered 
from comparing SFM1257 (3.43) to the compounds. 
As shown in Figure 3.12, the rate of cell death induction can vary dramatically 
from one therapeutic agent to another. Although there has not been a report published 
correlating the speed of cell death induction with clinical outcome, there are several 
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reasons to infer that rapid cell death may be a desirable characteristic. The rapid 
induction of cell death may compensate for poor pharmacokinetic characteristics of a 
cytotoxin because a shorter exposure time will be needed to elicit death. Additionally, 
rapid induction of cell death may reduce the probability of a cell developing resistance by 
limiting the amount of time each cell has to adapt to the toxic insult. Thus, eliciting rapid 
cell death may be a beneficial trait of SFM1257 (3.43) induced cell death. 
































































































3.3.4 Hemolysis Assays 
To further assess the translational value of these compounds, the derivatives were 
evaluated for their ability to elicit hemolysis. Drug induced immune-independent 
hemolytic anemia is a form of acute toxicity that will prevent a compound from 
progressing to the clinic. Most often, drug-induced hemolytic anemia occurs when a 
compound interferes with hemoglobin function, typically via oxidation of Fe2+ to Fe3+. 
For example, the antibiotic dapsone, which is used for the treatment of leprosy and other 
skin conditions, causes hemolysis when the compound is oxidized to the N-hydroxy 
moiety that in turn forms methemoglobin and leads to eventual lysis.141 Similarly, the 
antimalarial drug primaquine induces hemolysis via an accumulation of intracellular 
hydrogen peroxide. Indeed, individuals harboring mutations to glucose-6-phosphate 
dehydrogenase (G6PD) are more prone to hemolysis, which is likely due to a significant 
reduction in synthesis of the antioxidant NADPH. Thus, compounds that are easily 
oxidized or create an oxidative cellular environment run the risk of being hemolytic. 
Simple in vitro hemolysis assays were used to assess the potential for these 
compounds to induce immune system independent hemolysis, and in vitro analysis has 
been shown to be a good indicator of in vivo toxicity.142,143 Dr. Claire Knezevic and Dr. 
Besty Parkinson evaluated the hemolytic potential of SFM1257 (3.43) and other active 
derivatives by incubating washed and purified red blood cells with the test compound for 
2 h at 37 ºC. The supernant was then removed, and the absorbance at 540 nm, which 
corresponded to the amount of hemoglobin released, was determined. 
The dose-response curves for hemolysis (red) versus Hs578t toxicity (blue) are 
shown in the graphs in Figure 3.12. Most of the active anticancer compounds did not 
induce significant hemolysis (>10%) until a dose of 100 µM achieved. Unfortunately, the 
most potent compound SFM1257 (3.43) showed significant hemolytic activity at 30 
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µM.95 Fortunately, other derivatives with similar potency showed no hemolytic activity, 
leading one to reach several conclusions: 1) the mechanism of cell death in cancer cells is 
different from the mechanism that causes hemolysis; and 2) the hemolytic activity can be 
attenuated via structure-activity studies.  
Figure 3.14. Dose Response Curve for Hemolysis and Cell Death95 
  
   
  
3.3.5 Preliminary in vivo Analysis 
3.3.5.1 Determination of Maximum Tolerated Dose and Pharmacokinetic Analysis 
 Before the discovery that SFM1257 (3.43) induced hemolysis, preliminary in vivo 
mouse studies were performed by Dr. Hyang Yeon Lee, and it was found that SFM1257 
had a maximum tolerated dose (MTD) of 20 mg/kg for a single intraperitoneal (IP) 
injection with no lasting effects.144 Lethargy and minor weight loss was observed at 20 




























































































































































































































preliminary pharmacokinetic (PK) studies were undertaken. For the PK analysis, three 
C57/BL6 mice were injected (IP) with SFM1257 (3.43) at 20 mg/kg as a PEG 400 
formula, and the plasma concentrations were determined via HPLC. It was found that 
SFM1257 achieved a peak plasma concentration of 1.9 µM with a half-life of 5.8 
hours.144 The preliminary MTD analysis was promising because it demonstrated that 
SFM1257 (3.43) was not overtly toxic. Additionally, the preliminary PK study showed 
that the compound is stable in a living system. 
Figure 3.15. Pharmacokinetic Analysis of SFM1257 (3.43)144 
 
*N= 3, error bars represent standard error of mean (S.E.M.) 
Despite these promising results, in vivo work with SFM1257 (3.43) was halted 
due to concerns about its hemolytic properties. As a result, the focus of further animal 
studies was shifted to SFM1258 (3.44) because it did not elicit hemolysis at high 
concentrations and was comparable in activity to SFM1257 (3.43). The MTD analysis 
performed for SFM1257 (3.43) was repeated for SFM1258 (3.44), and Dr. Hyang Yeon 
Lee determined that SFM1258 (3.44) was better tolerated than SFM1257 (3.43), with a 























1 0.75 ± 0.34 
2 1.23 ± 0.12 
3 1.92 ± 0.26 
4 1.57 ± 0.48 
6 0.91 ± 0.1 
12 0.81 ± 0.06 
18 0.54 ± 0.17 
24 0.1 ± 0.07 
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lethargy, but the mice had recovered completely within 48 hours post treatment.96,144 No 
PK analysis was performed for SFM1258 (3.44). 
3.3.5.2 Evaluation in Mouse Model for Breast Cancer 
After determining that SFM1258 (3.44) was decently tolerated in mice and not 
overtly toxic, we sought to evaluate whether the compound had in vivo efficacy in a 
mouse model for breast cancer. The 4T1 syngeneic mouse model was used to evaluate 
the in vivo efficacy of the compound, and SFM1258 (3.44) was determined to be active 
against this particularly cell line (IC50= 10 ± 3.1 µM; Emax= 99.7 ± 0.5; HS = 4.0 ± 0.9). 
The 4T1 breast cancer model mimics very aggressive, highly metastatic breast 
cancer and correlates well to naturally occurring cancers. For starters, the tumor model is 
orthotopic and not a xenograph. Namely, the tumor is grown in the anatomically correct 
place, and the mouse has an intact immune system.145 Additionally, the 4T1 model 
develops metastases spontaneously from the primary tumor and spreads to the draining 
lymph nodes and other organs in a manner similar to that of human breast cancer.145 
The experiment was set up as follows: Ten eight-week-old female Balb/c mice 
were injected with 106 4T1 murine breast cancer cells, and the mice were injected on days 
7, 9, and 11 post inoculation (Figure 3.16) with SFM1258 (3.44) at 60 mg/kg IP in PEG-
400 or an equal volume of PEG-400 (vehicle). The tumor volume and mouse weight was 
recorded every 2-3 days, and on day 19, the mice were sacrificed and the tumors excised 
(Figure 3.16).96,144 
Upon completion of the study, average tumor volumes and masses of mice treated 
with SFM1258 (3.44) were significantly reduced over those of the control group (Figure 
3.16A and B), and an image of an excised tumor relative to the control is pictured in 
Figure 3.16D.96,144 Additionally, no overt toxicity was observed during the course of the 
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experiment, and although the mice did lose weight upon initial treatment of SFM1258 
(3.44), they were fully recovered by the end of the experiment (Figure 3.16C). This 
exciting data showed that the SFM1258 (3.44) was efficacious in a very challenging 
mouse model for breast cancer, further validating the translational potential for these 
compounds. 




A) Tumor volume of SFM1258 treated mice vs vehicle B) Average tumor weight of SFM1258 and vehicle treated mice 
after excision C) Average weight of SFM1258 and vehicle treated mice during course of experiment D) Image of 
excised tumors treated with vehicle (left) and SFM1258 (right) 
3.4 INVESTIGATION INTO MODE-OF-ACTION 
While efforts were underway to evaluate the translational potential of SFM1257 
(3.43) and SFM1258 (3.44), concurrent studies were being performed by Dr. Claire 
Knezevic to determine the mode-of-action for these compounds and identify their 
biological targets. Identifying the biological target will help guide structure-activity 





3.4.1 Cell Cycle Arrest Assays 
A cell cycle arrest analysis is a common experiment than can help elucidate the 
mode-of-action of a cytotoxin. For example, the FDA-approved chemotherapeutic 
paclitaxel (3.1) stabilizes microtubules and prevents chromosomse from achieving 
metaphase spindle configuration, subsequently blocking the progression of mitosis. 146,147 
As a result, cells dosed with paclitaxel or a different microtubule stabilizing reagent will 
overwhelmingly display G2/M cell cycle arrest.147 Similarly, the topoisomerase inhibitor 
topotecan arrests progression through the cell cycle and demonstrates G2/M cell arrest by 
causing replication fork collisions in dividing cells.148 Other toxins, such as the 
proteosome inhibitor bortezomib (velcade) or the nucleoside analog gemcitabine, induce 
cell death independent of the cell cycle phase.149 Due to the extended times required to 
induce cell death (days) and their relatively short half-lives in vivo (hours), drugs that rely 
heavily on the phase of the cell cycle often induce fractional killing.150 As a result, it has 
been shown that topotecan is more effective in treating ovarian cancer when delivered in 
smaller, more frequent doses than short exposure to high doses.151 Hence, knowledge 
pertaining to the cell cycle dependence of a drug is clinically relevant. Compounds that 
are associated with DNA damage, such as cis-platin, often show a preference for G1 
phase cell death.152 The tumor suppressor protein p53 is activated upon detection of DNA 
damage and regulates the G1/S cell cycle checkpoint.153 Thus, if a compound shows a 







Figure 3.17. The Cell Cycle and its Checkpoints154 
 
The cell cycle arrest analysis of SFM1257 (3.43) induced cell death proceeded as 
follows: Dr. Claire Knezevic synchronized U937 cells in the M phase using the non-toxic 
microtubule polymerization inhibitor nocodazole (3.52) (Figure 3.18).155 Once the cells 
were synchronized, they were pelleted and washed to remove the nocodazole. The cells 
were then dosed with 4 µM SFM1257 (3.43), and aliquots were removed and analyzed by 
flow cytometry. The phase of the cell cycle was determined by staining with propidium 
iodide (PI). PI is a DNA dye that fluoresces brightly when bound to DNA,156 and the 
phase of the cell cycle is determined by the relative amount of PI fluorescence for each 
cell. If the relative fluorescence is equal to one, then the cell is in the G1 phase, a 
fluorescence of two implies the G2/M phase, and an intermediate amount of fluorescence 
implies the S phase. It was found that SFM1257 (3.43) overwhelmingly elicited arrest of 
the cell cycle in the G1 phase (Figure 3.19).95 This indicates that SFM1257 (3.43) likely 
does not act through the stabilization or destabilization of microtubules or inhibition of 
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topoisomerase, as this would trigger G2/M arrest. It indicates that the mode-of-action 
may be p53 dependent, but further investigation is required to validate that assertion.  
Figure 3.18. The Structure of Nocodazole (3.52) 
 
Figure 3.19. Cell Cycle Analysis of SFM1257 (3.43) Induced Cytotoxicity95,120 
 
3.4.2 Annexin V and Propidium Iodide Staining  
Apoptosis is an extensively studied form of programmed cell death that has well 
defined and well characterized biochemical pathways.157-159 Although apoptosis occurs 
naturally as a way of discarding and recycling old or damaged cells, external insults like 
radiation, heat, or a small molecule can trigger apoptosis.158 An early indicator of 
apoptosis is the presence of phosphatidylserine (PTS) on the outer cell membrane. PTS is 
normally located on the inward-facing side of the cell membrane and inverts once the 
apoptotic mechanisms are triggered.158 Once activated, PTS serves as a marker for 
phagocytic recognition so that apoptotic cells can be recognized and recycled by the 
immune system.158 The fluorophore conjugated PTS antibody Annexin V-FITC is used to 


























































conjunction with the DNA dye propidium iodide (PI).156 In the context of flow cytometry, 
PI determines whether a cell is viable because PI cannot penetrate the cell membrane; 
thus if the wavelength for PI fluorescence is observed, the outer membrane of a cell has 
been compromised, and the cell is no longer viable.156 When Annexin-V and PI are used 
in unison, a cell that is postive for Annexin-V but negative for PI is in the early stages of 
apoptosis. If a cell is positive for PI and Annexin-V, the cell is no longer viable and may 
or may not have undergone apoptosis. 
To evaluate whether SFM1257 (3.43) elicits apoptotic cell death, U937 
lymphoma cells were incubated with 4 µM SFM1257 (3.43) for 16 hours, and the cells 
were evaluated by PI/Annexin V staining using flow cytometry.95 It was found that a 
small percentage of the cells (~15%) were in the classical apoptotic quadrant (PI 
negative/Annexin V positive; lower right corner Figure 3.20). 95 This result indicates that 
at least some of the cells underwent classical apoptosis. However, this result alone is not 
enough to unambiguously determine that apoptosis is the major driver of cell death; other 
experiments must be run to further validate this finding. 
Figure 3.20. Dot Plots for PI/Annexin V-FITC Staining 
 

















3.4.3 Small Molecule Inhibitors 
One way to probe the mechanism of action of a cytotoxic agent is to determine 
which proteins are necessary for its function. There is a litany of small molecule probes 
with well-defined and well-characterized biological targets that can be used to block 
specific cell signaling pathways. Thus, if a small molecule inhibitor reduces or prevents 
the toxicity attributed to a cytotoxin, it can be inferred that the pathway blocked by the 
inhibitor is involved in the mode-of-action of the cytotoxin. 
3.4.3.1 Small Molecule Inhibitors of Apoptosis 
Given that the preliminary flow cytometry experiments indicated that SFM1257 
(3.43) was causing apoptosis, Dr. Claire Knezevic screened numerous small molecule 
inhibitors of apoptosis (Figure 3.21, 3.53-63) to further evaluate that observation. A 
graphical depiction of the various apoptotic signal transduction pathways and known 
small molecule inhibitors of those pathways are shown in Figure 3.22. The general 
procedure for evaluating effect of tool compounds on SFM1257 (3.43) toxicity was to 
preincubate U937 cells with the tool compound for two hours, then add SFM1257 (3.43) 
as a DMSO solution so that the final concentration was 9 µM. After three hours of 
incubation with SFM1257 (3.43), the cellular viability was assessed via flow cytometry.95  































Figure 3.21., cont. 
 

















































































Initially, the pan-caspase inhibitor Q-VD-OPh (3.55) was used, and no 
cytoprotection was observed (Figure 3.23).95 Q-VD-OPh inhibits caspase 9/3, caspase 
8/10, and caspase 12;160 thus, Dr. Knezevic concluded that SFM1257 (3.43) does not rely 
exclusively on caspase activation to elicit cell death. Given that apoptosis can occur in 
both caspase-dependent and caspase-independent pathways, other apoptotic pathways 
were examined. 
The compounds antimycin A (3.57), rotenone (3.58), and FCCP (3.59) are 
chemical probes that disrupt ATP synthesis by interfering with oxidative 
phosphorylation; since ATP is required for apoptosis, blocking ATP production should 
prevent apoptosis.161,162 No protection was observed for rotenone (3.58) and FCCP (3.59), 
yet modest cytoprotection was seen with antimycin A (3.57) (Figure 3.23).95 Since 
antimycin A (3.57) was in disagreement with the rotenone (3.58) and FCCP (3.59), Dr. 
Knezevic concluded that the observed cytoprotection by antimycin A was likely 
attributed to something other than the decoupling of oxidative phosphorylation. 
Variations in cytosolic calcium levels effect mitochondrial function, and the 
regulation of mitochondrial calcium levels is key to preserving proper cellular function. 
When there is a build up of cytosolic calcium, the mitochondrial permeability transition 
pore (MPTP) is activated, and pro-apoptotic proteins, such as cytochrome C, are 
released.163 The ruthenium complex Ru360 (3.60) blocks the MPTP, affording 
cytoprotection.163 Since Dr. Knezevic observed no cytoprotection, it is likely that 
cytosolic calcium build up is not causing cell death (Figure 3.23).95 
The pifithrins are used to evaluate the role of p53 signalling in cell death. The 
transcription factor p53 is often referred to as the ‘tumor suppressor protein’ because it is 
capable of identifying DNA damage and triggering apoptosis.164,165 The compound 
pifithrin-α (3.61) blocks p53 from transcribing pro-apoptotic genes, and pifithrin-µ (3.63) 
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blocks pro-apoptotic signaling caused when p53 binds to the mitochondria and the 
mitochondrial proteins Bcl-xL and Bcl-2.164,166 Since no protection was observed with 
either compound, Dr. Knezevic concluded that p53 did not play a role in SFM1257 (3.43) 
induced cell death (Figure 3.23).95 
The compound BI-6C9 (3.53) inhibits the cleavage of the pro-apoptotic enzyme 
Bid by caspase 8 (Figure 3.22).167 The cleaved fragment of Bid, tBid, localizes to the 
mitochondria and causes the oligomerization of Bax and Bak, which in turn permiablizes 
the mitochondrial membrane to allow for release of the proapoptotic protein cytochrome 
C.167 The compounds iMAC-1 (3.54) and VPMLK (3.62) work to prevent Bax and Bak 
mediated release of cytochrome C.168,169 Since Dr. Knezevic observed no protection with 
any of the three compounds, it was concluded that Bid, Bax, or Bak do not play a key 
role in SFM1257 (3.43) mediated cell death (Figure 3.23).95 
In caspase-dependent apoptosis, cytochrome C is released from the mitochondria 
and combines with apaf-1 (apoptotic protease activating factor 1) to form a 700 kDa 
heptamer complex called the apoptosome, which in turn activates procaspase-9 and 
procaspase-3.170 The tool compound NS3694 (3.55) inhibits the formation of the 
apoptosome and prevents the activation of procaspase-9.171 Oddly, Dr. Knezevic found 
that NS3694 (3.55) afforded robust cytoprotection, implying that apoptosome formation 
is necessary for SFM1257 (3.43) induced cytotoxicity, but caspase activation and 
cytochrome C release is not.95 Given the inconsistent nature of these results, Dr. Knezevic 
hypothesized that NS3694 is preventing SFM1257 (3.43) toxicity through a manner other 





Figure 3.23. Tool Compounds Used to Block Apoptosis95 
 
3.4.3.2 Necrosis and Other inhibitors 
The lack of robust and consistent cytoprotection by apoptosis inhibitors led Dr. 
Knezevic to conclude that cell death caused by SFM1257 (3.43) is not exclusively 
apoptotic. To elucidate what other pathways may be involved, small molecule inhibitors 
of necrosis and other forms of cell death were investigated (Figure 3.24, 3.64-69). 

























































Necrosis is a form of non-programmed inflammatory cell death that is 
characterized by the rupturing of the cell membrane and the spilling of the cytosolic 
components into the extracellular space; it is typically a result of external factors such as 
infection, toxins, or trauma.157 Similarly, necroptosis is a form of cell death that is 
characterized by necrotic morphologies, yet it is activated through a well-defined 
nonapoptotic pathway.172 The kinase inhibitors necrostatin-1 (3.65) and SP600125 (3.66) 
target key signaling pathways involved in necroptosis; Necrostatin-1 (3.65) inhibits RIP 
Kinase (RIPK)172 and SP600125 (3.66) inhibits c-Jun N-terminal kinases (JNK).173 
Unfortunately, Dr. Knezevic observed that neither compound afforded significant 
protection from SFM1257 (3.43) induced cell death (Figure 3.25).95 
The calpains are a class of calcium-activated proteases that have roles in both 
apoptosis and necrosis; overactivity of the calpains is tied to neurological disorders and 
Alzheimer’s disease.174 The calpain inhibitor calpeptin (3.64)175 afforded no 
cytoprotection, meaning SFM1257 (3.43) toxicity is not coupled to calpain activity 
(Figure 3.25).95  
Excitotoxicity is a form of cell death caused by hyperactivity of the NMDA 
receptor, which leads to a massive influx of extracellular Ca2+.176 The NMDA antagonist 
MK-801,177 which blocks the extracellular Ca2+ influx associated with excitotoxicity and 
other neurological disorders, provided no cytoprotection from SFM1257 (3.43) induced 
cell death (Figure 3.25),95 indicating that extracellular calcium influx through the NMDA 
receptor is not a cause of cell death.  
Disruption of normal mitochondrial function can lead to an accumulation of 
reactive oxygen species (ROS), which in turn can cause DNA damage and PARP-1 
induced cell death, parthanatos.178 Dr. Knezevic evaluated the ROS scavenger N-acetyl 
cysteine (NAC)179 for its ability to mitigate SFM1257 (3.43) induced cytotoxicity, and 
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modest protection was observed (Figure 3.25).95 This implies that ROS generation may 
play a role in SFM1257 (3.43) toxicity, but ROS generation is only a minor driver of 
SFM1257 (3.43) induced cell death. 
The inositol triphosphate receptor (IP3R) is an endoplasmic reticulum membrane-
bound protein that regulates intracellular Ca2+ homeostasis, and consequences of IP3R 
dysregulation are tied to necrotic and apoptotic cell death.180,181 The antibiotic neomycin 
(3.69) binds to and sequesters inositol triphosphate (IP3), which is a native ligand for 
IP3R. If agonism of IP3R is causing SFM1257 (3.43) induced cell death, neomycin (3.69) 
should mitigate that effect.182 Dr. Knezevic found that neomycin (3.69) decreased 
sensitivity of U937 cells to SFM1257 (3.43), affording roughly 50% cytoprotection 
(Figure 3.25).95 Since dysregulation of IP3R is associated with endoplasmic reticulum 
(ER) stress, Dr. Knezevic determined that small molecule inhibitors of ER stress related 
pathways should be investigated next. 
Figure 3.25. Tool Compounds Used to Block Non-Apoptotic Cell Death95 
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3.4.3.3 Endoplasmic Reticulum Stress Inhibitors 
The unfolded protein response is a biochemical process used to mitigate cellular 
stress resulting from the accumulation of misfolded proteins in the endoplasmic reticulum 
(ER). ER stress can be caused by a number of diseases and pathologies, including 
cancer,183,184 viral infection,185 Alzheimer’s disease,186,187 and other neurological 
disorders.188 As a result, the biochemical constituents that control the UPR have become 
targets of interest for numerous drug discovery campaigns.189 
The UPR initiates when misfolded proteins accumulate in the ER and cause 
binding immunoglobulin protein (BiP) to dissociate from the luminal side of the 
transmembrane proteins inositol-requiring enzyme 1 alpha (IRE1α), protein kinase RNA-
like endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6) 
(Figure 3.26).190 Upon dissociation of BiP, PERK and IRE1α homodimerize and 
autophosphorylate, leading to downstream signaling of pro-survival processes, and ATF6 
translocates and serves as a transcription factor for pro-cell survival proteins.190 There is a 
delicate balance between the initial pro-survival signaling and eventual pro-death 
signaling of PERK, IRE1α, and ATF6; sustained activation of the UPR eventually leads 
to the transcription of pro-apoptotic proteins.190 To investigate the role of ER stress in 
SFM1257 (3.43) induced toxicity, Dr. Knezevic screened several small molecule 
inhibitors (Figure 3.27, 3.70-76) of ER stress related pathways. A diagram summarizing 
the signaling pathways involved in the UPR and their small molecule inhibitors is shown 





Figure 3.26. The Unfolded Protein Response Signaling Pathway and Its Small Molecule 
Inhibitors95  
 
































































One of the pro-survival mechanisms of IRE1α is its endonuclease activity, which 
works in parallel to its kinase activity.190 The chemical probe SF083010 (3.70) blocks the 
activation of X-box binding protein 1 (XBP1) mRNA by IRE1α, which in turn prevents 
the transcription of pro-survival proteins.191 It was found that SF083010 (3.70) enhanced 
SFM1257 (3.43) toxicity, indicating ER stress may play a role in the mode-of-action of 
SFM1257 (3.43) (Figure 3.28).95 
The small molecule GSK2606414 (3.71) is an inhibitor of PERK, and since 
prolonged activation of PERK leads to pro-apoptotic signaling, inhibition of PERK may 
impart cytoprotection in cell experiencing ER stress.192 the PERK inhibitor GSK2606414 
(3.71) afforded no cytoprotection against (Figure 3.28), implying PERK signaling is not 
necessary for SFM1257 (3.43) induced cell death.95 
ER stress can be a result of the accumulation of misfolded proteins; the small 
molecules TUDCA (3.73) and cycloheximide (3.72) are known to mitigate that insult. 
TUDCA (3.73) upregulates chaperone proteins that assist with folding and cycloheximide 
(3.72) inhibits protein translation.193,194 Dr. Knezevic observed that neither compound 
afforded cytoprotection (Figure 3.28), implying SFM1257 (3.43) does not cause a build 
up of misfolded proteins.95 
Since neomycin afforded cytoprotection, the role of calcium efflux was 
investigated further. The ryanodine receptor works in conjunction with the IP3R receptor 
to regulate cytosolic Ca2+ levels.195 The ryanodine receptor inhibitor dantrolene (3.75)196 
afforded no cytoprotection, implying calcium efflux through the ryanodine reception does 
not play a role in SFM1257 (3.43) toxicity (Figure 3.28).95 
The ER is also responsible for the synthesis of cholesterol, and interference with 
cholesterol synthesis can lead to ER stress.197 However, supplementing cholesterol 
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synthesis with mevalonolactone (3.76)197 afforded only slight cytoprotection (Figure 
3.28), indicating SFM1257 (3.43) is likely not due to inhibition of cholesterol synthesis.95 
The compound salubrinal (3.74) is an inhibitor of both the ER stress-induced 
holoenzyme protein phosphatase 1/growth arrest and DNA damage-inducible protein 34 
(PP1/GADD34) as well as the constitutively active holoenzyme phosphatase protein 
phosphatase 1/constitutive repressor of eIF2α phosphorylation (PP1/CreP).189,198 Dr. 
Knezevic found that salubrinal (3.74) provided robust protection against SFM1257 (3.43) 
toxicity (Figure 3.28), providing strong evidence that ER stress is one key driver of 
SFM1257 (3.43) cytotoxicity.95  
Figure 3.28. Tool Compounds Used to Mitigate Endoplasmic Reticulum Stress95 
 
The cytoprotective properties of salubrinal (3.74) are well documented; it has 
been demonstrated to mitigate the effects of ER stress caused by tunicamycin,198 
rotenone,199 and kainic acid200 but not thapsigargin.201 When the UPR is activated, PERK 
phosphorylates eukaryotic translation initiation factor 2 alpha (eIF2α), which in turn 
works to reduce the stress applied to the ER by halting met-tRNA initiated protein 
translation and upregulating translation of activating transcription factor 4 (ATF4) 
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(Figure 3.29).189 ATF4 is a transcription factor for GADD34, and the phosphatases 
PP1/CreP and PP1/GADD34 dephosphorylate p-eIF2α to return translation to normal 
levels; thus, GADD34 serves in a negative feedback loop.189 Salubrinal (3.74) inhibits 
both phosphatases and thus reduces ER stress by maintaining low levels of protein 
translation. Additionally, the decrease in global translation is accompanied by an increase 
in chaperone proteins that aid in protein folding.189 Thus, salubrinal (3.74) decreases the 
protein load applied to the ER and increases the folding capacity of the ER to counteract 
ER stress. Therefore, it is likely that SFM1257 (3.43) is causing toxic levels of ER stress 
that are capable of being mitigated through innate cellular processes.  
Figure 3.29. Schematic Representation of PERK Signalling189  
 
Copyright Nature Publishing Group, reproduced with permission 
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3.4.4 Western Blot Analysis for ER Stress Markers 
After discovering that salubrinal (3.74) provided robust cytoprotection from 
SFM1257 (3.43) induced cytotoxicity, ER stress was assigned as the mode-of-action for 
SFM1257 (3.43). To further validate this hypothesis, specific biochemical markers were 
analyzed and quantified. Since the unfolded protein response activates PERK and IRE1 
simultaneously, one would expect to see increased levels of p-eIF2α and p-IRE1 (Figure 
3.30). As expected, SFM1257 (3.43) caused an immediate and dramatic increase in the 
levels of p-eIF2α, yet little to no change was observed in p-IRE1 levels (Figure 3.30).95,96 
This would imply that PERK was activated in the absence of IRE1, which would be 
unlikely unless SFM1257 (3.43) was activating PERK directly. Given that the PERK 
inhibitor GSK2606414 (3.71) provided no cytoprotection (Figure 3.28), that hypothesis is 
unlikely. Additionally, one would expect the levels of p-eIF2α to be roughly equivalent 
with or without the addition of salubrinal (3.74). In fact, cells treated with salubrinal 
(3.74) typically see a slight increase in p-eIF2α levels because salubrinal (3.74) inhibits 
the phosphatases that reduce p-eIF2α levels.198 Instead, it was observed that salubrinal 
(3.74) prevented the phosphorylation of eIF2α. This observation has several potential 
implications: 1) though highly unlikely, salubrinal (3.74) may be reacting irreversibly 
with SFM1257 (3.43); 2) salubrinal (3.74) may prevent cellular uptake of SFM1257 
(3.43); and/or 3) salubrinal (3.74) may out compete SFM1257 (3.43) for the same target, 
implying SFM1257 (3.43) triggers ER stress by directly inhibiting eIF2α phosphatases 
PP1/GADD34 and PP1/CreP. Thus, additional small molecule inhibitors of eIF2α 
phosphatases need to be evaluated in order to verify that the observed protection with 




Figure 3.30. Western Blot Analysis of eIF2α and IRE1 Levels96 
 
3.4.5 Transcript Profiling and Connectivity Map Analysis 
To help shed further insight into the mode-of-action of SFM1257 (3.43), 
transcript profiling was performed to analyze how the transcriptome responds to 
SMF1257 (3.43). To describe simplistically, transcript profiling involves isolating the 
mRNA from a cell, using high-throughput microarray technology to determine the level 
of each transcript, and analyzing the levels of each transcript relative to a control.202  
3.4.5.1 Initial Results and Preliminary Analysis 
The transcript profiles of U937 cells incubated with SFM1257 (3.43), DMSO, and 
an unrelated cytotoxin were obtained. The collected data were converted to the heat map 
shown in Figure 3.31, and it was found that the transcript profile of SFM1257 (3.43) 
treated cells that differed from the DMSO controls.95 Additionally, the SFM1257 (3.43) 
transcript profile also differed from an unrelated cytotoxin, which is to be expected due 




Figure 3.31. Heat Map Analysis of Transcript Levels95 
 
The list of up- and down-regulated genes are listed in Table 3.3. The most up-
regulated gene was IFIT-2 (interferon-induced protein with tetracopeptide repeats 2), and 
IFIT-2 has been shown to promote apoptosis when it forms complexes with IFIT-1 and 
IFIT-3.203 Since IFIT-1 and IFIT-3 were upregulated as well, it is possible that the 
cyctotoxity of SFM1257 (3.43) is tied to these genes. The IFIT genes are involved in a 
number of cellular processes designed to fight viral infections, and coincidentally, ER 
stress plays a key role in stopping viral infections by preventing the synthesis of viral 
proteins.185,204 Therefore, SFM1257 (3.43) may induce ER stress in a manner that mimics 
a viral infection. The gene CCNG2 was enriched as well, which is interesting because 
CCNG2 codes for cylin G2, and cyclin G2 is known to cause G1 arrest, which is in 
agreement with cell cycle arrest studies (Figure 3.19).205 Additionally, there are 
automated analysis methods that are capable of comparing the transcript profile of a 
given compound a database of literature compounds that have known modes-of-action.206 











cytotoxin, it is likely they share a similar mode-of-action. One such analysis method is 
the Connectivity Map database developed by the Broad Institute. 
Table 3.3. Genes Significantly Up- and Down-regulated by SFM1257 (3.43)95  
Gene Name Fold Change Gene Name 
Fold 
Change 
IFIT2 11.17 TPGS1 -2.68 
CYP51A1 5.84 RRP9 -2.69 
RNA28S5 5.30 ZMAT5 -2.70 
CCNG2 4.75 LTBP3 -2.71 
PLEKHF2 4.54 LPHN1 -2.73 
RANGRF 4.54 MCAT -2.74 
SLC26A11 4.21 GAMT -2.75 
MSMO1 4.21 TMEM161A -2.77 
SLC38A2 3.91 ECE2 -2.79 
KRBA1 3.87 DESI1 -2.81 
LY96 3.87 PRAM1 -2.92 
CTH 3.81 ATP5D -3.02 
STAT2 3.65 LOC150223 -3.03 
TMUB2 3.61 HYAL2 -3.10 
TSC22D3 3.60 ZMAT5 -3.15 
INSIG1 3.55 BIK -3.23 
TXNIP 3.55 UNC93B1 -3.30 
ALB 3.53 CERCAM -3.30 
HMGCS1 3.49 TPSAB1 -3.50 
FAM214A 3.45 NFKBIB -3.50 
CLIC4 3.36 ADRM1 -3.51 
FAM27E3 3.35 TPSAB1 -3.57 
IFIT3 3.27 FAM108A1 -3.67 
IFIT1 3.25 FAM101B -3.71 
ASNS 3.14 AZU1 -3.76 
C4orf34 3.11 LRRC33 -3.83 
FAM214A 3.02 CCDC86 -4.08 
RGS12 3.02 SPI1 -4.35 
BCL2A1 3.00 NCF1 -4.36 
HAVCR2 2.98 PRTN3 -4.53 
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3.4.5.2 Connectivity Map Analysis 
The Broad Institute developed the Connectivity Map database (CMAP) to allow 
for the easy comparison of the transcript profiles for over 10,000 known compounds.206 
The use of the Connectivity Map to uncover the mode-of-action for a compound has been 
well documented and reviewed.202 Inputting the data obtained from the transcript 
profiling experiment to CMAP uncovered a number of compounds (Figure 3.32, 3.77-93) 
with high similarity; however, none of compounds identified would be described as 
anticancer agents. Instead, the majority of the matches are in use as antihistamines, 
antipsychotics, or antibiotics (Table 3.4).95 
The majority of the compounds identified can cause an imbalance in cytosolic 
Ca2+ level, thus indicating SFM1257 (3.43) may trigger an imbalance in Ca2+ levels. 
Since ER stress is often associated with changes in cytosolic Ca2+levels, it is not 
surprising the Ca2+ channel blockers tetrandine (3.84)207 and prenylamine (3.87)208 
showed high similarity to SFM1257 (3.43). Tetrandine (3.84) has also been shown to 
block autophagic flux and trigger apoptosis in cancer cells through lysosomal 
deacidification.209 The anti-diarrhea drug loperamide (3.86) is a µ-receptor agonist that 
has also been shown to act as a Ca2+ channel blocker.210 Dopamine receptors have also 
been shown to regulate intercellular calcium levels in neurons,211 so the similarity to the 
dopamine antagonists thioridazine (3.83), trifluoperazine (3.88), fluspirilene (3.89), 
prochlorperazine (3.90), and desipramine (3.92) is understandable.212 ER stress is also 
associated with the arrest of protein translation, so the high similarity to translation 
inhibiting aminonucleotide puromycin (3.81) is not unexpected.213 The heat shock protein 
90 (Hsp90) inhibitor geldanamycin (3.93) has been also shown to induce ER stress as 
well as hemolysis,214 which are both characteristics of the cellular response to SFM1257 
(3.43). 
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The highest similarity match was the antihistamine terfinadine (3.77), which is 
not longer used clinically due to concerns over cardiotoxicity.215 Like SFM1257 (3.43), 
terfinadine elicits G1 phase cell cycle arrest and apoptotic cell death.216 Additionally, it 
has also been shown that the anticancer effects of terfinadine (3.77) are not due to its 
antihistamine properties, but rather a result of large increases in cytosolic calcium 
levels.217 As a result, the CMAP analysis appears to indicate that Ca2+ regulation is key 



















Table 3.4. Compound Identified by Connectivity Map Analysis95 
Perturbagen Mean Score Clinical Use(s) Target (molecule/pathway) 
Terfenadine 
(3.77) 0.808 antihistamine, cardiotoxic histamine H1 receptor and HERG antagonist 
Mefloquine 
(3.78) 0.77 antimalarial 
heme polymerase inhibitor, analogous to 
chloroquine 
Benzethonium 
Chloride (3.79) 0.77 





(3.81) 0.749 antibiotic translation inhibitor, aminonucleoside  
MG-262 
(3.80) 0.702 Lon protease inhibitor selective and reversible inhibitor of proteosome 
Astemizole 
(3.81) 0.697 antihistamine 
histamine H1 receptor antagonist, similar to 
terfenadine 
Thioridazine 
(3.83) 0.685 antipsychotic 





2+ channel inhibitor, causes G1 arrest and 
apoptosis 
Metixene 
(3.85) 0.646 anticholinergenic muscarinic acetylcholine receptor M1-5 
Loperamide 
(3.86) 0.645 antidiarrheal (imodium) µ-opiod receptor agonist, similar to morphine 
Prenylamine 
(3.87) 0.642 Ca
2+ channel blocker depletes myocardial catecholamine stores, monoamine transporter inhibitor 
Trifluoperazine 
(3.88) 0.629 antipsychotic inhibits dopamine D1 and D2 receptors 
Fluspirilene 
(3.89) 0.628 antipsychotic 
inhibits dopamine D2 receptor and voltage-
dependent Ca2+ channel gamma-1 subunit 
Prochlorperazine 
(3.90) 0.617 antipsychotic inhibits dopamine receptor 
Rescinnamine 
(3.91) 0.609 antihypertensive angiotensin-converting enzyme inhibitor 
Desipramine 
(3.92) 0.608 antidepressant inhibits reuptake of norepinephrine and sertonin 
Geldanamycin 



















































































Figure 3.32., cont. 
 
3.4.6 Whole Genome shRNA Screening and siRNA Validation 
To further aid in the elucidation of the biological target of SFM1257 (3.43), Dr. 
Claire Knezevic performed a positive selection whole genome shRNA screen. In this 
experiment, MiaPaca-2 cells were virally transduced with over 200,000 shRNA 
constructs targeting 47,500 human genes (3-5 constructs per gene), so that the cells 




























































were then incubated with 6.5 µM SFM1257 (3.43) for six hours, which is a high enough 
concentration to elicit >90% cell death. The surviving cells were grown to confluency, 
and their DNA was isolated, amplified with PCR, and analyzed using next-gen 
sequencing.95 Of the roughly 200,000 constructs in the library, over 62,000 were present 
in the final samples, and those constructs represented approximately 44% of the human 
genome.95 
In theory, the remaining cells survived because the specific shRNA constructs 
mitigated the effects of SFM1257 (3.43) toxicity. The relative amounts of shRNA 
constructs identified in the surviving cells were compared to the shRNA constructs found 
in the DMSO control, and the fold changes varied from 383 to 33 (Table 3.5).95 The most 
enriched constructs in the SFM1257 (3.43) treated samples were ones coding for the 
ITPR3 gene, which codes for the inositol 1,4,5-triphosphate 3 receptors (IP3R).95 IP3R is a 
ligand-gated calcium channel on the ER that participates in ER stress signaling.218 The 
construct for gene ESR1, which codes for estrogen receptor alpha (ERα), was enriched as 
well, and ESR1 has also been implicated in ER stress pathways.219 Additionally, a 
number of the other enriched constructs code for proteins involved in glycosyl transfer or 
ubiquitination, which play roles key roles in ER function. To confirm these results, the 







Table 3.5. shRNA Constructs and Their Enrichment95 








ITPR3  inositol 1,4,5-triphosphate receptor 3  383 CDH18  cadherin 18  70 
NCF4  neutrophil cytosolic factor 4  333 POLR2J2  
polymerase (RNA) II 
(DNA directed) 
polypeptide J2  
70 
PRSS53  protease, serine, 53  315 ZNF148  zinc finger protein 148  66 
NCOA3  nuclear receptor coactivator 3  209 SKIV2L2  
superkiller viralicidic 
activity 2-like 2 (S. 
cerevisiae)  
65 
ELF1  E74-like factor 1 (ets domain transcription factor)  184 ZNF85  zinc finger protein 85  65 
GNAT2  guanine nucleotide binding protein (G protein)  165 FICD  FIC domain containing  64 
RNMT  RNA (guanine-7-) methyltransferase  150 MTMR9  
myotubularin related 
protein 9  64 
HNRNPH3  heterogeneous nuclear ribonucleoprotein H3 (2H9)  147 UAP1  
UDP-N-
acteylglucosamine 
pyrophosphorylase 1  
63 
RASA1  RAS p21 protein activator (GTPase activating protein) 1  141 DPPA4  
developmental 
pluripotency associated 4  63 
CACYBP  calcyclin binding protein  135 NIT2  nitrilase family  62 
IL17RB  interleukin 17 receptor B  134 PEBP1  phosphatidylethanolamine binding protein 1  62 
RRBP1  ribosome binding protein 1  133 IDH3A  isocitrate dehydrogenase 3 (NAD+) alpha  62 
CLK3  CDC-like kinase 3  124 CCPG1  cell cycle progression 1  61 





RNASE2  ribonuclease, Rnase A family, 2  116 SCNM1  
sodium channel modifier 
1  61 
GANAB  alpha glucosidase 2  111 VN1R1  vomeronasal 1 receptor 1  60 
TSC2  tuberous sclerosis 2  104 CYP2C19  cytochrome P450  60 
TTTY1  testis-specific transcript  102 CMTR1  cap methyltransferase 1  59 
UTP11L  UTP11-like  100 SUGP1  SURP and G patch domain containing 1  59 
NEIL3  nei endonuclease VIII-like 3  99 PERP  PERP, TP53 apoptosis effector  59 
PPM1H  protein phosphatase  94 TAF6L  TAF6-like RNA polymerase II  56 
SLC7A6  solute carrier family 7 (amino acid transporter light chain)  94 MRTO4  
mRNA turnover 4 
homolog (S. cerevisiae)  54 
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KIAA0430  KIAA0430  93 HS2ST1  heparan sulfate 2-O-sulfotransferase 1  54 
HIST1H2BG  histone cluster 1  92 LAMP1  lysosomal-associated membrane protein 1  53 
RTN3  reticulon 3  87 CFH  complement factor H  52 
ARHGAP1  Rho GTPase activating protein 1  85 DPYSL3  
dihydropyrimidinase-like 
3  52 
KBTBD7  kelch repeat and BTB (POZ) domain containing 7  84 SUPT7L  
suppressor of Ty 7 (S. 
cerevisiae)-like  51 
SLC22A4  
solute carrier family 22 
(organic cation/zwitterion 
transporter)  
83 SLC25A20  




FEZ2  fasciculation and elongation protein zeta 2 (zygin II)  82 UBA1  
ubiquitin-like modifier 
activating enzyme 1  47 
MEAF6  MYST/Esa1-associated factor 6  78 SYN1  synapsin I  46 
RAB26  RAB26, member RAS-oncogene family  77 CYP2A7P1  cytochrome P450  45 
ESRP1  epithelial splicing regulatory protein 1  77 PRC1  
protein regulator of 
cytokinesis 1  44 










MKRN2  makorin ring finger protein 2  75 DEK  DEK oncogene  44 
MAN1A2  mannosidase  74 RPN2  ribophorin II  43 
REEP5  receptor accessory protein 5  74 COL5A1  collagen  40 
SATL1  spermidine/spermine N1-acetyl transferase-like 1  74 MCF2  
MCF.2 cell line derived 
transforming sequence  39 
OSBPL7  oxysterol binding protein-like 7  74 STX16  syntaxin 16  39 
FLVCR1  
feline leukemia virus 
subgroup C cellular receptor 
1  
73 TJAP1  tight junction associated protein 1 (peripheral)  39 
SGMS2  sphingomyelin synthase 2  73 ELOVL6  ELOVL fatty acid elongase 6  38 
ESR1  estrogen receptor 1  72 PRRG4  
proline rich Gla (G-
carboxyglutamic acid) 4 
(transmembrane)  
37 
PPIE  peptidylprolyl isomerase E (cyclophilin E)  71 NFAT5  
nuclear factor of 
activated T-cells 5  34 
POU5F1  POU class 5 homeobox 1  71 GSDMB  gasdermin B  33 
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Dr. Betsy Parkinson validated the results of the whole genome shRNA study by 
selecting one or two siRNAs for 66 of the enriched genes and performing an siRNA 
knockdown study, and the toxicity of SFM1257 (3.43) at 6.5 µM in MiaPaca-2 cells 
transfected with each of these siRNA constructs was determined (Figure 3.33).96 In line 
with the observed cytoprotection seen by PP1/GADD34 inhibitor salubrinal (3.74), robust 
protection was afforded by siRNA for the gene PPP1R15A, which codes for the protein 
GADD34 (Figure 3.34).96 Additionally, the ER stress related genes ITPR3 and ESR1, 
which both showed enrichment in the shRNA screen, were also identified as 
cytoprotective in the siRNA validation screen (Figure 3.34), further supporting the ER 
stress hypothesis. 
Figure 3.33. Validation of shRNA Results with siRNA95 
 
*Red line represents average cell death caused by 6.5 µM SFM1257 (3.43) 




3.5 SUMMARY OF RESULTS AND FUTURE DIRECTIONS  
3.5.1 Optimization of Lead Compound 
Due to promising preliminary in vitro and in vivo results, a derivative of 
compound SFM1257 (3.43) is being developed for the ultimate purpose of clinical 
translation. Moving forward, additional derivatives must be synthesized with the goal of 
increasing potency while minimizing toxicity. From the initial data collected (Table 3.1, 
Figure 3.8), a preliminary structure-activity-relationship can be assembled (Figure 3.35). 
It is clear that large non-polar groups and carbamate groups on the basic nitrogen moiety 
(Figure 3.35, R1) are not tolerated (benzyl, dithioacetal, alloc), but smaller groups are 
tolerated (-H, alkyl, allyl). The oxygen moiety (Figure 3.35, R2) can be a free hydroxyl or 
a O-Me group, but acylation of the hydroxyl group to afford the corresponding ester is 
not tolerated. The 1,3-diol moiety (Figure 3.35, R3) is active when protected with an O-
benzyl group, but no cytotoxicity was observed when the benzyl groups were removed to 
give the free alcohols. In addition, substitution on the indole nitrogen atom (Figure 3.35, 
R4) is well tolerated (-H, Boc, methyl). 
Figure 3.35. Preliminary SAR Analysis 
 
Though the data presented in Figure 3.35 provides preliminary insight, additional 
analogs must be synthesized to more fully establish the SAR. Using SFM1257 (3.43) as 














R4= H, Methyl, Boc
R4
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thorough SAR profile (Figure 3.36). The substituents at those positions need to be varied 
iteratively in order to elucidate the effects of each position on the efficacy and potency of 
the compound (Figure 3.36). Reducing the complexity of the molecule is also of interest. 
It must be determined whether substituents smaller than benzyl are tolerated on the 1,3-
diol moiety. If the O-benzyl moieties could be replaced with O-Me or –H, the molar mass 
and complexity would be reduced dramatically. Once single site modifications are 
completed, the effects of modifying multiple sites simultaneously must be investigated. 
Additionally, all of derivatives synthesized to date are racemic. As these compounds 
continue down the pipeline for pre-clinical development, there will be a need to evaluate 
and determine the efficacy of each enantiomer independently because each enantiomer 
may be responsible for unique aspects of the phenotypic response to these compounds. 














Figure 3.36. Examples of Iterative Change to be Made to SFM1257 (3.43) 
 
3.5.2 Mode-of-Action Studies 
The mode-of-action for these compounds has tentatively been assigned as early 
induction of endoplasmic reticulum (ER) stress, followed by caspase-independent cell 
death. Through exhaustive analysis with small molecule chemical probes, it was 
determined that SFM1257 (3.43) can cause apoptotic cell death but can utilize non-
apoptotic pathways when apoptosis is inhibited. Additionally, the cytotoxicity of 
SFM1257 (3.43) has been correlated to the phosphorylation level of eIF2α, which is a 







































eIF2α phosphatase PP1/GADD34 reduces sensitivity to SFM1257 (3.43). Through 
transcriptomic analysis and RNA interference studies, it was determined that Ca2+ 
dysregulation, likely through the IP3R receptor, plays a role in the mode-of-action for 
SFM1257 (3.43), but it is not known whether the Ca2+ dysregulation causes ER stress or 
is a result of the ER stress. 
At the moment, the molecular targets of SFM1257 (3.43) remain unknown, and 
several additional experiments should be run to aid in elucidating the targets. Additional 
small molecule inhibitors need to be evaluated to validate the observation that inhibiting 
PP1/GADD34 is cytoprotective; this would further verify the observed response to 
salubrinal (3.74). To identify the biological targets, chemical probes with a tethered 
biotin (3.101) or tethered alkyne (3.102) can be used for biotin pull-down experiment and 
other photoaffinity studies (Figure 3.37). A biotin or alkyne handle would also allow for 
one to visualize the sub-cellular localization of the compounds via addition of a 
streptavidin bound fluorophore or a ‘click’ reaction with a fluorophore tethered to an 
azide. 




























Chapter 4: Synthesis and Biological Evaluation of Novel Tetracyclic 
Indole Derivatives and Tool Compounds 
4.1 INTRODUCTION 
It is clear from previous work that further investigations are required before more 
in vivo studies are performed on SFM1257 (3.43) and derivatives thereof. Additional 
biological analyses of toxicity induced by SFM1257 (3.43) with known chemical probes 
and novel SFM1257 (3.43)-derived tool compounds are needed to advance mode-of-
action studies. Specifically, derivatives of SFM1257 (3.43) that contain a tethered biotin 
moiety, and photoaffinity cross-linker are needed for target identification studies. 
Derivatives of SFM1257 (3.43) must also be synthesized and a more thorough structure-
activity-relationship established in order to maximize potency and minimize toxicity. 
Furthermore, pharmacophore minimization studies are needed to determine what 
structural characteristics contribute most to the biological activity. 
Figure 4.1. Structure of SFM1257 (3.43) 
 
4.2. TOOL COMPOUNDS FOR MODE-OF-ACTION STUDIES 
4.2.1. Introduction 
Determining the protein targets of bioactive small molecules is an important 
exercise that is used to expand the druggable genome and provide valuable insight into 










phenotypic screening will sometimes have an unknown or previously uncharacterized 
biological target, and there are several common methods and techniques used to aid in the 
identification of the target. There are several thorough reviews of the use of tool 
compounds for target identification studies and examples thereof.220-223  
4.2.1.1 Biotinylated Chemical Probes for Target Identification 
A common technique for target identification involves the use of a biotinylated 
probe.224-241 Biotin, vitamin B7, forms one of the strongest known non-covalent bonds 
(Kd~ 10-15 M) with the protein streptavidin,242 and as a result, small molecules with a 
biotin-terminated or containing tether are used to create non-covalent affinity matrices for 
protein isolation and purification.220 A standard biotin pull-down experiment can be 
performed in either whole cells or cellular lysate, and a simplified pictoral description is 
shown in Figure 4.2.  











Step 1: Dose Step 2: Incubate
Step 4: WashStep 3: Capture
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The first step in a biotin pull-down experiment is to incubate cells or cellular 
lysate with the biotin-conjugated bioactive small molecule (Step 1, Figure 4.2.). The 
small molecule will bind to the biological target (Step 2, Figure 4.2). The cells are then 
lysed, and a solid-supported streptavidin bead is added to the lysate. The streptavidin 
bead immediately binds to the biotin, forming a conjugate with the biological target (Step 
3, Figure 4.2.). The bead is then washed, removing all the miscellaneous proteins and 
biomolecules that are not bound to the bioactive small molecule. The streptavidin bead is 
then removed by boiling with a standard denaturant (i.e. SDS), leaving behind the 
isolated biological target (Step 4, Figure 4.2.). The biological target is then typically 
analyzed via tandem mass spectrometry to determine its sequence and identity.220  
The biotin tether does not necessarily have to be pre-installed on the molecular 
probe to perform the pull-down assay. A strategy that has proven to be very effective in 
recent years is to attach the biotin tether to the chemical probe after incubating the probe 
in the cells or cellular lysate via an azide-alkyne ‘click’ reaction.243-246 This strategy has 
several distinct advantages over pre-tethering the biotin, most notably because the biotin 
tag can make synthesis and purification of the probe difficult, adversely affect binding to 
the target, and negatively impact the solubility of the compound.220  
Biotinylated probes have spectacular utility in a vast number of target 
identification experiments. Imaging agents attached to streptavidin and biotin antibodies 
have been used for immunoblots and microscopy experiments,235 and the microscopy 
experiments would allow one to visualize where a compound may be localizing within a 
cell. Biotinylated probes have also been used to synthesize solid phase supports for 
protein purification via affinity chromatography. This approach has been used to isolate 
and identify novel insulin receptors,247 new phosphatase holoenzyme complexes,248 
previously unknown transcription factors,249  and many other proteins.250 In the context of 
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this work, the primary focus will be upon the design and synthesis of chemical probes for 
target identification via a standard pull-down experiment.  
4.2.1.2 Photoaffinity Probes and Their Use in Target Identification 
The strategy of tethering a biotin directly to a small molecule and performing a 
pull-down study works well if either the biological target is in high concentration or if the 
probe is a very strong binder; thus, pull down studies typically work best if the compound 
covalently binds to its biological target.238 If the small molecule is a weak binder or the 
biological target has a low abundance, a pull-down assay may yield inconclusive 
results.220 An advantage of this method is that one can potentially identify all of the 
biological targets that contribute to the phenotypic response of a drug. If one only 
identifies the highest affinity biological target of a compound, one may miss weaker 
binding targets that are associated with deleterious toxicity or off-target drug effects, 
which was illustrated by Peters et al in their method to assay the binding partners of 
kinase inhibitors.251 To address these issues, reactive cross-linking moieties were 
developed so that the small molecule probe covalently binds to the target protein.220 The 
most commonly employed photoaffinity cross-linking moieties are shown in Figure 4.3, 
and these four structural motifs have been effectively utilized in a number of 
photoaffinity studies.252-255 The reactive functional groups, upon exposure to UV light, 
create high energy nitrene, radical, or carbene species that insert very effectively into 






Figure 4.3. Commonly Used Photoaffinity Cross-Linking Moieties 
 
4.2.2. Synthesis and Evaluation of Tool Compounds 
Before commencing with the synthesis of a tool compound derived from 
SFM1257 (3.43), care had to be taken to ensure that the compound would not lose 
bioactivity. The preliminary structure-activity analysis indicated that large non-polar 
substitutents were not tolerated on the basic nitrogen moiety, yet large non-polar 
substituents were tolerated on the indole nitrogen atom (Figure 4.4). Thus, it was decided 





































Figure 4.4. Preliminary Structure-Activity Analysis 
 
4.2.2.1 Synthesis of Biotinylated Tool Compound 
Initially, we sought to synthesize a tool compound tethered directly to biotin. We 
thus envisioned that the biotinylated compound 4.10 could be synthesized from alkyne 
4.11 via an azide-alkyne ‘click’ reaction, and alkyne 4.11 could be accessed from 
compound 4.12. 
Figure 4.5. Retrosynthetic Analysis for Biotinylated Tool Compound 
 
The synthesis of a biotinylated tool compound began via protection of alcohol 
4.12 as the silyl ether. It was found that 4.12 could be converted to 4.13 quantitatively 











































was then alkylated with sodium hydride and propargyl bromide to give alkyne 4.14 in 
98% yield. The allyl carbamate of 4.14 was removed using Pd2dba3 and 1,3-
dimethylbarbituric acid (DMBA) as an allyl scavenger to give 4.15 and 4.16 in 27% and 
25% yields, respectively. Although the yield of the final deprotection was poor, a 
sufficient amount of material was synthesized, so optimization of the reaction was not 
undertaken.  
Scheme 4.1. Synthesis of Protected Alkyne 4.15 
 
With the synthesis of first half of the biotinylated derivative nearly completed, our 
focus was shifted to the preparation of the azide coupling partner for the impending 
‘click’ reaction (Scheme 4.2). The synthesis of 4.20 was carried out according to a 
literature procedure.256 Reaction of 1,6-dibromohexane (4.17), with sodium azide 
afforded the diazido compound that was subsequently selectively reduced to monoamine 
4.18 via a Staudinger reaction with a substoichiometric amount of triphenylphosphine. 














































DPPB= 1,4-bis(diphenylphosphino)butane; dba= dibenzylideneactone
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conditions (EDCI/OxymaPure®/DMF), and the desired biotin tethered azide 4.20 was 
synthesized in 63% yield. 
Scheme 4.2. Synthesis of Biotin Tether256 
 
Initially, we planned to complete the synthesis of 4.10 by performing the azide-
alkyne ‘click’ reaction last, so alkyne 4.15 was deprotected with Et3N•3HF to give 4.11 in 
38% yield. With alkyne 4.11 in hand, the click reaction with azide 4.20 was attempted. 
Unfortunately, the reaction afforded none of the desired product, and only returned 
starting material was isolated. Increasing the number of equivalents of CuSO4 or sodium 
ascorbate did not affect the reaction. Extended reaction times and elevated temperatures 
did not afford any of the desired cycloaddition product.  
Scheme 4.3. Initial Attempt at Formation of Biotinylate Derivative 
 
We hypothesized that the Lewis basic atoms on 4.11 may be chelating or binding 
to copper species preventing the reaction from proceeding as desired. To test this 
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     9:1 DMF:H2O
      80 °C, 83%
2) 0.95 eq PPh3, 2M HCl
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and the reaction proceeded cleanly to afford the biotin-tethered compound 4.21 in 
quantitative yield (Scheme 4.4).  
Scheme 4.4. Successful ‘Click’ Reaction 
 
Encouraged by this result, efforts were undertaken to deprotect compound 4.21. 
Unfortunately, attempts to remove the allyl carbmate group under the previous conditions 
were unsuccessful, and only starting material was observed (Scheme 4.5). Extended 
reaction times and increased Pd2dba3 loading did not afford any of the desired compound. 
When elevated temperatures were employed (100 ºC, DMF), decomposition of the 




































Scheme 4.5. Attempted Removal of Allyl Carbamate Group of 4.21 
 
Since we now had evidence to support the hypothesis that the Lewis basic 
moieties were likely inhibiting the ‘click’ reaction, the next logical step was to evaluate 
which Lewis basic site was preventing the progression of the reaction. Since compound 
4.15 had previously been synthesized, it was subjected to the ‘click’ reaction conditions, 
and the reaction furnished the biotin tether compound 4.22 in 72% yield (Scheme 4.6). 
The TBS group of 4.22 was then removed using Et3N•3HF to afford the desired 





























DPPB= 1,4-bis(diphenylphosphino)butane; dba= dibenzylideneactone
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Scheme 4.6. Synthesis of Biotinylated Probe 4.10 
 
4.2.2.2 Evaluation of Biotinylated Tool Compound 
After completing the synthesis of 4.10, its biological activity was evaluated by Dr. 
Betsy Parkinson. It was found that 4.10 was active against U937 lymphoma cells (IC50= 
34.9 ± 6.1 µM) (Figure 4.6), but the activity was diminished by a factor of 10 when 
compared to the parent compound, SFM1257 (3.43) (IC50= 3.3 ± 0.2 µM). Additionally, 
it was found that compound 4.11 containing the alkyne handle was cytotoxic against 


















































assay if the ‘click’ reaction were done in the cellular lysate. At this time, we became 
concerned that these compounds may not be binding to their biological target with 
particularly high affinity because of the high micromolar IC50 values. Thus, it was 
determined that the best course of action would be to synthesize a different derivative 
containing a photoaffinity cross-linker. 



























Hill slope 9.3 ± 3.9 
Emax 99.9 ± 0.1 
U937 IC50 (µM) 22.5 ± 4.7 
Hemolysis IC50 (µM) >333 
4.10 
Hill slope 1.9 ± 0.2 
Emax 101 ± 1.5 
U937 IC50 (µM) 34.9 ± 6.1 








4.2.3.1 Synthesis of Photoaffinity Probe 
Given that there are several common cross-linking moieties found in the literature 
(Figure 4.3), we sought to use a cross linker that could be easily attached to the indole 
nitrogen atom of 4.13. While determining which approach to take to design a 
photoaffinity tether, we became aware of a report by Li et al in which they designed and 
evaluated the diazirine tether shown in Scheme 4.7.257 We were drawn to this approach 
for several reasons: 1) the tether could be synthesized on large scale from cheap 
materials; 2) the tether could be appended to our scaffold via alkylation (4.23), 
nucleophilic addition (4.25), or peptide coupling (4.24); and 3) the authors applied the 
tether to proteomic analysis of several known kinase inhibitors. Following literature 
procedures, 4.23, 4.24, and 4.25 were synthesized (Scheme 4.7).257 
Scheme 4.7. Photoaffinity Tether Published by Li et al257 
 
Initial attempts to append the photoaffinity probe to the indole nitrogen atom of 
4.13 by alkylation with iodide 4.23 were unsuccessful (Scheme 4.8). The 1H-NMR 
spectra of the crude reaction mixture showed alkene 4.27 and unreacted starting material. 
Increasing the number of equivalents of 4.23 or inverting the order of addition (adding 
4.13/NaH to 4.23) did not change the product distribution. We speculated that the 




















preventing nucleophilic attack. To overcome this preference for elimination, we proposed 
that a more reactive electrophile that cannot eliminate would be better severed to alkylate 
the indole nitrogen atom. 
Scheme 4.8. Initial Attempt to Alkylate Indole Nitrogen 
 
Although the synthesis of 4.23 was straightforward, it was a time-consuming, 
seven-step reaction sequence. As such, we felt that it would be a more prudent use of 
material if a short carbon linker was attached to the indole nitrogen atom, so the 
photoaffinity tether could be subsequently appended to the linker.  By so doing, more 
reactive electrophiles could be used to alkylate or acylate the indole nitrogen atom, and 
then the photoaffinity tether can be readily attached to the linker.  






























Various electrophiles (Scheme 4.9, 4.29-34) were screened for their ability to 
alkylate or acylate the indole nitrogen atom of 4.13. All of these electrophiles had two 
electrophilic sites so that the indole nitrogen atom could occupy one site, and amine 4.25 
would be attached to the second site. Unfortunately, all attempts to alkylate 4.13 with 
these electrophiles were unsuccessful, and only starting material was returned in every 
attempt.  
Scheme 4.9. Attempted Alkylation With Various Electrophiles  
 
Due to our inability to acylate or alkylate the indole nitrogen atom, we determined 
that an electrophile that cannot eliminate or enolize would be better suited for this 
transformation. We found that ethylene oxide did alkylate the indole nitrogen atom at 50 
ºC, but the resulting alcohol reacted with additional equivalents of ethylene oxide to 












































Scheme 4.10. Attempted Alkylation with Ethylene Oxide 
 
After determining that ethylene oxide was not a good choice for a linker, epi-
chlorohydrin was examined. We discovered that quantitative deprotonation of 4.13 with 
sodium hydride in dimethylformamide (DMF) followed by addition of epi-chlorohydrin 
afforded the desired product 4.35 in 30-50% yield (Table 4.1, entry 1); the majority of the 
mass balance was unreacted starting material. Adding sodium iodide to the reaction to 
form the more reactive alkyl iodide in situ did not improve the yield (Table 4.1, entry 2). 
Switching to potassium hydride provided no benefit over sodium hydride (Table 4.1, 
entry 3). N-Methylpyrrolidone (NMP) was evaluated as a solvent, and it was found that 
the reaction profile was cleaner with NMP than DMF, but the yields still varied greatly 
(Table 4.1, entry 4). Attempts to deprotonate 4.13 with dimsyl anion (deprotonated 
DMSO) and alkylate in THF (Table 4.1, entry 5) also afforded none of the desired 
product. Additionally, use of acetonitrile as the solvent resulted in no formation of the 
desired product (Table 4.1, entry 6). The most consistent yields were obtained with the 
polar aprotic solvent hexamethylphosphoramide (HMPA), and the alkylated indole 4.35 















0 ºC → 50 ºC
Polyalkylation
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Table 4.1. Successful Alkylation with epi-Chlorohydrin 
 
With an appreciable amount of epoxide 4.35 in hand, the allyl carbamate group 
was removed using Pd2dba3/DPPB and 1,3-dimethylbarbituric acid (DMBA) as an allyl 
scavenger to afford compound 4.36 in 66% yield. Secondary amine 4.36 was converted to 
the tertiary amine 4.37 via a reductive amination with 37% aqueous formaldehyde and 
NaBH(OAc)3. After work up, the crude reaction mixture containing 4.37 was dissolved in 
methanolic ammonia and heated at 60 ºC for 36 hours in a sealed tube to provide amino 
alcohol 4.38; the crude reaction mixture was carried on without performing an aqueous 
workup or further purification. The amino alcohol 4.38 was then coupled to carboxylic 
acid 4.24 using the peptide coupling reagent N,N-dicyclohexylcarbodiimide (DCC) to 
afford compound 4.39. After a quick aqueous work up, the crude reaction mixture was 
stirred at room temperature in a mixture (1:3 v/v) of Et3N•3HF and CH2Cl2 to afford 

























 NaH, epi-chlorohydrin, DMF
NaH, epi-chlorohydrin, NaI, DMF
 KH, epi-chlorohydrin, DMF
NaH, epi-chlorohydrin, NMP













Scheme 4.11. Completion of the Photoaffinity Probe 
 
4.2.3.2 Evaluation of Photoaffinity Probe 
Having completed the synthesis of photoaffinity probe 4.40, it was evaluated for 
its ability to induce cell death in U937 lymphoma cells (Figure 4.8) and was found to be 
active in vitro (IC50= 14.5 ± 0.8), although it was approximately four-fold less active than 
SFM1257 (3.43). Notably, 4.40 was approximately two-fold more active than the 
biotinylated derivative 4.10 (IC50= 34.9 ± 6.1 µM) and slightly more active than the N-



































































DPPB= 1,4-bis(diphenylphosphino)butane; dba= dibenzylideneactone
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probe 4.40 would likely be the better choice going forward for subsequent pull-down 
studies.  
Figure 4.8. Biological Evaluation of Photoaffinity Probe 
 
4.2.4. Evaluation SFM1257 Mode-of-Action With Small Molecule Tool Compounds 
While work was being done to synthesize the new chemical probes in the 
previous section, the mode-of-action of SFM1257 (3.43) was being further evaluated 
using known tool compounds. Initial work performed by Dr. Claire Knezevic found the 
tool compound salubrinal (3.74), which is known to reduce endoplasmic reticulum (ER) 
stress, was cytoprotective against SFM1257 (3.43)-induced toxicity.95 To investigate 
whether the protection afforded by salubrinal (3.74) was due to PP1/GADD34 inhibition, 
the selective PP1/GADD34 inhibitor guanabenz258 (4.41) was used. 





















Hill slope 6.3 ± 1.0 
Emax 100 ± 0.4 
U937 IC50 (µM) 14.5 ± 0.8 
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4.2.4.1 Guanabenz as a Cytoprotectant 
Guanabenz (4.41) is an alpha agonist of the α2-adrenergic receptor, and it was 
approved by the FDA in 1982 for the treatment of hypertension.259 However, Bertolotti et 
al discovered in 2011 that guanabenz (4.41) also selectively inhibited growth arrest and 
DNA damage inducible protein (GADD34), which is the regulatory subunit of protein 
phospatase 1 (PP1).258 When a cell experiences ER stress, it activates the unfolded protein 
response (UPR), and the ER signaling protein PERK phosphorylates eIF2α (Figure 
4.10).189 The phosphorylation of eIF2α causes a reduction in protein translation and 
upregulates other proteins designed to mitigate ER stress. The two phosphatases that act 
on p-eIF2α are PP1/GADD34 and PP1/CReP; these holoproteins work to resume normal 
levels of protein translation.198,258 By inhibiting these phosphatases, salubrinal (3.74) and 
guanabenz (4.41) reduce the protein production rate to a level manageable by the ER, 
thereby mitigating the ER stress.  
Figure 4.10. ER Stress and the Inhibitors Salubrinal (3.74) and Guanabenz (4.41)189 
 
 Copyright Nature Publishing Group; Reproduced with permission189  
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Guanabenz (4.41) is considered a better tool to for studying the effects of ER 
stress because it is selective for the stress induced phosphatase PP1/GADD34 and does 
not affect the constitutively active phosphatase PP1/CReP, whereas salubrinal inhibits 
both phosphatases. Because salubrinal (3.74) inhibits the constitutively active 
phosphatase PP1/CReP, cells incubated with salubrinal (3.74) will show an increase in 
the level of p-eIF2α regardless of whether the cell is undergoing ER stress. On the other 
hand, cells incubated with guanabenz (4.41) will only show an increase in p-eIF2α levels 
if the cell has activated the UPR because PP1/GADD34 is only transcribed when the 
UPR is initiated.260 
4.2.4.2 Evaluation of Guanabenz 
To evaluate the cytoprotective ability of guanabenz (4.41), U937 cells were 
incubated with 2.5 µM guanabenz (4.41) for two hours, and SFM1257 (3.43) was then 
added so that the final concentration of SFM1257 (3.43) was 9 µM. After three hours, the 
viability of the cells was determined via flow cytometry by staining with PI/Annexin V-
FITC (Figure 4.11). It was observed that guanabenz (4.41) provided robust cytoprotection 
(~67%) against SFM1257 (3.43)-induced cell death. This result provided one more piece 
of evidence that SFM1257 (3.43)-induced cell death results from ER stress and further 
validated that the results obtained with salubrinal (3.74). Additionally, it demonstrated 







Figure 4.11. Guanabenz (4.41) Protects against SFM1257 (3.43) Induced Cytotoxicity 
 
4.2.5 Future Studies 
Moving forward, additional studies must be performed to identify the biological 
target and correlate the cytotoxicity to a biochemical marker. Before the photoaffinity 
probe (4.41) can be used to perform target identification studies via biotin pull-down 
experiments, it would be prudent to verify that 4.41 has the same mode-of-action as 
SFM1257 (3.43). At the moment, it has only been shown that 4.41 is cytotoxic. To 
validate that 4.41 has the same mode-of-action as SFM1257 (3.43), cytoprotection should 
be observed with salubrinal (3.74) and guanabenz (4.41). Additionally, further studies 
must be performed to evaluate the connection between p-eIF2α levels and cell death. 
Previous work by Dr. Claire Knezevic95 and Dr. Betsy Parkinson96 has shown high levels 
of p-eIF2α were seen in cell incubated with cytotoxic amounts of SFM1257 (3.43), and 
normal levels were seen when the cytoprotectant small molecule salubrinal (3.74) was 
used. It would be of interest to see if similar results are obtained when guanabenz (4.41) 
is used as a cytoprotectant. Another experiment that would provide further insight into 
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the mode-of-action would be to evaluate SFM1257 (3.43) against cells that are eIF2α 
phosphorylation incompetent. By preventing the formation of p-eIF2α, one would be able 
to determine whether phosphorylation is a direct cause of the cell death or is secondary 
effect of SFM1257 (3.43) toxicity. 
4.3 STRUCTURE ACTIVITY ANALYSIS OF NOVEL TETRACYLIC INDOLE DERIVATIVES 
4.3.1 Introduction 
Prior to the commencement of this work, a number of novel tetracylic indole 
containing derivatives had been synthesized and their anticancer properties had been 
evaluated (Table 4.2).95,96,120 From these data, a preliminary structure-activity-relationship 
(SAR) was formed (Table 4.2). It was clear that large non-polar groups and carbamates 
on the basic nitrogen moiety (benzyl, dithioacetal, alloc) (Table 4.2, R1) were not 
tolerated, but smaller groups (-H, alkyl, allyl) were. The oxygen moiety (Table 4.2, R2) 
could be left as the free hydroxyl group or methylated to the O-Me, but acylation with 
acetyl and benzoyl chloride to afford the corresponding ester was not tolerated. 
Derivatives with an O-benzyl group on the 1,3-diol moiety (Table 4.2, R3) were 
biologically active, but no cytotoxicity was observed when the benzyl groups were 
removed to give the free alcohols. In addition, substitution at the indole nitrogen atom 
(Table 4.2, R4) was well tolerated (-H, Boc, methyl). Although these data provided some 
initial insights of the SAR, it was not clear what constituted the minimum active 
pharmacophore, nor was it obvious if the Lewis basic positions (Table 4.2, R1, R2, R4) 




Table 4.2. Preliminary SAR and Evaluation of Cytotoxicity95,96,120 
 
Hs578t U937 Hemolysis Compound R1 R2 R3 R4 IC50 (µM) IC50 (µM) IC50 (µM) 
3.38 Allyl OH OBn H 63 ± 16.0 14.1 >100 µM 
3.39 H OH OBn H 14.9 ± 4.8 ND >100 µM 
-CH2CH(OH) 3.40 CH2OH 
OH OBn H 20.4 ± 3.6 ND >100 µM 
3.41 n-Propyl OH OBn H 13.2 ± 1.3 9.8 >100 µM 
3.42 Me OH OBn H 12.6 ± 2.5 9.6 ~100 µM 
3.43 H OH OBn Boc 6.6 ± 0.7 3.3 ± 0.2 28 µM 
3.44 Allyl OMe OBn Me 15.5 ± 2.8 ND >100 µM 
3.25 -CH2CH2- =O OBn H 11.2 ± 1.9 ND >100 µM 
3.32 Allyl OAc OBn H >100 µM ND ND 
3.33 Allyl OBz OBn H >100 µM ND ND 
3.34 Alloc OTMS OBn H >100 µM ND ND 
3.35 Alloc OTMS OBn Boc >100 µM ND ND 
3.36 Alloc OH OBn Boc >100 µM ND ND 
3.29 Bn OH OBn H >100 µM ND ND 
3.31 n-Propyl OH OH H >100 µM ND ND 
3.24 H =O OBn Boc >100 µM ND ND 
3.30 -CH2CH(SEt)2 OH OBn H >100 µM ND ND 














R4= H, Methyl, Boc
R4
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4.3.2 Structure Activity Relationship of Lewis Basic Atoms 
We commenced our studies by focusing, on determining how substitution at the 
Lewis basic sites modulated the biological activity of the two lead compounds, SFM1257 
and SFM1258. The initial derivatives screened (Table 4.2) had sporadic substitution 
patterns that made it difficult to draw conclusions. For example, we observed a drop in 
potency between SFM1257 (3.43) and SFM1258 (3.44), but we were not sure whether 
modification of the basic amine, indole nitrogen atom, or alcohol group was responsible 
for the loss in potency. Thus, we sought to make iterative changes to the scaffold so that 
direct comparisons between analogs could be made, and the effect of substitution at each 
Lewis basic position could be deduced. Additionally, the Lewis basic positions were 
chosen first because they could be accessed from known intermediates in the synthesis of 
(±)-actinophyllic acid (3.7) by Martin et al (Figure 4.12).100 







































4.3.2.1 Synthesis of Tetracyclic Derivatives 
We began by synthesizing analogs of SFM1257 (3.43) and SFM1258 (3.44) that 
possessed different substituents at single Lewis basic sites. Thus, the N-methyl SFM1257 
(3.43) analog was synthesizes in 54% yield via a reductive amination of 3.43 with 
formaldehyde (Scheme 4.12). 
Scheme 4.12. Synthesis of Derivative 4.43 
 
Additional derivatives of SFM1257 (3.43) and SFM1258 (3.44) were synthesized 
from compounds 4.12 and 3.36, which were readily accessible intermediates from the 
Martin synthesis of (±)-actinophyllic acid (3.7) (Scheme 4.13).122 Alkylation of 4.12 and 
3.36 with sodium hydride and methyl p-toluenesulfonate afforded compounds 4.44a and 
4.44b in 84% and 71% yields, respectively. The allyl carbamate protecting group was 
removed with Pd2dba3/DPPB and 1,3-dimethylbarbituric acid (DMBA) to give 
compounds 4.45a and 4.45b in 83% and 61% yields. Lastly, a reductive amination of 























*Reaction was only run once
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Scheme 4.13. Synthesis of Derivatives 4.45a, 4.45b, 4.46a, and 4.46b 
 
To gauge the importance of the Boc group on SFM1257 (3.43) bioactivity, 
various substitution patterns on the indole nitrogen atom were investigated (Scheme 
4.14). From the work done to synthesize the photoaffinity tethered compound 4.40, we 
knew that only highly reactive electrophiles without acidic protons would readily alkylate 
the indole nitrogen atom. Thus, compound 4.13 was alkylated with methyl p-















































*Reaction was only run once
Series a: R=  Me
 b: R= Boc
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Scheme 4.14. Alkylation of Indole Nitrogen Atom 
 
With compounds 4.47a and 4.47b in hand, the TBS group and allyl carbamate 
moiety were removed to afford new derivatives with differing substitution on the indole 
nitrogen atom. The allyl carbamate of 4.47a was removed with Pd2dba3/DPPB using 1,3-
dimethylbarbituric acid (DMBA) as the allyl scavenger to afford 4.48 in 81% yield. A 
small amount of 4.48 was reserved for biological evaluation, and the remaining material 
was deprotected with NEt3•3HF to give 4.49 in 23% yield after HPLC purification. 
Additionally, allyl derivative 4.51 was formed in two steps from 4.47b by TBS removal 
with TBAF•3H2O to afford 4.50, then allyl carbamate removal with 
Pd2dba3/DPPB/DMBA to give 4.51 in 28% yield over two steps (Figure 4.13). 




















































































*Reaction was only run once
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Unexpectedly, removing the allyl carbamate group from 4.50 with Pd2dba3/DPPB 
did not proceed in THF or refluxing dioxane. Instead, heating the reaction to 130 ºC in 
DMF was required. Given that the allyl carbamate group was removed from similar 
compounds without employing such harsh conditions,100,122 it was postulated that the Pd0 
species in the reaction might be coordinating with the indole N-allyl group first, then 
forming a chelate with the Lewis basic oxygen, thereby preventing the metal from 
performing the desired transformation. (Figure 4.14).  
Figure 4.14. Proposed Intramolecular Palladium Chelate 
 
In the course of synthesizing the biotin tethered derivative 4.10, an appreciable 
amount of compound 4.16 was isolated as an unintended byproduct. Thus, we decided to 
use 4.16 to synthesize additional derivates (Scheme 4.15). Accordingly, a portion of 4.16 
was quantitatively reduced to compound 4.53 using Pd/C and hydrogen gas. Compounds 
4.16 and 4.53 were deprotected to give 4.54a and 4.54b in 59% and 83% yields, 















Scheme 4.15. Reduction of Compound 4.16 
 
Scheme 4.16. Synthesis of Derivatives 4.54a and 4.54b 
 
4.3.2.2 Evaluation of Tetracyclic Derivatives 
Upon completing the synthesis of these novel derivatives, the compounds were 
evaluated for their ability to induce cell death in Hs578t cells (triple negative breast 




































4.16, 4.53 4.54a: R1= propargyl (59%)*
           R2= allyl
4.54b:  R1= n-propyl (83%)*
           R2= n-propyl
NEt3•3HF
CH2Cl2, rt
*Reaction was only run once
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Table 4.3.  Evaluation of Varying Substitution at Lewis Basic Sites 
 
Hs578t U937 Hem* Entry Cmpd R1 R2 R3 IC50 (µM) IC50 (µM) IC50 (µM) 
1 1257 (3.43) H H Boc 6.6 ± 0.7
* 3.3 ± 0.2* 28 
2 4.43 Me H Boc ND 5.3 ± 0.1* 140 ± 60 
3 4.45b H Me Boc ND 4.0 ± 0.1* 50 ± 12 
4 4.46b Me Me Boc ND 57.0 ± 1.5* >333 
5 1258 (3.44) Allyl Me Me 20 ± 2.9
* 5.6 ± 2.3* >100 
6 4.45a H Me Me ND 12.0 ± 0.2* 170 ± 60 
7 4.46a Me Me Me ND 8.5 ± 0.7* 120 ± 40 
8 4.49 H H Me 6.5 ± 0.6 6.8 ± 0.2 ND 
9 4.48 H TBS Me 5.2 ± 0.3 6.8 ± 2.4 ND 
10 4.51 H H Allyl ND 10.7 ± 0.4* 110 ± 10 
11 4.11 H H Propargyl ND 22.5 ± 4.7* >333 
12 4.54a Allyl H Propargyl ND 9.4 ± 0.1* >333 
13 4.54b n-Pr H n-Pr ND 4.0 ± 0.1* 54 ± 9.8 
ND= Not Determined; *Data collected by Dr. Betsy Parkinson96 
After analyzing the data, several conclusions were drawn about the structure-









(R2) is likely neither a hydrogen bond donor nor a major contributor to the phenotypic 
response. That observation is supported by comparing entry 1 to entry 3 and entry 8 to 
entry 9. When the oxygen atom was alkylated to the methyl ether (Table 4.3, entry 1 to 
entry 3), there was no significant change in activity. Additionally, blocking the oxygen 
atom with a large, greasy silyl group (Table 4.3, entry 8 and entry 9) did not impact the 
cytotoxicity of the compound. It is also clear that a Boc group on the indole nitrogen 
atom enhances cytotoxicty but it is not necessary. When the Boc group was substituted 
for a methyl group (Table 4.3, entry 1 and entry 8), no significant difference in activity 
was seen. However, the N-allyl and N-propargyl derivatives (Table 4.3, entry 10 and 
entry 11) showed a decrease in activity. One rather unexpected observation was that 
methylating both the basic nitrogen atom (R1) and oxygen atom (R2) of SFM1257 (3.43) 
caused a 10-fold reduction in potency (Table 4.3, entry 4), but methylating each position 
individually (Table 4.3, entry 2 and entry 3) had only a nominal impact on activity. A 
positive trend was observed in regards to hemolytic activity; methylation of the 
secondary amine of SFM1257 (3.43) (Table 4.3, entry 2) resulted in a dramatic decrease 
in hemolytic activity (28 µM vs 140 µM) but little to no loss in cytotoxicity. Overall, the 
SAR provided little insight, as various modifications across the scaffold provided little to 
no change in potency. Thus, we determined that substitution at the Lewis basic positions 
were not major contributors to the cytotoxicity of SFM1257 (3.43) and SFM1258 (3.44).  
4.3.2.3 Synthesis of Pentacyclic Derivatives 
An appreciable amount of the advanced intermediate 3.25 remained from the 
synthesis of (±)-actinophyllic acid (3.7) by Dr. Brett Granger. Since the pentacyclic 
derivative 3.25 was shown to be biologically active in the initial cytotoxicity screens 
(Table 4.2, 3.25), we decided to prepare several pentacyclic derivatives to examine how 
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forming the additional ring affected the SAR. In addition, we found it curious that 
compound 3.25 was biologically active, but 3.24 was not (Figure 4.15). Given that 
tetracyclic compound 3.24 is known to degrade under acidic conditions,120 we 
hypothesized that the lack of observed cytotoxicity may be due to degradation in vitro. 
Thus, pentacyclic compounds derived from 3.25 may be useful to help mitigate potential 
issues that may arise if our lead compound shows poor oral bioavailability due to rapid in 
vivo degradation.  
Figure 4.15. Comparison of Pentacyclic 3.25 to Tetracyclic 3.24 
 
The syntheses of the novel pentacyclic derivatives 4.56-59 are shown in Scheme 
4.17. Beginning from the pentacycle 3.25, the ketone moiety was reduced to the alcohol 
4.56 in 90% yield. The Boc groups of 3.25 and 4.56 were removed with NaOH/MeOH to 
give 4.58 and 4.57 in 65% and 85% yields, respectively. Lastly, a methoxymethyl ether 
























Scheme 4.17. Synthesis of Pentacyclic Derivatives 4.56, 4.57, 4.58, and 4.59. 
 
4.3.2.4 Evaluation of Pentacyclic Derivatives 
Upon completing the synthesis of these novel derivatives, the compounds were 
evaluated for their ability to induce cell death in U937 cells (human lymphoma) and red 






















































*Reaction was only run once
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Table 4.4. Evaluation of Pentacyclic Derivatives 
 
Hs578t* U937* Hem* Entry Compound R1 R2 IC50 (µM) IC50 (µM) IC50 (µM) 
1 3.25 Boc =O 11.2 ± 1.9 ND ND 
2 4.56 Boc OH ND 6.9 ± 0.5 80 ± 10 
3 4.57 H OH ND 10.8 ± 0.3 210 ± 40 
4 4.58 H =O ND 12.1 ± 0.1 >333 
5 4.59 Boc OMOM ND 12.6 ± 0.1 140 ± 30 
  *Data collected by Dr. Betsy Parkinson96 
The pentacyclic derivatives were found to be either comparable to or slightly less 
potent than the analogous tetracyclic compounds. However, the IC50 data collected for 
these derivatives does provide additional insight into the role of the oxygen moiety (R2) 
in the active pharmacophore. For example, comparing 4.57 to 4.58 (Table 4.4, entry 3 
and entry 4) shows that the oxidation state of the alcohol does not affect the potency of 
the compound. Additionally, it was found that a Boc group on the indole nitrogen atom 
slightly improved potency, but activity was not dependent on the Boc group (Table 4.4, 
entry 2 and entry 3). Given that pentacyclic compounds 4.56-59 showed no clear 










4.3.3 Structure Activity Relationship Associated with Indole Ring 
After evaluating the SAR of the Lewis basic moieties on the tetra- and pentacyclic 
systems, we expanded into new a chemical space by synthesizing derivatives with 
substitution at the 5- and 6-positions of the indole ring. In addition, we sought to explore 
how derivatives based on 7-azaindole would affect the biological activity because the 
additional Lewis basic position would improve the water solubility and decrease the 
ClogD. Unfortunately, the substitution that we desired would not be accessible via late 
stage functionalization of SFM1257 (3.43) or SFM1258 (3.44), so it was necessary to use 
a prefunctionalized indole species from the beginning. To form the desired 5- and 6-
substituted indole derivatives, we envisioned that the analogs could be formed from the 
common tetracyclic intermediate 4.61, which in turn could be synthesized from 
substituted indole (4.62), π-nucleophile 3.10, and ketone 3.17 (Figure 4.16). 
Figure 4.16. Indole Ring SAR Studies 
 
4.3.3.1 Synthesis of 5- and 6-Substituted Indole Derivatives 
To install substituents at the 5- and 6-position of the indole ring, we reasoned that 























and 6-chloroindole (4.63a,b). This approach would allow us to synthesize a diverse 
library of compounds via palladium catalyzed cross couplings. 
The chemistry developed by Dr. Ivan Jewitt and Dr. Brett Granger for the 
synthesis of (±)-actinophyllic acid (3.7) worked well on the corresponding substituted 
indoles. Using the five step one-pot protocol, 5- and 6-chloroindole (4.63a,b) were 
converted to the corresponding 2-substituted indole acetates 4.64a,b in 40% and 52% 
yields, respectively. Compounds 4.64a,b were then combined with 3.10 and TMS-OTf to 
form the corresponding tetracyclic compounds 4.65a,b in 69% and 89% yields. 
Reduction of 4.65a,b with lithium borohydride gave the corresponding alcohols 4.66a,b 
in 81% and 91% yields (Scheme 4.18).  
Scheme 4.18. Synthesis of 5- and 6-Chloro Indole Scaffolds 
 
With compounds 4.66a,b in hand, the allyl carbamate was removed with 











































0 ºC → rt
TBAF= tetrabutylammonium fluoride; DTBMP= 2,6-di-tert-butyl-4-methylpyridine
1The alcohol (4.64c) was isolated in 31% yield
*Reaction was only run once
CH2Cl2
–78 ºC → rt
4. 3.17
5. Ac2O
Series a: R1= Cl,R2=  H
  b: R1= H, R2= Cl
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respectively (Scheme 4.19). Compounds 4.67a,b were converted to the corresponding 
tertiary amines 4.68a,b in 34% and 60% yields. 
Scheme 4.19. Synthesis of 5- and 6-Chloro Derivative 4.67a-b and 4.68a-b 
 
 The 5- and 6-chloroindole derivatives of SFM1257 (3.43) were then prepared in 
three steps from ketones 4.65a,b (Scheme 4.20). The indole nitrogen atom of compounds 
4.65a,b were protected with di-tert-butyldicarbonate and 4-dimethylaminopyridine to 
afford 4.69a,b in 68% and 78% yields, respectively. Compounds 4.69a,b were reduced 
with lithium aluminum hydride to provide alcohols 4.70a,b in 62% and 63% yields. The 
allyl carbamate of 4.70a,b was removed with Pd2dba3/DPPB/DMBA to give 4.71a,b in 
82% and 81% yield. Additionally, the N-allyl derivative 4.71c was isolated as a minor 





































DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone
*Reaction was only run once
Series a: R1= Cl,R2=  H
  b: R1= H, R2= Cl
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Scheme 4.20. Synthesis of 5- and 6-Chloro Derivatives of SFM1257 (3.43) 
 
The synthesis of 5- and 6-substituted derivatives continued with methylation of 
4.66a,b using sodium hydride and methyl p-toluenesulfonate to give 4.72a,b in 99% and 
94% yield (Scheme 4.21). The allyl carbamates of 4.72a,b were removed with 
Pd2dba3/DPPB/DMBA to give the corresponding amines 4.73a-b in 88% and 66% yield. 
Subsequent reductive amination with 37% aqueous formaldehyde and sodium 













































4.71a: R3= H    (82%)*
4.71b: R3= H    (81%)*









DPPB= 1,4-bis(diphenylphosphino)butane; DMAP= Dimethylaminopyridine
DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone; Boc2O= di-tert-butyldicarbonate
*Reaction was only run once
Series a: R1= Cl,R2=  H
  b,c: R1= H, R2= Cl
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Scheme 4.21. Synthesis of 5- and 6-Substituted Derivatives 4.73a,b and 4.74a,b 
 
The 5- and 6-chloro derivative of SFM1258 (3.44) were prepared in one step from 
compounds 4.72a,b. A palladium catalyzed decarboxylative allylation using Pd(Ph3)4 
afforded the 5- and 6-chloro-N-allyl derivatives (4.75a,b) in 44% and 28% yields, 
respectively (Scheme 4.22).  
Scheme 4.22. Synthesis of 5- and 6-Chloro Analogs of SFM1258 (3.44) 
 
To expand further into new chemical space, preliminary work was undertaken to 















































DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone
Series a: R1= Cl,R2=  H





















*Reaction was only run once
Series a: R1= Cl,R2=  H
  b: R1= H, R2= Cl
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Using conditions developed by Buchwald et al,261 a Suzuki coupling on 4.74a with 
phenylboronic acid and 4-(trifluoromethyl)phenylboronic acid using 
Pd(OAc)2/SPhos/K3PO4 in toluene at 100 ºC afforded the desired products 4.75a,b in 
33% and 17% yield (Scheme 4.23). 
Scheme 4.23. Synthesis of Suzuki Adducts 4.76a-b 
 
4.3.3.2 Evaluation 
Upon completing the synthesis of these novel 5- and 6-substituted indole 
derivatives, the compounds were evaluated for their ability to induced cell death in 
Hs578t cells (triple negative breast cancer) U937 cells (human lymphoma), and red blood 




































*Reaction was only run once
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Table 4.5. Evaluation of 5- and 6-Substituted Derivatives 
 
Hs578t U937 Hem Entry Cmpd R1  R2  R3  R4  R5  IC50 (µM) IC50 (µM)  IC50 (µM)   
1 1257 (3.43) H H Boc H H 6.6 ± 0.7
* 3.3 ± 0.2* 28* 
2 1258 (3.44) Allyl Me Me H H 20 ± 2.9
* 5.6 ± 2.3* >100 
3 4.68a Me H H H Cl ND 4.9 ± 0.1* 190 ± 60* 
4 4.67a H H H H Cl ND 6.0 ± 0.2* 120 ± 20* 
5 4.68b Me H H Cl H 5.9 ± 0.4 6.7 ± 0.9 ND 
6 4.67b H H H Cl H 3.1 ± 0.4 4.5 ± 1.0 ND 
7 4.71a H H Boc H Cl 5.1 ± 1.0 3.8 ± 0.4 ND 
8 4.71b H H Boc Cl H 4.8 ± 1.0 3.9 ± 0.5 ND 
9 4.71c Allyl H Boc Cl H 15.1 ± 2.9 12.2 ± 2.0 ND 
10 4.75a Allyl Me Me H Cl 36.4 ± 2.3 11.9 ± 0.5 ND 
11 4.73a H Me Me H Cl 7.2 ± 1.1 9.0 ± 1.6 ND 
12 4.74a Me Me Me H Cl 6.9 ± 0.6 6.0 ± 0.2 ND 
13 4.75b Allyl Me Me Cl H 32.5 ± 3.8 12.8 ± 0.2 ND 
14 4.73b H Me Me Cl H 5.6 ± 0.3 4.5 ± 0.5 ND 
15 4.74b Me Me Me Cl H 4.5 ± 0.8 5.1 ± 1.4 ND 
16 4.76a Me Me Me H Ph 10.2 ± 1.6 6.9 ± 0.7 ND 
17 4.76b Me Me Me H p-PhCF3 6.3 ± 0.1 6.2 ± 0.1 ND 










Analysis of the data presented in Table 4.5 shed light on several trends with the 5- 
and 6-chloroindole derivatives. First and foremost, all of the 5- and 6-chloroindoles as 
well as the 5-phenyl derivatives were active in vitro (IC50< 20 µM). However, there were 
no significant differences in potency between the 5- and 6-chloro derivatives and no 
enhancement in activity over the unsubstituted derivatives. For example, the most potent 
compound SFM1257 (3.43) showed almost identical activity to its 5- and 6-chloro 
analogs (Table 4.5, entry 1 vs. entry 7 and entry 8), and the 5- and 6-chloro analogs of 
SFM1258 (3.44) showed a slight drop in potency (entry 2 vs. entry 10 and entry 13). 
However, the data did clearly showed that an allyl group on the basic nitrogen atom (R1) 
causes a significant reduction in cytoxicity (Table 4.5, entry 7 vs. entry 9, entry 10 vs. 
entry 11, entry 13 vs. entry 14). On a positive note, the two derivatives that were 
evaluated for hemolytic activity (Table 4.5, entry 3 and entry 4) had an IC50> 100 µM.  
4.3.3.3 Synthesis of 7-Azaindole Derivatives 
After evaluating the effects of substitution at the 5- and 6-positions, we 
investigated whether 7-azaindole derivatives would be tolerated in our system. The 
synthesis of 7-azaindole derived compounds commenced with the synthesis of indolo-
acetate 4.78. Using the five step one-pot protocol, 7-azaindole (4.77) was converted to 
indolo-acetate 4.78 in 42% overall yield.  














*Reaction was only run once
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With indolo-acetate 4.78 in hand, the cascade sequence was performed to deliver 
4.79 in 78% yield (Scheme 4.25). Notably, this reaction required an excess of TMS-OTf 
(5 eq) to go to completion. We hypothesized that the excess Lewis acid was required 
because the additional Lewis basic position of the 7-azaindole moiety sequestered the 
TMS-OTf, which inhibits carbocation formation. Indeed, Zhang et al made a similar 
hypothesis in Friedel-Crafts acylations of 7-azaindole (4.77), when they observed that an 
excess of aluminum trichloride was needed to obtain optimum yields.262 They 
hypothesized that the AlCl3 reacted with azaindole (4.77) to give complex 4.80 before 
activating the acylating agents (Scheme 4.26).  
Scheme 4.25. Synthesis of 7-Azaindole Derived Tetracycle 4.79 
 
Scheme 4.26. Friedel Craft Acylation of 7-Azaindole262 
 
After successfully synthesizing tetracyclic 4.79, the ketone moiety was reduced to 





































4.82 was removed with Pd2dba3/DPPB/DMBA to provide 4.83a and 4.83b in 38% and 
12% yield, respectively.  
Scheme 4.27. Synthesis of 7-Azaindole Derivatives 4.83a and 4.83b 
 
4.3.3.4 Evaluation of 7-Azaindole Derived Compounds 
Upon completing the synthesis of the 7-azaindole derivatives, the compounds 
were evaluated for their ability to induce cell death in Hs578t cells (triple negative breast 
cancer) and U937 cell (human lymphoma) (Table 4.6). Unfortunately, the derivatives 
derived from 7-azaindole did not see an enhancement in potency. As a result, this series 
















4.83a: R= H     (38%)*




















DPPB= 1,4-bis(diphenylphosphino)butane; DMBA= 1,3-dimethylbarbituric acid
dba= dibenzylideneactone
*Reaction was only run once
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Table 4.6. Evaluation of 7-Azaindole Derivatives 
 
Hs578t U937 Compound X R IC50 (µM) IC50 (µM) 
3.39 C H 14.9 ± 4.8 ND 
3.38 C Allyl 63 ± 16.0 14.1 
4.83a N H 23.7 ± 4.3 11.9 ± 1.7 
4.83b N Allyl 44.6 ± 0.6 28.4 ± 0.5 
   ND= Not Determined 
4.3.3.4 Attempted Synthesis of Oxindole Derivatives 
During the course of these studies, we became curious as to whether major 
structural changes in the conformation of the indole moiety would affect biological 
activity. We hypothesized that an oxidative rearrangement of the indole moiety to 2-
oxindole 4.84 (Figure 4.17) would dramatically alter the orientation of the molecule. If no 
changes in cytoxicity were observed upon rearrangement, we would conclude that the 
indole moiety has a nominal role in binding to the biological target. 
















We found that compounds 4.12 and 4.13 underwent facile rearrangment upon 
reaction with meta-chloroperoxybenzoic acid to give the 3-oxindole 4.86a, not the 2-
oxindole 4.85 that was initially expected (Scheme 4.28). Indeed, free alcohol 4.12 and the 
TBS-protected alcohol 4.13 afforded the highly fluorescent 3-oxindole species as a single 
diastereomer in 80% and 77% yields, respectively. The structure and the relative 
stereochemistry of 4.86b was unambiguously determined via X-ray crystallography 
(Figure 4.18).  
Scheme 4.28. Synthesis of 3-Oxidole Derivative 4.86a and 4.86b  
 
Figure 4.18. X-Ray Structures of Both 4.86b Enantiomers 
 
Unfortunately, attempts to remove the allyl carbamate from 4.86a or the TBS 



















4.85 4.12: R= H
4.13: R= TBS
4.86a: R= H     (80%)
4.86b: R= TBS (77%)
m-CPBA
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of the crude reaction mixtures showed a variety of compounds with mass hits 
corresponding to either addition of DMBA or HF. We hypothesized that the acidic 
conditions of these transformations may be causing a retro-mannich reaction that would 
cleave the bridgehead C-C bond and react with whatever nucleophile is in the reaction. 
Because of concerns that these compounds may not be stable in a biological system, we 
did not pursue them any further.  
Figure 4.19: Attempted Deprotection of 3-Oxindole Derivative 
 
4.3.4 Minimization of 1,3-Diol Moiety 
After exploring the SAR of substitution on the indole ring, we next sought to 
explore the chemical space around the 1,3-diol moiety. Specifically, we wanted to 
determine whether the 1,3-diol structural moiety was necessary for SFM1257 (3.43) 
bioactivity. If the 1,3-diol structural motif was deemed unnecessary, derivatives the form 
4.87 would dramatically reduce the molecular weight and ClogD (Figure 4.20). The 
synthesis of these derivatives would require modification of the 1,3-diol functionality at 
the beginning of the synthesis. In particular, we envisioned that analogs of SFM1257 























which in turn could be synthesized from the primary acetate 4.89 and π-nucleophile 3.10 
(Figure 4.20). 
Figure 4.20. Proposed Synthesis of Derivatives Lacking 1,3-Diol Moiety 
 
4.3.4.1 Attempted Synthesis of Derivatives Lacking the 1,3-Diol Moiety 
The attempted synthesis of 4.88 began with commercially available indole-2-
carboxylic acid (4.90) (Table 4.7). Following literature procedures, compound 4.90 was 
reduced with lithium aluminum hydride to the corresponding primary alcohol, which was 
acylated with acetic anhydride to give 4.89 in 63% yield over two steps.263 When attempts 
were made to react 4.89 with 3.10 using the previously optimized conditions (TMS-OTf, 
DTBMP, CH2Cl2, –78 ºC), no reaction was observed, and starting material was 
recovered. When the reaction was warmed to room temperature or higher, none of the 
desired product 4.91 was detected by 1H-NMR or LCMS analysis, and degradation of 
4.89 was observed. Identical results were obtained when acetonitrile was used as solvent. 
Hypothesizing that the reaction occurs through an SN1 pathway, it is not surprising that 
4.89 is less prone to ionization than the original substrate 3.11 because 4.89 would 

























previous work in the Martin lab in which compound 4.92 did not react with ketene acetals 
in the presence of Lewis acid (Scheme 4.29).264  
Table 4.7. Attempted Cascade Reaction on Primary Acetate 
 
Scheme 4.29. Previous Work in Martin Group264 
 
4.3.4.2 Synthesis of gem-Dimethyl Derivative 
Given the unreactive nature of 4.89, we turned our attention to gem-dimethyl 
derivatives with the general form of 4.95 (Figure 4.21). Analogous to the previous 
compounds, we envisioned that these would arise via a Lewis acid mediated addition of 





















TMS-OTf, 3.10, DTBMP, CH2Cl2, –78 ºC → rt














4.93 4.94fd4.X4 .92: R= H, Ac, CONHPh




Figure 4.21. Revised Approach to Derivatives Lacking 1,3-Diol Moiety 
 
Synthetic efforts towards gem-dimethyl derivatives 4.95 commenced from 
commercially available indole-2-methyl ester 4.98. Following literature procedure, 
methyl ester 4.98 was converted to tertiary alcohol 4.99 by reaction with 
methyllithium.265 Unfortunately, attempts at acylation of alcohol 4.99 did not afford any 
isolable quantities of acetate 4.97 (Table 4.8). Instead, elimination product 4.100 and 
other unidentified dimeric compounds were observed by 1H-NMR spectroscopy and 
LCMS analysis of crude reaction mixtures. These results were somewhat unexpected, 
because Dr. Ivan Jewett successfully converted 4.101 to 3.11 in 74% yield (Scheme 
4.30).121 We hypothesized that the inductively withdrawing O-benzyl substituents make 
3.11 less prone to ionization than 4.97, thereby stabilizing 3.11. Thus, we hypothesized 
that a methyl ether derivative of 4.99 might be sufficiently stable to isolate yet labile 





























Table 4.8. Attempted Synthesis of Acetate 4.97 
 
Scheme 4.30. Previously Reported Conversion of 4.101 to 3.11121 
 
Numerous conditions were examined to optimize the solvolysis of 4.99 to give the 
methyl ether 4.102 (Table 4.9). For example, it was found that heating 4.99 in anhydrous 
methanol under reflux for extended reaction times returned only starting material (Table 
4.9, entry 1). Several Brønsted acids were then screened, and it was found that 1 M HCl 
provided methyl ether 4.102 in 46% yield (Table 4.9, entry 2), whereas 10 mol% p-
toluenesulfonic acid lead to an intractable mixture (Table 4.9, entry 3). The less acidic 
Brønsted acid pyridinium p-toluenesulfonate afforded methyl ether 4.102 in 85% yield 
but some elimination was also observed (Table 4.9, entry 4). We then found that silica gel 
slowly catalyzed the conversion of 4.99 to 4.102 (Table 4.9, entry 5). As a result, several 
Brønsted acid-doped silica gels were prepared and evaluated, and it was found that 10% 























20% DMAP, 2 eq NEt3, Ac2O
1.1 eq DMAP, Ac2O:CH2Cl2 (1:1)
15% DMAP, 10 eq DIPEA, 5 eq Ac2O, CH2Cl2
1.05 eq DMAP, 1.1 eq Ac2O, CH2Cl2
Results



























scale (Table 4.9, entry 8). However, the reaction did not go to completion once scaled up 
to 250 mg, affording 4.102 in 75% yield (98% BRSM) (Table 4.9, entry 9).   
Table 4.9. Optimization of Solvolysis Reaction with MeOH 
 
With an appreciable amount of 4.102 in hand, it was treated with 3.10 in the 
presence of TMS-OTf and DTBMP to give 4.96 in 22% yield (Table 4.10, entry 1). 
Significant amount of starting material remained, so we hypothesized that increasing the 
solvent polarity by changing the solvent from CH2Cl2 to MeCN might facilitate the 
ionization of 4.102 and lead to higher conversion. Indeed, higher conversion was 
observed, but a significant amount of gramine fragmentation was also observed (Table 
4.10, entry 2), which we attributed to the higher reaction temperature (–40 ºC vs. –78 ºC). 
Because MeCN freezes below –40 ºC, a mixture (2:3) of MeCN/CH2Cl2 was used to 
increase the solvent polarity but still allow the reaction to be performed at –78 ºC. The 
mixed solvent system reaction afforded 4.96 in 43% yield (Table 4.10, entry 3). Although 

























MeOH, reflux   
1 M HCl, MeOH, 100 ºC (sealed tube)
10% p-TsOH, MeOH
10% PPTS, MeOH, rt
SiO2, MeOH, 100 ºC (sealed tube)
10% H3PO4/SiO2, MeOH, rt
10% fumaric acid/SiO2, MeOH, rt
10% oxalic acid/SiO2, MeOH, rt
10% oxalic acid/SiO2, MeOH, rt
Results
No Reaction  
46% 4.102 (100% conversion)
intractible mixture (100% conversion)
~85% 4.102 (100% conversion)
~20% 4.102 (~20% conversion)
~50% 4.102 (~50% conversion)
~50% 4.102 (~50% conversion)
quant (25 mg scale)
75% (98 BRSM) (250 mg scale)
PPTS= pyridinium p-toluenesulfonate
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Table 4.10. Synthesis of Tetracyle 4.96 
 
The synthesis of gem-dimethyl derivatives commenced via the reduction of 4.96 
with lithium borohydride to give alcohol 4.103 in 93% yield, and dimethylation with 
NaH/MeOTs then furnished compound 4.104 in 76% yield (Scheme 4.31).  
Scheme 4.31. Reduction and Alkylation of gem-Dimethyl Tetracycle 4.104 
 
Removal of the allyl carbamate from 4.104 using Pd2dba3/DPPB/DMBA afforded 
amine 4.105 in 77% yield. Alternatively, removal of the allyl carbamate with Pd(PPh3)4 

























CH2Cl2, –78 ºC 
MeCN, –40 ºC







































Scheme 4.32. Synthesis of Derivative 4.105 and 4.106 
 
4.3.4.4 Evaluation of Derivatives 
The gem-dimethyl derivatives were then evaluated by Dr. Betsy Parkinson for 
their ability to induce cell death in U937 cells (human lymphoma) and human red blood 
cells (Table 4.11).96 Because the gem-dimethyl compounds showed no biological activity, 
this series was not pursued further. However, these results provide valuable insight to 
what constitutes the active pharmacophore. It is clearly evident that the oxygen atoms 
and/or the benzyl groups are necessary for biological activity. 
Table 4.11. Evaluation of gem-Dimethyl Derivatives 
 
U937* Hem* Entry Cmpd R1 R2 R3 IC50 (µM) IC50 (µM) 
1 4.106 Allyl Me Me >100 >333 
2 4.105 H Me Me >100 >333 
*Data collected Dr. Betsy Parkinson96 
4.3.5 Further Pharmacophore Elucidation  
We sought to further to determine which structural features were necessary for 






























DPPB= 1,4-bis(diphenylphosphino)butane; DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone








moieties were necessary for biological activity. As a result, we sought to simplify the 
carbon structure to determine how dependent the biological activity was on the tetracyclic 
framework. Accordingly, we decided to evaluate compounds 4.107 and 4.108 (Figure 
4.22). Compound 4.107 would elucidate whether the basic nitrogen atom was needed for 
biological activity, and compound 4.108 would inform us as to what extent the observed 
biological activity was dependent on the O-benzyl groups.  
Figure 4.22. Derivatives to Further Minimize Pharmacophore 
 
4.3.5.1 Synthesis of Dissected Carbon Framework 
Compounds 4.107 and 4.108 were readily synthesized from indolo-acetate 3.11. 
For example, heterogeneous transfer hydrogenation of 3.11 with ammonium formate and 
Pd/C afforded compound 4.108 in 55% yield. Utilizing the conditions reported by Li et 
al, compound 4.107 was synthesized in 51% yield using 37% aqueous formaldehyde, 

























Scheme 4.33. Synthesis of Derivatives 4.107 and 4.108 
 
4.3.5.2 Evaluation of Compounds 4.107 and 4.108 
Compounds 4.107 and 4.108 were evaluated for their ability to induce cell death 
in Hs578t cells (triple negative breast cancer) and U937 cells (human lymphoma) (Table 
4.12). Compound 4.108 was slightly active in vitro (Hs578t IC50 >100 µM and U937 
IC50= 48.0 ± 11.4 µM); whereas, compound 4.107 was significantly more active (Hs578t 
IC50= 24.4 ± 1.9 µM and U937 IC50= 17.8 ± 3.9 µM). These data suggest that the basic 
nitrogen atom is necessary for biological activity.  
Table 4.12. Evaluation of Compounds 4.107 and 4.108 
 
Hs578t U937 Compound IC50 (µM) IC50 (µM) 
4.108 >100 48.0 ± 11.4 
4.107 24.4 ± 1.9 17.8 ± 3.9 
4.3.6 Structure Activity Relationship of 1,3-Diol Moiety 
As a result of the studies thus far, it seemed clear that the 1,3-diol moiety played 









































synthesize several O-substituted derivatives in order to probe the SAR in that section of 
the molecule (Figure 4.23, 4.109). Specifically, we wanted to explore the effects that 
exchanging the O-benzyl moieties for O-methyl, O-phenyl, and substituted O-phenyl 
groups would have on the biological activity of these compounds. Because these 
structural variations could not be introduced via late stage functionalization of SFM1257 
(3.43) or SFM1258 (3.44), we embarked on their de novo synthesis. We envisioned that 
the analogs could be formed from common tetracyclic intermediate 4.110, which in turn 
could be synthesized from indole (3.18), π-nucleophile 3.10, and the desired substituted 
ketone (4.111) (Figure 4.23). 
Figure 4.23. Retrosynthetic Analysis for 1,3-Diol Substituted Derivatives  
 
4.3.6.1 Synthesis of O-Substituted Derivatives 
The synthesis of the 1,3-diol derivatives commenced with the formation of the 
desired substituted ketone. These compounds were synthesized in two steps according to 
literature procedures (Scheme 4.34).267 Starting with the substituted phenols 4.112a-c, a 
double nucleophilic substitution with epi-chlorohydrin (4.113) afforded alcohols 4.114a-c 
in 55-86% yield. The alcohols 4.114a-c were oxidized to the corresponding ketones 
























synthesized in two steps via double substitution of MeOH with epi-chlorohydin (4.113) 
to give alcohol 4.116 in 79% yield, and subsequent TEMPO oxidation to give ketone 
4.117 in 24% yield (Scheme 4.34).268 
Scheme 4.34. Synthesis of Ketone 4.114a-c 
 
Scheme 4.35. Synthesis of Ketone 4.117 
 
The synthesis of the differentially substituted 1,3-diol derivatives continued with 
the formation of indolo-acetates 4.118a-d in 19-73% yield via the five step one-pot 
procedure utilizing ketones 4.117 and 4.115a-c (Scheme 4.36).  The indolo-acetate 
compounds 4.118a-d were next subjected to the cascade reaction conditions to provide 
the desired tetracycles 4.119a-d in 44-81% yield. The tetracyclic compounds (4.119a-d) 
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Scheme 4.36. Synthesis of Differentially Substituted 1,3-Diol Scaffold 
 
The allyl carbamate groups in 4.120a-d were then removed with 
Pd2dba3/DPPB/DMBA to afford 4.121a-d in 58-85% yield. Compound 4.122a was 
prepared via reductive amination of 4.121a with 37% aqueous formaldehyde to provide 











































TBAF= tetrabutylammonium fluoride; DTBMP= 2,6-di-tert-butyl-4-methylpyridine
#BRSM; *Reaction only run once
4. 4.117,
    4.115a-c
5. Ac2O
CH2Cl2
–78 ºC → rt
LiBH4
MeOH










Scheme 4.37. Synthesis of Derivative 4.121a-d and 4.122a 
 
To prepare analogs structurally similar to SFM1257 (4.43), the indole nitrogen 
atom of 4.119a,b was protected with DMAP/Boc2O to afford compounds 4.123a,b in 
63% and 40% yield, respectively. Ketones 4.123a,b were reduced with lithium aluminum 
hydride to afford alcohols 4.124a,b in 57% and 62% yield. The allyl carbamate of 
4.124a,b was removed with Pd2dba3/DPPB/DMBA to provide derivatives 4.125a,b in 

































DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone
DPPB= 1,4-bis(diphenylphosphino)butane





















Scheme 4.38. Synthesis of Derivative 4.125a,b 
 
In other experiments, alkylation of 4.120a,b with NaH/MeOTs gave compounds 
4.126a,b in 99% yield each. Removal of the allyl carbamate group from compound 
4.126a with Pd2dba3/DPPB/DMBA provided amine 4.127a in 85% yield, and removal of 
the allyl carbamate group from 4.126b furnished compound 4.127b and the N-allyl 
derivative 4.127c in 66% and 18% yields, respectively. A reductive amination of 4.127a 













































0 ºC → rt
THF, rt
DPPB= 1,4-bis(diphenylphosphino)butane; DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone
#BRSM; *Reaction only run once
Series a: R= Me
b: R= Ph
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Scheme 4.39. Synthesis of Derivatives 4.127a-c and 4.128a 
 
Several additional analogs of SFM1258 (3.44) were synthesized from 4.127a-b by 
a decarboxylative allylation to afford N-allyl compounds 4.129 and 4.127c in 90% and 
55% yield (Scheme 4.40). 





























4.127a R2= H    (85%)*
4.127b R2= H    (66%)*
4.127c R2= Allyl (18%)*
DPPB= 1,4-bis(diphenylphosphino)butane; DMBA= 1,3-dimethylbarbituric acid; dba= dibenzylideneactone





























4.127c: R= Ph (55)*
4.129: R= Me (90)*
*Reaction was only run once
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4.3.6.2 Evaluation of O-Substituted Derivatives 
These novel 1,3-diol analogs were evaluated for their ability to induce cell death 
in Hs578t cells (triple negative breast cancer) U937 cells (human lymphoma), and human 
red blood cells (Table 4.13). The data collected for these derivatives provided further 
insight into the structure-activity-relationship of the compounds. In particular, 
exchanging the O-benzyl groups for O-methyl groups rendered the compounds inactive 
(Table 4.13, entries 3-8). On the other hand, exchanging the O-benzyl groups for O-
phenyl or p-substituted O-phenyl groups did not dramatically affect potency (Table 4.13, 
entries 9-14). However, the O-phenyl derivative of SFM1257 (3.43) and SFM1258 (3.44) 
did show a slight reduction in potency (Table 4.13, entry 1 vs. entry 11 and entry 2 vs. 
10). These data indicate that larger, non-polar moieties on the 1,3-diol are necessary for 
biological activity. Additionally, the p-substituted phenyl groups on the 1,3-diol were 
biologically active, and the p-chloro derivative 4.121c showed comparable activity to 
SFM1257 (3.43) (Table 4.13, entry 1 and entry 13). Interestingly, the p-methoxy phenyl 
substituted derivative 4.121d showed comparable activity to p-chloro derivative 4.121c 
(Table 4.13, entry 13 vs 14), thereby indicating that the electronics of the arene may not 
be very relevant for binding to the biological target. This series of compound also 
reinforced the previous observation that appending an allyl group to the basic nitrogen 








Table 4.13.  Evaluation of Differentially Substituted 1,3-Diol Derivatives 
 
Hs578t U937 Hem* Entry Compound R1 R2 R3 R4 IC50 (µM) IC50 (µM) IC50 (µM) 
1 SFM1257 (3.43) H H Boc Bn 6.6 ± 0.7 3.3 ± 0.2 28 
2 SFM1258 (3.44) Allyl Me Me Bn 20 ± 2.9 5.6 ± 2.3 >100 
3 4.121a H H H Me ND >100* >333 
4 4.122a Me H H Me ND >100* >333 
5 4.127a H Me Me Me ND >100* >333 
6 4.128a Me Me Me Me ND >100* >333 
7 4.129 Allyl Me Me Me ND >100* >333 
8 4.125a H H Boc Me ND >100* >333 
9 4.127b H Me Me Ph 5.3 ± 0.9 6.4 ± 0.1 ND 
10 4.127c Allyl Me Me Ph 35.4 ± 6.2 20.9 ± 1.5 ND 
11 4.125b H H Boc Ph 9.2 ± 1.2 7.2 ± 0.9 ND 
12 4.121b H H H Ph 6.1 ± 0.1 6.4 ± 0.1 ND 
13 4.121c H H H p-PhCl 4.7 ± 0.3 4.2 ± 0.6 ND 
14 4.121d H H H p-PhOMe 10.2 ± 1.6 4.4 ± 1.0 ND 









4.4 PRELIMINARY EFFORTS TOWARDS THE SYNTHESIS OF ENANTIOENRICHED 
DERIVATIVES  
4.4.1 Introduction 
All of the derivatives prepared to date have been racemic, but it is necessary to 
evaluate the biological properties for each enantiomer independently because each 
enantiomer may be responsible for a unique aspect of the phenotypic response. 
Enantiopure material may be obtained by chiral HPLC separation or chiral resolution 
with a chiral auxiliary, but given the impracticality of large-scale chiral HPLC separation 
and the step-inefficiency of a resolution with a chiral auxiliary, enantioselective synthesis 
is the method of choice. In the synthesis of SFM1257 (3.43), the addition of π-
nucleophile 3.10 to tertiary carbocation 3.20 is the chirality-determining step, so the 
focus of these efforts will be to impart stereoselectivity onto this transformation (Figure 
4.24).  
Figure 4.24.  The Chirality Forming Step in the Synthesis of SFM1257 (3.43) 
 
4.4.2 Strategies For Stereoselective Additions to Carbocations 
There are three general strategies employed to perform these types of 
transformations asymmetrically: substrate control, catalyst control, and reagent control 













Substrate control (Figure 4.25, 1): stereochemistry is controlled by a chiral group 
covalently attached to the carbocation. This approach has been successfully employed in 
natural product synthesis and on kilogram scale of an active pharmaceutical ingredient 
(API).270-276 Catalyst control (Figure 4.25, 2): a prochiral carbocation forms an ion pair 
with a chiral counterion by blocking one face of the carbocation that subsequently 
controls stereochemistry. This strategy has been used for enantioselective polyene 
cyclization,277 Friedel-Crafts alkylation and acylation,278,279 allylic substitution,280 and 
enamide addition.281 Reagent control (Figure 4.25, 3): stereochemistry at an achiral 
carbocation is controlled through stereochemical interaction with a chiral nucleophile. 
This approach has been used effectively with a chiral ketene acetal,264 enamine,282-285 and 
thiourea catalysis.286,287 In the context of our system, substrate control is not an option 
because both of the reactants (3.10 and 3.11) are achiral. Catalyst control cannot be 
applied given that carbocation 3.20 is not prochiral. Thus, the better option for our system 
is reagent control with a chiral nucleophile.  
Figure 4.25 Carbocations in Asymmetric Synthesis 
 




























4.4.3 Chiral Boron Enolate Strategy 
Towards the goal of stereoselective addition to carbocation 3.20, we envision that 
the π-nucleophile 3.10 can be modified to include an easily removed chiral auxiliary in 
place of the TIPS groups (Figure 4.26). This would impart chirality onto π-nucleophile 
3.10 and hopefully afford a product with high levels of enantioenrichment after removal 
of the auxiliary. 
Figure 4.26. Proposed Strategy for Obtaining Enantioenriched Material 
 
We reasoned that use of a chiral boron enolate would be the optimal strategy to 
make the transformation of 3.11 to 4.139 stereoselective because the reactivity of such 
enolates is analogous to a silyl enol ether (Scheme 4.41). One could envision a reaction 
pathway in which chiral borate 4.136 would coordinate with the acetoxy group of 3.10 to 
facilitate ionization and give carbocation 3.20 and boronate 4.137. Chiral boronate 4.137 
would then react with carbocation 3.20 to afford the N-acyliminium species 4.138, which 
































envision the key stereodetermining step would be the alkylation of 3.20 with 4.137, and 
the stereochemistry of the alkylation would be controlled by the chirality of the boronate. 
Scheme 4.41. Proposed Enantioselective Cascade Reaction 
 
There are a number of chiral groups that could be attached to the boron for 
potential use in this transformation,288-292 The boron enolate derived from 
diisopinocampheylborane (4.140) was chosen for initial investigation in this system 
because the reagent can be readily prepared on decagram scale from cheap materials,293 
and its use in enantioselective aldol reactions for reagent control of absolute 













































Figure 4.27. Structure of (IPC)2BH 
 
4.4.4 Cycloheptanone Model Study 
Given the complexity of this transformation, cycloheptanone was chosen as a 
model system to evaluate the Lewis acidity of the boron enolate. In this model study, the 
IPC boron enolate 4.141 was first formed in situ using general base catalysis with a 
titrated298 solution of (IPC)2BOTf in CH2Cl2, followed by dropwise addition of a solution 
of 3.10 in CH2Cl2. The initial attempts with triethylamine as the base failed to facilitate 
the addition of 4.141 to 3.11 (Scheme 4.42). Since no reaction was observed and only 
starting material was recovered, the boron enolate did not appear to be sufficiently Lewis 
acidic to initiate the reaction. To verify that boron enolate 4.141 was being formed, a 
control reaction was run with 4.141 and benzaldehyde. The base used to form the boron 
enolate can also coordinate to the boron, thereby attenuating Lewis acidity (Scheme 
4.43). For that reason, several additional bases were screened (i-Pr2NEt, 2,6-lutidine, and 
2,6-di-tert-butyl-4-methylpyridine), each subsequent base bulkier than the previous 
(Scheme 4.42). It was found that switching to a bulkier base did not sufficiently enhance 










Scheme 4.42. Initial Attempts with Cycloheptanone Model System 
 
Scheme 4.43. Base Can Coordinate to Boron Enolate 
 
We reasoned that a Lewis acid co-catalyst might be necessary to initiate the 
reaction. When TMS-OTf was added to the reaction, ionization of the indolo-acetate 
(3.11) occurred, but no addition of the boron enolate to the indolo-acetate was observed. 
Instead, elimination of the acetate (4.143) as well as dimerization of the starting material 
was observed upon quenching the reaction (Scheme 4.44). Thus, we concluded that boron 















Bases Screened: NEt3, i-Pr2NEt, 2,6-lutidine, 2,6-di-tert-butyl-4-methylpyridine
No Reaction
CH2Cl2













Scheme 4.44. Cycloheptanone Model System With Lewis Acid Co-catalyst 
 
4.4.5 Vinylogous Amide Boron Enolate Formation Using Weak Base 
After the failure with the cycloheptanone model system, we turned our attention 
to forming the boron enolate of the vinylogous amide 4.144 because we predicted the 
resulting boron enolate would be significantly more nucleophilic (Figure 4.28). To 
evaluate whether the boron enolate could be formed under general base conditions, the 
spectroscopy reaction was performed in CD2Cl2, and aliquots were analyzed via 1H-NMR 
and 13C-NMR by monitoring the carbonyl resonance in the 13C-NMR spectra and the 
alpha proton resonance in the 1H-NMR spectra of 4.144. It was found that the base 
chosen had a dramatic effect on the outcome of the reaction. The very bulky base 2,6-di-
tert-butyl-4-methylpyridine (DTBMP) afforded none of the desired boron enolate. A 
complete loss of the carbonyl resonance was observed in the 13C-NMR specctra, but no 
discernable resonances were observed in the 1H-NMR. On the other hand, approximately 
~70% conversion was observed when i-Pr2NEt was used as the base. This conclusion was 
supported by the loss of resonance at 4 ppm in the 1H-NMR spectra, and a new doublet 
1H-NMR resonance at 5.2 ppm. We believe the doublet at 5.2 ppm is the boron enolate 
proton (4.145, H1) because the analogous proton on 3.10 comes at roughly the same ppm 
(Figure 4.29). Additionally, the carbonyl peak was sill seen in the 13C-NMR, but its 





















Figure 4.28. Observations From 1H-NMR Studies of Boron Enolate Formation 
 


















































We hypothesized that the inability of DTBMP to convert 4.144 to 4.145 was due 
to protonation of boron enolate 4.144 by the resulting conjugate acid of DTBMP which 
has a pKa of 4.95 (Scheme 4.45).299 Given that TIPS enol ether 3.10 is very acid labile 
and rapidly decomposes on silica, it is not surprising that decomposition of the material 
was observed. Despite successfully forming 4.145 with i-Pr2NEt, previous reports by Dr. 
Brett Granger120 and Dr. Ivan Jewett121 found that the TMS-OTf mediated reaction 
between 3.11 and 3.10 does not proceed cleanly if bases other than DTBMP are used. 
Thus, we concluded that forming the boron enolate under general base condition is not a 
viable approach to this transformation.  
Scheme 4.45. Rationalization for Lack of Boron Enolate Formation with DTBMP 
 
4.4.6 Future Studies 
The development of a stereoselective variant of the Lewis acid catalyzed reaction 
between 3.10 and 3.11 is an ongoing effort. Moving forward, we believe the best course 
of action will be to synthesize the boron enolate by first quantitatively forming the 
lithium enolate with a bulky base, then reacting the lithium enolate with (IPC)2BOTf 
(Scheme 4.46). The use of a strong base to quantitatively deprotonate 4.144 will mitigate 
























Scheme 4.46. Proposed Future Attempt at Boron Enolate Formation 
 
After the boron enolate has been successfully synthesized, the addition of 4.145 to 
3.11 will be attempted with and without the addition of TMS-OTf. If it is found that the 
reaction proceeds, but does not impart significant enantioenrichment, additional boron 
enolates can be evaluated (Figure 4.30).288-292 
Figure 4.30. Additional Boron Reagent Capable of Controlling Absolute Stereochemistry 
 
4.5 CONCLUSION 
A number of significant advances have been made towards understanding how 
SFM1257 (3.43) interacts with biological systems. For example, the hypothesis that 
SFM1257 (3.43) induces cell death via induction of ER stress was supported by 
demonstrating that guanabenz (4.41), a small molecule inhibitor of PP1/GADD34, 
afforded robust cytoprotection against SFM1257 (3.43) induced toxicity. This also 
demonstrated that inhibition of PP1/CReP was not necessary to mitigate the effects of 
SFM1257 (3.43). Additionally, two novel tool compounds containing a tethered biotin 
































 Through the synthesis and biological evaluation of over 40 novel derivatives of 
SFM1257 and SFM1258, an extensive structure-activity-relationship has been established 
for these compounds, and key insights have been developed as summarized in Figure 
4.31. Through the synthesis of truncated derivatives, we have determined that the key 
structural features that contribute significantly to the biological activity are large, non-
polar groups on the 1,3-diol moiety (Figure 4.31, R3). If the O-benzyl groups (Figure 
4.31, R3) are exchanged for O-Me or –H, the compounds show no in vitro potency. 
Further studies demonstrated that the alcohol moiety (Figure 4.31, R2) is likely not 
critical for binding to the biological target. It was found that substitution is tolerated at 
the 5- and 6-postion on the indole ring (Figure 4.31, R5 and R6), but decreasing the 
electron density of the indole ring leads to less potent compounds (Figure 4.31, X= N). 
These studies have also indicated that the availability of the basic nitrogen atom to act as 
a hydrogen bond donor or acceptor is crucial to maintaining activity. If a carbamate or 
large, non-polar group is appended to the basic amine (Figure 4.31: R1= benzyl, alloc), 
potency is decreased. However, smaller alkyl substituents are tolerated on the basic 
amine and also lead to lower levels of hemolysis. Overall, the SAR of these compounds 
has not been very pronounced, and many fairly large changes have resulted in only small 
differences in potency (i.e. Figure 4.31: IC50≈ R5= H, Cl, Ph, and p-CF3Ph). These data, 
combined with the previous biological evaluation by the Hergenrother lab, has led us to 
conclude that these compounds are likely not binding to an individual target with high 
affinity (IC50 < 1 µM). Thus, it is not clear that future SAR studies would lead to a 





Figure 4.31. Summary of SAR to Date 
 
Preliminary work has also been undertaken to access enantioenriched material. It 
has been found that formation of a chiral boron enolate using DTBMP is not a viable 
approach to this transformation, likely due a deleterious reaction between the conjugate 
acid and the boron enolate. Thus, future studies will focus on the formation of the boron 






















R3≠ OH, -H, O-Me
R4= H, Methyl, Boc
R5= H, Cl








Chapter 5: Experimental Procedures 
5.1 GENERAL EXPERIMENTAL SECTION 
Methanol (MeOH), acetonitrile (MeCN), and N,N-dimethylformamide (DMF) 
were dried by filtration through two column of activated molecular sieves. 
Tetrahydrofuran (THF) and toluene were passed through two columns of activated 
neutral alumina prior to use. Triethylamine (Et3N), diisopropylethylamine (DIPEA), N,N-
diisopropylamine (i-Pr2NH), pyridine, trimethylsilyl chloride (TMS-Cl), benzene, 
dichloromethane (CH2Cl2), trimethylsilyl trifluoromethanesulfonate (TMS-OTf), acetic 
anhydride (Ac2O), 2,6-lutidine, and tert-butyldimethylsilyl trifluoromethanesulfonate 
(TBS-OTf) were distilled fresh from CaH2. N-vinylpyrrolidone was distilled under 
reduced pressure prior to use. All other reagents and solvents were reagent grade and 
were purchased and used as received unless otherwise noted. Water sensitive reactions 
were performed with oven- or flame-dried glassware, stir-bars, and steel needles. 
Reaction temperatures are reported as the temperature of the bath surrounding the vessel. 
Sensitive reagents and solvents were transferred using plastic syringes and steel needles 
using standard techniques. Thin layer chromatography (TLC) was performed on EMD 60 
F254 glass-backed pre-coated silica gel plates and were visualized using one or more of the 
following techniques: UV light (254 nm) and staining with basic potassium 
permanganate (KMnO4) or p-anisaldehyde (PAA). Flash chromatography was performed 
using glass columns and Silicycle SiliaFlash F60 (40-63 µm) silica gel eluting with the 
solvents indicated according to Still.300 Purity was determined using an LCMS system 
comprised of an Agilent 1200 Series HPLC and an Agilent 6130 Series single quadrupole 
mass spectrometer. Samples were injected onto a Phenomenex Gemini C18 column (5 
micron, 2.1 x 50 mm) and eluted at 0.7 mL/min using a gradient of 10-90% acetonitrile, 
0.1% formic acid (11 minute linear ramp). Positive mode electrospray ionization was 
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used to verify the identity of the major component, and a UV chromatogram recorded as 
214 nm was integrated to determine compound purity. Reverse phase high performance 
liquid chromatography (RP HPLC) was conducted using a binary solvent system, where 
solvent A was 0.1% aqueous TFA and solvent B was 0.1% TFA in MeCN, with a 
Phenomenex Gemini C18 column (10 μm particle size, 300Å pore size), 250 mm x 21.2 
mm diameter (flow rate of 15 mL/min) being used for preparative work. Proton nuclear 
magnetic resonance (1H-NMR) and carbon nuclear magnetic resonance (13C-NMR) 
chemical shifts are reported in parts per million (ppm, δ), downfield from 
tetramethylsilane (TMS, δ= 0.00 ppm) and referenced to residual solvent. Coupling 
constants (J) are reported in hertz (Hz) and the resonance abbreviations used are: s, 
singlet; d, doublet; t, triplet; dt, doublet of triplets; td, triplet of doublets; dd, doublet of 
doublets; ddd, doublet of doublet of doublets; m, multiplet; comp, overlapping multiplets 
of magnetically non-equivalent protons. The abbreviations br and app stand for broad and 
apparent, respectively. Melting points were measured on a Thomas-Hoover capillary tube 
apparatus and are uncorrected. Infrared spectra were recorded with a Nicolet FT-IR 
spectrophotometer as thin films on a NaCl disc unless otherwise noted. 
Hs578t (human breast cancer) cells were cultured in Dulbecco’s modified Eagle 
medium (DMEM) containing 4.5 g/L glucose and supplemented with 10% (v/v) fetal 
bovine serum (Gemini Bio-Products, West Sacramento, CA), 1 mM sodium pyruvate, 
100 U/ml penicillin (Cellgro, Manassas, VA), and 100 µg/mL streptomycin (Cellgro, 
Manassas, VA). U937 (human lymphoma) cells were grown in RPMI 1640 supplemented 
with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 µg/mL streptomycin. All 
cells were maintained in a humidified atmosphere with 95% air and 5% CO2. All 
adherent cell lines were detached using 0.05% trypsin/EDTA. 
 232 
5.2 EXPERIMENTAL PROCEDURES AND COMPOUND CHARACTERIZATION 
Dose Response (IC50) curves 
To a 96-well plate, 100 μL of 2% compound dilution or 2% DMSO-containing 
media were added (final volume of 1% DMSO in all wells). On each plate at least 3 wells 
per compound concentration were prepared. Next, 100 μL of a 150,000-300,000 cells/mL 
suspension was added to each well, yielding a final concentration of 3,000 (Hs578t) or 
5,000 cells/well (U937). To multiple wells in column 2 was added 20 μL of 10 mM 
doxorubicin (final concentration of 100 μM) as a positive control. Plates were sealed with 
gas-permeable seals and incubated at 37 °C for 48 h. At that time, 50 μL of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in sterile PBS (3 mg/mL) 
was added, and the plates were re-sealed and incubated for 4-8 hours. The plates were 
subsequently aspirated and the precitate formazan was dissolved in 50 µL DMSO. 
Absorbance values at 560-650 nm were measured using a microplate reader (Molecular 
Devices, Sunnyvale, CA) and normalized to the average of non-edge untreated wells (0% 
cell death) and the average of 100 μM doxorubicin wells (100% cell death). The data 
were plotted as compound concentration versus percent dead cells, and fitted to a logistic-
dose response curve using OriginPro. Hill Slope values were obtained from curve fitted 
by OriginPro. The data were generated in triplicate, and IC50 values are reported as the 
average of three separate experiments along with standard error of the mean. 
 
Cell viability via flow cytometry 
U937 cells were plated at 300,000 cells/well in 500 μL in 24-plates 2 h prior to 
addition of cytotoxic compound. A 500X dilution of compound in DMSO was added to 
media, followed by agitation to mix. The cells were incubated for the indicated time, and 
then transferred to polystyrene flow tubes. The tubes were centrifuged (3 min, 500xg) 
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and the supernatant was aspirated. The pellet was resuspended in binding buffer (10 mM 
HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH = 7.4) containing 2 μg/mL propidium iodide 
and 1X Annexin V-FITC Conjugate antibody. Cell suspensions were placed on ice and 
analyzed by flow cytometry, where cells were considered viable if they were both PI- and 
AnnV-negative.  
 
With use of protectant compounds 
Protectant compounds were added as DMSO stocks to wells prior to addition of cell 
suspension, such that cells were pre-incubated with protectant compound for 2 h prior to 
cytotoxin addition. DMSO or 500X compound was then added and incubated for the 
indicated time period before analysis as described above. 
 
 
4'-((tert-Butyldimethylsilyl)oxy)-[1,1'-biphenyl]-2-amine. (2.4). (WLM5_120). 
To a degassed (30 min Ar) mixture of 1,4-dioxane (75 mL) and water (25 mL) was added 
powdered K2CO3 (4.1 g, 29.64 mmol), 2-bromoaniline (1.70 g, 9.88 mmol), boroxine 
1.120 (3.00 g, 4.28 mmol), Pd(dppf)Cl2 dichloromethane adduct (403 mg, 0.494 mmol), 
and 2,6-di-tert-butyl-4 methylphenol (BHT) (spatula tip). The mixture was then heated to 
100 °C under an argon atmosphere for 6 hours until all starting material was consumed, 
as judged by TLC. The resulting dark colored solution was diluted with EtOAc (1 L), 
washed with H2O (500 mL), brine (500 mL), dried with Na2SO4, and concentrated under 




with Hexanes : EtOAc (10:1) to give 2.96 g (90%) of 2.4 as a brown oil: 1H-NMR (400 
MHz, CDCl3) δ 7.35 (d, J = 8.8 Hz, 2 H) 7.19-7.14 (comp, 2 H) 6.95 (d, J = 8.4 Hz, 2 H) 
6.85 (td, J = 8.0 Hz, 1 H) 6.78 (d, J = 7.6 Hz, 1 H) 3.77 (br, 2 H) 1.06 (s, 9 H) 0.29 (s, 6 
H); 13C-NMR (100 MHz, CDCl3) δ 154.9, 143.7, 132.4, 130.6, 130.2, 128.2, 127.6, 
120.4, 118.7, 115.6, 25.8, 18.3, -4.2; IR (thin film) 3470, 3377, 2956, 2929, 2885, 2858 




methylbenzenesulfonamide. (2.12). (WLM3_6). To a solution of 2.4 (973 mg, 3.25 
mmol) in pyridine (6.5 mL) at 0 °C was added p-toluenesulfonyl chloride (1.25 g, 6.5 
mmol). The reaction was allowed stir overnight until all starting material was consumed, 
as judged by TLC. The resulting brown solution was diluted with EtOAc (50 mL), 
washed with H2O (25 mL), brine (25 mL), dried with Na2SO4, and concentrated in vacuo 
to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 25 mL). 
Subsequent purification by flash chromatography eluting with Hexanes : EtOAc (10:1) 
gave 1.47 g (quant) of 2.12 as a sappy clear oil that solidified upon standing: 1H-NMR 
(400 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 1 H) 7.47 (d, J = 8.8 Hz, 2 H) 7.29 (td, J = 8.2 
Hz, 1 H) 7.18 (d, J = 8.4 Hz, 2 H) 7.13-7.06 (comp, 2 H), 6.80 (d, J = 8.8, 2 H) 6.72 (d, J 
= 8.8 Hz, 2 H) 6.67 (br, 1 H) 2.38 (s, 3 H) 1.03 (s, 9 H) 0.26 (s, 6 H); 13C-NMR (100 
MHz, CDCl3) δ 155.9, 144.1, 136.4, 134.1, 134.0, 130.7, 130.3, 130.2, 129.8, 128.6, 









biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.13). (WLM6_66). To a solution of 
Br2 (2.63 g, 0.85 mL, 16.44 mmol) in CH2Cl2 (41 mL) at 0 °C under argon was added 
ethyl vinyl ether (1.48 g, 1.98 mL, 20.55 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (4.25 g, 5.73 
mL, 32.88 mmol) was added. After 30 min, a solution of 2.12 (3.73 g, 8.22 mmol) in 
CH2Cl2 (41 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (75 mL) and extracted with EtOAc (3 x 75 mL). The combined extracts 
were washed with H2O (100 mL), brine (100 mL), dried with Na2SO4, and concentrated 
in vacuo. The resulting brown oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (20:1) gave 5.0 g (quant) of 2.13 as a clear oil that crystallized upon 
standing: M.p. 118-122 °C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 
7.83-7.78 (comp, 2 H) 7.54-7.49 (comp, 2 H) 7.42-7.34 (comp, 4 H) 7.29-7.17 (m, 1 H) 
7.00-6.84 (comp, 3 H) 5.10-4.93 (m, 1 H) 3.27-3.18 (m, 1 H) 3.09-3.03 (m, 1 H) 2.87-
2.83 (m, 1 H) 2.70-2.66 (m, 1 H) 2.48 (s, 3 H) 1.02 (s, 9 H) 0.94-0.86 (comp, 3 H) 0.24 







144.1, 143.9, 138.3, 137.6, 135.0, 132.8, 132.6, 132.4, 132.1, 131.8, 131.2, 130.9, 129.7, 
129.6, 129.3, 129.1, 129.0, 128.4, 128.1, 127.2, 127.2, 119.9, 119.7, 91.5, 89.8, 66.9, 
65.3, 33.6, 33.5, 25.7, 21.6, 18.3, 18.2, 14.5, 14.2, -4.4; IR (thin film) 3065, 3031, 2956, 





4-one. (2.14). (WLM6_72). To a solution of 2.13 (4.43 g, 7.33 mmol) in anhydrous DMF 
(73 mL, stored over 4Å molecular sieves) at 50 °C was added flame-dried CsF (3.34 g, 
21.98 mmol). The reaction mixture was immediately heated to 130 °C for 1 h under an 
argon atmosphere. After complete consumption of the starting material, as judged by 
TLC, the reaction mixture was diluted with EtOAc (200 mL), washed with H2O (100 
mL), brine (100 mL), dried with Na2SO4, and concentrated in vacuo to afford a brown oil. 
Purification by flash chromatography eluting with Hexanes : EtOAc (3:1) to afford 2.88 g 
(96%) of 2.14 as a white crystalline solid: M.p. 158-160 °C; 1H-NMR (400 MHz, CDCl3) 
δ 7.92 (d, J = 9.2 Hz, 1 H) 7.43 (d, J = 8.4 Hz, 2 H) 7.30 (td, J = 4.4 Hz, 1 H) 7.27-7.24 
(comp, 3 H) 7.12 (td, J = 8.0 Hz, 1 H) 6.86 (dd, J = 9.2 Hz, 1 H) 6.12 (dd, J = 12.0 Hz, 1 
H) 6.07 (dd, J = 12.0 Hz, 1 H) 5.71 (dd, J = 19.6 Hz, 1 H) 5.67 (t, J = 2.8 Hz, 1 H) 3.84-
3.76 (m, 1 H) 3.64-3.56 (m, 1 H) 2.41 (s, 3 H) 1.92 (dd, J = 16.8 Hz, 1 H) 1.58 (dd, J = 
18.0 Hz, 1 H) 1.13 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 185.9, 155.3, 






125.1,83.0, 63.8, 41.6, 35.0, 21.8, 15.0; IR (thin film) 3058, 2976, 2929, 1668 cm-1. 
HRMS (CI) m/z observed 409.1346 [C23H23NO4S (M)+ requires 409.1348]. 
 
 




nitrobenzenesulfonamide. (2.16). (WLM4_132). To a solution of 2.4 (284 mg, 0.95 




nitrosulfonyl chloride (420 mg, 1.90 mmol). The reaction was allowed stir overnight until 
all starting material was consumed, as judged by TLC. The resulting brown solution was 
diluted with EtOAc (50 mL), washed with H2O (25 mL), brine (25 mL), dried with 
Na2SO4, and concentrated in vacuo to give a brown oil, which was subsequently 
azeotroped with cyclohexane (3 x 15 mL). Purification by flash chromatography eluting 
with Hexanes : EtOAc  (8:1) gave 313 mg (68%) of 2.16 as a yellow solid: M.p. 127-
129°C; 1H-NMR (400 MHz, CDCl3) δ 8.16 (d, J = 8.8 Hz, 2 H) 7.65 (d, J = 8.8 Hz, 2 H) 
7.68-7.66 (m, 1 H) 7.34 (td, J = 7.8, 1.6 Hz, 1 H) 7.19 (td, J = 7.6, 1.2 Hz, 1 H) 7.10 (dd, 
J = 7.6, 1.6 Hz, 1 H) 6.78 (d, J = 8.4 Hz, 2 H) 6.70 (d, J = 8.8 Hz, 2 H) 1.02 (s, 9 H) 0.26 
(s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 155.9, 150.2, 144.7, 135.0, 132.6, 130.7, 129.8, 
129.7, 128.6, 128.4, 126.3, 124.1, 123.1, 120.7, 25.7, 18.3, -4.3; IR (thin film) 3338, 
2930, 2858, 1532, 1348 cm-1; HRMS (ESI) m/z observed 507.13911 [C24H28N2O5SSi 





(2.17). (WLM4_50). To a solution of 2.4 (213 mg, 0.71 mmol) in CH2Cl2 (6 mL) under 
argon at 0 °C was added triethylamine (108 mg, 1.07 mmol, 0.15 mL) and 
methanesulfonyl chloride (1 M in CH2Cl2, 0.71 mL). After 3 hr, the reaction was poured 
onto saturated aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 15 mL). The 




Na2SO4 and concentrated under reduced pressure. The resulting a brown oil was purified 
by flash chromatography eluting with Hexanes : EtOAc (4:1) to afford 187 mg (69%) of 
2.17 as a yellow oil: 1H-NMR (400 MHz, CDCl3) δ 7.63 (dd, J = 8.8 Hz, 1 H) 7.35 (td, J 
= 8.0 Hz, 1 H) 7.25 (dd, J = 7.6 Hz, 1 H) 7.22-7.18 (comp, 3 H) 6.95 (d, J = 8.8 Hz, 2 H) 
6.56 (br, 1 H) 2.85 (s, 3 H) 1.02 (s, 9 H) 0.26 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
156.1, 134.3, 133.4, 131.2, 130.4, 130.3, 128.9, 125.1, 121.2, 120.3, 39.9, 25.9, 18.4, -
4.1. IR (thin film) 3355, 3064, 3034, 2956, 2886, 2858 cm-1; HRMS (ESI) m/z observed 




biphenyl]-2-yl)-4-nitrobenzenesulfonamide. (2.18). (WLM4_133). To a solution of Br2 
(133 mg, 0.043 mL, 0.834 mmol) in CH2Cl2 (2.1 mL) at 0°C under argon was added ethyl 
vinyl ether (75 mg, 0.10 mL, 1.05 mmol) drop-wise until the solution turned colorless. 
The mixture was stirred for 30 min and diisopropylethylamine (217 mg, 0.29 mL, 1.68 
mmol) was added. After 30 min, a solution of 2.16 (202 mg, 0.42 mmol) in CH2Cl2 (2.1 
mL) was added drop-wise, and the mixture was allowed to slowly warm to room 
temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (25 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts 
were washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated 







eluting with Hexanes : EtOAc (10:1) to afford 230 mg (87%) of 2.18 as a yellow solid: 
M.p. 140-143°C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 8.42-8.38 
(comp, 2 H) 8.16-8.05 (comp, 2 H) 7.48-7.41 (comp, 4 H) 7.28-7.24 (m, 1 H) 6.96-6.83 
(comp, 3 H) 5.15-4.83 (m, 1 H) 3.47-2.56 (comp, 4 H) 1.03 (s, 9 H) 1.92-1.87 (comp, 3 
H) 0.26 (s, 6 H); 13C-NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 155.9, 155.7, 
150.3, 147.3, 146.3, 144.3, 144.0, 136.0, 133.3, 132.7, 132.4, 131.6, 131.2, 131.0, 130.0, 
129.9, 129.6, 128.5, 127.9, 127.7, 124.2, 120.2, 120.1, 93.7, 90.6, 67.3, 66.4, 33.7, 33.9, 
25.9, 18.4, 14.7, 14.6, -4.2; IR (thin film) 2956, 2929, 2858, 1533, 1349 cm-1; HRMS 




biphenyl]-2-yl)methanesulfonamide. (2.19). (WLM4_51). To a solution of Br2 (157 
mg, 0.051 mL, 0.985 mmol) in CH2Cl2 (3 mL) at 0°C under argon was added ethyl vinyl 
ether (89 mg, 0.12 mL, 1.23 mmol) drop-wise until the solution turned colorless. The 
mixture was stirred for 30 min and diisopropylethylamine (255 mg, 0.34 mL, 1.97 mmol) 
was added. After 30 min, a solution of 2.17 (187 mg, 0.493 mmol) in CH2Cl2 (3 mL) was 
added drop-wise, and the mixture was allowed to slowly warm to room temperature 
overnight under an argon atmosphere. After complete consumption of starting material, 
as judged by TLC, the reaction mixture was poured onto saturated aqueous NH4Cl (25 







H2O (25 mL), brine (25 mL), dried with Na2SO4, and concentrated under reduced 
pressure. The resulting brown oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (10:1) to afford 192 mg (74%) of 2.19 as a yellow oil: 1H-NMR (400 
MHz, CDCl3, as a mixture of rotamers) δ 7.48-7.35 (comp, 6 H) 6.95-6.89 (comp, 2 H) 
5.05-4.80 (m, 1 H) 3.80-2.75 (comp, 7 H) 1.26-1.19 (comp, 3 H) 1.03-1.0 (comp, 9 H) 
0.23-0.21 (comp, 6 H); 13C-NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 155.5, 
155.3, 143.8, 143.2, 136.0, 133.1, 132.7, 132.5, 132.3, 132.2, 131.7, 130.9, 130.8, 129.3, 
129.1, 129.0, 127.9, 120.1, 119.8, 119.7, 92.3, 89.9, 67.3, 66.1, 43.2, 42.9, 41.1, 33.5, 
32.5, 25.6, 18.2, 14.9, 14.6, -4.4; IR (thin film) 2957, 2930, 2896, 2858 cm-1; HRMS 




1,4'-quinolin]-4-one. (2.20). (WLM4_54). To a solution of 2.19 (159 mg, 0.301 mmol) 
in anhydrous DMF (3 mL, stored over 4Å molecular sieves) at 50 °C was added flame-
dried CsF (228 mg, 1.504 mmol). The reaction mixture was immediately heated to 130 
°C for 1 h under an argon atmosphere. After complete consumption of the starting 
material, as judged by TLC, the reaction mixture was diluted with EtOAc (30 mL), 
washed with H2O (20 mL), brine (20 mL), dried with Na2SO4, and concentrated under 
reduced pressure. The resulting brown oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (3:2) to afford 83 mg (83%) of 2.20 as a white crystalline solid: 






7.42 (dd, J = 10.0, 3.2 Hz, 1 H) 7.29 (td, J = 8.0, 1.6 Hz, 1 H) 7.09 (td, J = 8.0 Hz, 1 H) 
7.01 (dd, J = 8.0, 1.6 Hz, 1 H) 6.76 (dd, J = 10.0, 3.2 Hz, 1 H) 6.36 (dd, J = 10.0, 2.0 Hz, 
1 H) 6.19 (dd, J =10.0, 2.0 Hz, 1 H) 5.76 (t, J = 3.2 Hz, 1 H) 3.75-3.67 (m, 1 H) 3.61-
3.54 (m, 1 H) 3.07 (s, 3 H) 2.29 (d, J = 3.2 Hz, 2 H) 1.16 (t, J = 7.6 Hz, 3 H); 13C-NMR 
(100 MHz, CDCl3) δ 185.7, 154.6, 154.1, 133.6, 129.7, 129.0, 128.4, 125.4, 125.1, 125.0, 
122.8, 82.4, 63.7, 41.9, 40.0, 36.7, 14.8; IR (thin film) 2976, 2931, 1663 cm-1; HRMS 




spiro[cyclohexa[2,5]diene-1,4'-quinolin]-4-one. (2.21). (WLM5_7). To a solution of 
2.18 (135 mg, 0.212 mmol) in anhydrous DMF (2.2 mL, stored over 4Å molecular 
sieves) at 50 °C was added flame-dried CsF (161 mg, 1.06 mmol). The reaction mixture 
was immediately heated to 130 °C for 1 h under an argon atmosphere. After complete 
consumption of the starting material, as judged by TLC, the reaction mixture was diluted 
with EtOAc (25 mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and 
concentrated under reduced pressure. The resulting brown oil was purified by flash 
chromatography eluting with Hexanes : EtOAc (1:1) to afford a semi-crude white solid 
that was subsequently recrystalized from MeOH to give 50 mg (34%) of pure 2.21: 1H 
NMR (500 MHz, CDCl3) δ 8.32 (d, J = 9.0 Hz, 2 H) 7.90 (dd, J = 8.75, 1.75 Hz, 1 H) 
7.80 (d, J = 9.0 Hz, 2 H) 7.33 (td, J = 7.5 Hz, 1 H) 7.25 (dd, J = 8.4, 3.0 Hz, 1 H) 7.17 (td, 






6.10 (dd, J = 10.0 Hz, 2.0 Hz, 1 H) 5.79 (dd, J = 10.0, 3.0 Hz, 1 H) 5.77-5.76 (m, 1 H) 
3.84-3.78 (m, 1 H) 3.67-3.61 (m, 1 H) 2.06 (dd, J = 14.5, 2.5 Hz, 1 H) 1.63 (dd, J = 14.5, 
3.5 Hz, 1 H) 1.17 (t, J = 7.0 Hz, 1 H); 13C-NMR (125 MHz, CDCl3) δ 185.3, 154.3, 
153.1, 150.3, 144.4, 132.2, 129.7, 128.9, 128.6, 128.4, 126.7, 126.6, 126.1, 125.2, 124.4, 
83.2, 64.0, 41.4, 35.7, 14.7; IR (thin film) 3104, 2973, 1668, 1539, 1351 cm-1; HRMS 




(WLM4_148). To a degassed (30 min) mixture of 1,4-dioxane (4.0 mL) and water (1.3 
mL) was added powdered K2CO3 (224 mg, 1.62 mmol), 2.26a (100 mg, 0.54 mmol), 
1.120 (165 mg, 0.234 mmol), Pd(dppf)Cl2 dichloromethane adduct (13 mg, 0.0159 
mmol), and 2,6-di-tert-butyl-4-methylphenol (BHT) (spatula tip). The mixture was then 
heated to 100 °C under an argon atmosphere for 4 hours until all starting material was 
consumed, as judged by TLC. The resulting dark colored solution was diluted with 
EtOAc (20 mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and 
concentrated under reduced pressure. The resulting black oil was purified by flash 
chromatography eluting with Hexanes: EtOAc (10:1) to afford 99 mg (59% yield) of 
2.27a as a brown oil: 1H NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.4 Hz, 2 H) 6.97-6.96 
(comp, 2 H) 6.92 (d, J = 8.4 Hz, 2 H) 6.69 (d, J = 8.8 Hz, 1 H) 3.64 (br, 2 H) 2.29 (s, 3 
H) 1.04 (s, 9 H) 0.26 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 154.9, 141.2, 132.6, 131.2, 










(WLM3_84). To a degassed (30 min) mixture of 1,4-dioxane (40 mL) and water (13 mL) 
was added powdered K2CO3 (2.5g, 17.8 mmol), 2.26b (1.23 g, 5.94 mmol), 1.120 (1.81 g, 
2.57 mmol), Pd(dppf)Cl2 dichloromethane adduct (240 mg, 0.297 mmol), and 2,6-di-tert-
butyl-4 methylphenol (BHT) (spatula tip). The mixture was then heated to 100 °C under 
an argon atmosphere for 6 hours until all starting material was consumed, as judged by 
TLC. The resulting dark colored solution was diluted with EtOAc (250 mL), washed with 
H2O (125 mL), brine (125 mL), dried with Na2SO4, and concentrated under reduced 
pressure. The resulting black oil was purified by flash chromatography eluting with 
Hexanes: EtOAc (10:1) to afford 1.830 g (93%) of 2.27b as a brown oil: 1H NMR (400 
MHz, CDCl3) δ 7.34 (d, J = 8.8 Hz, 2 H) 6.93 (d, J = 8.4 Hz, 2 H) 6.78-6.71 (comp, 3 H) 
3.78 (s, 3 H) 3.71 (br, 2 H) 1.04 (s, 9 H) 0.27 (s, 6 H); 13C NMR (100 MHz, CDCl3) δ 
155.2, 153.0, 137.5, 132.6, 130.4, 128.9, 120.6, 117.1, 116.0, 114.3, 56.0, 26.0, 18.5, -
4.1; IR (thin film) 3444, 3362, 3031, 2930, 2857, 2831 cm-1; HRMS (ESI) m/z observed 








(WLM4_154). To a degassed (30 min) mixture of 1,4-dioxane (9.0 mL) and water (3.0 
mL) was added powdered K2CO3 (560 mg, 4.05 mmol), 2-bromo-4-chloroaniline (278 
mg, 1.35 mmol), 2 (441 mg, 1.75 mmol), Pd(dppf)Cl2 dichloromethane adduct (55 mg, 
0.0675 mmol), and 2,6-di-tert-butyl-4-methylphenol (BHT) (spatula tip). The mixture 
was then heated to 100 °C under an argon atmosphere for 4 hours until all starting 
material was consumed, as judged by TLC. The resulting dark colored solution was 
diluted with EtOAc (50 mL), washed with H2O (25 mL), brine (25 mL), dried with 
Na2SO4, and concentrated under reduced pressure. The resulting black oil was purified by 
flash chromatography eluting with Hexanes: EtOAc (10:1) to afford 342 mg (76% yield) 
of 2.27c as a clear oil: 1H-NMR (400 MHz, CDCl3) δ 7.33 (d, J = 8.8 Hz, 2 H) 7.15 (d, J 
= 2.4 Hz, 1 H) 7.11 (dd, J = 8.6 Hz, 2.6 Hz, 1 H) 6.99 (d, J = 8.4 Hz, 2 H) 6.66 (d, J = 
8.4 Hz, 1 H) 3.77 (br, 2 H) 1.12 (s, 9 H) 0.34 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
155.3, 142.4, 131.2, 130.1, 130.0, 128.7, 127.8, 122.9, 120.5, 116.6, 25.8, 18.3, -4.3; IR 
(thin film) 3474, 3385, 2931, 2886, 2861 cm-1; HRMS (ESI) m/z observed 334.13890 









(WLM3_82). To a degassed (30 min) mixture of 1,4-dioxane (40 mL) and water (13 mL) 
was added powdered K2CO3 (2.36 g, 17.1 mmol), 2.26d (1.18 g, 5.69 mmol), 1.120 (1.73 
g, 2.46 mmol), Pd(dppf)Cl2 dichloromethane adduct (230 mg, 0.284 mmol), and 2,6-di-
tert-butyl-4-methylphenol (BHT) (spatula tip). The mixture was then heated to 50 °C 
under an argon atmosphere for 12 hours until all starting material was consumed, as 
judged by TLC. The resulting dark colored solution was diluted with EtOAc (100 mL), 
washed with H2O (50 mL), brine (50 mL), dried with Na2SO4, and concentrated under 
reduced pressure. The resulting black oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (10:1) to give 1.69 g (90% yield) 2.27d as a brown oil; 1H NMR 
(400 MHz, CDCl3) δ (2H, d, J = 8.8 Hz) 7.056-7.040 (comp, 2 H) 6.87 (d, J = 8.4 Hz, 2 
H) 6.80 (d, J = 8.4 Hz, 1 H) 4.07 (br, 2 H) 3.94 (s, 3 H) 1.07 (s, 9 H) 0.29 (s, 6 H); 13C 
NMR (100 MHz, CDCl3) δ 154.8, 147.9, 135.2, 135.1, 132.2, 127.8, 120.6, 119.7, 115.7, 
109.4, 55.8, 26.0, 18.6, -4.1; IR (thin film) 3380, 2956, 2930, 2857 cm-1; HRMS (CI) m/z 











(WLM3_76). To a degassed (30 min) mixture of 1,4-dioxane (6.0 mL) and water (2.0 
mL) was added powdered K2CO3 (315 mg, 2.29 mmol), 2-bromoaniline (135 mg, 0.762 
mmol), (4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)boronic acid (235 mg, 0.897 
mmol), Pd(dppf)Cl2 dichloromethane adduct (30 mg, 0.038 mmol), and 2,6-di-tert-butyl-
4 methylphenol (BHT) (spatula tip). The mixture was then heated to 100 °C under an 
argon atmosphere for 6 hours until all starting material was consumed, as judged by TLC. 
The resulting dark colored solution was diluted with EtOAc (20 mL), washed with H2O 
(10 mL), brine (10 mL), dried with Na2SO4, and concentrated under reduced pressure. 
The resulting black oil was purified by flash chromatography eluting with Hexanes: 
EtOAc (10:1) to afford 200 mg (80%) of 2.27e as a brown oil: 1H-NMR (400 MHz, 
CDCl3) δ 7.20-7.16 (comp, 2 H) 7.01-6.94 (comp, 3 H) 6.86 (dt, J = 7.6 Hz, 1 H) 6.78 (d, 
J = 8.0 Hz, 1 H) 3.86 (s, 3 H) 3.85 (br, 2 H) 1.11 (s, 9 H) 0.28 (s, 6 H); 13C NMR (100 
MHz, CDCl3) δ 151.3, 144.5, 143.9, 133.3, 130.7, 128.5, 128.0, 121.7, 121.4, 118.8, 
115.8, 113.3, 55.8, 26.1, 18.8, -4.2; IR (thin film) 3470, 3376, 2929, 2895, 2857 cm-1; 




(WLM4_135). To a degassed (30 min) mixture of 1,4-dioxane (13.5 mL) and water (4.5 





(380 mg, 1.76 mmol), 1.120 (536 mg, 0.763 mmol), Pd(dppf)Cl2 dichloromethane adduct 
(72 mg, 0.088 mmol), and 2,6-di-tert-butyl-4-methylphenol (BHT) (spatula tip). The 
mixture was then heated to 100 °C under an argon atmosphere for 4 hours until all 
starting material was consumed, as judged by TLC. The resulting dark colored solution 
was diluted with EtOAc (100 mL), washed with H2O (50 mL), brine (50 mL), dried with 
Na2SO4, and concentrated under reduced pressure. The resulting black oil was purified by 
flash chromatography eluting with Hexanes : EtOAc (10:1) to afford 399 mg (66%) of 
2.29a as a yellow oil and 60 mg (15%) of 2.29c as a brown oil: 1H-NMR (400 MHz, 
CDCl3) δ 7.07 (d, J = 0.8 Hz, 1 H) 7.38 (dd, J = 8.0, 1.2 Hz, 1 H) 7.30 (d, J = 8.0 Hz, 1 
H) 7.17 (d, J = 8.8 Hz, 2 H) 6.87 (d, J = 8.4 Hz, 2 H) 2.45 (s, 3 H) 1.00 (s, 9 H) 0.24 (s, 6 
H); 13C-NMR (100 MHz, CDCl3) δ 155.9, 149.4, 138.3, 133.3, 133.0, 131.8, 130.3, 
129.3, 124.4, 120.4, 25.8, 21.0, 18.4, -4.2; IR (thin film) 2956, 2930, 2858, 1532, 1352 
cm-1; HRMS (ESI) m/z observed 366.15041 [C19H25NO3Si (M+Na)+ required 366.14959]. 
 
 
4'-Methyl-2'-nitro-[1,1'-biphenyl]-4-ol. (2.29c). Isolated as a by-product: 1H-
NMR (400 MHz, CDCl3) δ 7.61 (d, J = 0.8 Hz, 1 H) 7.39 (dd, J = 8.0, 1.6 Hz, 1 H) 7.29 
(d, J = 7.6 Hz, 1 H) 7.16 (d, J = 8.8 Hz, 2 H) 6.85 (d, J = 8.8 Hz, 2 H) 5.90 (br, 1 H) 2.44 
(s, 3 H); 13C-NMR (100 MHz, CDCl3) δ 155.9, 149.2, 138.4, 133.2, 131.9, 129.6, 129.4, 
124.5, 115.9, 20.9; IR (thin film) 3421, 1517, 1354 cm-1; HRMS (ESI) m/z observed 








(2.29b). (WLM3_64). To a degassed (30 min) mixture of 1,4-dioxane (15 mL) and water 
(5 mL) was added powdered K2CO3 (1.07 g, 7.76 mmol) 1-bromo-4-methoxy-2-
nitrobenzene (600 mg, 2.59 mmol), 1.120 (787 mg, 1.12 mmol), Pd(dppf)Cl2 
dichloromethane adduct (106 mg, 0.130 mmol), and 2,6-di-tert-butyl-4 methylphenol 
(BHT) (spatula tip). The mixture was then heated to 100 °C under an argon atmosphere 
for 6 hours until all starting material was consumed, as judged by TLC. The resulting 
dark colored solution was diluted with EtOAc (100 mL), washed with H2O (50 mL), 
brine (50 mL), dried with Na2SO4, and concentrated under reduced pressure. The resulting 
black oil was purified by flash chromatography eluting with Hexanes : EtOAc (10:1) to 
afford 761 mg (82%) of 2.29b as a yellow oil: 1H-NMR (400 MHz, CDCl3) δ 7.33-7.32 
(d, J = 2.8 Hz, 1 H) 7.31 (d, J = 3.2 Hz, 1 H) 7.15 (d, J = 8.8 Hz, 2 H) 7.11 (dd, J = 11.2 
Hz, 1 H) 6.88 (d, J = 8.8 Hz, 2 H) 3.87 (s, 3 H) 1.02 (s, 9 H) 0.25 (s, 6 H); 13C-NMR (100 
MHz, CDCl3) δ 159.0, 155.8, 149.9, 133.0, 130.3, 129.4, 128.5, 120.4, 118.7, 109.1, 
56.1, 25.9, 18.4, -4.1; IR (thin film) 2956, 2930, 2858, 1534, 1265 cm-1; HRMS (ESI) m/z 








(WLM4_136). A suspension of 2.29a (347 mg, 1.01 mmol) and palladium 10% wt on 
activated carbon (54 mg) in EtOAc (5 mL) was allowed to stir overnight at room 
temperature under a hydrogen atmosphere. After complete consumption of starting 
material, as judged by TLC, the suspension was diluted with EtOAc (25 mL) and filtered 
through a pad of Celite® that was subsequently washed with EtOAc (3 x 25 mL). The 
resulting filtrate was concentrated in vacuo to give 240 mg (76%) of 2.30a as a brown oil 
that required no further purification: 1H-NMR (400 MHz, CDCl3) δ 7.31 (d, J = 8.8 Hz, 2 
H) 7.02 (d, J = 8.0 Hz, 1 H) 6.91 (d, J = 8.8 Hz, 2 H) 6.65 (dd, J = 8.0, 0.8 Hz, 1 H) 6.61 
(s, 1 H) 3.65 (br, 2 H) 2.31 (3H, s) 1.03 (s, 9 H) 0.25 (s, 6 H); 13C-NMR (100 MHz, 
CDCl3) δ 154.8, 143.5, 138.2, 132.5, 130.5, 130.3, 125.0, 120.4, 119.7, 116.4, 25.9, 21.4, 
18.4, -4.1; IR (thin film) 3465, 3373, 2956, 2929, 2858 cm-1; HRMS (ESI) m/z observed 











(WLM3_65). A suspension of 2.29b (355 mg, 0.988 mmol) and palladium 10% wt on 
activated carbon (100 mg) in EtOAc (3 mL) was allowed to stir overnight at room 
temperature under a hydrogen atmosphere. After complete consumption of starting 
material, as judged by TLC, the suspension was diluted with EtOAc (25 mL) and filtered 
through a pad of Celite® that was subsequently washed with EtOAc (3 x 25 mL). The 
resulting filtrate was concentrated in vacuo to give 321 mg (99%) of 2.30b as a yellow oil 
that required no further purification: 1H-NMR (400 MHz, CDCl3) δ 7.32 (d, J = 8.4 Hz, 2 
H) 7.06 (d, J = 8.0 Hz, 1 H) 6.94 (d, J = 8.4 Hz, 2 H) 6.42 (dd, J = 10.4 Hz, 1 H) 6.34 (d, 
J = 2.4 Hz, 1 H) 3.81 (s, 3 H) 1.06 (s, 9 H) 0.29 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
160.1, 154.9, 145.0, 132.4, 131.5, 130.5, 120.9, 120.6, 104.4, 101.3, 55.4, 26.0, 18.5, -
4.1; IR (thin film) 34712, 3377, 2956, 2858 cm-1; HRMS (ESI) m/z observed 330.18820 




methylbenzenesulfonamide. (2.31a). (WLM4_152). To a solution of 2.27a (100 mg, 
0.32 mmol) in pyridine (3 mL) at 0 °C was added p-toluenesulfonyl chloride (122 mg, 
0.638 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (20 
mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated in 





mL). Purification by flash chromatography eluting with Hexanes : EtOAc (SiO2 10:1) 
gave 110 mg (74%) of 2.31a as a brown oil: 1H-NMR (400 MHz, CDCl3) δ 7.56 (d, J = 
8.4 Hz, 1 H) 7.44 (d, J = 8.4 Hz, 2 H) 7.17 (d, J = 8.0 Hz, 2 H) 7.11 (dd, J = 8.4, 2.0 Hz, 
1 H) 6.88 (d, J = 2.0 Hz, 1 H) 6.77 (d, J = 8.4 Hz, 2 H) 6.67 (d, J = 8.4 Hz, 2 H) 6.53 (s, 
1 H) 2.39 (s, 3 H) 2.29 (s, 3 H) 1.03 (s, 9 H) 0.26 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
155.6, 143.8, 136.4, 134.8, 134.1, 131.3, 131.1, 130.3, 130.1, 129.6, 129.1, 127.3, 122.0, 
120.6, 25.8, 21.7, 20.9, 18.4, -4.2; IR (thin film) 3346, 2955, 2929, 2858 cm-1; HRMS 




methylbenzenesulfonamide. (2.31b). (WLM3_53). To a solution of 2.27b (165 mg, 
0.501 mmol) in pyridine (2 mL) at 0 °C was added p-toluenesulfonyl chloride (191 mg, 
1.001 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (20 
mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 15 
mL). Purification by flash chromatography eluting with Hexanes: EtOAc (10:1) to afford 
207 (86%) of 2.31b as a white solid: M.p. 91-93 °C; 1H-NMR (400 MHz, CDCl3) δ 7.62 
(d, J = 8.8 Hz, 1 H) 7.34 (d, J = 8.4 Hz, 2 H) 7.14 (d, J = 8.0 Hz, 2 H) 6.86 (dd, J = 12.0 
Hz, 1 H) 6.73 (d, J = 8.0 Hz, 2 H) 6.61-6.59 (comp, 3 H) 6.45 (s, 1 H) 3.76 (s, 3 H) 2.39 





136.7, 136.3, 130.4, 130.0, 129.7, 127.4, 126.8, 125.2, 120.6, 115.8, 113.8, 55.7, 25.9, 
21.8, 18.5, -4.1; IR (thin film) 3346, 2955, 2930, 2858 cm-1; HRMS (ESI) m/z observed 




methylbenzenesulfonamide. (2.31c). (WLM5_4). To a solution of 2.27c (352 mg, 1.05 
mmol) in pyridine (5 mL) at 0 °C was added p-toluenesulfonyl chloride (402 mg, 2.11 
mmol). The reaction was allowed stir overnight until all starting material was consumed, 
as judged by TLC. The resulting brown solution was diluted with EtOAc (50 mL), 
washed with H2O (25 mL), brine (25 mL), dried with Na2SO4, and concentrated in vacuo 
to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 15 mL). 
Purification by flash chromatography eluting with Hexanes : EtOAc (10:1) afforded 411 
mg (84%) of 2.31c as a white solid: M.p. 101-102°C; 1H-NMR (400 MHz, CDCl3) δ 7.64 
(d, J = 8.8 Hz, 1 H) 7.45 (d, J = 8.4 Hz, 2 H) 7.26 (dd, J = 8.6 Hz, 2.6 Hz, 1 H) 7.20 (d, J 
= 8.0 Hz, 2 H) 7.07 (d, J = 2.8 Hz, 1 H) 6.79 (d, J = 8.8 Hz, 2 H) 6.68 (d, J = 8.8 Hz, 2 
H) 6.57 (s, 1 H) 2.41 (s, 3 H) 1.02 (s, 9 H) 0.25 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
156.2, 144.2, 136.1, 135.5, 132.7, 130.4, 130.3, 130.0, 129.8, 128.8, 128.5, 127.3, 122.8, 
120.9, 25.8, 21.7, 18.4, -4.2; IR (thin film) 3344, 2955, 2929, 2857 cm-1; HRMS (ESI) 








methylbenzenesulfonamide. (2.31d). (WLM3_69). To a solution of 2.30a (145 mg, 
0.44 mmol) in pyridine (2 mL) at 0 °C was added p-toluenesulfonyl chloride (168 mg, 
0.88 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (20 
mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 15 
mL). Purification by flash chromatography eluting with Hexanes: EtOAc (10:1) to give 
194 mg (91%) of 2.31d as a white solid: M.p. 90-92 °C; 1H-NMR (400 MHz, CDCl3) δ 
7.51 (d, J = 8.4 Hz, 2 H) 7.28 (d, J = 2.4 Hz, 1 H) 7.18 (d, J = 7.6 Hz, 2 H) 6.97 (d, J = 
8.4 Hz, 1 H) 6.80 (d, J = 8.4 Hz, 2 H) 6.71 (d, J = 8.4 Hz, 2 H) 6.67 (s, 1 H) 6.64 (dd, J 
= 10.4 Hz, 1 H) 3.79 (s, 3 H) 2.37 (s, 3 H) 1.03 (s, 9 H) 0.26 (s, 6 H); 13C-NMR (100 
MHz, CDCl3) δ 159.7, 155.7, 144.1, 136.4, 135.0, 131.4, 130.6, 130.1, 129.8, 127.4, 
126.2, 120.8, 111.0, 106.7, 55.6, 25.9, 21.779, 18.5, -4.1; IR (thin film) 3346, 2930, 2858 








methylbenzenesulfonamide. (2.31e). (WLM4_137). To a solution of 2.30b (240 mg, 
0.766 mmol) in pyridine (4 mL) at 0 °C was added p-toluenesulfonyl chloride (292 mg, 
1.531 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (20 
mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 10 
mL). Purification by flash chromatography eluting with Hexanes : EtOAc (10:1) gave 
342 mg (96%) of 2.31e as a brown oil: 1H-NMR (400 MHz, CDCl3) δ 7.54 (s, 1 H) 7.47 
(d, J = 8.4 Hz, 2 H) 7.17 (d, J = 8.4 Hz, 2 H) 6.97-6.91 (comp, 2H) 6.79 (d, J = 8.4 Hz, 2 
H) 6.69 (d, J = 8.4 Hz, 2 H) 6.62 (s, 1 H) 2.38 (s, 3 H) 2.37 (s, 3 H) 1.03 (s, 9 H) 0.26 (s, 
6 H); 13C-NMR (100 MHz, CDCl3) δ 155.5, 143.7, 138.3, 136.3, 133.6, 131.1, 130.2, 
130.1, 130.1, 129.5, 127.2, 125.8, 122.1, 120.5, 25.7, 21.6, 21.4, 18.3, -4.3; IR (thin film) 
3347, 2955, 2929, 2858 cm-1; HRMS (ESI) m/z observed 490.18537 [C26H33NO3SSi 











methylbenzenesulfonamide. (2.31f). (WLM3_54). To a solution of 2.27d (272 mg, 
0.825 mmol) in pyridine (2 mL) at 0 °C was added p-toluenesulfonyl chloride (315 mg, 
1.65 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (30 
mL), washed with H2O (15 mL), brine (15 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 15 
mL). Purification by flash chromatography eluting with Hexanes : EtOAc (10:1) to afford 
355 mg (89%) of 2.31f as a white solid: M.p. 78-80 °C; 1H-NMR (400 MHz, CDCl3) δ 
7.68 (d, J = 8.4 Hz, 1 H) 7.46 (d, J = 8.4 Hz, 2 H) 7.31-7.26 (m, 1 H) 7.16 (d, J = 8.0 Hz, 
2 H) 7.11 (d, J = 4.0 Hz, 2 H) 6.82 (d, J = 7.6 Hz, 1 H) 6.78 (s, 1 H) 6.44 (d, J = 2.0 Hz, 
1 H) 6.33 (dd, J = 10.0 Hz, 1 H) 3.72 (s, 3 H) 2.37 (s, 3 H) 1.04 (s, 9 H) 0.22 (s, 6 H); 
13C-NMR (100 MHz, CDCl3) δ 151.5, 145.2, 143.9, 136.6, 134.2, 134.1, 130.8, 130.6, 
129.8, 128.6, 127.4, 125.1, 121.5, 121.5, 121.3, 113.0, 55.7, 26.0, 21.8, 18.7, -4.2; IR 
(thin film) 3340, 2955, 2929, 2857 cm-1; HRMS (ESI) m/z observed 484.19695 




[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32a). (WLM5_6). To a solution 
of Br2 (85 mg, 0.03 mL, 0.531 mmol) in CH2Cl2 (1.5 mL) at 0 °C under argon was added 








colorless. The mixture was stirred for 30 min and diisopropylethylamine (136 mg, 0.18 
mL, 1.06 mmol) was added. After 30 min, a solution of 2.31a (124 mg, 0.265 mmol) in 
CH2Cl2 (1.5 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts 
were washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes: EtOAc (20:1) to give 159 mg (97%) of 2.32a as a white solid: M.p. 
125-128°C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.82-7.78 (comp, 2 
H) 7.53-7.48 (comp, 2 H) 7.37-7.73 (comp, 2 H) 7.23-7.19 (m, 1 H) 7.09-6.98 (m, 1 H) 
6.93-6.70 (comp, 3 H) 5.09-4.94 (m, 1 H) 3.23-3.16 (m, 1 H) 3.08-3.04 (m, 1 H) 2.86-
2.81 (m, 1 H) 2.71-2.64 (m, 1 H) 2.48 (s, 3 H) 2.38-2.35 (comp, 3 H) 1.03-1.01 (comp, 9 
H) 0.94-0.86 (comp, 3 H) 0.24 (s, 6 H); 13C-NMR (100 MHz, CDCl3, as a mixture of 
rotamers) δ 155.6, 155.3, 144.3, 144.2, 144.0, 143.7, 139.5, 139.2, 138.6, 137.9, 133.6, 
133.1, 133.0, 132.8, 132.4, 131.8, 131.3, 131.1, 130.0, 129.8, 129.7, 129.0, 128.6, 128.3, 
128.2, 128.1, 120.1, 119.8, 91.6, 89.9, 67.1, 65.3, 33.8, 33.7, 25.9, 21.8, 21.3, 21.2, 18.5, 
18.4, 14.7, 14.4, -4.2; IR (thin film) 2956, 2929, 2896, 2858 cm-1; HRMS (ESI) m/z 











[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32b). (WLM3_90). To a 
solution of Br2 (240 mg, 0.077 mL, 1.49 mmol) in CH2Cl2 (4 mL) at 0°C under argon was 
added ethyl vinyl ether (135 mg, 0.18 mL, 1.87 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (387 mg, 0.52 
mL, 2.99 mmol) was added. After 30 min, a solution of 2.31b (361 mg, 0.75 mmol) in 
CH2Cl2 (4 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 10 mL). The combined extracts 
were washed with H2O (20 mL), brine (20 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes: EtOAc (10:1) to afford 464 mg (98%) of 2.32b as a clear oil that 
crystallized upon standing: M.p. 126-127°C; 1H-NMR (400 MHz, CDCl3, as a mixture of 
rotamers) δ 7.81-7.77 (comp, 2 H) 7.57-7.52 (comp, 2 H) 7.37-7.34 (comp, 2 H) 6.94-
6.88 (comp, 3 H) 6.81-6.69 (comp, 2 H) 5.11-4.97 (m, 1 H) 3.82-3.79 (comp, 3 H) 3.27-
3.11 (m, 1 H) 3.11-3.04 (m, 1 H) 2.86-2.78 (m, 1 H) 2.72-2.61 (m, 1 H) 2.47 (s, 3 H) 
1.03-1.03 (comp, 9 H) 0.95-0.87 (comp, 3 H) 0.25 (s, 6 H); 13C-NMR (100 MHz, CDCl3, 
as a mixture of rotamers) δ 159.9, 159.5, 155.8, 155.5, 146.1, 145.5, 144.3, 144.1, 138.6, 
137.9, 133.2, 132.8, 131.4, 131.2, 130.5, 130.0, 129.8, 128.6, 128.3, 127.5, 125.2, 120.2, 
119.9, 117.7, 117.0, 113.2, 113.1, 91.5, 89.9, 67.2, 65.3, 55.7, 33.9, 33.7, 26.0, 21.9, 18.5, 
18.5, 14.8, 14.5, -4.1; IR (thin film) 2956, 2930, 2897, 2858 cm-1; HRMS (ESI) m/z 





biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32c). (WLM5_8). To a solution of 
Br2 (211 mg, 0.07 mL, 1.322 mmol) in CH2Cl2 (3.5 mL) at 0°C under argon was added 
ethyl vinyl ether (119 mg, 0.16 mL, 1.65 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (342 mg, 0.46 
mL, 2.644 mmol) was added. After 30 min, a solution of 2.31c (322 mg, 0.661 mmol) in 
CH2Cl2 (3.5 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (30 mL) and extracted with EtOAc (3 x 30 mL). The combined extracts 
were washed with H2O (45 mL), brine (45 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes : EtOAc (20:1) to afford 413 mg (98%) of 2.32c as a white solid: 
M.p. 144-145°C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.80-7.76 
(comp, 2 H) 7.52-7.47 (comp, 2 H) 7.42-7.35 (comp, 3 H) 7.25-7.15 (m, 1 H) 6.94-6.77 
(comp, 3 H) 5.10-4.93 (m, 1 H) 3.26-3.14 (m, 1 H) 3.08-3.03 (m, 1 H) 2.83-2.78 (m, 1 H) 
2.68-2.62 (m, 1H) 2.48 (s, 3 H) 1.01 (s, 9 H) 0.95-0.85 (comp, 3 H) 0.23 (s, 6 H); 13C-
NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 156.1, 155.8, 146.5, 145.9, 144.6, 
144.4, 138.2, 137.5, 135.2, 134.9, 133.6, 133.3, 132.9, 132.1, 131.8, 131.4, 131.3, 131.1, 








21.8, 18.5, 18.4, 14.7, 14.4, -4.2; IR (thin film) 2956, 2929, 2858 cm-1; HRMS (ESI) m/z 




[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32d). (WLM3_25). To a 
solution of Br2 (330 mg, 0.11 mL, 2.067 mmol) in CH2Cl2 (5 mL) at 0 °C under argon 
was added ethyl vinyl ether (186 mg, 0.25 mL, 2.585 mmol) drop-wise until the solution 
turned colorless. The mixture was stirred for 30 min and diisopropylethylamine (535 mg, 
0.72 mL, 4.136 mmol) was added. After 30 min, a solution of 2.31d (500 mg, 1.034 
mmol) in CH2Cl2 (5 mL) was added drop-wise, and the mixture was allowed to slowly 
warm to room temperature overnight under an argon atmosphere. After complete 
consumption of starting material, as judged by TLC, the reaction mixture was poured 
onto saturated aqueous NH4Cl (50 mL) and extracted with EtOAc (3 x 25 mL). The 
combined extracts were washed with H2O (50 mL), brine (50 mL), dried with Na2SO4, 
and concentrated under reduced pressure. The resulting brown oil was purified by flash 
chromatography eluting with Hexanes: EtOAc (10:1) to afford 647 mg (99%) of 2.32d as 
a clear oil that crystallized upon standing: M.p. 99-101 °C; 1H-NMR (400 MHz, CDCl3, 
as a mixture of rotamers) δ 7.86-7.81 (comp, 2 H) 7.50-7.46 (comp, 2 H) 7.38-7.34 
(comp, 2 H) 7.32-7.26 (m, 1 H) 7.00-6.88 (comp, 3 H) 6.56-6.42 (m, 1 H) 5.11-4.92 (m, 








2.73-2.65 (m, 1 H) 2.47 (s, 3 H) 1.02 (s, 9 H) 0.95-0.87 (comp, 3 H) 0.24 (s, 6 H); 13C-
NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 158.5, 155.4, 155.2, 144.5, 144.2, 
138.6, 137.8, 136.8, 136.5, 136.2, 133.5, 133.4, 132.8, 132.7, 132.6, 131.5, 131.3, 129.9, 
129.8, 128.7, 128.5, 127.3, 122.6, 120.1, 119.9, 117.6, 115.3, 115.1, 114.6, 92.1, 90.0, 
67.2, 65.6, 55.5, 33.7, 25.927, 21.8, 21.2, 18.5, 18.4, 14.8, 14.5, -4.2; IR (thin film) 
2930.09, 2858.21 cm-1; HRMS (ESI) m/z observed 656.14749 [C30H40BrNNaO5SSi 




[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32e). (WLM4_138). To a 
solution of Br2 (205 mg, 0.066 mL, 1.28 mmol) in CH2Cl2 (3 mL) at 0°C under argon was 
added ethyl vinyl ether (115 mg, 0.15 mL, 1.6 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (331 mg, 0.45 
mL, 2.56 mmol) was added. After 30 min, a solution of 2.31e (299 mg, 0.64 mmol) in 
CH2Cl2 (3 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts 
were washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated 








eluting with Hexanes: EtOAc (20:1) to afford 391 mg (99%) of 2.32e as a white solid: 
M.p. 144-146°C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.82-7.78 
(comp, 2 H) 7.52-7.44 (comp, 2 H) 7.39-7.35 (comp, 2 H) 7.31-7.16 (comp, 2 H) 6.94-
6.6.86 (comp, 2 H) 6.81-6.63 (m, 1 H) 5.08-5.05 (m, 1 H) 3.27-3.18 (m, 1 H) 3.10-3.02 
(m, 1 H) 2.88-2.81 (m, 1 H) 2.74-2.64 (m, 1 H) 2.49-2.48 (comp, 3 H) 2.32-2.26 (comp, 
3 H) 1.03-1.01 (comp, 9 H) 0.96-0.86 (comp, 3 H) 0.24 (s, 6 H); 13C-NMR (100 MHz, 
CDCl3, as a mixture of rotamers) δ 155.5, 155.2, 144.3, 144.1, 141.6, 141.0, 138.6, 137.8, 
137.2, 134.8, 133.0, 132.8, 132.7, 132.4, 132.0, 131.3, 131.1, 130.2, 129.9, 129.8, 129.7, 
129.6, 128.6, 128.4, 120.1, 119.8, 91.5, 90.0, 67.1, 65.4, 33.8, 33.7, 21.8, 21.0, 21.0, 18.4, 
18.4, 14.6, 14.4, -4.2; IR (thin film) 2928, 2896, 2858 cm-1; HRMS (ESI) m/z observed 




[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32f). (WLM3_86). To a 
solution of Br2 (196 mg, 0.063 mL, 1.23 mmol) in CH2Cl2 (3mL) at 0 °C under argon was 
added ethyl vinyl ether (111 mg, 0.15 mL, 1.54 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (320 mg, 0.43 
mL, 2.46 mmol) was added. After 30 min, a solution of 2.31f (298 mg, 0.616 mmol) in 
CH2Cl2 (3 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 







aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts 
were washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes: EtOAc (20:1) to afford 335 mg (86%) of 2.32f as a brown oil: 1H-
NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.65 (d, J = 8.0 Hz, 2 H), 7.44 (d, J 
= 8.4 Hz, 2 H) 7.25 (d, J = 8.0 Hz, 2 H) 7.13-7.11 (m, 1 H) 7.05-7.03 (m, 1 H) 6.94-6.90 
(m, 1 H) 6.91 (d, J = 8.4 Hz, 2 H) 5.65-5.49 (m, 1 H) 4.09-3.08 (comp, 7 H) 2.41 (s, 3 H) 
1.30-1.16 (comp, 3 H) 1.01 (s, 9 H) 0.24 (s, 6 H); 13C-NMR (100 MHz, CDCl3, as a 
mixture of rotamers) δ 159.2, 158.5, 157.9, 156.0, 144.1, 144.0, 143.8, 143.6, 143.5, 
138.2, 137.8, 136.3, 135.2, 133.7, 133.1, 129.4, 129.3, 128.5, 128.1, 124.2, 121.5, 120.7, 
120.6, 119.4, 118.8, 115.6, 111.1, 110.2, 89.2, 88.5, 88.4, 65.7, 65.2, 55.6, 55.2, 33.0, 
32.8, 32.7, 30.0, 26.0, 21.8, 18.5, 15.5, 14.9, 14.8, -4.1; IR (thin film) 2956, 2928, 2857 





[1,1'-biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.32g). (WLM3_83). To a 
solution of Br2 (218 mg, 0.046 mL, 0.90 mmol) in CH2Cl2 (2 mL) at 0°C under argon was 
added ethyl vinyl ether (81 mg, 0.11 mL, 1.13 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (234 mg, 0.31 








CH2Cl2 (2 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 10 mL). The combined extracts 
were washed with H2O (20 mL), brine (20 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil. Purification by flash chromatography eluting with Hexanes : 
EtOAc (20:1) to afford 250 mg (87%) 2.32g as a clear oil that crystallized upon standing: 
M.p. 123-124 °C; 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.84-7.80 
(comp, 2 H) 7.62-7.52 (m, 1 H) 7.49-7.36 (comp, 4 H) 7.28-7.18 (m, 1 H) 6.94-6.82 
(comp, 3 H) 5.12-4.89 (m, 1 H) 3.91 (s, 3 H) 3.25-3.14 (m, 1 H) 3.14-3.06 (m, 1 H) 2.88-
2.84 (m, 1 H) 2.67-2.56 (m, 1 H) 2.49 (s, 3 H) 1.03 (s, 9 H) 0.90 (t, J = 7.2 Hz, 3 H) 
0.21-0.19 (m, 6 H); 13C-NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 150.8, 
150.6, 145.0, 144.8, 144.7, 144.5, 144.4, 144.2, 138.9, 138.1, 135.7, 133.5, 133.3, 133.0, 
132.8, 132.4, 131.8, 130.0, 129.9, 129.6, 129.3, 129.1, 128.5, 128.3, 127.5, 122.7, 122.2, 
121.1, 121.0, 114.4, 92.2, 90.0, 67.2, 65.7, 55.9, 33.9, 33.8, 30.4, 26.0, 21.9, 18.8, 18.8, 
14.7, 14.6, -4.3, -4.4; IR (thin film) 2956, 2928, 2857 cm-1; HRMS (ESI) m/z observed 




quinolin]-4-one. (2.33a). (WLM5_12). To a solution of 2.32a (93 mg, 0.15 mmol) in 







dried CsF (114 mg, 0.75 mmol). The reaction mixture was immediately heated to 130 °C 
for 1 h under an argon atmosphere. After complete consumption of the starting material, 
as judged by TLC, the reaction mixture was diluted with EtOAc (15 mL), washed with 
H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated under reduced 
pressure. The resulting brown oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (3:1) to provide 57 mg (89%) of 2.33a as a white crystalline solid: M.p. 
186-187°C; 1H-NMR (400 MHz, CDCl3) δ 7.79 (d, J = 8.4 Hz, 1 H) 7.42 (d, J = 8.0 Hz, 
2 H) 7.26-7.23 (comp, 3 H) 7.10 (dd, J = 8.4 Hz, 1.6 Hz, 1 H) 6.63 (d, J = 1.6 Hz, 1 H) 
6.12 (dd, J = 9.8 Hz, 1.8 Hz, 1 H) 6.07 (dd, J = 10.2 Hz, 1.8 Hz, 1 H) 5.69 (dd, J = 10.0, 
2.8 Hz, 1 H) 5.61-5.63 (m, 1 H) 3.83-3.75 (m, 1 H) 3.63-3.55 (m, 1 H) 2.41 (s, 3 H) 2.23 
(s, 3 H) 1.88 (dd, J = 14.4, 2.4 Hz, 1 H) 1.53 (dd, J = 14.4, 3.6 Hz, 1 H) 1.12 (t, J = 7.0 
Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 185.9, 155.4, 154.4, 144.4, 136.2, 135.9, 130.4, 
129.9, 129.6, 129.6, 128.1, 127.3, 127.1, 126.1, 124.9, 82.9, 63.7, 41.5, 34.8, 21.7, 21.0, 
14.9; IR (thin film) 2972, 2927, 1668 cm-1; HRMS (ESI) m/z observed 446.14047 




1,4'-quinolin]-4-one. (2.33b). (WLM3_81). To a solution of 2.32b (209 mg, 0.33 mmol) 
in anhydrous DMF (3.5 mL, stored over 4Å molecular sieves) at 50 °C was added flame-
dried CsF (250 mg, 1.65 mmol). The reaction mixture was immediately heated to 130 °C 







as judged by TLC, the reaction mixture was diluted with EtOAc (30 mL), washed with 
H2O (15 mL), brine (15 mL), dried with Na2SO4, and concentrated under reduced 
pressure. The resulting brown oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (3:1) to afford 143 mg (99%) of 2.32a as a white crystalline solid: M.p. 
125-126 °C; 1H-NMR (400 MHz, CDCl3) δ 7.81 (d, J = 8.8 Hz, 1 H) 7.37 (d, J = 8.0 Hz, 
2 H) 7.23-7.19 (comp, 3 H) 6.83 (dd, J = 11.6 Hz, 1 H) 6.33 (d, J = 2.8 Hz, 1 H) 6.07 
(dd, J = 11.6 Hz, 1 H) 6.02 (dd, J = 11.6 Hz, 1 H) 5.62-5.58 (comp, 2 H) 3.79-3.72 (m, 1 
H) 3.68 (s, 3 H) 3.60-3.52 (m, 1 H) 2.38 (s, 3 H) 1.82 (dd, J = 16.8 Hz, 1 H) 1.48 (dd, J = 
18.0 Hz, 1 H) 1.09 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 185.8, 157.8, 
155.4, 154.2, 144.5, 135.7, 130.0, 128.9, 128.2, 128.1, 127.4, 125.7, 124.9, 114.4, 114.0, 
82.9, 63.6, 55.6, 41.7, 34.6, 21.8, 15.0; IR (thin film) 2974, 1668 cm-1; HRMS (ESI) m/z 




quinolin]-4-one. (2.33c). (WLM5_9). To a solution of 2.32c (227 mg, 0.355 mmol) in 
anhydrous DMF (3.6 mL, stored over 4Å molecular sieves) at 50 °C was added flame-
dried CsF (270 mg, 1.78 mmol). The reaction mixture was immediately heated to 130 °C 
for 1 h under an argon atmosphere. After complete consumption of the starting material, 
as judged by TLC, the reaction mixture was diluted with EtOAc (50 mL), washed with 
H2O (25 mL), brine (25 mL), dried with Na2SO4, and concentrated under reduced 







Hexanes : EtOAc (3:1) to afford 155 mg (98%) of 2.33c as a white crystalline solid: M.p. 
169-170°C; 1H-NMR (400 MHz, CDCl3) δ 7.90 (d, J = 9.2 Hz, 1 H) 7.46 (d, J = 8.4 Hz, 
2 H) 7.31-7.23 (comp, 4 H) 6.84 (d, J = 2.8 Hz, 1 H) 6.16 (dd, J = 10.0 Hz, 2.5 Hz, 1 H) 
6.12 (dd, J = 10.0 Hz, 1.6 Hz, 1 H) 5.71 (dd, J = 10.0 Hz, 2.8 Hz, 1 H) 5.67-5.66 (m, 1 H) 
3.83-3.75 (m, 1 H) 3.65-3.57 (m, 1 H) 2.44 (s, 3 H) 1.94 (dd, J = 14.8 Hz, 2.4 Hz, 1 H) 
1.55 (dd, J = 14.8 Hz, 3.2 Hz, 1 H) 1.15 (t, J = 7.0 Hz, 3 H); 13C-NMR (100 MHz, 
CDCl3) δ 185.3, 154.3, 153.2, 144.8, 135.5, 131.8, 131.6, 130.0, 129.1, 128.9, 128.6, 
128.5, 128.4, 127.2, 125.4, 82.8, 63.8, 41.3, 34.7, 21.7, 14.8; IR (thin film) 2972, 2928, 





1,4'-quinolin]-4-one. (2.33d). (WLM3_27). To a solution of 2.32d (150 mg, 0.24 mmol) 
in anhydrous DMF (2.5 mL, stored over 4Å molecular sieves) at 50 °C was added flame-
dried CsF (180 mg, 1.18 mmol). The reaction mixture was immediately heated to 130 °C 
for 1 h under an argon atmosphere. After complete consumption of the starting material, 
as judged by TLC, the reaction mixture was diluted with EtOAc (20 mL), washed with 
H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated under reduced 
pressure.The resulting brown oil was purified by flash chromatography eluting with 
Hexanes: EtOAc (3:1) to afford 99 mg (95%) of 2.33d as a white crystalline solid: M.p. 






6.74 (d, J = 8.8 Hz, 1 H) 6.68 (dd, J = 11.2 Hz, 1 H) 6.09 (dd, J = 12.0 Hz, 1 H) 6.03 
(dd, J = 12 Hz, 1 H) 5.69 (dd, J = 12.8 Hz, 1 H) 5.66 (t, J = 2.4 Hz, 1 H) 3.83 (s, 3 H) 
3.84-3.76 (m, 1 H) 3.64-3.58 (m, 1 H) 2.40 (s, 3 H) 1.89 (dd, J = 17.2 Hz, 1 H) 1.51 (dd, 
J = 17.6 Hz, 1 H) 1.13 (t, J = 6.8 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 186.0, 159.5, 
155.6, 154.7, 144.7, 135.9, 134.1, 130.2, 130.0, 128.0, 127.4, 124.8, 118.0, 113.3, 111.6, 
83.1, 63.9, 55.7, 41.2, 34.9, 21.8, 15.0; IR (thin film) 2974, 2932, 1668 cm-1; HRMS 




quinolin]-4-one. (2.33e). (WLM4_139). To a solution of 2.32e (186 mg, 0.3 mmol) in 
anhydrous DMF (3.0 mL, stored over 4Å molecular sieves) at 50 °C was added flame-
dried CsF (228 mg, 1.5 mmol). The reaction mixture was immediately heated to 130 °C 
for 1 h under an argon atmosphere. After complete consumption of the starting material, 
as judged by TLC, the reaction mixture was diluted with EtOAc (40 mL), washed with 
H2O (20 mL), brine (20 mL), dried with Na2SO4, and concentrated under reduced 
pressure. The resulting brown oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (4:1) to afford 124 mg (98%) of 2.33e as a white crystalline solid: M.p. 
163-164°C; 1H-NMR (500 MHz, CDCl3) δ 7.71 (s, 1 H) 7.42 (dd, J = 6.5 Hz, 1.5 Hz, 2 
H) 7.24 (d, J = 8.0 Hz, 2 H) 7.21 (dd, J = 10.0 Hz, 3.0 Hz, 1 H) 6.92 (dd, J = 8.5, 1.5 Hz, 
1 H) 6.73 (d, J = 8.0 Hz, 1 H) 6.09 (dd, J = 10.0, 2.0 Hz, 1 H) 6.03 (dd, J = 10.0, 2.0 Hz, 






(m, 1 H) 2.39 (s, 3 H) 2.35 (s, 3 H) 1.88 (dd, J = 14.5 Hz, 2.0 Hz, 1 H) 1.53 (dd, J = 14.5 
Hz, 3.5 Hz, 1 H) 1.11 (t, J = 7.25 Hz, 3 H); 13C-NMR (125 MHz, CDCl3) δ 185.5, 155.1, 
154.1, 144.2, 138.5, 135.7, 132.6, 129.6, 128.8, 127.8, 127.3, 127.1, 127.0, 124.6, 123.1, 
82.7, 63.4, 41.1, 34.7, 21.7, 21.4, 14.8; IR (thin film) 3032, 2975, 2928 cm-1; HRMS 




1,4'-quinolin]-4-one. (2.33g). (WLM3_87). To a solution of 2.32g (105 mg, 0.165 
mmol) in anhydrous DMF (2 mL, stored over 4Å molecular sieves) at 50 °C was added 
flame-dried CsF (125 mg, 0.827 mmol). The reaction mixture was immediately heated to 
130 °C for 1 h under an argon atmosphere. After complete consumption of the starting 
material, as judged by TLC, the reaction mixture was diluted with EtOAc (20 mL), 
washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated under 
reduced pressure. The resulting brown oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (3:1) to afford 66 mg (91%) of a 5 : 4 diasteromeric mixture of 
cis-2.33g : trans-2.33g as a white crystalline solids. 
cis-2.33g: 1H-NMR (400 MHz, CDCl3) δ 7.94 (dd, J = 9.2 Hz, 1 H) 7.43 (dd, J = 
8.4 Hz, 2 H) 7.32-7.24 (comp, 3 H) 7.11 (dt, J = 8.0 Hz, 1 H) 6.77 (dd, J = 9.2 Hz, 1 H) 
6.35 (dd, J = 2.4 Hz, 1 H) 6.16 (d, J = 9.6 Hz, 1 H) 5.75 (dd, J = 12.4 Hz, 1 H) 5.71 (t, J 
= 2.8 Hz, 1 H) 3.86-3.82 (m, 1 H) 3.64-3.60 (m, 1 H) 3.53 (s, 3 H) 2.41 (s, 3 H) 1.95 (dd, 












MHz, CDCl3) δ 180.8, 154.4, 148.2, 144.4, 135.7, 132.7, 129.8, 129.1, 128.3, 127.6, 
127.4, 127.1, 126.7, 126.1, 124.0, 82.9, 63.6, 54.6, 42.0, 35.9, 21.6, 14.7; IR (thin film) 
2974, 1674 cm-1; HRMS (ESI) m/z observed 462.13438 [C24H25NO5S (M+Na)+ requires 
462.13456]. 
 
ORTEP view of cis-2.33g. Displacement ellipsoids are scaled to the 50% probability 
level.  
 
trans-2.33g: 1H NMR (400 MHz, CDCl3) δ 7.87 (dd, J = 9.6 Hz, 1 H) 7.43 (dd, J 
= 8.4 Hz, 2 H) 7.31-7.21 (comp, 3 H) 7.14 (dd, J = 8.8 Hz, 1 H) 7.12 (dt, J = 7.6 Hz, 1 
H) 6.87 (dd, J = 9.2 Hz, 1 H) 6.08 (d, J = 10.0 Hz, 1 H) 5.64 (t, J = 2.8 Hz, 1 H) 4.54 (d, 
J = 2.4 Hz, 1 H) 3.81-3.77 (m, 1 H) 3.62-3.57 (m, 1 H) 3.39 (s, 3 H) 2.37 (s, 3 H) 1.93 
(1H, dd, J = 16.8 Hz) 1.67 (dd, J = 18.0 Hz, 1 H) 1.12 (t, J = 7.2 Hz, 3 H); 13C-NMR 
(100 MHz, CDCl3) δ 180.8, 155.2, 150.3, 144.0, 136.0, 132.7, 129.6, 129.0, 128.3, 128.1, 
127.6, 127.5, 126.4, 124.2, 122.4, 83.3, 63.6, 54.5, 41.8, 35.7, 21.5, 14.7; IR (thin film) 
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methylbenzenesulfonamide. (2.34). (WLM3_91). To a solution of 2.32f (298 mg, 0.47 
mmol) in anhydrous DMF (5 mL, stored over 4Å molecular sieves) at 50 °C was added 
flame-dried CsF (360 mg, 2.35 mmol). The reaction mixture was immediately heated to 
130 °C for 1 h under an argon atmosphere. After complete consumption of the starting 
material, as judged by TLC, the reaction mixture was diluted with EtOAc (60 mL), 
washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated under 
reduced pressure. The resulting brown oil was purified by flash chromatography eluting 
with Hexanes: EtOAc (3:1) to afford 39 mg (16%) of 2.32f as a yellow oil: 1H NMR (400 
MHz, CDCl3) δ 7.57 (d, J = 8.4 Hz, 2 H) 7.25 (d, J = 8.8 Hz, 2 H) 7.04 (d, J = 8.0 Hz, 1 
H) 6.97-6.80 (comp, 3 H) 6.71 (d, J = 8.4 Hz, 2 H) 5.51-5.39 (m, 1 H) 3.83-3.00 (comp, 
4 H) 3.58 (s, 3 H) 3.36 (s, 3 H) 2.31 (s, 3 H) 1.17-1.07 (comp, 3 H); 13C-NMR (100 MHz, 
CDCl3) δ 158.8, 157.5, 156.3, 143.9, 143.7, 143.5, 143.4, 137.5, 137.4, 134.6, 132.5, 
131.9, 129.1, 129.0, 128.2, 127.6, 120.6, 119.8, 118.9, 118.3, 115.6, 110.5, 109.7, 88.8, 
88.2, 65.4, 65.0, 60.5, 55.1, 54.8, 32.5, 32.3, 25.5, 25.5, 21.4, 20.9, 15.4, 14.4, 14.3, 14.0; 
IR (thin film) 3441, 3033, 2975 cm-1; HRMS (ESI) m/z observed 542.0206000 









(4-((tert-Butyldimethylsilyl)oxy)naphthalen-1-yl)boronic acid. (2.37). 
(WLM4_5). To a solution of 2.36 (6.09 g, 18.05 mmol) in THF (20 mL) at −78 °C was 
added drop-wise n-butyllithium (2.5 M in hexanes, 45 mL, 45.13 mmol). After letting stir 
for 1 h, triisopropylborate (20.8 mL, 90.27 mmol) was added drop-wise to above 
solution, and the mixture was allowed to slowly warm to room temperature overnight. 
The mixture was poured onto 10% aqueous KHSO4 (30 mL) and extracted with EtOAc (3 
x 100 mL). The combined organic extracts were washed with H2O (100 mL), brine (100 
mL), dried with Na2SO4, and concentrated under reduced pressure. The crude white solid 
was purified by flash chromatography eluting with Hexanes: EtOAc (5:1 → 100% 
EtOAc) to afford 3.60 g (66%) of 2.37 as a white solid; 1H-NMR (400 MHz, CDCl3) δ 
9.01 (d, J = 8.0 Hz, 1 H) 8.28 (d, J = 7.6 Hz, 1 H) 7.65-7.45 (comp, 3 H) 6.92 (d, J = 7.6 
Hz, 1 H) 1.11 (s, 9 H) 0.33 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 156.1, 139.4, 138.8, 
127.9, 127.7, 127.0, 124.8, 122.9, 111.9, 13.9, -4.2; IR (thin film) 3217, 2958, 2928, 












1,4-dioxane (9 mL) and water (3 mL) was added powdered Na2CO3 (324 mg, 3.054 
mmol), 2.36 (400 mg, 1.32 mmol), 2-bromoaniline (179 mg, 1.018 mmol), Pd(dppf)Cl2 
dichloromethane adduct (42 mg, 0.0509 mmol), and 2,6-di-tert-butyl-4 methylphenol 
(BHT) (spatula tip). The mixture was then heated to 50 °C under an argon atmosphere for 
12 hours until all starting material was consumed, as judged by TLC. The resulting dark 
colored solution was diluted with EtOAc (30 mL), washed with H2O (10 mL), brine (10 
mL), dried with Na2SO4, and concentrated in vacuo to yield a black oil. The crude 
mixture was then dissolved in pyridine (6 mL) and cooled to 0 °C. p-Toluenesulfonyl 
chloride (388 mg, 2.036 mmol) was then added and the reaction was allowed to stir 
overnight under argon. The reaction mixture was then diluted with EtOAc (30 mL), 
washed with H2O (15 mL), brine (15 mL), dried with Na2SO4 and concentrated under 
reduced pressure. The resulting brown oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (10:1) to afford 123 mg (24%) of 2.38 as a yellow oil: 1H-NMR 
(400 MHz, CDCl3) δ 8.25 (dd, J = 8.8 Hz, 1 H) 7.82 (dd, J = 9.2 Hz, 1 H) 7.48 (dt, J = 
8.0 Hz, 1 H) 7.40 (dt, J = 8.0 Hz, 1 H) 7.32 (d, J = 8.0 Hz, 1 H) 7.25 (dt, J = 7.6 Hz, 1 
H) 7.17 (dt, J = 7.6 Hz, 1 H) 7.12 (dd, J = 7.6 Hz, 1 H) 7.07 (d, J = 9.2 Hz, 2 H) 7.01 (d, 
J = 8.4 Hz, 1 H) 6.76 (d, J = 7.6 Hz, 1 H) 6.69 (d, J = 7.6 Hz, 1 H) 6.31 (s, 1 H) 2.38 (s, 
3 H) 1.15 (s, 9 H) 0.39 (s, 3 H) 0.35 (s, 3 H); 13C-NMR (100 MHz, CDCl3) δ 152.2, 
143.6, 135.9, 135.0, 133.0, 131.5, 131.5, 129.4, 128.7, 128.0, 127.5, 127.2, 127.1, 126.6, 
125.5, 124.9, 124.6, 123.1, 120.7, 111.8, 25.9, 21.6, 18.5, -4.1, -4.2; IR (thin film) 3337, 
3064, 2956, 2929, 2885, 2858 cm-1; HRMS (CI) m/z observed 503.1952 [C29H33NO3SSi 





1-yl)phenyl)-4-methylbenzenesulfonamide. (2.39). (WLM4_34). To a solution of Br2 
(51 mg, 0.016 mL, 0.318 mmol) in CH2Cl2 (0.75 mL) at 0°C under argon was added ethyl 
vinyl ether (29 mg, 0.4 mL, 0.397 mmol) drop-wise until the solution turned colorless. 
The mixture was stirred for 30 min and diisopropylethylamine (82 mg, 0.11 mL, 0.635 
mmol) was added. After 30 min, a solution of 2.38 (80 mg, 0.159 mmol) in CH2Cl2 (0.75 
mL) was added drop-wise, and the mixture was allowed to slowly warm to room 
temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 5 mL). The combined extracts 
were washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes : EtOAc (10:1) to afford 84 mg (81%) of 2.39 as a yellow oil. 1H 
NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 8.27-8.23 (m, 1H) 7.92-7.70 (comp, 
3 H) 7.53-6.97 (comp, 10 H) 4.89-4.01 (m, 1 H) 3.51-2.57 (comp, 2 H) 2.48-2.38 (comp, 
3 H) 1.66-1.59 (m, 1 H) 1.37-1.30 (m, 1 H) 1.15-1.13 (comp, 9 H) 0.95-0.38 (comp, 3 H) 
0.35-0.32 (comp, 6 H); 13C-NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 151.5, 
145.7, 145.4, 144.6, 143.9, 143.8, 142.5, 138.5, 136.8, 134.7, 134.2, 134.1, 133.9, 132.8, 
130.2, 129.8, 129.6, 129.5, 129.4, 129.2, 128.8, 128.5, 128.5, 128.3, 128.2, 128.1, 128.0, 
127.9, 127.7, 127.6, 127.3, 127.2, 127.1, 126.7, 126.3, 125.8, 125.2, 125.1, 124.9, 124.8, 







30.8, 25.9, 25.9, 25.9, 21.7, 21.6, 18.6, 18.5, 14.2, 13.6, 13.4, -4.1, -4.2, -4.3; IR (thin 
film) 3065, 2957, 2929, 2896, 2858 cm-1; HRMS (ESI) m/z observed 676.15299 




one 55. (2.40). (WLM4_35). To a solution of 2.39 (75 mg, 0.115 mmol) in anhydrous 
DMF (1. mL, stored over 4Å molecular sieves) at 50 °C was added flame-dried CsF (87 
mg, 0.573 mmol). The reaction mixture was immediately heated to 130 °C for 1 h under 
an argon atmosphere. After complete consumption of the starting material, as judged by 
TLC, the reaction mixture was diluted with EtOAc (20 mL), washed with H2O (10 mL), 
brine (10 mL), dried with Na2SO4, and concentrated under reduced pressure. The 
resulting brown oil was purified by PTLC eluting with Hexanes : EtOAc (8:1) to afford 
44 mg (84%) of a 4:1 inseparable diasteromeric mixture of 2.40 
major product 2.40: 1H-NMR (400 MHz, CDCl3) δ 8.10 (dd, J = 8.0, 1.2 Hz, 1 H) 
7.84 (dd, J = 8.2 Hz, 1 H) 7.59 (d, J = 8.4 Hz, 2 H) 7.55 (dd, J = 8.2 Hz, 1 H) 7.43 (td, J 
= 8.0 Hz, 1 H) 7.37-7.24 (comp, 4 H) 6.99 (td, J = 7.6 Hz, 1 H) 6.47 (dd, J = 7.8 Hz, 1 
H) 5.95 (d, J = 10.0 Hz, 1 H) 5.73 (dd, J = 4.8, 2.0 Hz, 1 H) 5.32 (d, J = 10.0 Hz, 1 H) 
3.85-3.79 (m, 1 H) 3.65-3.59 (m, 1 H) 2.44 (s, 3 H) 2.36 (dd, J = 15.2, 1.6 Hz, 1 H) 2.25 
(dd, J = 15.2, 4.8 Hz, 1 H) 1.17 (t, J = 7.6 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 
184.6, 154.6, 149.8, 144.4, 136.6, 133.9, 133.2, 133.0, 131.2, 130.6, 129.9, 129.8, 128.0, 









3066, 2973, 2927, 1665 cm-1; HRMS (ESI) m/z observed 482.13948 [C27H25NO4S 




(WLM3_148). To a degassed (30 min) mixture of 1,4-dioxane (3 mL) and water (1 mL) 
was added powdered K2CO3 (170 mg, 1.22 mmol), 2-bromoaniline (72 mg, 0.408 mmol), 
2.41 (160 mg, 0.529 mmol), Pd(dppf)Cl2 dichloromethane adduct (17 mg, 0.0204 mmol), 
and 2,6-di-tert-butyl-4 methylphenol (BHT) (spatula tip). The mixture was then heated to 
100 °C under an argon atmosphere for 6 hours until all starting material was consumed, 
as judged by TLC. The resulting dark colored solution was diluted with EtOAc (20 mL), 
washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated under 
reduced pressure. The resulting black oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (10:1) to afford 90 mg (63%) of 2.41b as a brown oil: 1H-NMR 
(400 MHz, CDCl3) δ 7.87 (s, 1 H) 7.78 (t, J = 9.6 Hz, 1 H) 7.56 (dd, J = 12.4 Hz, 1 H) 
7.27-7.18 (comp, 3H ) 7.14 (dd, J = 11.2 Hz, 1 H) 6.89 (dt, J = 7.2 Hz, 1 H) 6.82 (dd, J 
= 8.8 Hz, 1 H) 3.82 (br, 2 H) 1.07 (s, 9 H) 0.30 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 
153.7, 143.7, 134.8, 133.6, 130.6, 129.4, 128.4, 127.6, 127.5, 127.1, 122.5, 118.7, 115.6, 
114.8, 25.7, 18.3, -4.3; IR (thin film) 3470, 3377, 3053, 3024, 2929, 2885, 2857 cm-1; 







methylbenzenesulfonamide. (2.42). (WLM3_145). To a solution of 2.41b (84 mg, 0.24 
mmol) in pyridine (2.5 mL) at 0 °C was added p-toluenesulfonyl chloride (92 mg, 0.48 
mmol). The reaction was allowed stir overnight until all starting material was consumed, 
as judged by TLC. The resulting brown solution was diluted with EtOAc (20 mL), 
washed with H2O (10 mL), brine (10 mL), dried with Na2SO4, and concentrated in vacuo 
to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 5 mL). 
Purification by flash chromatography eluting with Hexanes : EtOAc (10:1) gave 117 mg 
(97%) of 2.42 as a brown solid: M.p. 109-111 °C; 1H-NMR (400 MHz, CDCl3) δ 7.78 (d, 
J = 8.0 Hz, 1 H) 7.68 (d, J = 8.4 Hz, 1 H) 7.60 (d, J = 8.8 Hz, 1 H) 7.44 (d, J = 8.4 Hz, 2 
H) 7.38-7.35 (m, 1 H) 7.24 (d, J = 2.0 Hz, 1 H) 7.19-7.14 (comp, 6 H) 6.93 (dd, J = 8.4 
Hz, 1 H) 6.67 (s, 1 H) 2.41 (s, 3 H) 1.07 (s, 9 H) 0.31 (s, 6 H); 13C-NMR (100 MHz, 
CDCl3) δ 154.1, 143.7, 136.1, 134.2, 133.8, 132.3, 130.4, 129.5, 129.3, 129.0, 128.5, 
127.7, 127.5, 127.1, 126.7, 125.0, 123.0, 121.7, 114.8, 25.7, 21.5, 18.3, -4.3; IR (thin 
film) 3340, 3054, 2955, 2929, 2885, 2858 cm-1; HRMS (ESI) m/z observed 504.20180 






2-yl)phenyl)-4-methylbenzenesulfonamide. (2.43). (WLM4_6). To a solution of Br2 
(126 mg, 0.04 mL, 0.786 mmol) in CH2Cl2 (2 mL) at 0°C under argon was added ethyl 
vinyl ether (71 mg, 0.1 mL, 0.983 mmol) drop-wise until the solution turned colorless. 
The mixture was stirred for 30 min and diisopropylethylamine (204 mg, 0.27 mL, 1.57 
mmol) was added. After 30 min, a solution of 2.42 (198 mg, 0.393 mmol) in CH2Cl2 (2 
mL) was added drop-wise, and the mixture was allowed to slowly warm to room 
temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (10 mL) and extracted with EtOAc (3 x 15 mL). The combined extracts 
were washed with H2O (20 mL), brine (20 mL), dried with Na2SO4, and concentrated 
under reduced pressure. The resulting brown oil was purified by flash chromatography 
eluting with Hexanes : EtOAc (10:1) to afford 206 mg (80%) of 2.43 as a yellow foam: 
1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 8.05-8.04 (m, 1 H) 7.83-7.12 
(comp, 12 H) 6.94-6.92 (d, 1 H) 5.64-5.03 (m, 1 H) 3.30-2.55 (comp, 4 H) 2.48-2.46 
(comp, 3 H) 1.06-1.05 (comp, 9 H) 0.95-0.55 (comp, 3 H) 0.31-0.28 (comp, 6 H); 13C-
NMR (100 MHz, CDCl3, as a mixture of rotamers) δ 153.9, 153.6, 144.9, 144.2, 144.1, 
144.0, 138.2, 137.4, 135.2, 135.2, 134.6, 134.5, 133.9, 133.7, 133.6, 132.9, 132.8, 132.4, 
132.1, 130.6, 129.8, 129.7, 129.5, 129.5, 129.4, 129.3, 129.1, 128.9, 128.8, 128.7, 128.4, 







89.7, 88.6, 67.0, 66.8, 65.4, 33.6, 33.1, 32.9, 21.6, 18.2, 18.2, 14.7, 14.5, 13.9, -4.3; 
HRMS (ESI) m/z observed 676.15164 [C33H40BrNO4SSi (M+Na)+ requires 676.15229]. 
 
 
2'-((tert-Butyldimethylsilyl)oxy)-[1,1'-biphenyl]-2-amine (2.47). (WLM3_128). 
A suspension of 2.51 (252 mg, 0.765 mmol) and palladium 10% wt on activated carbon 
(50 mg) in EtOAc (1.5 mL) was allowed to stir overnight at room temperature under a 
hydrogen atmosphere. After complete consumption of starting material, as judged by 
TLC, the suspension was diluted with EtOAc (25 mL) and filtered through a pad of 
Celite® that was subsequently washed with EtOAc (3 x 15 mL). The resulting filtrate 
was concentrated under reduced pressure to give 222 mg (97%) of 2.47 as a yellow oil 
that required no further purification; 1H-NMR (400 MHz, CDCl3) δ 7.32-7.26 (comp, 2 
H) 7.19-7.07 (comp, 3 H) 6.97 (d, J = 8.0 Hz, 1 H) 6.83 (dt, J = 8.2 Hz, 1 H) 6.75 (d, J = 
7.6 Hz, 1 H) 3.81 (br, 2 H) 0.84 (s, 9 H) 0.09 (s, 3 H) -0.11 (s, 3 H); 13C-NMR (100 MHz, 
CDCl3) δ 153.0, 144.9, 132.1, 131.8, 131.6, 128.9, 128.6, 125.9, 122.4, 120.6, 118.5, 
116.0, 25.7, 18.2; IR (thin film) 3466, 3382, 3062, 3024, 2955, 2929, 2884, 2857 cm-1; 








2'-Nitro-[1,1'-biphenyl]-2-ol. (2.50). (WLM3_123). To a degassed (30 min) 
mixture of 1,4-dioxane (3 mL) and water (1 mL) was added powdered Cs2CO3 (503 mg, 
1.54 mmol), 2-nitrobromobenzene (104 mg, 0.515 mmol), 2.48 (92 mg, 0.669 mmol), 
Pd(dppf)Cl2 dichloromethane adduct (21mg, 0.0257 mmol), and 2,6-di-tert-butyl-4 
methylphenol (BHT) (spatula tip). The mixture was then heated to 100 °C under an argon 
atmosphere for 6 hours until all starting material was consumed, as judged by TLC. The 
resulting dark colored solution was diluted with EtOAc (50 mL), washed with H2O (25 
mL), brine (25 mL), dried with Na2SO4, and concentrated under reduced pressure. The 
resulting black oil was purified by flash chromatography eluting with Hexanes : EtOAc 
(5:1) to afford 110 mg (99% yield) of 2.50 as a yellow solid: M.p. 134-136 °C; 1H-NMR 
(400 MHz, CDCl3) δ 7.97 (dd, J = 9.2 Hz, 1 H) 7.66 (dt, J = 8.0 Hz, 1 H) 7.51 (dt, J = 
8.4 Hz, 1 H) 7.44 (dd, J = 8.8 Hz, 1 H) 7.29-7.23 (comp, 2 H) 7.04 (t, J = 7.6 Hz, 1 H) 
6.83 (d, J = 8.4 Hz, 1 H) 5.15 (br, 1 H); 13C-NMR (100 MHz, CDCl3) δ 152.3, 149.6, 
132.9, 132.7, 132.6, 129.9, 128.5, 125.0, 124.2, 121.4, 115.7; IR (thin film) 3447, 3067, 





(WLM3_127). To a stirred solution of 2.50 (302 mg, 1.40 mmol) in 1,2 dichloroethane 
(2 mL) at room temperature was added imidazole (285 mg, 4.2 mmol). After 15 min, tert-




was stired at room temperature until all starting material was consumed, as judged by 
TLC. The mixture was cooled to rt, poured onto saturated NH4Cl (25 mL) and extracted 
with EtOAc (4 x 20 mL). The combined organic extracts were washed with H2O (25 mL), 
brine (25 mL), dried with Na2SO4, and concentrated under reduced pressure. The 
resulting yellow oil was purified by flash chromatography eluting with Hexanes : EtOAc 
(10:1) to give 445 mg (96%) of 2.51 as a yellow oil that crystalized upon standing: M.p. 
74-76 °C; 1H-NMR (400 MHz, CDCl3) δ 7.98 (dd, J = 9.6 Hz, 1 H) 7.63 (dt, J = 7.8 Hz, 
1 H) 7.47 (dt, J = 8.8 Hz, 1 H) 7.42 (dd, J = 9.2 Hz, 1 H) 7.31-7.26 (comp, 2 H) 7.08 (dt, 
J = 8.2 Hz, 1 H) 6.89 (d, J = 8.0 Hz, 1 H) 0.73 (s, 9 H) 0.00 (br, 6 H); 13C-NMR (100 
MHz, CDCl3) δ 152.6, 149.9, 134.4, 133.0, 132.8, 130.2, 129.9, 129.7, 128.3, 124.4, 
122.0, 119.7, 25.6, 18.2, -4.3; IR (thin film) 3066, 3026, 2956, 2930, 2885, 2858, 1532, 




methylbenzenesulfonamide. (2.52). (WLM3_129). To a solution of 2.47 (220 mg, 
0.735 mmol) in pyridine (1 mL) at 0 °C was added p-toluenesulfonyl chloride (280 mg, 
1.47 mmol). The reaction was allowed stir overnight until all starting material was 
consumed, as judged by TLC. The resulting brown solution was diluted with EtOAc (30 
mL), washed with H2O (15 mL), brine (15 mL), dried with Na2SO4, and concentrated in 
vacuo to give a brown oil, which was subsequently azeotroped with cyclohexane (3 x 10 






316 mg (95%) of 2.52 as a white solid: 1H-NMR (400 MHz, CDCl3) δ 7.67 (dd, J = 9.2 
Hz, 1 H) 7.37 (dt, J = 8.8 Hz, 1 H) 7.34 (s, 1 H) 7.23 (dt, J = 8.4 Hz, 1 H) 7.21-7.16 (m, 
1 H) 7.07-7.03 (comp, 3 H) 6.89 (d, J = 8.0 Hz, 2 H) 6.86 (dd, J = 9.2 Hz, 1 H) 6.74 (dt, 
J = 8.2 Hz, 1 H) 6.34 (dd, J = 9.6 Hz, 1 H) 2.32 (s, 3 H) 0.77 (s, 9 H) 0.08 (s, 3 H) -0.33 
(s, 3 H); 13C-NMR (100 MHz, CDCl3) δ 151.1, 142.6, 136.1, 134.5, 134.0, 131.5, 130.8, 
130.1, 129.1, 128.9, 128.5, 126.9, 126.6, 126.5, 122.1, 120.3, 25.3, 21.4, 17.9, -4.3, -5.3; 
IR (thin film) 3304, 2930, 2859 cm-1; HRMS (ESI) m/z observed 454.18690 




biphenyl]-2-yl)-4-methylbenzenesulfonamide. (2.53). (WLM3_130). To a solution of 
Br2 (140 mg, 0.045 mL, 0.86 mmol) in CH2Cl2 (2 mL) at 0°C under argon was added 
ethyl vinyl ether (140 mg, 0.104 mL, 1.075 mmol) drop-wise until the solution turned 
colorless. The mixture was stirred for 30 min and diisopropylethylamine (223 mg, 0.3 
mL, 1.72 mmol) was added. After 30 min, a solution of 2.52 (195 mg, 0.43 mmol) in 
CH2Cl2 (2 mL) was added drop-wise, and the mixture was allowed to slowly warm to 
room temperature overnight under an argon atmosphere. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was poured onto saturated 
aqueous NH4Cl (20 mL) and extracted with EtOAc (3 x 20 mL). The combined extracts 
were washed with H2O (30 mL), brine (30 mL), dried with Na2SO4, and concentrated 







eluting with Hexanes : EtOAc (10:1) to afford 142 mg (55%) of 2.53 as a clear oil that 
solidified upon standing: 1H-NMR (400 MHz, CDCl3, as a mixture of rotamers) δ 7.80-
7.74 (comp, 2 H) 7.47-7.16 (comp, 7 H) 7.05-6.84 (m, 3 H) 4.91-4.80 (m, 1 H) 3.63-3.58 
(m, 1 H) 3.22-3.05 (comp, 2 H) 2.47-2.41 (comp, 4 H) 1.00-0.82 (comp, 3 H) 0.71-0.68 
(comp, 9 H) 0.21-0.15 (comp, 6 H); 13C-NMR (100 MHz, CDCl3 as a mixture of 
rotamers) δ 152.9, 152.7, 143.5, 140.2, 138.8, 138.3, 133.6, 133.4, 132.4, 132.0, 131.7, 
130.2, 129.3, 129.1, 129.0, 128.4, 128.1, 128.0, 127.5, 127.4, 120.7, 120.4, 118.4, 118.0, 
93.3, 66.5, 65.6, 34.4, 33.2, 25.4, 21.6, 17.8, 14.5, 1.00, -3.7, -4.2, -4.4, -4.5; IR (thin 
film) 3064, 2958, 2929, 2896, 2857 cm-1; HRMS (ESI) m/z observed 626.13697 




(WLM3_96). To a solution of 2.55 (102 mg, 0.169 mmol) in anhydrous DMF (2 mL, 
stored over 4Å molecular sieves) at 50 °C was added flame-dried CsF (130 mg, 0.843 
mmol). The reaction mixture was immediately heated to 130 °C for 1 h under an argon 
atmosphere. After complete consumption of the starting material, as judged by TLC, the 
reaction mixture was diluted with EtOAc (30 mL), washed with H2O (20 mL), brine (20 
mL), dried with Na2SO4, and concentrated under reduced pressure. The resulting brown 
oil was purified by flash chromatography eluting with Hexanes: EtOAc (5:1) gave 69 mg 
(quant) of 2.56 as a white crystalline solid: M.p. 137-140 °C; 1H-NMR (400 MHz, 




8.4 Hz, 1 H) 6.75 (d, J = 8.0 Hz, 2 H) 6.70-6.64 (comp, 2 H) 6.47 (1H, dd, J = 9.2, 2.0 
Hz) 5.65 (dd, J = 8.4, 4.0 Hz, 1 H) 4.21-4.13 (m, 1 H) 4.03 (dd, J = 13.0, 4.0 Hz, 1 H) 
3.95 (dd, J =13.0, 8.4 Hz, 1 H) 3.86-3.78 (m, 1 H) 2.24 (s, 3 H) 1.28 (t, J = 7.2 Hz, 3 H); 
13C-NMR (100 MHz, CDCl3) δ 155.3, 142.7, 141.8, 136.5, 134.3, 134.1, 130.8, 130.2, 
129.7, 128.8, 128.1, 126.8, 123.6, 120.9, 119.7, 82.8, 66.7, 64.1, 21.4, 14.9; IR (thin film) 
3063, 2978, 2929, 2881 cm-1; HRMS (ESI) m/z observed 410.14171 [C23H23NO4S 




(WLM3_45). To a stirred solution of 2.14 (29 mg, 0.071 mmol) and m-
chloroperoxybenzoic acid (61 mg, 0.354 mmol) in CH2Cl2 (0.7 mL) was added BF3•OEt2 
(cat) under argon. The reaction was stirred at room temperature for 2 h. After complete 
consumption of the starting matierial, as judged by TLC, the reaction mixture was 
purified via PTLC eluting with Hexanes : EtOAc (3:1) to afford 15 mg (55%) of 2.73 as a 
white solid: M.p. 177 °C (decomp); 1H-NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 2 
H) 7.80 (d, J = 8.0 Hz, 1 H) 7.43 (dt, J = 7.6 Hz, 1 H) 7.41 (d, J = 8.0 Hz, 2 H) 7.26 (dt, 
J = 7.6 Hz, 1 H) 7.13 (dd, J = 9.2 Hz, 1 H) 6.78 (d, J = 10.0 Hz, 2 H) 6.37 (d, J = 9.6 
Hz, 2 H) 2.72 (s, 2 H) 2.48 (s, 3 H); 13C-NMR (100 MHz, CDCl3) δ 184.5, 167.6, 147.8, 
145.9, 135.7, 135.1, 130.3, 129.6, 129.2, 129.1, 128.7, 127.1, 126.1, 124.4, 44.2, 43.0, 
21.8; IR (thin film) 3070, 2921, 1719, 1670 cm-1; HRMS (ESI) m/z observed 380.0952 









quinolin]-4-one. (2.74). (WLM4_65). To a stirred solution of 2.14 (50 mg, 0.122 mmol) 
in dry CH2Cl2 (0.4 mL) and dry MeOH (0.8 mL) was added trifluoroacetic acid (0.1 mL). 
The reaction was stirred at 50 °C under argon for 48 hr. After complete consumption of 
starting material, as judged by TLC, the reaction mixture was purified via PTLC eluting 
with Hexanes : EtOAc (4:1) to afford 34 mg (71%) of 2.74 as a white solid: M.p. 150-
151°C; 1H-NMR (400 MHz, CDCl3) δ 7.94 (dd, J = 8.4 Hz, 1 H) 7.44 (d, J = 8.4 Hz, 2 
H) 7.31 (td, J = 7.2 Hz, 1 H) 7.26 (d, J = 8.4 Hz, 2 H) 7.21 (dd, J = 10.0, 3.0 Hz, 1 H) 
7.12 (td, J = 8.0 Hz, 1 H) 6.87 (dd, J = 8.0, 1.6 Hz, 1 H) 6.12 (dd, J = 10.0, 2.0 Hz, 1 H) 
6.06 (dd, J = 10.4, 2.0 Hz, 1 H) 5.71 (dd, J = 10.0, 2.8 Hz, 1 H) 5.56 (m, 1 H) 3.42 (s, 3 
H) 2.41 (s, 3 H) 1.94 (dd, J = 14.4, 2.4 Hz, 1 H) 1.60 (dd, J = 14.4, 3.2 Hz, 1 H); 13C-
NMR (100 MHz, CDCl3) δ 185.5, 154.8, 153.9, 144.4, 135.6, 132.7, 129.8, 129.2, 128.6, 
128.0, 127.2, 127.0, 126.4, 126.2, 124.8, 84.4, 55.7, 41.3, 34.7, 21.6; IR (thin film) 3065, 



















(2.81). (WLM3_66). A stirred solution of 2.14 (134 mg, 0.33 mmol) in 1M HCl (1 mL) 
and dioxane (3 mL) was heated at 100 °C for 6 hr under argon. After complete 
consumption of the starting material, as judged by TLC, the reaction was diluted with 
EtOAc (15 mL), washed with H2O (10 mL), brine (10 mL), dried with Na2SO4 and 
concentrated under reduced pressure. The resulting white solid was purified by flash 
chromatography eluting with Hexanes : EtOAc (1:1) to afford 109 mg (84%) of 2.81 as a 
2:1 mixture of diastereomers: 1H NMR (400 MHz, (CD3)2SO) δ 7.70 (d, J = 8.4 Hz, 2 H) 
7.64 (d, J = 8.4 Hz, 2 H) 7.58 (d, J = 8.0 Hz, 1 H) 7.57 (d, J = 8.0 Hz, 1 H) 7.35-7.26 
(comp, 6 H) 7.13-7.07 (comp, 2 H) 6.78 (d, J = 4.8 Hz, 1 H) 6.52 (d, J = 4.8 Hz, 1 H) 
5.57-5.54 (m, 1 H) 5.47-5.44 (m, 1 H) 4.45 (t, J = 4.8 Hz, 1 H) 4.23-4.20 (comp, 2 H) 
4.12 (t, J = 4.0 Hz, 1 H) 3.34 (dd, J = 4.4 Hz, 1 H) 3.16 (dd, J = 17.6, 4.0 Hz, 1 H) 3.03 
(dd, J = 16.8, 4.8 Hz, 1 H) 2.86 (dd, J = 17.6, 4.0 Hz, 1 H) 2.53-2.44 (comp, 2 H) 2.38 
(dd, J = 13.6, 4.5 Hz, 1 H) 2.34-2.28 (m, 1 H) 2.31 (s, 6 H) 2.25 (dd, J = 14.4 Hz, 5.6 Hz, 
1 H) 2.18-2.08 (comp, 2 H) 1.63 (dd, J = 14.0, 2.4 Hz, 1 H); 13C-NMR (100 MHz, 
(CD3)2SO) δ 206.7, 206.3, 144.8, 144.8, 141.3, 140.9, 133.4, 133.0, 132.2, 131.7, 129.9, 
129.0, 128.9, 127.8, 127.5, 125.0, 124.0, 115.4, 115.1, 97.4, 96.9, 82.0, 80.8, 67.8, 67.3, 
52.4, 51.4, 48.2, 48.0, 42.1, 40.5, 39.2, 21.0; IR (thin film) 3503, 2925, 1718 cm-1; HRMS 
(ESI) m/z observed 400.12109 [C21H22NO5S (M+H)+ requires 400.12132]. 
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View of 2.81a showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  The diastereomer shown has an R, R, R 
configuration at C7, C9a and C14, respectively.  The hydrogen atom on O9a was not 




4-ol. (2.120). (WLM3_136). To a stirred solution of 2.14 (394 mg, 0.962 mmol) in 
MeOH (2 mL) and CH2Cl2 (2 mL) at 0 °C was added CeCl3•7H2O (717 mg, 1.92 mmol). 
After stirring for 30 min, NaBH4 (75 mg, 1.92 mmol) was added in one portion. After 30 
min, the reaction was quenched with saturated NH4Cl (2 mL) and extracted with EtOAc 
(3 x 10 mL). The combined organic extracts were washed with H2O (15 mL), brine (15 
mL), dried with Na2SO4, and concentrated under reduced pressure. The resulting white 
solid was purified by flash chromatography eluting with Hexanes : EtOAc (2:1) to afford 










2.120a: 1H-NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 8.0 Hz, 1 H) 7.40 (d, J = 8.4 
Hz, 2 H) 7.24-7.19 (comp, 3 H) 7.12 (td, J = 7.2 Hz, 1 H) 7.04 (dd, J = 8.0 Hz, 1 H) 6.10 
(dm, 1 H) 5.77 (dm, 1 H) 5.68 (dm, 1 H) 5.59 (m, 1 H) 4.70 (dm, 1 H) 4.46 (m, 1 H) 
3.81-3.73 (m, 1 H) 3.61-3.53 (m, 1 H) 2.38 (s, 3 H) 1.81 (dd, J = 14.4 Hz, 1 H) 1.72 (br, 
1 H) 1.41 (dd, J = 14.4 Hz, 1 H) 1.11 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 MHz, CDCl3) δ 
143.9, 137.5, 136.0, 135.5, 132.8, 132.6, 130.3, 129.6, 127.3, 127.2, 126.7, 126.1, 125.8, 
123.2, 83.6, 63.3, 61.4, 38.6, 37.8, 21.5, 14.8; IR (thin film) 3420, 3026, 2975, 2928 cm-1; 
HRMS (ESI) m/z observed 434.10000 [C23H25NO4S (M+Na)+ requires 434.10000]. 
 
2.120b: 1H-NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 8.0 Hz, 1 H) 7.50 (d, J = 8.4 
Hz, 2 H) 7.24-7.19 (comp, 3 H) 7.10 (td, J = 7.2, 1.2 Hz, 1 H) 6.87 (dd, J = 7.6, 1.2 Hz, 1 
H) 6.19 (dm, 1 H) 5.79 (dm, 1 H) 5.72 (dm, 1 H) 5.58 (m, 1 H) 4.68 (dm, 1 H) 4.54 (m, 1 
H) 3.80-3.73 (m, 1 H) 3.61-3.53 (m, 1 H) 2.38 (s, 3 H) 1.86 (dd, J = 14.4, 2.4 Hz, 1 H) 
1.70 (br, 1 H) 1.46 (dd, J = 14.4, 3.2 Hz, 1 H) 1.10 (t, J = 7.2 Hz, 3 H); 13C-NMR (100 
MHz, CDCl3) δ 144.0, 137.4, 136.5, 135.9, 133.0, 132.4, 130.1, 129.6, 127.4, 127.2, 
126.5, 126.3, 125.8, 123.2, 83.5, 63.3, 61.4, 38.1, 37.8, 21.5, 14.8; IR (thin film) 3392, 













spiro[cyclohexa[2,5]diene-1,4'-quinoline]. (2.121). (WLM3_147_2). To a stirred 
solution of 2.120 (127 mg, 0.309 mmol) in DCE (3.0 mL) under argon was added 
imidazole (65 mg, 0.925 mmol). The reaction mixture was stirred for 15 min, then tert-
butyldimethylsilylchloride (70 mg, 0.463 mmol) was added and the reaction was allowed 
to stir overnight. After complete consumption of the starting material, as judged by TLC, 
the reaction was poured onto saturated NH4Cl (5.0 mL) and extracted with EtOAc (3 x 5 
mL). The combined organic extracts were washed with H2O (10.0 mL), brine (10.0 mL), 
dried with Na2SO4, and concentrated under reduced pressure. The resulting yellow oil 
was purified by flash chromatography eluting with Hexanes: EtOAc (10:1) to afford 157 
mg (97%) of 2.121a and 2.121b as a waxy white solid. 
 
2.121a: 1H-NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 8.4, 1.2 Hz, 1 H) 7.39 (dd, J 
= 8.4, 1.2 Hz, 2 H) 7.23-7.19 (comp, 4 H) 7.12 (td, J = 6.4 Hz, 1 H) 6.04 (dt, J = 10.4, 
2.0 Hz, 1 H) 5.67-5.63 (dm, 1 H) 5.59-5.54 (comp, 3 H) 4.63 (dt, J = 10.0, 2.0 Hz, 1 H) 
4.51-4.48 (m, 1 H) 3.81-3.74 (m, 1 H) 3.61-3.53 (m, 1 H) 2.38 (s, 3 H) 1.80 (dd, J = 14.4, 
2.4 Hz, 1 H) 1.39 (dd, J = 14.4, 3.6 Hz, 1 H) 1.10 (t, J = 7.2 Hz, 3 H) 0.92 (s, 9 H) 0.10 
(s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 143.8, 136.5, 136.0, 134.7, 133.3, 132.4, 131.3, 
130.8, 129.5, 127.6, 127.2, 125.9, 124.1, 83.7, 63.2, 61.8, 38.6, 37.6, 25.9, 21.5, 18.3, 
14.8, -4.5; IR (thin film) 3027, 2928, 2856 cm-1; HRMS (ESI) m/z observed 548.22710 
[C29H39NO4S (M+Na)+ requires 548.22613]. 
 
2.121b: 1H NMR (400 MHz, CDCl3) δ 7.82 (dd, J = 8.4, 1.2 Hz, 1 H) 7.39 (d, J = 
8.4 Hz, 2 H) 7.23-7.19 (comp, 3 H) 7.11 (td, J = 7.8, 1.2 Hz, 1 H) 6.88 (dd, J = 7.8 Hz, 1 
H) 6.12 (dt, J = 10.0, 2.0 Hz, 1 H) 5.68-5.64 (dm, 2 H) 5.62-5.56 (comp, 2 H) 4.67-4.65 
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(m, 1 H) 4.61 (dt, J = 10.0, 2.0 Hz, 1 H) 3.78-3.72 (m, 1 H) 3.61-3.55 (m, 1 H) 2.39 (s, 3 
H) 1.93 (dd, J = 14.8, 2.4 Hz, 1 H) 1.43 (dd, J = 14.4 Hz, 3.6 Hz, 1 H) 1.10 (t, J = 7.8 Hz, 
3 H) 0.90 (s, 9 H) 0.10 (s, 6 H); 13C-NMR (100 MHz, CDCl3) δ 143.9, 136.0, 135.9, 
135.3, 133.7, 132.6, 130.0, 129.5, 127.2, 127.2, 126.3, 125.7, 124.0, 83.6, 63.3, 62.3, 
37.8, 37.7, 26.0, 21.5, 18.4, 14.7, -4.3; IR (thin film) 3026, 2955, 2928, 2885, 2856 cm-1; 





quinoline]-2,5-dien-4-one. (2.147). (WLM6_79). Freshly distilled boron trifluoride 
etherate (651 mg, 4.59 mmol, 0.56 mL) was added dropwise to a solution of 2.14 (940 
mg, 2.30 mmol) and 2.158 (782 mg, 4.59 mmol) in dry MeCN (11.5 mL) at 0 ºC, and the 
reaction was stirred for 6 h at 0 ºC. The reaction mixture was quenched with saturated aq 
NaHCO3 (5.0 mL) and stirred at room temperature for 10 min. The reaction mixture was 
diluted with H2O (20 mL) and extracted with CH2Cl2 (3 x 20 mL). The combined organic 
extracts were washed with brine (40 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a yellow oil. Subsequent purification by flash chromatography eluting 
with Hexanes : EtOAc (3 : 1) provided 934 mg (97%) of 2.147 as a white solid: 1H-NMR 
(400 MHz, CDCl3) δ 7.84 (d, J = 8.0 Hz, 0.4 H) 7.78 (d, J = 8.0 Hz, 0.6 H) 7.41-7.40 






6.80 (d, J = 10.4 Hz, 0.8 Hz) 6.21 (d, J = 10.0 Hz, 0.6 H) 6.15 (d, J = 10.0 Hz, 0.4 H) 
5.86-5.64 (comp, 2 H) 5.43 (d, J = 9.2 Hz, 0.6 H) 5.33 (d, J = 9.6 Hz, 0.4 H) 5.06-4.82 
(comp, 2 H) 4.19 (comp, 1 H) 2.58 (m, 0.6 H) 2.49 (m, 0.4 H) 1.90-1.80 (comp, 2 H) 1.09 
(d, J = 6.4 Hz, 1.2 H) 1.00 (d, J = 6.0 Hz, 1.8 H); 13C-NMR (100 MHz, CDCl3) δ 185.2, 
185.1, 153.5, 152.9, 152.9, 152.8, 144.3, 144.3, 140.1, 139.2, 136.4, 136.3, 134.6, 134.2, 
129.9, 129.8, 129.5, 129.3, 128.7, 128.6, 128.2, 128.1, 127.5, 127.4, 127.0, 126.9, 126.6, 
126.5, 126.3, 117.2, 115.4, 57.8, 41.9, 41.6, 40.8, 40.6, 32.7, 32.5, 21.6, 18.1, 15.3; 




dien-2'-yl)propanal. (2.162). (WLM6_88). Sodium periodate (224 mg, 1.048 mmol) 
was added to a solution of 2.147 (110 mg, 0.262 mmol), 2,6-lutidine (55 mg, 0.524 
mmol, 59 µL), and K2OsO4•2H2O (5 mg, 0.0131 mmol) in dioxane/H2O (4:1) (5.2 mL) at 
room temperature. After 12 h, the reaction mixture was diluted with H2O (10 mL) and 
extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were washed with 
brine (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a brown oil. 
Subsequent purification by flash chromatography eluting with Hexanes : EtOAc (3 : 2) 
provided 89 mg (81%) of 2.162 as a white solid: 1H-NMR (400 MHz, CDCl3) δ 9.72 (d, J 
= 2.0 Hz, 0.5 H) 9.70 (d, J = 2.0 Hz, 0.5 H) 7.90 (d, J = 8.8 Hz, 0.5 H) 7.84 (d, J = 8.8 







H) 7.26 (d, J = 8.8 Hz, 2 H) 7.16 (t, J = 8.0 Hz, 1 H) 6.89 (dd, J = 8.0, 2.0 Hz, 1 H) 6.78 
(dd, J = 10.8, 3.2 Hz, 0.5 H) 6.71 (dd, J = 10.8, 3.2 Hz, 0.5 H) 6.26 (dd, J = 10.8, 1.6 Hz, 
0.5 H) 6.24 (dd, J = 10.8, 1.6 = Hz, 0.5 H) 5.85 (dd, J = 10.4, 1.6 Hz, 0.5 H) 5.83 (dd, J = 
10.4, 1.6 Hz, 0.5 H) 5.35 (dd, J = 10.4, 2.8 Hz, 0.5 H) 5.30 (dd, J = 10.4, 2.8 Hz, 0.5 H) 
4.70 (q, J = 6.0 Hz, 0.5 H) 4.59 (q, J = 6.0 Hz, 0.5 H) 2.97 (m, 0.5 H) 2.82 (m, 0.5 H) 
2.41 (s, 3 H) 1.95-1.80 (comp, 2 H) 1.23 (d, J = 7.2 Hz, 1.5 Hz) 1.14 (d, J = 7.2 Hz, 1.5 
Hz); 13C-NMR (100 MHz, CDCl3) δ 202.4, 201.9, 185.1, 185.0, 152.2, 152.2, 151.9, 
145.0, 144.9, 135.8, 135.5, 134.2, 130.2, 129.7, 129.6, 129.2, 129.1, 128.5, 128.3, 128.2, 
128.0, 127.6, 127.6, 127.5, 127.3, 127.1, 127.0, 54.2, 53.9, 49.8, 49.5, 41.7, 41.7, 35.0, 





spiro[cyclohexane-1,4'-quinoline]-2,5-dien-4-one. (2.165). (WLM6_83). Freshly 
distilled tert-butyldimethylsilyl triflate (226 mg, 0.854 mmol) was added to a solution of 
2.162 (36 mg, 0.85 mmol) and imidazole (87 mg, 1.281 mmol) in dry CH2Cl2 (0.85 mL), 
and the reaction was stirred at room temperature overnight. The reaction was quenched 
with saturated aq NaHCO3 (1.0 mL) and stirred at room temperature for 10 min. The 
reaction mixture was diluted with H2O (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 












concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with Hexanes : EtOAc (6 : 1) provided 29 mg (63%) of 2.165 as 
a clear oil: 
2.165a: 1H-NMR (400 MHz, CDCl3) δ 7.70 (dd, J = 8.0, 1.0 Hz, 1 H) 7.59 (d, J = 8.4 Hz, 
2 H) 7.30-7.26 (comp, 3 H) 7.07 (td, J = 7.6, 1.2 Hz, 1 H) 6.90 (dd, J = 8.0, 1.6, 1 H) 6.82 
(dd, J = 10.0, 3.0 Hz, 1 H) 6.33-6.27 (comp, 3 H) 6.11 (dd, J = 10.0, 2.0 Hz, 1 H) 4.90 (t, 
J = 7.2 Hz, 1 H) 2.42 (s, 3 H) 2.01 (dd, J = 13.6, 7.6 Hz, 1 H) 1.82 (dd, J = 14.0, 6.4 Hz, 
1 H) 1.47 (d, J = 1.2 Hz, 3 H) 0.85 (s, 9 H) 0.06 (s, 3 H) 0.04 (s, 3 H); 13C-NMR (100 
MHz, CDCl3) δ 185.7, 152.4, 151.3, 144.2, 139.1, 137.3, 136.3, 129.9, 129.7, 128.9, 
128.5, 128.4, 127.8, 127.5, 125.9, 125.7, 114.3, 56.3, 43.1, 37.7, 25.7, 21.8, 18.3, 9.8, -
5.1, -5.2; HRMS (ESI) m/z observed 558.21060 [C30H37NO4SSi (M+Na)+ requires 
558.21050]. 
2.165b: 1H-NMR (400 MHz, CDCl3) δ 7.97 (d, J = 7.2 Hz, 1 H) 7.50 (d, J = 8.0 Hz, 2 H) 
7.34 (td, J = 8.0, 3.2 Hz, 1 H) 7.23 (d, J = 8.0 Hz, 2 H) 7.09 (td, J = 7.2, 1.2 Hz, 1 H) 6.89 
(dd J = 7.6, 1.2 Hz, 1 H) 6.76 (dd, J = 10.0, 3.2 Hz, 1 H) 6.35 (dd, J = 10.0, 1.6 Hz, 1 H) 
6.06 (s, 1 H) (dd) (dd) 5.21 (dd, J = 10.4, 6.8 Hz, 1 H) 2.41 (s, 3 H) 1.91 (dd, J = 13.2, 
6.8 Hz, 1 H) 1.84 (dd, J = 13.6, 6.8 Hz, 1 H) 1.52 (d, J = 1.2 Hz, 3 H) 0.92 (9 H) 0.20 (s, 
3 H) 0.10 (s, 3 H); 13C-NMR (100 MHz, CDCl3) δ 185.6, 152.7, 150.1, 144.4, 136.4, 
135.4, 135.0, 131.8, 129.9, 129.5, 128.8, 127.9, 127.7, 127.0, 125.6, 117.2, 52.5, 43.6, 
39.3, 29.9, 25.7, 21.7, 18.2, 12.7, -5.0, -5.1; IR (thin film) 2953, 2928, 2856, 1670 cm-1; 





dien-4-one. (2.112). (WLM6_49). Sodium periodate (40 mg, 0.185 mmol) was added to 
a solution of 2.165 (20 mg, 0.037 mmol) and K2OsO4•2H2O (0.7 mg, 0.00187 mmol) in 
acetone/H2O (10:1) (0.4 mL) at room temperature. After 5 h, the reaction mixture was 
diluted with H2O (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organic 
extracts were washed with brine (5 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a brown oil. Subsequent purification by flash chromatography eluting 
with Hexanes : EtOAc (1 : 1) provided 12 mg (79%) of 2.112 as a white solid: 1H-NMR 
(400 MHz, CDCl3) δ 8.06 (d, J = 8.8 Hz, 1 H) 7.48 (d, J = 8.0 Hz, 2 H) 7.38 (td, J = 7.2, 
1.6 Hz, 1 H) 7.28 (d, J = 8.0 Hz, 2 H) 7.15 (t, 7.2, 1 H) 6.89 (dd, J = 8.0, 1.6 Hz, 1 H) 
6.73 (dd, J = 10.0, 3.2 Hz, 1 H) 6.25 (dd, J = 10.0, 1.6 Hz, 1 H) 5.83 (dd, J = 10.0, 1.6 
Hz, 1 H) 5.21 (dd, J = 10.4, 3.2 Hz, 1 H) 4.72 (t, J = 6.4 Hz, 1 H) 2.42 (s, 3 H) 2.33 (s, 3 
H) 2.25 (dd, J = 14.0, 6.4 Hz, 1 H) 1.90 (dd, J = 14.0, 6.4 Hz, 1 H); 13C-NMR (125 MHz, 
CDCl3) δ 206.5, 184.9, 152.4, 151.1, 145.1, 134.8, 134.2, 130.1, 129.1, 129.1, 128.4, 
127.7, 127.5, 127.4, 126.8, 126.7, 62.3, 41.5, 32.9, 26.3, 21.6; HRMS (ESI) m/z observed 












yl)pentanamide. (4.10). (WLM7_270_2). NEt3•3HF (0.1 mL) was added to a solution 
of 4.21 (11.5 mg, 0.012 mmol) in CH2Cl2 (0.1 mL) in a plastic vial. The reaction was 
stirred at room temperature for 36 h, whereupon excess NEt3•3HF was quenched with 
SiO2 (spatula tip). The reaction mixture was diluted with MeOH (1.0 mL) and filtered 
through a sub-micron syringe filter. Subsequent purification by RP HPLC H2O : MeCN 
(10% MeCN → 95% MeCN over 30 min) provided 8.1 mg (79%) of 4.10 as a white 
solid: 1H-NMR (500 MHz, CD3OD) δ 7.60 (m, 1 H) 7.25-7.21 (comp, 7 H) 7.17-7.13 
(comp, 5H) 7.13-7.08 (comp, 2H) 5.82 (d, J = 12.5 Hz, 1 H) 5.47 (d, 12.0 Hz, 1 H) 5.31 
(d, J = 5.0 Hz, 1 H) 4.49-4.44 (m, 1 H) 4.41 (d, J = 11.0 Hz, 1 H) 4.35 (d, J = 12.0 Hz, 2 
H) 4.30-4.24 (m, 1 H) 4.21 (d, J = 10.5 Hz, 1 H) 4.14-4.05 (comp, 3 H) 3.99 (d, J = 11.0 
Hz, 1 H) 3.95 (d, J = 9.5 Hz, 1 H) 3.20-3.15 (comp, 2 H) 3.06 (t, J = 7.0 Hz, 2 H) 3.02-
2.94 (comp, 3 H) 2.93-2.87 (m, 1 H) 2.68 (t, J = 13.0 Hz, 1 H) 2.28 (dm, J = 15.5 Hz, 1 
H), 2.20-2.15 (comp, 3 H) 1.93 (m, 1 H) 1.74-1.55 (comp, 6 H) 1.45-1.34 (comp, 4 H) 


















139.2, 139.0, 138.9, 129.5, 129.4, 128.9, 128.8, 128.8, 128.7, 127.6, 124.0, 123.7, 121.6, 
118.5, 114.9, 111.4, 110.3, 76.6, 75.4, 74.6, 74.2, 74.1, 63.4, 61.6, 57.2, 51.4, 51.2, 50.8, 
49.9, 43.7, 42.0, 41.0, 40.2, 40.1, 36.8, 31.0, 30.2, 29.8, 29.5, 28.9, 27.5, 27.2, 27.0; 




hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.11). (WLM7_279_2). 
NEt3•3HF (0.05 mL) was added to a solution of 4.15 (12 mg) in CH2Cl2 (0.1 mL) in a 
plastic vial. The reaction was stirred at room temperature for 36 h, whereupon excess 
NEt3•3HF was quenched with SiO2 (spatula tip). The reaction mixture was diluted with 
MeOH (1.0 mL) and filtered through a sub-micron syringe filter. Subsequent purification 
by RP HPLC H2O : MeCN (10% MeCN → 95% MeCN over 30 min) provided 4 mg 
(38%) of 4.15 as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.57 (d, J = 8.0 Hz, 1 H) 
7.47 (d, J = 8.5 Hz, 1 H) 7.29-7.16 (comp, 12 H) 5.36 (dd, J = 9.0, 2.0 Hz, 1 H) 5.26 (d, J 
= 5.5 Hz, 1 H) 4.87 (dd, J = 9.0, 2.0 Hz, 1 H) 4.59 (d, J = 12.0 Hz, 1 H) 4.53 (d, J = 12.0 
Hz, 1 H) 4.50 (d, J = 12.0 Hz, 1 H) 4.45 (d, J = 12.0 Hz, 1 H) 4.38 (td, J = 9.0, 2.0 Hz, 1 
H) 4.18 (d, J = 10.5 Hz, 1 H) 4.09 (d, J = 10.5 Hz, 3 H) 2.95-2.87 (comp, 4 H) 2.68 (t, J = 
2.5 Hz, 1 H) 2.25 (m, 1 H) 2.11 (dd, J = 14.0, 9.0 Hz, 1 H) 1.91 (m , 1 H); 13C-NMR (150 
MHz, CD3OD) δ 141.2, 139.2, 139.0, 138.6, 129.4, 129.4, 129.2, 128.9, 128.8, 127.3, 











Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.57 (d, J = 8.0 Hz, 1 H, C5-H) 
7.47 (d, J = 8.5 Hz, 1 H, C8-H) 7.29-7.16 (comp, 12 H) 5.36 (dd, J = 9.0, 2.0 Hz, 1 H, 
C10-H) 5.26 (d, J = 5.5 Hz, 1 H, C16-H) 4.87 (dd, J = 9.0, 2.0 Hz, 1 H, C10-H) 4.59 (d, J 
= 12.0 Hz, 1 H, C21-H or C29-H) 4.53 (d, J = 12.0 Hz, 1 H, C21-H or C29-H) 4.50 (d, J 
= 12.0 Hz, 1 H, C21-H or C29-H) 4.45 (d, J = 12.0 Hz, 1 H, C21-H or C29-H) 4.38 (td, J 
= 9.0, 2.0 Hz, 1 H, C18-H) 4.18 (d, J = 10.5 Hz, 1 H, C20-H or C28-H) 4.09 (d, J = 10.5 
Hz, 3 H, C20-H2 or C28-H2) 2.95-2.87 (comp, 4 H, C12-H, C15-H2, and C17-H) 2.68 (t, J 
= 2.5 Hz, 1 H, C37-H) 2.25 (m, 1 H, C13-H) 2.11 (dd, J = 14.0, 9.0 Hz, 1 H, C17-H) 1.91 
(m , 1 H, C13-H); 13C-NMR (150 MHz, CD3OD) δ 141.2, 139.2, 139.0, 138.6, 129.4, 
129.4, 129.2, 128.9, 128.8, 127.3, 124.0 (C7), 121.7 (C6), 118.3 (C5), 111.3 (C8), 110.1 
(C3), 80.1 (C37), 77.0 (C36), 76.0 (C20 or C28), 75.3 (C20 or C28), 74.5 (C18), 74.4 
(C21 or C29), 74.3 (C21 or C29), 51.0 (C11), 50.7 (C16), 49.8 (C12), 41.9 (C14), 39.5 














































carboxylate. (4.13). (WLM7_123_2_frac1). A mixture of 4.12 (33 mg, 0.058 mmol) 
and freshly distilled 2,6-lutidine (31 mg, 0.291 mmol, 33 µL) in CH2Cl2 (0.6 mL) at room 
temperature under N2 was added freshly distilled tert-butlyldimethylsilyl 
trifluoromethanesulfonate (39 mg, 0.146 mmol, 33 µL) and the reaction was stirred for 2 
h at room temperature. The reaction was quenched with saturated aq NaHCO3 (1.0 mL), 
diluted with H2O (1.0 mL), and extracted with CH2Cl2 (3 x 1.5 mL). The combined 
organic extracts were washed with brine (3.0 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afforded a clear oil. Subsequent purification by flash 
chromatography Hexanes : EtOAc  (5 : 1) afforded 36 mg (91%) of 4.13 as a clear oil: 
1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.29 (br, 1 H) 7.39 (d, J = 8.0 Hz, 1 H) 7.37-7.20 
(comp, 11 H) 7.10 (app t, J = 8.0 Hz, 1 H) 7.03 (app t, J = 7.0 Hz, 1 H) 6.03 (br, 1 H) 
5.56 (d, J = 6.5 Hz, 1 H) 5.35 (br, 1 H) 5.23 (br, 1 H) 4.65 (m, 2 H) 4.62 (d, J = 12.0 Hz, 
1 H) 4.59 (d, J = 12.0 Hz, 1 H) 4.50 (d, J = 12.5 Hz, 1 H) 4.47 (d, J = 12.5 Hz, 1 H) 4.36 
(t, J = 9.0 Hz, 1 H) 4.28 (d, J = 9.5 Hz, 1 H) 4.06 (d, J = 9.5 Hz, 1 H) 3.93 (d, J = 9.5 Hz, 
1 H) 3.80 (m, 1 H) 3.68 (d, J = 9.5 Hz, 1 H) 2.96 (m, 1 H) 2.69 (m, 1 H) 2.62 (m, 1 H) 
1.98-1.96 (m, 1 H) 1.89-1.85 (m, 1 H) 1.80-1.73 (m, 1 H) 0.85 (s, 9 H) 0.03 (s, 3 H) 0.03 
(s, 3 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 156.4, 141.2, 140.2, 140.1, 136.9, 135.2, 
129.7, 129.5, 129.4, 129.1, 129.0, 128.9, 128.8, 128.8, 128.7, 128.5, 127.6, 122.7, 120.5, 
118.3, 117.4, 113.1, 112.1, 77.3, 74.5, 74.5, 74.3, 72.5, 66.6, 48.7, 48.3, 47.7, 41.9, 31.1, 





Assignments: 1H-NMR: δ 9.29 (br, 1 H, N1-H) 7.39 (d, J = 8.0 Hz, 1 H, C5-H) 
7.37-7.20 (comp, 11 H, C8-H, C22-H, C23-H, C24-H, C25-H, C26-H, C28-H, C29-H, 
C30-H, C31-H, C32-H) 7.10 (app t, J = 8.0 Hz, 1 H, C7-H) 7.03 (app t, J = 7.0 Hz, 1 H, 
C6-H) 6.03 (br, 1 H, C34-H) 5.56 (d, J = 6.5 Hz, 1 H, C14-H) 5.35 (br, 1 H, C35-H) 5.23 
(br, 1 H, C35-H) 4.65 (m, 2 H, C33-H2) 4.62 (d, J = 12.0 Hz, 1 H, C19-H or C20-H) 4.59 
(d, J = 12.0 Hz, 1 H, C19-H or C20-H) 4.50 (d, J = 12.5 Hz, 1 H, C19-H or C20-H) 4.47 
(d, J = 12.5 Hz, 1 H, C19-H or C20-H) 4.36 (t, J = 9.0 Hz, 1 H, C12-H) 4.28 (d, J = 9.5 
Hz, 1 H, C18-H) 4.06 (d, J = 9.5 Hz, 1 H, C17-H) 3.93 (d, J = 9.5 Hz, 1 H, C17-H) 3.80 
(m, 1 H, C15-H) 3.68 (d, J = 9.5 Hz, 1 H, C18-H) 2.96 (m, 1 H, C13-H) 2.69 (m, 1 H, 
C15-H) 2.62 (m, 1 H, C11-H) 1.98-1.96 (m, 1 H, C16-H) 1.89-1.85 (m, 1 H, C13-H) 
1.80-1.73 (m, 1 H, C16-H) 0.85 (s, 9 H, C37-CH3) 0.03 (s, 3 H, C36-CH3) 0.03 (s, 3 H, 
C36-CH3); 13C-NMR: δ 156.4 (C39), 141.2, 140.2, 140.1, 136.9, 135.2, 129.7, 129.5, 
129.4, 129.1, 129.0, 128.9, 128.8, 128.8, 128.7, 128.5, 127.6, 122.7 (C7), 120.5 (C6), 
118.3 (C5), 117.4, 113.1, 112.1 (C8), 77.3 (C12), 74.5 (C17 or C19 or C20), 74.5 (C17 or 
C19 or C20), 74.3 (C17 or C19 or C20), 72.5 (C18), 66.6 (C33), 48.7 (C10), 48.3 (C14), 






















































(1S/R, 5R/S, 12R/S)-allyl 6,6-bis((benzyloxy)methyl)-12-((tert-
butyldimethylsilyl)oxy)-7-(prop-2-yn-1-yl)-3,4,5,6-tetrahydro-1H-5,1-
ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.14). (WLM7_257_2). A mixture of 
4.13 (150 mg, 0.22 mmol) and 60% NaH dispersion in mineral oil (18 mg, 0.44 mmol) in 
DMF (1.1 mL) at 0 °C under N2 was stirred for five min and propargyl bromide (131 mg 
of 80% solution in toluene, 0.88 mmol, 95 µL) was added in one portion. After 1 h, the 
reaction was quenched with saturated aq NaHCO3 (1.5 mL), diluted with H2O (1.5 mL), 
and extracted with EtOAc (3 x 20 mL). The combined organic extracts were washed with 
brine (25 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. 
Purification by flash chromatography eluting with Hexanes : EtOAc (10 : 1) to provide 
155 mg (98%) of 4.14 as a clear oil: 1H-NMR (500 MHz, CD3CN, rotamers) δ 7.41-7.07 
(comp, 14 H) 6.09-6.03 (m, 0.5 H) 5.98-5.92 (m, 0.5 H) 5.74 (d, J = 2.5 Hz, 0.5 H) 5.70 
(d, J = 2.5 Hz, 0.5 H) 5.57 (d, J = 7.0 Hz, 0.5 H) 5.54 (d, J = 7.0 Hz, 0.5 H) 5.39 (d, J = 
17.5 Hz, 0.5 H) 5.48 (d, J = 12.0 Hz, 1 H) 5.16 (d, J = 11.0 Hz, 0.5 H) 4.89 (d, J = 2.5 
Hz, 0.5 H) 4.86 (d, J = 2.5 Hz, 0.5 H) 4.74-4.70 (m, 0.5 H) 4.63 (m, 1 H) 4.59-4.50 
(comp, 2.5 H) 4.49-4.44 (comp, 2 H) 4.32 (d, J = 10.0 Hz, 1 H) 4.29 (m, 1 H) 4.13 (d, J = 
10.0 Hz, 1 H) 3.97 (d, J = 10.0 Hz, 1 H) 3.92 (dd, J = 10.0, 3.0 Hz, 1 H) 3.77 (dd, J = 
14.0, 6.0 Hz, 1 H) 3.71 (dd, J = 14.0, 6.0 Hz, 1 H) 2.85 (m, 1 H) 2.72 (m, 1 H) 2.57 (td, J 
= 13.5, 4.0 Hz, 0.5 H) 2.52 (m, 1 H) 2.49 (td, J = 13.5, 4.0 Hz, 0.5 H) 1.89-1.70 (comp, 3 
H) 0.834 (s, 9 H) 0.01 (s, 6 H); 13C-NMR (125 MHz, CD3CN, rotamers) δ 155.8, 141.0, 







117.4, 116.9, 115.5, 110.9, 81.0, 76.5, 75.2, 74.0, 73.9, 73.7, 73.3, 66.4, 66.1, 50.7, 50.7, 
48.3, 48.1, 41.6, 41.2, 40.1, 37.3, 32.6, 31.33, 30.7, 30.4, 26.3, 18.6, -4.7, -4.7; HRMS 





ethanoazocino[4,3-b]indole. (4.15). (WLM7_258_2). A round bottom flask charged 
with Pd2(dba)3 (2.0 mg, 0.0022 mmol) and 1,4-bis(diphenylphosphino)butane (1.8 mg, 
0.0043 mmol) was placed under vacuum and backfilled with N2 three times. A second 
round bottom flask was charged with 4.14 (155 mg, 0.22 mmol) and 1,3-
dimethylbarbituric acid (337 mg, 2.16 mmol) and placed under vacuum and backfilled 
with N2 three times. THF (1.0 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. The Pd/ligand mixture was added via 
syringe to the flask containing 4.15, and stirring was continued at room temperature until 
4.15 was gone by TLC. The reaction was quenched with saturated aq NaHCO3 (2.0 mL) 
and stirred at room temperature for 15 min. The reaction mixture was diluted with H2O 
(10 mL) extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were washed 
with brine (25 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a brown 
oil. Subsequent purification by flash chromatography eluting with Hexanes : EtOAc (1 : 1 
to 100% EtOAc) provided 31 mg (27%) of 4.15 and 37 mg (25%) of 4.16 as a white 







7.33-7.14 (comp, 12 H) 5.77 (dd, J = 9.0, 2.5 Hz, 1 H) 5.29 (br, 1 H) 4.73 (dd, J = 9.0, 
2.5 Hz, 1 H) 4.69 (app t, J = 9.0 Hz, 1 H) 4.60 (d, J = 12.0 Hz, 1 H) 4.57 (d, J = 12.0 Hz, 
1 H) 4.46 (d, J = 12.5 Hz, 1 H) 4.41 (d, J = 11.5 Hz, 1 H) 4.26 (d, J = 9.5 Hz, 1 H) 4.11 
(d, J = 10.5 Hz, 1 H) 3.97 (d, J = 10.0 Hz, 1 H) 3.96 (d, J = 10.5 Hz, 1 H) 3.03 (comp, 3 
H) 2.81 (comp, 2 H) 2.21 (app t, J = 2.5 Hz, 1 H) 2.17-2.10 (comp, 2 H) 0.84 (s, 9 H) 
0.06 (s, 3 H) 0.03 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ 140.89, 137.90, 137.73, 
137.45, 128.56, 128.54, 128.18, 127.98, 127.89, 127.84, 123.28, 121.05, 118.04, 109.97, 
109.18, 79.59, 77.73, 74.70, 73.98, 73.64, 73.57, 72.85, 72.36, 50.00, 49.32, 48.37, 40.36, 
39.40, 36.74, 27.16, 25.94, -4.89, -5.08. HRMS (ESI) m/z observed 657.34680 





ethanoazocino[4,3-b]indole. (4.16). (WLM7_258_2). 1H-NMR (500 MHz, CD3CN) δ 
7.46 (d, J = 8.0 Hz, 1 H) 7.34 (d, J = 8.5 Hz, 1 H) 7.31-7.16 (comp, 11 H) 7.07 (td, J = 
7.0, 2.0 Hz, 1 H) 5.96 (m, 1 H) 5.79 (dd, J = 9.0, 2.5 Hz, 1 H) 5.28 (dm, J = 17.0 Hz, 1 
H) 5.15 (dd, J = 10.5, 1.5 Hz, 1 H) 4.84 (dd, J = 9.0, 2.5 Hz, 1 H) 4.58 (d, J = 12.0 Hz, 1 
H) 4.55 (d, J = 12.0 Hz, 1 H) 4.50 (td, J = 9.0, 2.0 Hz, 1 H) 4.44 (d, J = 12.0 Hz, 1 H) 
4.41 (d, J = 12.0 Hz, 1 H) 4.38 (d, J = 9.5 Hz, 1 H) 4.05 (d, J = 10.0 Hz, 1 H) 3.95 (d, J = 
9.5 Hz, 1 H) 3.93 (d, J = 10.0 Hz, 1 H) 3.28-3.23 (m, 1 H) 2.99-2.95 (m, 1 H) 2.68 (m, 1 







Hz, 1 H) 2.07 (td, J = 12.5, 3.5 Hz, 1 H) 1.96 (m, 1 H) 1.78-1.68 (comp, 2 H) 0.84 (s, 9 
H) 0.03 (s, 6 H); 13C-NMR (125 MHz, CD3CN) δ 140.3, 139.5, 139.5, 139.0, 138.1, 
129.2, 129.2, 129.1, 128.8, 128.7, 128.5, 128.4, 122.7, 120.5, 119.4, 116.8, 110.4, 105.7, 
81.2, 76.8, 76.0, 74.0, 73.9, 73.5, 73.1, 62.6, 53.7, 50.8, 50.2, 49.9, 43.9, 37.2, 31.3, 28.7, 







thieno[3,4-d]imidazol-4-yl)pentanamide. (4.21). (WLM7_260_2). A mixture of tert-
BuOH : H2O (1 : 1) (0.4 mL) was added to a flask charged with CuSO4•5H2O (1.2 mg, 
0.0049 mmol), 4.14 (31 mg, 0.049 mmol), azide 4.20 (27 mg, 0.073 mmol) and sodium 
ascorbate (1.9 mg, 0.0098 mmol). The reaction mixture was heated to 70 ºC. After 1.5 h, 
the reaction was cooled to room temperature, and aq ammonia (0.3 mL) was added. The 
reaction was then diluted with MeOH (2 mL) and extracted with CH2Cl2 (3 x 5 mL). The 


















concentrated under reduced pressure to afford a brown solid. Purification by flash 
chromatography eluting with CH2Cl2 : MeOH (100% CH2Cl2 → 95:5 → 80:20) 
containing 1% NEt3 provided 35.5 mg (72%) of 4.21 as a white solid: 1H-NMR (500 
MHz, CD3OD) δ 7.59 (d, J = 8.4 Hz, 1 H) 7.31 (s, 1 H) 7.26-7.22 (comp, 3 H) 7.21-7.13 
(comp, 6 H) 7.12-7.09 (comp, 4 H) 6.15 (d, J = 18.0 Hz, 1 H) 5.51 (d, J = 18.0 Hz, 1 H) 
5.29 (d, J = 5.4 Hz, 1 H) 4.50-4.44 (comp, 2 H) 4.47 (d, J = 12.6 Hz, 1 H) 4.43 (d, J = 
12.0 Hz, 1 H) 4.37 (d, J = 12.0 Hz, 1 H) 4.34 (d, J = 11.4 Hz, 1 H) 4.26 (m, 1 H) 4.19-
4.15 (comp, 2 H) 4.12-4.01 (comp, 2 H) 4.06 (d, 10.2 Hz, 1 H) 4.02 (d, J = 10.2 Hz, 1 H) 
3.18-3.16 (m, 1 H) 3.07 (t, J = 7.2 Hz, 2 H) 2.99 (dd, J = 13.2, 6.0 Hz, 1 H) 2.92-2.86 
(comp, 4 H) 2.67 (d, J = 13.2 Hz, 1 H) 2.26 (dm, J = 16.8 Hz, 1 H) 2.20-2.17 (m, 1 H) 
2.17 (t, J = 7.2 Hz, 2 H) 1.88 (m, 1 H) 1.73-1.54 (comp, 6 H) 1.44-1.36 (comp, 4 H) 1.24 
(m, 2 H) 1.16 (m, 2 H) 0.87 (s, 9 H) 0.09 (s, 6 H); 13C-NMR (125 MHz, CD3OD) δ 175.9, 
166.1, 142.7, 139.3, 139.2, 139.1, 129.4, 129.4, 128.9, 128.8, 128.7, 128.7, 128.6, 127.5, 
124.1, 123.6, 121.6, 118.4, 111.5, 109.7, 75.7, 75.3, 74.5, 74.2, 74.1, 63.4, 61.6, 57.0, 
51.4, 51.2, 49.8, 49.6, 44.3, 41.7, 41.0, 40.4, 40.1, 36.8, 31.0, 30.2, 29.8, 29.8, 29.5, 28.5, 
27.2, 27.0, 26.4, 18.8, -4.7, -4.7; HRMS (ESI) m/z observed 1025.54580 [C56H78N8O5SSi 
(M+Na)+ requires 1025.54770]. 
 
 
Allyl (1S/R, 5R/S, 12R/S)-6,6-Bis((benzyloxy)methyl)-12-((tert-
butyldimethylsilyl)oxy)-7-(oxiran-2-ylmethyl)-1,3,4,5,6,7-hexahydro-2H-5,1-








in mineral oil (21 mg, 0.521 mmol) was added to a solution of 4.13 (71 mg, 0.104 mmol) 
in HMPA (0.52 mL) at 0 ºC. After 15 min, epi-chlorohydrin (96 mg, 1.04 mmol, 82 µL) 
was added in one portion. The cooling bath was removed, and the reaction was stirred a rt 
for 36 h. The reaction mixture was quenched via the addition of saturated aq NaHCO3 
(1.0 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were 
washed with 1 M HCl (15 mL), brine (15 mL), dried (Na2SO4), filtered, and concentrated 
in vacuo to afford a yellow oil. Subsequent purification by flash chromatography eluting 
with Hexanes : EtOAc (10 : 1) to afford 49 mg (64%) 4.35 and 26 mg (36%) of 4.13: 1H-
NMR (500 MHz, CD3CN, 70 ºC) δ 7.51 (dd, J = 19.0, 8.0 Hz, 1H), 7.33 (comp, 13H), 
7.19 – 7.06 (m, 1H), 6.21 – 5.98 (m, 1H), 5.66 (d, J = 6.7 Hz, 1H), 5.40 (comp, 3H), 4.74 
(comp, 2H), 4.63 (comp, 3H), 4.58 – 4.46 (m, 3H), 4.41 (t, J = 9.2 Hz, 1H), 4.33 (d, J = 
9.8 Hz, 1H), 4.21 (comp, 1H), 4.08 (comp, 2H), 3.91 (comp, 2H), 3.20 – 3.04 (m, 1H), 
3.04 – 2.92 (m, 1H), 2.87 (comp, 1H), 2.70 (comp, 1H), 2.48 (comp, 1H), 0.94 (s, 10H), 
0.11 (s, 6H); 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 156.3, 139.8, 139.8, 139.7, 139.7, 
139.5, 135.2, 129.5, 129.5, 129.5, 129.0, 129.0, 128.9, 128.8, 128.8, 128.7, 128.7, 127.9, 
123.3, 123.2, 121.0, 121.0, 115.9, 112.1, 112.1, 111.3, 77.1, 76.1, 75.8, 74.4, 74.3, 74.3, 
74.2, 66.6, 53.3, 53.0, 51.7, 51.4, 51.3, 50.1, 49.5, 48.8, 46.2, 46.1, 42.0, 30.6, 26.6, 18.9, 













ethanoazocino[4,3-b]indole. (4.36). (WLM9_76). A round bottom flask charged with 
Pd2(dba)3 (15 mg, 0.0166 mmol) and 1,4-bis(diphenylphosphino)butane (14 mg, 0.0332 
mmol) was placed under vacuum and backfilled with N2 three times. A second round 
bottom flask was charged with 4.35 (49 mg, 0.0665 mmol) and 1,3-dimethylbarbituric 
acid (104 mg, 0.665 mmol) and placed under vacuum and backfilled with N2 three times. 
THF (0.5 mL) was then added to both flasks, and the mixtures were stirred at room 
temperature under N2 for 5 min. An aliquot of the Pd/ligand mixture (50 µL) was added 
via syringe to the flask containing 4.35, and stirring was continued at room temperature 
until 4.35 was gone by TLC. The reaction was quenched with saturated aq NaHCO3 (1.0 
mL) and stirred at room temperature for 15 min. The reaction mixture was diluted with 
H2O (5 mL) extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
washed with brine (15 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford 
a brown oil. Subsequent purification by flash chromatography eluting with EtOAc : 
Hexanes (10 : 1 → 100% EtOAc) containing 1% NEt3 provided 28.5 mg (66%) of 4.36 as 
a white solid: 1H-NMR (500 MHz, CD3CN) δ 7.51 – 7.44 (m, 1H), 7.40 (comp, 1H), 7.25 
(comp, 10H), 7.11 (comp, 1H), 7.03 (comp, 1H), 5.43 (comp, 1H), 4.79 (comp, 1H), 4.57 
(comp, 4H), 4.43 (comp, 2H), 4.28 (comp, J = 9.5, 6.7 Hz, 1H), 4.01 (comp, 3H), 3.78 
(comp, 1H), 3.10 – 2.96 (m, 1H), 2.71 (comp, 2H), 2.54 (comp, 2H), 2.36 (comp, 3H), 
2.05 – 1.96 (m, 1H), 1.89 – 1.79 (m, 1H), 1.77 – 1.57 (m, 1H), 0.87 (comp, 9H), 0.06 
(comp, 6H); 13C NMR (125 MHz, CD3CN) δ 140.8, 140.8, 139.6, 139.6, 139.6, 139.4, 
139.3, 129.3, 129.3, 129.2, 129.2, 129.2, 128.8, 128.7, 128.7, 128.7, 128.6, 128.6, 128.6, 
128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.4, 128.4, 128.4, 128.4, 127.7, 122.5, 122.3, 
120.1, 120.0, 118.5, 118.5, 116.5, 116.4, 111.6, 111.5, 77.1, 77.1, 76.2, 76.0, 73.9, 73.9, 
 307 
73.9, 73.8, 73.8, 73.7, 53.2, 52.9, 51.2, 51.0, 51.0, 51.0, 49.8, 48.7, 48.2, 48.2, 45.9, 45.6, 
44.5, 44.5, 42.5, 42.5, 32.2, 26.4, 26.4, 18.7, 18.7, 18.6, -4.5, -4.6, -4.6; HRMS (ESI) m/z 





(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)propanamide. (4.40). (WLM9_87).  37% aq 
formaldehyde (1.2 mg, 0.0398 mmol, 3.3 µL) was added to a stirred solution of 4.36 (13 
mg, 0.0199 mmol) in CH2Cl2 (0.2 mL). After 5 min, sodium triacetoxyborohydride (12.7 
mg, 0.0597 mmol) was added in one portion. After 1 h, the reaction was quenched with 
saturated aq NaHCO3 (0.3 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a yellow oil. The crude reaction mixture was dissolved in 
saturated methanolic ammonia (0.5 mL) and heated to 80 ºC in a sealed vial for 48 h. 
Upon cooling the reaction to rt, the solvent was removed in vacuo to afford a yellow oil. 
The crude reaction mixture was subsequently dissolved in CH2Cl2 (0.2 mL) and cooled to 
0 ºC. After stirring for 5 min, 4.24 (3.6 mg, 0.0219) and N,N’-dicyclohexylcarbodiimide 
(4.5 mg, 0.0219 mmol) were added to the reaction. After 10 min, the reaction was 
quenched with saturated aq NaHCO3 (0.5 mL) and extracted with CH2Cl2 (3 x 10 mL). 












and concentrated in vacuo to afford a yellow oil. The crude reaction mixture was 
dissolved in CH2Cl2 (0.3 mL) and NEt3•3HF (0.1 mL) and stirred at rt. After 36 h, SiO2 
(10 mg) was added to quench excess HF. The solvent was removed in vacuo and MeOH 
(1.0 mL) was added to the crude reaction mixture. The reaction mixture was filtered with 
a submicron syringe filter and purified via RPHPLC eluting with H2O : MeCN (75 : 25 
→ 90 : 10 over 120 min) containing 0.1% TFA to afford 0.85 mg (6%) of 4.40 as a white 
solid: 1H-NMR (600 MHz, CD3OD) δ 7.59 (comp, J = 8.0, 4.8 Hz, 1H), 7.57 – 7.50 (m, 
1H), 7.25 (comp, 11H), 7.13 – 7.08 (m, 1H), 5.18 (d, J = 5.7 Hz, 1H), 4.43 (comp, 9H), 
4.11 (dd, J = 29.9, 10.2 Hz, 1H), 3.94 (dd, J = 40.9, 10.1 Hz, 1H), 3.47 – 3.35 (m, 1H), 
3.20 (comp, 3H), 3.05 (comp, 3H), 2.85 (s, 4H), 2.35 – 2.20 (m, 1H), 2.04 (comp, 4H), 
1.97 (comp, 2H), 1.76 (comp, 2H), 1.57 (td, J = 7.4, 2.6 Hz, 2H); HRMS (ESI) m/z 
observed 718.39600 [C43H51N5O5 (M+H)+ requires 718.39630]. 
 
 
(1S/R, 5R/S, 12R/S)-tert-Butyl 6,6-bis((benzyloxy)methyl)-12-hydroxy-2-
methyl-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-7(2H)-carboxylate. 
(4.43). (WLM7_176_2). A mixture of 3.34 (5.5 mg, 0.00944 mmol) and 37% aq 
formaldehyde solution (7.7 mg, 0.0944 mmol, 7.7 µL) in CH2Cl2 (0.3 mL) was stirred for 
5 min at room temperature and sodium cyanoborohydride (9 mg, 0.142 mmol) was added 
in one portion. Stirring was continued for 3 h at room temperature. The reaction was 
quenched with saturated aq Rochelle’s salt (0.1 mL), diluted with MeOH (0.5 mL), and 
extracted with CH2Cl2 (3 x 2 mL). The combined organic extracts were washed with 








Subsequent purification by RPHPLC H2O : MeCN (90 : 10 → 5 : 95 over 20 min) 
afforded 3.0 mg (54%) of 4.43 as a white solid. 1H-NMR (500 MHz, CD3OD) δ 7.76 (d, J 
= 8.5 Hz, 1 H) 7.65 (d, J = 7.5 Hz, 1 H) 7.38 (t, J = 8.0 Hz, 1 H) 7.31 (t, J = 7.5 Hz, 1 H) 
7.22-7.17 (comp, 7 H) 7.14 (comp, 3 H) 5.24 (d, J = 5.0 Hz, 1 H) 4.54-4.38 (comp, 7 H) 
4.32 (td, J = 8.5 Hz, 1 H) 3.67 (d, J = 10.0 Hz, 1 H) 3.06-2.96 (comp, 3H) 2.91-2.88 (m, 
1 H) 2.86 (s, 3 H) 2.27-2.18 (comp, 2 H) 1.93 (m, 1 H) 1.60 (s, 9 H); 13C-NMR (125 
MHz, CD3OD) δ 152.4, 142.1, 139.4, 139.0, 137.8, 129.3, 129.3, 129.0, 128.8, 128.7, 
128.6, 128.1, 125.9, 123.9, 118.8, 115.3, 113.8, 86.8, 77.7, 74.7, 74.3, 74.2, 73.9, 59.9, 
53.2, 53.1, 46.4, 38.7,  30.7, 29.6, 28.2; HRMS (ESI) m/z observed 597.33250 
[C37H44N2O5 (M+H)+ requires 597.33230]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.76 (d, J = 8.5 Hz, 1 H, C8-H) 
7.65 (d, J = 7.5 Hz, 1 H, C5-H) 7.38 (t, J = 8.0 Hz, 1 H, C7-H) 7.31 (t, J = 7.5 Hz, 1 H, 
C6-H) 7.22-7.17 (comp, 7 H) 7.14 (comp, 3 H) 5.24 (d, J = 5.0 Hz, 1 H, C16-H) 4.54-
4.38 (comp, 7 H, C20-H and C21-H and C28-H and C29-H) 4.32 (td, J = 8.5 Hz, 1 H, 
C18-H) 3.67 (d, J = 10.0 Hz, 1 H, C20-H or C21-H or C28-H or C29-H) 3.06-2.96 
(comp, 3H, C14-H2 and C17-H) 2.91-2.88 (m, 1 H, C12-H) 2.86 (s, 3 H, C36-H3) 2.27-
2.18 (comp, 2 H, C13-H and C17-H) 1.93 (m, 1 H, C13-H) 1.60 (s, 9 H, C38-H3); 13C-











































128.8, 128.7, 128.6, 128.1, 125.9, 123.9, 118.8 (C5), 115.3 (C8), 113.8 (C3), 86.8 (C10), 
77.7 (C20 or C21 or C28 or C29), 74.7 (C20 or C21 or C28 or C29), 74.3 (C18), 74.2 
(C20 or C21 or C28 or C29), 73.9 (C20 or C21 or C28 or C29), 59.9 (C16), 53.2 (C12), 





(WLM7_114_2). A mixture of 4.12 (43 mg, 0.076 mmol) and 60% NaH dispersion in 
mineral oil (30 mg, 0.76 mmol) in DMF (0.75 mL) at 0 °C under N2 was stirred for five 
min and methyl p-toluenesulfonate (71 mg, 0.38 mmol) was added in one portion. The 
reaction was allowed to warm slowly to room temperature overnight. The reaction was 
quenched with saturated aq NaHCO3 (0.75 mL), diluted with H2O (5 mL), and extracted 
with EtOAc (3 x 10 mL). The combined organic extracts were washed with brine (20 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. Purification 
by flash chromatography eluting with Hexanes : EtOAc (4:1 → 2:1) to provide 38 mg 
(84%) of 4.44a as a clear oil: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 7.38 (d, J = 8.0 Hz, 
1 H) 7.33-7.22 (comp, 9 H) 7.19-7.18 (comp, 2 H) 7.15 (td, J = 7.0, 1.0 Hz, 1 H) 7.04 (td, 
J = 7.5, 1.0 Hz, 1 H) 6.03 (br, 1 H) 5.66 (d, J = 6.5 Hz, 1 H) 5.34 (br, 1 H) 5.22 (br, 1 H) 
4.66 (br, 1 H) 4.53-4.47 (comp, 3 H) 4.42 (d, J = 12.0 Hz, 1 H) 4.38 (d, J = 10.5 Hz, 1 H) 
3.99 (d, J = 9.5 Hz, 1 H) 3.96 (d, J = 9.5 Hz, 1 H) 3.95 (d, J = 10.5 Hz, 1 H) 3.83 (s, 3 H) 
3.78 (app t, J = 8.8 Hz, 1 H) 3.31 (s, 3 H) 3.05-3.00 (comp, 2 H) 2.82 (br, 1 H) 2.16 (dt, J 








140.8, 140.1, 139.5, 139.0, 135.3, 129.5, 129.5, 129.0, 128.9, 128.8, 128.6, 127.5, 122.9, 
120.5, 117.4, 115.5, 110.3, 86.4, 78.1, 75.3, 74.3, 74.0, 66.6, 57.5, 50.6, 48.5, 47.0, 42.1, 





(4.44b). (WLM7_122_2_frac1). A mixture of 3.36 (44 mg, 0.0659 mmol) and 60% NaH 
dispersion in mineral oil (10.5 mg, 0.2636 mmol) in DMF (0.6 mL) under N2 at 0 °C was 
stirred for five min and methyl p-toluenesulfonate (24.5 mg, 0.1318 mmol) was added in 
one portion. The reaction was allowed to warm slowly to room temperature overnight. 
The reaction was quenched with saturated aq NaHCO3 (0.75 mL), diluted with H2O (5 
mL), and extracted with EtOAc (3 x 10 mL). The combined organic extracts were washed 
with brine (20 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear 
oil. Subsequent purification by flash chromatography eluting with Hexanes : EtOAc (4 : 1 
→ 2 : 1) afforded  32 mg (71%) of 4.44b as a white solid: 1H-NMR (500 MHz, C6D6, 
mixture of rotamers) δ 7.92-7.88 (m, 0.5 H) 7.68-7.57 (m, 0.5 H) 7.41-7.38 (m, 1 H) 
7.28-7.02 (comp, 10 H) 6.98-6.89 (comp, 2 H) 6.16 (d, J = 6.5 Hz, 0.5 H) 5.95-5.73 (dm, 
1 H) 5.29-5.25 (m, 0.5 H) 5.11-5.00 (comp, 1 H) 4.95-4.92 (m, 0.5 H) 4.83-4.81 (m, 0.5 
H) 4.77-4.73 (m, 1 H) 4.71-4.65 (comp, 1 H) 4.62-4.58 (m, 1 H) 4.56-4.53 (m, 1 H) 4.48-
4.45 (m, 1 H) 4.34-4.19 (comp, 3 H) 4.14-4.02 (comp, 1 H) 3.86-3.71 (m, 1 H) 3.65-3.60 
(m, 1 H) 3.43-3.37 (m, 1 H) 3.17-3.02 (comp, 4 H) 2.97-2.89 (comp, 1 H) 2.18-2.06 








(125 MHz, C6D6, mixture of rotamers) δ 204.6, 155.4, 155.3, 151.5, 139.9, 139.8, 139.3, 
139.1, 139.1, 138.7, 138.5, 138.0, 136.9, 134.0, 133.8, 128.8, 128.6, 128.5, 127.6, 127.4, 
127.1, 127.1, 126.5, 126.4, 124.6, 122.6, 122.5, 122.4, 122.3, 122.1, 121.9, 118.7, 118.2, 
117.2, 116.9, 114.6, 114.5, 85.3, 83.3, 83.2, 78.8, 78.6, 73.8, 73.6, 73.3, 73.1, 72.6, 72.5, 
72.4, 66.1, 57.0, 56.9, 50.1, 47.5, 47.2, 46.7, 46.1, 41.5, 41.2, 37.9, 36.6, 33.9, 32.3, 32.2, 
31.4, 30.1, 30.1, 30.0, 29.8, 29.8, 29.6, 29.4, 27.8, 25.1, 23.1, 14.3, 1.4; HRMS (ESI) m/z 





(WLM7_116_2_frac2). A round bottom flask charged with Pd2(dba)3 (0.7 mg, 0.00079 
mmol) and 1,4-bis(diphenylphosphino)butane (0.34 mg, 0.00079 mmol) was placed 
under vacuum and backfilled with N2 three times. A second round bottom flask was 
charged with 4.44a (47 mg, 0.079 mmol) and 1,3-dimethylbarbituric acid (123 mg, 0.79 
mmol) and placed under vacuum and backfilled with N2 three times. THF (0.4 mL) was 
then added to both flasks, and the mixtures were stirred at room temperature under N2 for 
5 min. The Pd/ligand mixture was added via syringe to the flask containing 4.44a, and 
stirring was continued at room temperature until 4.44a was gone by TLC. The reaction 
was quenched with saturated aq NaHCO3 (0.8 mL) and stirred at room temperature for 15 
min. The reaction mixture was diluted with H2O (2 mL) extracted with Et2O (3 x 10 mL). 
The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, 








chromatography eluting with EtOAc : MeOH (9 : 1 → 5 : 1) to provide 33 mg (83%) of 
4.45a as a white solid: 1H-NMR (500 MHz, CD3CN) δ 7.44 (d, J = 8.0 Hz, 1 H) 7.33-
7.17 (comp, 11 H) 7.10 (td, J = 7.5, 1.0 Hz, 1 H) 6.99 (td, J = 7.5, 1.0 Hz, 1 H) 4.60 (d, J 
= 6.5 Hz, 1 H) 4.50-4.44 (comp, 3 H) 4.37 (app t, 2 H) 3.97 (td, J = 9.3, 2.0 Hz, 1 H) 3.94 
(d, J = 9.5 Hz, 1 H) 3.88 (d, J = 10.0 Hz, 1 H) 3.86 (d, J = 9.0 Hz, 1 H) 3.79 (s, 3 H) 3.30 
(s, 3 H) 2.93 (m, 1 H) 2.72-2.67 (m, 1 H) 2.54-2.47 (comp, 2 H) 2.20 (br, 1 H) 2.11 (dm, 
J = 14.0 Hz, 1 H) 1.75 (ddd, J = 14.0, 9.5, 1.0 Hz, 1 H) 1.64-1.57 (m, 1 H); 13C-NMR 
(125 MHz, CD3CN) δ 139.9, 139.5, 139.4, 138.7, 129.2, 129.2, 128.7, 128.6, 128.5, 
128.4, 127.3, 122.0, 119.5, 116.5, 109.7, 86.7, 78.3, 75.3, 73.8, 73.5, 57.2, 50.0, 48.0, 




Assignments: 1H-NMR: δ 7.44 (d, J = 8.0 Hz, 1 H, C5-H) 7.33-7.17 (comp, 11 
H, C8-H, C23-H, C24-H, C25-H, C26-H, C27-H, C31-H, C32-H, C33-H, C34-H, C35-
H) 7.10 (td, J = 7.5, 1.0 Hz, 1 H, C7-H) 6.99 (td, J = 7.5, 1.0 Hz, 1 H, C6-H) 4.60 (d, J = 
6.5 Hz, 1 H, C16-H) 4.50-4.44 (comp, 3 H, C21-H2, C29-H or C21-H, C29-H2) 4.37 
(app t, 2 H, C20-H, C21-H or C29-H) 3.97 (td, J = 9.3, 2.0 Hz, 1 H, C18-H) 3.94 (d, J = 
9.5 Hz, 1 H, C20-H or C28-H) 3.88 (d, J = 10.0 Hz, 1 H, C20-H or C28-H) 3.86 (d, J = 



































H, C12-H) 2.72-2.67 (m, 1 H, C17-H) 2.54-2.47 (comp, 2 H, C14-H2) 2.20 (br, 1 H, 
N15-H) 2.11 (dm, J = 14.0 Hz, 1 H, C13-H) 1.75 (ddd, J = 14.0, 9.5, 1.0 Hz, 1 H, C17-H) 
1.64-1.57 (m, 1 H, C13-H). 13C-NMR: δ 139.9, 139.5, 139.3, 138.7, 129.2, 129.2, 128.7, 
128.6, 128.5, 128.4, 127.3, 122.0 (C7), 119.5 (C6), 116.5 (C5), 109.7 (C8), 86.7 (C18), 
78.3 (C20), 75.3 (C28), 73.8 (C21 or C29), 73.5 (C21 or C29), 57.2 (C19), 50.0 (C11), 





(WLM7_134_2). A round bottom flask charged with Pd2(dba)3 (0.43 mg, 0.00047 mmol) 
and 1,4-bis(diphenylphosphino)butane (0.20 mg, 0.00047 mmol) was placed under 
vacuum and backfilled with N2 three times. A second round bottom flask was charged 
with 4.44b (32 mg, 0.047 mmol) and 1,3-dimethylbarbituric acid (73 mg, 0.47 mmol) and 
placed under vacuum and backfilled with N2 three times. THF (0.25 mL) was then added 
to both flasks, and the mixtures were stirred at room temperature under N2 for five min. 
The Pd/ligand mixture was added via syringe to the flask containing 4.44b, and stirring 
was continued at room temperature until 4.44b was gone by TLC. The reaction was 
quenched with saturated aq NaHCO3 (1.0 mL) and stirred at room temperature for 15 
min. The reaction mixture was diluted with H2O (1.0 mL) extracted with Et2O (3 x 5 mL). 
The combined organic extracts were washed with brine (10.0 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a brown oil. Subsequent purification by flash 








of 4.45b as a white solid: 1H-NMR (600 MHz, CD3OD) δ 7.77 (dm, J = 8.4 Hz, 1 H) 7.59 
(d, J = 7.8 Hz, 1 H) 7.37-7.31 (comp, 5 H) 7.27-7.24 (comp, 2 H) 7.13-7.01 (comp, 3 H) 
7.05-7.04 (comp, 2 H) 5.29 (d, J = 5.4 Hz, 1 H) 4.81 (d, J = 7.8 Hz, 1 H) 4.62 (d, J = 10.2 
Hz, 1 H) 4.54 (d, J = 7.8 Hz, 1 H) 4.52 (d, J = 8.4 Hz, 1 H) 4.45 (d, J = 12.0 Hz, 1 H) 
4.41 (d, J = 12.0 Hz, 1 H) 4.09 (d, J = 8.4 Hz, 1 H) 3.86 (t, J = 9.6 Hz, 1 H) 3.73 (d, J = 
10.8 Hz, 1 H) 3.40 (s, 3H) 3.28 (m, 1H) 2.98 (m, 1H) 2.87 (dd, J = 13.8, 4.8 Hz, 1 H) 
2.73 (td, J = 13.8, 4.8 Hz, 1 H) 2.29-2.22 (comp, 2 H) 1.82 (tm, 1 H) 1.59 (s, 9H); 13C-
NMR (150 MHz, CD3OD) δ 152.2, 141.5, 139.9, 139.0, 137.7, 129.2, 129.1, 128.4, 
128.3, 128.3, 127.7, 127.2, 125.9, 123.3, 118.5, 115.9, 115.0, 86.2, 84.8, 78.6, 73.8, 73.6, 
73.5, 58.0, 51.1, 45.8, 42.0, 37.1, 29.2, 28.3; HRMS (ESI) m/z observed 597.33210 
[C37H44N2O5 (M+H)+ requires 597.33230]. 
 
 
Assignments: 1H-NMR δ 7.77 (dm, J = 8.4 Hz, 1H, C8-H) 7.59 (d, J = 7.8 Hz, 
1H, C5-H) 7.37-7.31 (comp, 5H) 7.27-7.24 (comp, 2H) 7.13-7.10 (comp, 3H) 7.05-7.04 
(comp, 2H) 5.29 (d, J = 5.4 Hz, 1H, C14-H) 4.81 (d, J = 7.8 Hz, 1H, C17-H or C18-H 
C19-H or C20-H) 4.62 (d, J = 10.2 Hz, 1H, C17-H or C18-H C19-H or C20-H) 4.54 (d, J 
= 7.8 Hz, 1H, C17-H or C18-H C19-H or C20-H) 4.52 (d, J = 8.4 Hz, 1H, C17-H or C18-
H C19-H or C20-H) 4.45 (d, J = 12.0 Hz, 1H, C17-H or C18-H C19-H or C20-H) 4.41 














































C19 or C20) 3.86 (t, J = 9.6 Hz, 1H, C12-H) 3.73 (d, J = 10.8 Hz, 1H, C17-H or C18-H 
C19-H or C20-H) 3.40 (s, 3H, C34-H3) 3.28 (m, 1H, C11-H) 2.98 (m, 1H, C13-H) 2.87 
(dd, J = 13.8, 4.8 Hz, 1H, C15-H) 2.73 (td, J = 13.8, 4.8 Hz, 1H, C15-H) 2.29-2.22 
(comp, 2H, C13-H and C16-H) 1.82 (tm, 1H, C16-H) 1.59 (s, 9H, C37-H3); 13C-NMR δ 
152.2 (C35), 141.5, 139.9, 139.0, 137.7, 129.2, 129.1, 128.4, 128.3, 128.3, 127.7, 127.2, 
125.9, 123.3, 118.5 (C6), 115.9, 115.0 (C8), 86.2 (C36), 84.8 (C12), 78.6 (C17 or C18 or 
C19 or C20), 73.8 (C17 or C18 or C19 or C20), 73.6 (C17 or C18 or C19 or C20), 73.5 
(C17 or C18 or C19 or C20), 58.0 (C34), 51.1 (C10), 45.8 (C11), 42.0 (C15), 37.1 (C13), 




2,3,4,5,6,7-hexahydro-1H-5,1-ethanoazocino[4,3-b]indole (4.46a). (WLM7_121_2). A 
mixture of 4.45a (10 mg, 0.0196 mmol) and 37% aq formaldehyde solution (16 mg, 
0.196 mmol, 16 µL) in CH2Cl2 (0.2 mL) was stirred for 5 min at room temperature and 
sodium cyanoborohydride (18.5 mg, 0.294 mmol) was added in one portion. Stirring was 
continued for 3 h at room temperature. The reaction was quenched with saturated aq 
Rochelle’s salt (1.0 mL), diluted with MeOH (1.0 mL), and extracted with CH2Cl2 (3 x 2 
mL). The combined organic extracts were washed with brine (3 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (9 : 1) afforded 6.3 mg (61%) of 4.46a as a 
yellow solid. 1H-NMR (600 MHz, CD3CN) δ 7.51 (d, J = 7.8 Hz, 1H) 7.36-7.32 (comp, 








(comp, 2 H) 7.11 (td, J = 7.2, 0.6 Hz, 1 H) 4.87 (d, J = 5.4 Hz, 1 H) 4.50 (d, J = 12.0 Hz, 
1 H) 4.47-4.44 (comp, 3 H) 4.39 (d, J = 12.0 Hz, 1 H) 4.17 (td, J = 9.0, 1.8 Hz, 1 H) 4.01 
(d, J = 9.6 Hz, 1 H) 3.85 (d, J = 9.0 Hz, 1 H) 3.81 (s, 3 H) 3.79 (d, J = 10.8 Hz, 1 H) 3.33 
(s, 3 H) 3.27-3.21 (m, 1 H) 3.08 (m, 1 H) 2.84-2.81 (comp, 2 H) 2.61 (s, 3 H) 2.26-2.21 
(m, 1 H) 2.16 (m, 1 H) 1.92-1.90 (m, 1 H); 13C-NMR (150 MHz, CD3CN) δ 141.6, 139.6, 
138.7, 138.6, 129.4, 129.3, 129.0, 128.8, 128.6, 128.5, 128.0, 123.0, 121.1, 118.3, 110.5, 
84.6, 78.6, 74.5, 74.0, 73.4, 58.6, 57.7, 52.2, 50.0, 45.8, 44.8, 37.8, 33.4, 29.1; HRMS 
(ESI) m/z observed 525.31090 [C34H40N2O3 (M+H)+ requires 525.31120]. 
 
 
Assignments: 1H-NMR: 7.51 (d, J = 7.8 Hz, 1 H, C5-H) 7.36-7.32 (comp, 5 H, 
C8-H, C23-H, C27-H, C31-H, C35-H) 7.30-7.28 (m, 1 H, C24-H or C26-H or C32-H or 
C34-H) 7.26-7.22 (comp, 3 H, C24-H or C26-H or C32-H or C34-H) 7.19 (td, J = 7.8, 
1.2 Hz, 1 H, C7-H) 7.16-7.15 (comp, 2 H, C25-H, C33-H) 7.11 (td, J = 7.2, 0.6 Hz, 1 H, 
C6-H) 4.87 (d, J = 5.4 Hz, 1 H, C16-H) 4.50 (d, J = 12.0 Hz, 1 H, C21-H or C29-H) 
4.47-4.44 (comp, 3 H, C20-H, C21-H2 or C29-H2) 4.39 (d, J = 12.0 Hz, 1 H, C21-H or 
C29-H) 4.17 (td, J = 9.0, 1.8 Hz, 1 H, C18-H) 4.01 (d, J = 9.6 Hz, 1 H, C28-H) 3.85 (d, J 
= 9.0 Hz, 1 H, C28-H) 3.81 (s, 3 H, C10-CH3) 3.79 (d, J = 10.8 Hz, 1 H, C20-H) 3.33 (s, 
3 H, C19-CH3) 3.27-3.21 (m, 1 H, C17-H) 3.08 (m, 1 H, C12-H) 2.84-2.81 (comp, 2 H, 





































1.90 (m, 1 H, C17-H). 13C-NMR: 141.6, 139.6, 138.7, 138.6, 129.4, 129.3, 129.0, 128.8, 
128.6, 128.5, 128.0, 123.0 (C7), 121.1 (C6), 118.3 (C5), 110.5 (C8), 84.6 (C18), 78.6 
(C20), 74.5 (C28), 74.0 (C29), 73.4 (C21), 58.6 (C16), 57.7 (C19), 52.2 (C14), 50.0 





(4.46b). (WLM7_139_2). A mixture of 4.45b (4.5 mg, 0.00754 mmol) and 37% aq 
formaldehyde solution (6 mg, 0.0754 mmol, 6 µL) in CH2Cl2 (0.3 mL) was stirred for 
five min at room temperature and sodium cyanoborohydride (7 mg, 0.1131 mmol) was 
added in one portion. Stirring was continued for 3 h at room temperature. The reaction 
was quenched with saturated aq Rochelle’s salt (1.0 mL), diluted with MeOH (1.0 mL) 
and extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with 
brine (10.0 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a brown 
oil. Subsequent purification by preparative RP HPLC H2O : MeCN (90 : 10 → 5 : 95  
over 30 min) afforded 3 mg (67%) of 4.46b as a white solid: 1H-NMR (500 MHz, 
CD3OD) δ 7.76 (d, J = 8.5 Hz, 1 H) 7.64 (d, J = 7.5 Hz, 1 H) 7.38-7.26 (comp, 7 H) 7.17-
7.09 (comp, 5 H) 5.25 (d, J = 5.5 Hz, 1 H) 4.77 (d, J = 8.5 Hz, 1H) 4.61 (d, J = 10.5 Hz, 1 
H) 4.55 (d, J = 8.5 Hz, 1H) 4.53 (d, J = 8.0 Hz, 1 H) 4.44 (d, J = 10.5 Hz, 1 H) 4.42 (d, J 
= 12.0 Hz, 1 H) 4.08 (d, J = 8.0 Hz, 1 H) 3.84 (t, J = 9.0 Hz, 1 H) 3.73 (d, J = 10.5 Hz, 1 
H) 3.40 (s, 3 H) 3.25 (m, 1 H) 3.10-3.06 (m, 1 H) 2.98-2.97 (m, 1 H) 2.93-2.90 (m, 1 H) 








MHz, CD3OD) δ 152.3, 142.3, 140.0, 139.2, 137.8, 129.3, 128.7, 128.6, 128.5, 128.5, 
128.0, 125.9, 123.9, 118.8, 115.2, 113.5, 86.7, 84.7, 78.6, 74.1, 73.8, 73.7, 59.7, 58.1, 
53.2, 51.3, 46.5, 45.3, 37.1, 29.6, 28.2. HRMS (CI) m/z observed 609.3318 [C38H45N2O5 
(M)+ requires 609.3328]. 
 
 
Assignments: 1H-NMR: δ 7.76 (d, J = 8.5 Hz, 1 H, C8-H) 7.64 (d, J = 7.5 Hz, 1 
H, C5-H) 7.38-7.26 (comp, 7 H) 7.17-7.09 (comp, 5 H) 5.25 (d, J = 5.5 Hz, 1 H, C14-H) 
4.77 (d, J = 8.5 Hz, 1 H, C17-H or C18-H) 4.61 (d, J = 10.5 Hz, 1 H, C17-H or C18-H) 
4.55 (d, J = 8.5 Hz, 1 H, C20-H or C21-H) 4.53 (d, J = 8.0 Hz, 1 H, C20-H or C21-H) 
4.44 (d, J = 10.5 Hz, 1 H, C20-H or C21-H) 4.42 (d, J = 12.0 Hz, 1 H, C20-H or C21-H) 
4.08 (d, J = 8.0 Hz, 1 H, C17-H or C18-H) 3.84 (t, J = 9.0 Hz, 1 H, C12-H) 3.73 (d, J = 
10.5 Hz, 1 H, C17-H or C18-H) 3.40 (s, 3 H, C34-H3) 3.25 (m, 1 H, C11-H) 3.10-3.06 
(m, 1 H, C13-H) 2.98-2.97 (m, 1 H, C15-H) 2.93-2.90 (m, 1 H, C15-H) 2.88 (s, 3 H, 























































Allyl (1S/R, 5R/S, 12R/S)-6,6-bis((benzyloxy)methyl)-12-((tert-
butyldimethylsilyl)oxy)-7-methyl-1,3,4,5,6,7-hexahydro-2H-5,1-ethanoazocino[4,3-
b]indole-2-carboxylate. (4.47a). (WLM8_210). A mixture of 4.13 (28 mg, 0.0411 
mmol) and 60% NaH dispersion in mineral oil (5 mg, 0.123 mmol) in DMF (0.4 mL) at 0 
°C under N2 was stirred for five min and methyl p-toluenesulfonate (15 mg, 0.0822 
mmol) was added in one portion. The reaction was allowed to warm slowly to room 
temperature overnight. The reaction was quenched with saturated aq NH4Cl (2 mL), 
diluted with H2O (10 mL), and extracted with Et2O (3 x 15 mL). The combined organic 
extracts were washed with brine (20 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a clear oil. Purification by flash chromatography eluting with Hexanes : 
EtOAc (20 : 1 → 10 : 1) to provide 21 mg (73%) of 4.47a as a clear oil: 1H-NMR (500 
MHz, CD3OD) δ 7.39 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.27 (comp, 10H), 
7.19 (td, J = 7.7, 1.3 Hz, 1H), 7.07 (td, J = 7.7, 0.5 Hz, 1H), 6.05 (br, 1H), 5.62 (d, J = 6.7 
Hz, 1H), 5.42 (br, J = 34.7 Hz, 1H), 5.25 (br, 1H), 4.67 (dd, J = 13.9, 4.6 Hz, 2H), 4.56 
(comp, 2H), 4.52 (d, J = 12.1 Hz, 1H), 4.45 (d, J = 12.2 Hz, 1H), 4.36 (t, J = 8.9 Hz, 1H), 
4.31 (d, J = 9.9 Hz, 1H), 4.17 (d, J = 10.0 Hz, 1H), 4.12 (d, J = 9.9 Hz, 1H), 3.99 (d, J = 
10.1 Hz, 1H), 3.92 (s, 3H), 3.86 – 3.66 (m, 1H), 3.08 – 2.81 (m, 1H), 2.72 (comp, 2H), 
2.21 – 2.07 (m, 1H), 1.94 – 1.87 (m, 1H), 1.86 – 1.71 (m, 1H), 0.91 (s, 9H), 0.08 (s, 3H), 
0.08 (s, 3H). 13C-NMR (125 MHz, CD3OD) δ 156.3, 141.6, 139.9, 139.7, 139.2, 135.2, 
129.4, 129.4, 128.9, 128.8, 128.7, 128.6, 127.4, 122.8, 120.4, 118.1, 115.1, 110.4, 106.0, 
77.3, 75.9, 75.9, 74.3, 74.2, 66.5, 53.2, 51.2, 48.7, 42.0, 34.2, 31.9, 26.6, 26.6, 18.9, -4.4, 




Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.39 (d, J = 7.9 Hz, 1H, C5-H), 
7.33 (d, J = 8.4 Hz, 1H, C8-H), 7.27 (comp, 10H, C24-H, C25-H, C26-H, C27-H, C28-H, 
C29-H, C30-H, C31-H, C32-H, and C33-H), 7.19 (td, J = 7.7, 1.3 Hz, 1H, C7-H), 7.07 
(td, J = 7.7, 0.5 Hz, 1H, C6-H), 6.05 (br, 1H, C35-H), 5.62 (d, J = 6.7 Hz, 1H, C14-H), 
5.42 (br, J = 34.7 Hz, 1H, C36-H), 5.25 (br, 1H, C36-H), 4.67 (dd, J = 13.9, 4.6 Hz, 2H, 
C34-H2), 4.56 (comp, 2H, C18-H2 or C19-H2), 4.52 (d, J = 12.1 Hz, 1H, C18-H or C19-
H), 4.45 (d, J = 12.2 Hz, 1H, C18-H or C19-H), 4.36 (t, J = 8.9 Hz, 1H, C12-H), 4.31 (d, 
J = 9.9 Hz, 1H, C20-H or C21-H), 4.17 (d, J = 10.0 Hz, 1H, C20-H or C21-H), 4.12 (d, J 
= 9.9 Hz, 1H, C20-H or C21-H), 3.99 (d, J = 10.1 Hz, 1H, C20-H or C21-H), 3.92 (s, 
3H), 3.86 – 3.66 (m, 1H, C16-H), 3.08 – 2.81 (m, 1H, C13-H), 2.72 (comp, 2H, C11-H 
and C16-H), 2.21 – 2.07 (m, 1H, C17-H), 1.94 – 1.87 (m, 1H, C13-H), 1.86 – 1.71 (m, 
1H, C17-H), 0.91 (s, 9H, C39-H3), 0.08 (s, 3H, C37-H3), 0.08 (s, 3H, C37-H3). 13C-NMR 
(125 MHz, CD3OD) δ 156.3 (C15), 141.6 (C2), 139.9 (C22 or C23), 139.7 (C22 or C23), 
139.2 (C9), 135.2 (C35), 129.4 (C24 and C32 or C25 and C33), 129.4 (C24 and C32 or 
C25 and C33), 128.9 (C26 and C30 or C27 and C31), 128.8 (C26 and C30 or C27 and 
C31), 128.7 (C28 or C29), 128.6 (C28 or C29), 127.4 (C4), 122.8 (C7), 120.4 (C6), 118.1 
(C5), 115.1 (C36), 110.4 (C8), 106.0 (C3), 77.3 (C12), 75.9 (C18 or C19), 75.9 (C18 or 






















































carboxylate (4.47b). (WLM7_126_2). A mixture of 4.13 (32 mg, 0.047 mmol) and 60% 
NaH dispersion in mineral oil (19 mg, 0.47 mmol) in DMF (0.5 mL) was stirred for 5 min 
at 0 °C under N2 and allyl chloride (18 mg, 0.235 mmol) was added in one portion. The 
reaction was allowed to warm slowly to room temperature overnight. The reaction was 
quenched with saturated aq NaHCO3 (2.0 mL), diluted with H2O (2.0 mL), and extracted 
with EtOAc (3 x 10 mL). The combined organic extracts were wash with brine (15.0 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. Subsequent 
purification by flash chromatography eluting with Hexanes : EtOAc (8 : 1) afford 20 mg 
(59%) of 4.4.47b as a clear oil: 1H-NMR (500 MHz, CDCl3, mixture of rotamers) δ 7.56 
(d, J = 7.5 Hz, 0.5 H) 7.45 (d, J = 8.0 Hz, 0.5 H) 7.34-7.24 (comp, 8 H) 7.21-7.16 (comp, 
4 H) 7.14-7.10 (m, 1 H) 6.12-6.05 (m, 0.5 H) 6.01-5.93 (m, 0.5 H) 5.89-5.82 (m, 1 H) 
5.77 (d, J = 6.5 Hz, 0.5 H) 5.67-5.62 (comp, 1.5 H) 5.44 (dd, J = 17.0, 1.5 Hz, 0.5 H) 
5.32-5.28 (comp, 1 H) 5.20 (app d, 0.5 H) 5.06 (app d, 1 H) 4.83-4.68 (comp, 2.5 H) 
4.63-4.59 (comp, 1.5 H) 4.58-4.52 (comp, 2 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.43 (d, J = 
12.0 Hz, 1 H) 4.36 (d, J = 9.0 Hz, 0.5 H) 4.32 (d, J = 9.5 Hz, 0.5 H) 2.29 (d, J = 9.5 Hz, 1 







0.5 H) 3.74 (dd, J = 9.5, 1.5 Hz, 1 H) 2.30 (m, 0.5 H) 2.89 (m, 0.5 H) 2.86 (m, 1 H) 2.79-
2.66 (m, 1 H) 1.99-1.90 (comp, 2 H) 1.86-1.71 (m, 1 H) 0.87 (s, 9 H) 0.06-0.04 (comp, 6 
H); 13C-NMR (125 MHz, CDCl3, mixture of rotamers) δ 155.4, 155.1, 140.4, 140.3, 
138.3, 138.2, 138.2, 137.7, 137.6, 135.1, 135.0, 133.5, 128.2, 127.6, 127.5, 127.5, 127.5, 
127.4, 126.5, 126.4, 122.0, 119.5, 117.9, 117.5, 117.3, 116.8, 115.3, 115.2, 114.1, 114.0, 
110.3, 110.1, 75.8, 75.6, 75.0, 74.9, 73.3, 73.2, 72.0, 71.8, 65.9, 65.6, 49.9, 49.8, 49.1, 
48.7, 47.6, 47.3, 40.9, 40.8, 40.5, 39.5, 30.7, 30.0, 25.8, 18.0, -4.8, -4.9, -5.0; HRMS 





b]indole. (4.48). (WLM8_214). A round bottom flask charged with Pd2(dba)3 (2.8 mg, 
0.0030 mmol) and 1,4-bis(diphenylphosphino)butane (2.6 mg, 0.006 mmol) was placed 
under vacuum and backfilled with N2 three times. A second round bottom flask was 
charged with 4.47a (21 mg, 0.030 mmol) and 1,3-dimethylbarbituric acid (47 mg, 0.302 
mmol) and placed under vacuum and backfilled with N2 three times. THF (0.3 mL) was 
then added to both flasks, and the mixtures were stirred at room temperature under N2 for 
5 min. A 30 µL aliquot of the Pd/ligand mixture was added via syringe to the flask 
containing 4.47a, and stirring was continued at room temperature until 4.47a was gone by 
TLC. The reaction was quenched with saturated aq NaHCO3 (2 mL) and stirred at room 
temperature for 15 min. The reaction mixture was diluted with H2O (5 mL) extracted with 








dried (Na2SO4), filtered, and concentrated in vacuo to afford a brown oil. Subsequent 
purification by flash chromatography eluting with EtOAc (100%) containing 1% NEt3 
provided 15 mg (81%) of 4.48 as a white solid. 1H-NMR (500 MHz, CD3OD) δ 7.51 (dt, 
J = 7.8, 1.0 Hz, 1H), 7.29 (comp, 11H), 7.17 (td, J = 7.7, 1.1 Hz, 1H), 7.06 (td, J = 7.5, 
0.9 Hz, 1H), 4.71 (dd, J = 7.0, 1.2 Hz, 1H), 4.62 (td, J = 9.0, 1.7 Hz, 1H), 4.57 (d, J = 
11.6 Hz, 1H), 4.55 (d, J = 6.7 Hz, 1H), 4.51 (d, J = 12.2 Hz, 1H), 4.45 (d, J = 12.2 Hz, 
1H), 4.30 (d, J = 9.8 Hz, 1H), 4.12 (d, J = 9.9 Hz, 1H), 4.10 (d, J = 10.1 Hz, 1H), 3.98 (d, 
J = 9.9 Hz, 1H), 3.92 (s, 3H), 2.68 (comp, 2H), 2.58 (ddd, J = 12.8, 6.6, 1.5 Hz, 1H), 2.45 
(td, J = 12.9, 4.1 Hz, 1H), 2.18 – 2.06 (m, 1H), 1.96 – 1.85 (m, 1H), 1.83 – 1.66 (m, 1H), 
0.92 (s, 9H), 0.11 (s, 3H), 0.10 (dd, J = 7.6, 1.3 Hz, 3H). 13C-NMR (125 MHz, CD3OD) δ 
141.2, 140.2, 140.0, 139.3, 129.7, 129.7, 129.1, 129.1, 129.0, 128.8, 127.7, 122.6, 120.0, 
118.9, 115.8, 110.4, 77.6, 76.4, 76.3, 74.3, 74.3, 53.5, 51.3, 48.5, 44.7, 42.8, 34.3, 32.8, 




Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.51 (dt, J = 7.8, 1.0 Hz, 1H, C5-
H), 7.29 (comp, 11H, C5-H, C24-H, C25-H, C26-H, C27-H, C28-H, C29-H, C30-H, 
C31-H, C32-H, and C33-H), 7.17 (td, J = 7.7, 1.1 Hz, 1H, C7-H), 7.06 (td, J = 7.5, 0.9 












































H), 4.57 (d, J = 11.6 Hz, 1H, C20-H or C21-H), 4.55 (d, J = 6.7 Hz, 1H, C20-H or C21-
H), 4.51 (d, J = 12.2 Hz, 1H, C20-H or C21-H), 4.45 (d, J = 12.2 Hz, 1H, C20-H or C21-
H), 4.30 (d, J = 9.8 Hz, 1H, C18-H or C19-H), 4.12 (d, J = 9.9 Hz, 1H, C18-H or C19-H), 
4.10 (d, J = 10.1 Hz, 1H, C18-H or C19-H), 3.98 (d, J = 9.9 Hz, 1H, C18-H or C19-H), 
3.92 (s, 3H, C1-H3), 2.68 (comp, 2H, C11-H, C13-H), 2.58 (ddd, J = 12.8, 6.6, 1.5 Hz, 
1H, C16-H), 2.45 (td, J = 12.9, 4.1 Hz, 1H, C16-H), 2.18 – 2.06 (m, 1H, C17-H), 1.96 – 
1.85 (m, 1H, C13-H), 1.83 – 1.66 (m, 1H, C17-H), 0.92 (s, 9H), 0.11 (s, 3H), 0.10 (s, 
3H). 13C-NMR (125 MHz, CD3OD) δ 141.2 (C2), 140.2 (C22 or C23), 140.0 (C22 or 
C23), 139.3 (C9), 129.7 (C26 and C30 or C27 and C31), 129.7 (C26 and C30 or C27 and 
C31), 129.1 (C24 and C32 or C25 and C33), 129.1 (C24 and C32 or C25 and C33), 129.0 
(C28 or C29), 128.8 (C28 or C29), 127.7 (C4), 122.6 (C7), 120.0 (C6), 118.9 (C5), 115.8 
(C3), 110.4 (C8), 77.6 (C12), 76.4 (C20 or C21), 76.3 (C20 or C21), 74.3 (C18 or C19), 
74.3 (C18 or C19), 53.5 (C11), 51.3 (C10), 48.5 (C14), 44.7 (C13), 42.8 (C16), 34.3 





(WLM7_133_2). A mixture of 4.47b (20 mg, 0.028 mmol) and tetrabutylammonium 
fluoride trihydrate (18 mg, 0.0555 mmol) in DMF (0.3 mL) was stirred at room 
temperature under N2 until starting material was gone by TLC. The reaction was diluted 







extracts were wash with brine (15 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a clear oil. Subsequent purification by flash chromatography Hexanes : 
EtOAc (10 : 1 → 4 : 1) afford 15 mg (89%) of 4.50 as a white solid: 1H-NMR (500 MHz, 
CD3CN, 70 °C) δ 7.39 (d, J = 9.0 Hz, 1 H) 7.32-7.20 (comp, 11 H) 7.14 (td, J = 7.0, 1.0 
Hz, 1 H) 7.05 (td, J = 7.0 Hz, 0.5 Hz, 1 H) 6.03 (br, 1 H) 5.90-5.83 (m, 1 H) 5.64 (d, J = 
6.0 Hz, 1 H) 5.33 (br, 1 H) 5.22 (br, 1 H) 5.16 (dm, J = 18.5 Hz, 1 H) 5.07 (dd, J = 10.5, 
1.5 Hz, 1 H) 4.81-4.73 (comp, 2 H) 4.65 (br, 2 H) 4.49-4.43 (comp, 4 H) 4.27 (m, 1 H) 
4.10 (d, J = 10.0 Hz, 1 H) 4.05 (d, J = 10.5 Hz, 2 H) 3.95 (d, J = 10.0 Hz, 1 H) 3.82-3.79 
(m, 1 H) 3.39-3.36 (m, 1 H) 2.93 (m, 1 H) 2.83 (m, 1 H) 2.76 (m, 1 H) 2.07-1.97 (m, 1 H) 
1.86 (m, 1 H) 1.81-1.75 (m, 1 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 156.4, 140.4, 
139.6, 139.5, 138.9, 136.2, 135.3, 129.6, 129.2, 129.2, 128.9, 128.0, 123.2, 120.8, 117.4, 
116.5, 116.1, 111.6, 76.4, 76.1, 76.0, 74.4, 66.7, 51.9, 50.6, 49.8, 42.2; HRMS (ESI) m/z 
observed 629.29880 [C38H42N2O5 (M+Na)+ requires 629.29860]. 
 
 
Assignments: 1H-NMR: δ 7.39 (d, J = 9.0 Hz, 1 H, C5-H) 7.32-7.20 (comp, 11 
H, C8-H, C22-H, C23-H, C24-H, C25-H, C26-H, C28-H, C29-H, C30-H, C31-H, C32-
H) 7.14 (td, J = 7.0, 1.0 Hz, 1 H, C7-H) 7.05 (td, J = 7.0 Hz, 0.5 Hz, 1 H, C6-H) 6.03 (br, 












































C35-H) 5.22 (br, 1 H, C35-H) 5.16 (dm, J = 18.5 Hz, 1 H, C38-H) 5.07 (dd, J = 10.5, 1.5 
Hz, 1 H, C40-H) 4.81-4.73 (comp, 2 H, C40-H and C38-H) 4.65 (br, 2 H, C33-H) 4.49-
4.43 (comp, 4 H, C19-H2 and C20-H) 4.27 (m, 1 H, C12-H) 4.10 (d, J = 10.0 Hz, 1 H, 
C17 or C18-H) 4.05 (d, J = 10.5 Hz, 2 H, C17-H2 or C18-H2) 3.95 (d, J = 10.0 Hz, 1 H, 
C17-H or C18-H) 3.82-3.79 (m, 1 H, C15-H) 3.39-3.36 (m, 1 H, O37-H) 2.93 (m, 1 H, 
C13-H) 2.83 (m, 1 H, C11-H) 2.76 (m, 1 H, C15-H) 2.07-1.97 (m, 1 H, C16-H) 1.86 (m, 
1 H, C13) 1.81-1.75 (m, 1 H, C16-H); 13C-NMR: δ 156.4 (C-36), 140.4, 139.6, 139.5, 
138.9, 136.2 (C39), 135.3, 129.6, 129.2, 129.2, 128.9, 128.0, 123.2 (C7), 120.8 (C6), 
117.4, 116.5, 116.1 (C40), 111.6 (C8), 76.4 (C17 or C18), 76.1 (C17 or C18), 76.0 (C12), 




hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.49). (WLM8_230). NEt3•3HF 
(50 µL) was added to a solution of 4.48 (15 mg, 0.0246 mmol) in CH2Cl2 (0.1 mL) in a 
plastic vial. The reaction was stirred at room temperature for 36 h, whereupon excess 
NEt3•3HF was quenched with SiO2 (spatula tip). The reaction mixture was diluted with 
MeOH (1 mL) and filtered through a sub-micron syringe filter. Subsequent purification 
by RP HPLC H2O : MeCN (75 : 25  → 95 : 5 over 30 min) provided 2.85 mg (23%) of 
4.49 as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.58 (d, J = 7.9 Hz, 1H), 7.39 (d, J 
= 8.3 Hz, 1H), 7.27 (comp, 4H), 7.23 (comp, 5H), 7.16 (comp, 3H), 5.28 (dd, J = 5.3, 1.1 
Hz, 1H), 4.55 (d, J = 11.9 Hz, 1H), 4.53 (d, J = 11.4 Hz, 1H), 4.51 (d, J = 11.6 Hz, 1H), 








1H), 3.87 (d, J = 10.5 Hz, 1H), 3.79 (s, 3H), 2.96 (comp, 4H), 2.37 (dt, J = 13.7, 3.9 Hz, 
1H), 2.15 (ddd, J = 14.8, 9.0, 1.6 Hz, 1H), 1.95 (tdd, J = 15.7, 6.2, 2.9 Hz, 1H). 13C-NMR 
(125 MHz, CD3OD) δ 140.1, 137.8, 137.8, 137.5, 128.0, 128.0, 127.7, 127.4, 127.4, 
127.4, 125.6, 122.2, 119.7, 116.6, 109.0, 108.2, 76.6, 73.5, 73.3, 72.8, 72.7, 51.2, 49.1, 
48.5, 40.5, 38.3, 31.8, 27.9. HRMS (ESI) m/z observed 497.27960 [C32H36N2O3 (M+H)+ 
requires 497.27990]. 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.58 (d, J = 7.9 Hz, 1H, C5-H), 
7.39 (d, J = 8.3 Hz, 1H, C8-H), 7.27 (comp, 4H, C24-H or C25-H or C26-H or C27-H or 
C30-H or C31-H or C32-H or C33-H or C28-H or C29-H), 7.23 (comp, 5H, C24-H or 
C25-H or C26-H or C27-H or C30-H or C31-H or C32-H or C33-H or C28-H or C29-H), 
7.16 (comp, 3H, C6-H, C7-H, and C28-H or C29-H), 5.28 (dd, J = 5.3, 1.1 Hz, 1H, C14-
H), 4.55 (d, J = 11.9 Hz, 1H, C20-H or C21-H), 4.53 (d, J = 11.4 Hz, 1H, C20-H or C21-
H), 4.51 (d, J = 11.6 Hz, 1H, C20-H or C21-H), 4.45 (d, J = 12.0 Hz, 1H, C20-H or C21-
H), 4.41 (comp, 2H, C12-H and C18-H or C19-H), 4.13 (d, J = 9.6 Hz, 1H, C18-H or 
C19-H), 3.97 (d, J = 9.5 Hz, 1H, C18-H or C19-H), 3.87 (d, J = 10.5 Hz, 1H, C18-H or 
C19-H), 3.79 (s, 3H, C1-H3), 2.96 (comp, 4H, C11-H, C13-H, C16-H2), 2.37 (dt, J = 
13.7, 3.9 Hz, 1H, C17-H), 2.15 (ddd, J = 14.8, 9.0, 1.6 Hz, 1H, C13-H), 1.95 (tdd, J = 
15.7, 6.2, 2.9 Hz, 1H, C17-H). 13C-NMR (125 MHz, CD3OD) δ 140.1, 137.8, 137.8, 







































(C8), 108.2 (C3), 76.6 (C18 or C19), 73.5 (C12), 73.3 (C18 or C19), 72.8 (C20 or C21), 
72.7 (C20 or C21), 51.2 (C11), 49.1 (C10), 48.5 (C14), 40.5 (C16), 38.3 (C13), 31.8 




1H-5,1-ethanoazocino[4,3-b]indol-12-ol (4.51). (WLM7_138_2). A round bottom flask 
charged with Pd2(dba)3 (0.23 mg, 0.000247 mmol) and 1,4-bis(diphenylphosphino)butane 
(0.11 mg, 0.000247 mmol) was placed under vacuum and backfilled with N2 three times. 
A second round bottom flask was charged with 4.50 (15 mg, 0.0247 mmol) and 1,3-
dimethylbarbituric acid (39 mg, 0.247 mmol) and placed under vacuum and backfilled 
with N2 three times. DMF (0.2 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. The Pd/ligand mixture was added via 
syringe to the flask containing 4.50. The reaction was then heated to 130 °C and stirred 
for 5 h. The reaction was cooled to room temperature, quenched with saturated aq 
NaHCO3 (0.5 mL), and stirred at room temperature for 15 min. The reaction mixture was 
diluted with MeOH (1.0 mL) and extracted with CH2Cl2 (3 x 5.0 mL). The combined 
organic extracts were washed with H2O (5.0 mL) brine (5.0 mL), dried (Na2SO4), filtered, 
and concentrated in vacuo to afford a yellow oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (100% to 19 : 1 to 4 : 1) afforded 4 mg 
(31%) of 4.51 as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.59 (d, J = 8.5 Hz, 1 H) 







1 H) 5.27 (dd, J = 6.5, 1.5 Hz, 1 H) 5.06 (dm, J = 18.5 Hz, 1 H) 5.02 (d, J = 11.0 Hz, 1 
H) 4.71 (dm, J = 18.5 Hz, 1 H) 4.66 (d, J = 17.5 Hz, 1 H) 4.53 (d, J = 12.0 Hz, 1 H) 4.50 
(d, J = 12.0 Hz, 1 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.41 (td, J = 9.0, 2.0 Hz, 1 H) 4.39 (d, J = 
12.0 Hz, 1 H) 4.09 (d, J = 10.5 Hz, 1 H) 4.09 (d, J = 9.5 Hz, 1 H) 3.96 (d, J = 10.5 Hz, 1 
H) 3.95 (d, J = 9.5 Hz, 1 H) 2.99-2.92 (comp, 4 H) 2.30-2.27 (m, 1 H) 2.14 (ddd, J = 
14.5, 9.0, 1.5 Hz, 1 H) 1.95-1.90 (m, 1 H); 13C-NMR (125 MHz, CD3OD) δ 141.3, 139.2, 
138.9, 138.8, 135.4, 129.4, 129.4, 129.2, 129.1, 128.9, 128.9, 127.3, 123.7, 121.3, 118.2, 
116.4, 111.7, 109.8, 76.6, 75.1, 74.7, 74.2, 74.1, 50.8, 50.6, 50.0, 49.5, 42.0, 40.0, 29.0; 
HRMS (CI) m/z observed 521.2789 [C34H37N2O3 (M)+ requires 521.2804]. 
 
 
Assignments: 1H-NMR: δ 7.59 (d, J = 8.5 Hz, 1 H, C5-H) 7.30-7.25 (comp, 7 H) 
7.24-7.20 (comp, 5 H) 7.16 (td, J = 7.0, 1.0 Hz, 1 H, C6-H) 5.82-5.76 (m, 1 H, C36-H) 
5.27 (dd, J = 6.5, 1.5 Hz, 1 H, C14-H) 5.06 (dm, J = 18.5 Hz, 1 H, C35-H) 5.02 (d, J = 
11.0 Hz, 1 H, C37-H) 4.71 (dm, J = 18.5 Hz, 1 H, C37-H) 4.66 (d, J = 17.5 Hz, 1 H, C35-
H) 4.53 (d, J = 12.0 Hz, 1 H, C19-H of C20-H) 4.50 (d, J = 12.0 Hz, 1 H, C19-H or C20-
H) 4.47 (d, J = 12.0 Hz, 1 H, C19-H or C20-H) 4.41 (td, J = 9.0, 2.0 Hz, 1 H, C12-H) 
4.39 (d, J = 12.0 Hz, 1 H, C19-H or C20-H) 4.09 (d, J = 10.5 Hz, 1 H, C17-H or C18-H) 
4.09 (d, J = 9.5 Hz, 1 H, C17-H or C18-H) 3.96 (d, J = 10.5 Hz, 1 H, C17-H or C18-H) 







































C15-H and C16-H) 2.30-2.27 (m, 1 H, C15-H or C16-H) 2.14 (ddd, J = 14.5, 9.0, 1.5 Hz, 
1 H, C13-H) 1.95-1.90 (m, 1 H, C15-H or C16-H). 13C-NMR: δ 141.3, 139.2, 138.9, 
138.8, 135.4, 129.4, 129.4, 129.2, 129.1, 129.0, 128.9, 127.3, 123.7, 121.3 (C6), 118.2 
(C5), 116.4 (C37), 111.7, 109.8, 76.6 (C17 or C18 or C19 or C20), 75.1 (C17 or C18 or 
C19 or C20), 74.7 (C12), 74.2 (C17 or C18 or C19 or C20), 74.1 (C17 or C18 or C19 or 





ethanoazocino[4,3-b]indole. (4.53). (WLM7_274). Compound 4.16 (16 mg, 0.025 
mmol) was stirred with 10% Pd/C (1.6 mg) in MeOH (0.25 mL) under and atmosphere of 
H2 (balloon) for 14 h. The reaction mixture was filtered through a pad of celite and 
concentrated under reduced pressure to afford 16 mg (quant) of 4.53. The crude material 
was carried on to the next step without additional purification: 1H-NMR (500 MHz, 
CDCl3) δ 7.46-7.06 (comp, 14 H) 4.76 (m, 1 H) 4.62-4.58 (comp, 2 H) 4.47-4.36 (comp, 
3 H) 4.10 (d, J = 9.5 Hz, 1 H) 3.97 (m, 1 H) 3.89-3.77 (comp, 2 H) 2.83 (m, 1 H) 2.65-
2.61 (comp, 2 H) 2.49-2.28 (comp, 2 H) 1.98-1.94 (comp, 2 H) 1.89 (m, 1 H) 1.75 (comp, 
4 H) 1.65 (m, 1 H) 1.54 (m, 1 H) 1.09 (m, 1 H) 0.96 (t, J = 7.5 Hz, 3 H) 0.87 (s, 9 H) 0.78 
(t, J = 7.5 Hz, 3 H) 0.07 (s, 3 H) 0.05 (s, 3 H); HRMS (ESI) m/z observed 681.44390 












(WLM7_275_2). NEt3•3HF (0.1 mL) was added to a solution of 4.16 (13.5 mg, 0.020 
mmol) in CH2Cl2 (0.1 mL) in a plastic vial. The reaction was stirred at room temperature 
for 36 h, whereupon excess NEt3•3HF was quenched with SiO2 (spatula tip). The reaction 
mixture was diluted with MeOH (1.0 mL) and filtered through a sub-micron syringe 
filter. Subsequent purification by RP HPLC H2O : MeCN (10% MeCN → 95% MeCN 
over 30 min) provided 11.0 mg (98%) of 4.54a as a white solid: 1H-NMR (500 MHz, 
CD3OD) δ 7.57 (d, J = 8.0 Hz, 1 H) 7.50 (d, J = 8.0 Hz, 1 H) 7.32-7.17 (comp, 12 H) 
6.02 (m, 1 H) 5.56 (d, J = 10.0 Hz, 1 H) 5.47 (d, J = 17.0 Hz, 1 H) 5.31 (dd, J = 14.0, 2.5 
Hz, 1 H) 5.22 (d, J = 4.5 Hz, 1 H) 4.90 (dd, J = 19.0, 2.5 Hz, 1 H) 4.59 (d, J = 11.5 Hz, 1 
H) 4.52 (d, J = 12.0 Hz, 1 H) 4.49 (d, J = 11.5 Hz, 1 H) 4.43 (d, J = 12.0 Hz, 1 H) 4.39 
(td, J = 9.0, 2.0 Hz, 1 H) 4.21 (d, J = 10.5 Hz, 1 H) 4.11 (d, J = 10.0 Hz, 1 H) 4.07 (d, J = 
9.5 Hz, 1 H) 4.00 (d, J = 10.5 Hz, 1 H) 3.97 (dd, J = 13.5, 6.5 Hz, 1 H) 3.43 (dd, J = 13.5, 
7.5 Hz, 1 H) 3.10 (dd, J = 13.5, 4.0 Hz, 1 H) 3.02 (m, 1 H) 2.96-2.89 (comp, 2 H) 2.71 
(m, 1 H) 2.30 (dm, J = 16.5 Hz, 1 H) 2.12 (dd, J = 13.5, 8.5 Hz, 1 H) 1.92 (m, 1 H); 13C-
NMR (125 MHz, CD3OD) δ 141.9, 139.1, 138.8, 138.4, 129.4, 129.4, 129.3, 129.2, 
129.0, 128.9, 128.7, 128.6, 125.9, 124.1, 122.3, 118.1, 111.6, 108.1, 79.8, 76.4, 75.3, 
74.8, 74.4, 74.3, 61.6, 59.4, 50.7, 50.6, 50.4, 49.6, 47.9, 39.6, 37.0, 28.9; HRMS (ESI) 









Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.57 (d, J = 8.0 Hz, 1 H, C5-H) 
7.50 (d, J = 8.0 Hz, 1 H, C8-H) 7.32-7.17 (comp, 12 H) 6.02 (m, 1 H, C15-H) 5.56 (d, J = 
10.0 Hz, 1 H, C23b-H) 5.47 (d, J = 17.0 Hz, 1 H, C23a-H) 5.31 (dd, J = 14.0, 2.5 Hz, 1 H, 
C1-H) 5.22 (d, J = 4.5 Hz, 1 H, C16-H) 4.90 (dd, J = 19.0, 2.5 Hz, 1 H, C1-H) 4.59 (d, J 
= 11.5 Hz, 1 H, C21-H or C22-H) 4.52 (d, J = 12.0 Hz, 1 H, C21-H or C22-H) 4.49 (d, J 
= 11.5 Hz, 1 H, C21-H or C22-H) 4.43 (d, J = 12.0 Hz, 1 H, C21-H or C22-H) 4.39 (td, J 
= 9.0, 2.0 Hz, 1 H, C18-H) 4.21 (d, J = 10.5 Hz, 1 H, C19-H or C20-H) 4.11 (d, J = 10.0 
Hz, 1 H, C19-H or C20-H) 4.07 (d, J = 9.5 Hz, 1 H, C19-H or C20-H) 4.00 (d, J = 10.5 
Hz, 1 H, C19-H or C20-H) 3.97 (dd, J = 13.5, 6.5 Hz, 1 H, C14-H) 3.43 (dd, J = 13.5, 7.5 
Hz, 1 H, C14-H) 3.10 (dd, J = 13.5, 4.0 Hz, 1 H, C13-H) 3.02 (m, 1 H, C17-H) 2.96-2.89 
(comp, 2 H, C11-H and C13-H) 2.71 (m, 1 H, C26-H) 2.30 (dm, J = 16.5 Hz, 1 H, C12-
H) 2.12 (dd, J = 13.5, 8.5 Hz, 1 H, C17-H) 1.92 (m, 1 H, C12-H); 13C-NMR (125 MHz, 
CD3OD) δ 141.9, 139.1, 138.8, 138.4, 129.4, 129.4, 129.3, 129.2, 129.0, 128.9, 128.7 
(C15), 128.6, 125.9 (C23), 124.1 (C7), 122.3 (C6), 118.1 (C5), 111.6 (C8), 108.1 (C3), 
79.8 (C25 or C26), 76.4 (C19 or C20), 75.3 (C19 or C20), 74.8 (C21 or C22), 74.4 (C21 
or C22), 74.3 (C18), 61.6 (C14), 59.4 (C16), 50.7 (C11), 50.6 (C13), 50.4 (C10), 39.6 













































hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.54b). (WLM7_283). NEt3•3HF 
(0.1 mL) was added to a solution of 4.53 (14.5 mg, 0.021 mmol) in CH2Cl2 (0.1 mL) in a 
plastic vial. The reaction was stirred at room temperature for 36 h, whereupon excess 
NEt3•3HF was quenched with SiO2 (spatula tip). The reaction mixture was diluted with 
MeOH (1.0 mL) and filtered through a sub-micron syringe filter. Subsequent purification 
by RP HPLC H2O : MeCN (10% MeCN → 95% MeCN over 30 min) provided 10.0 mg 
(83 %) of 4.54b as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.50 (d, J = 8.0 Hz, 1 
H) 7.31-7.19 (comp, 13 H) 5.23 (d, J = 4.0 Hz, 1 H) 4.56 (d, J = 11.5 Hz, 1 H) 4.51-4.48 
(comp, 2 H) 4.40 (m, 1 H) 4.37 (d, J = 12.0 Hz, 1 H) 4.19-4.10 (comp, 3 H) 3.97-3.86 
(comp, 3 H) 3.18-3.11 (m, 1 H) 3.04-2.93 (comp, 2 H) 2.84-2.76 (m, 1 H) 2.34 (dm, J = 
16.0 Hz, 1 H) 2.15- 2.09 (m, 1 H) 2.01-1.94 (comp, 2 H) 1.77 (m, 1 H) 1.69 (m, 1 H) 1.55 
(m, 1 H) 0.99 (t, J = 7.5 Hz, 3 H) 0.80 (t, J = 7.5 Hz, 3 H); 13C-NMR (125 MHz, CD3OD) 
δ 141.6, 139.1, 138.8, 138.4, 129.5, 129.5, 129.3, 129.2, 129.1, 129.0, 128.9, 123.7, 
121.8, 117.8, 111.6, 107.3, 77.0, 74.9, 74.5, 74.3, 74.0, 71.5, 60.9, 59.4, 51.1, 50.6, 50.1, 
49.5, 39.9, 29.1, 23.6, 19.6, 11.4, 11.3; HRMS (ESI) m/z observed 567.35700 










Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.50 (d, J = 8.0 Hz, 1 H, C5-H) 
7.31-7.19 (comp, 13 H) 5.23 (d, J = 4.0 Hz, 1 H, C16-H) 4.56 (d, J = 11.5 Hz, 1 H, C21-
H or C29-H) 4.51-4.48 (comp, 2 H, C21-H2 or C29-H2) 4.40 (m, 1 H, C18-H) 4.37 (d, J = 
12.0 Hz, 1 H, C21-H or C29-H) 4.19-4.10 (comp, 3 H, C10-H, C20-H, and C28-H) 3.97-
3.86 (comp, 3 H, C10-H, C20-H, and C28-H) 3.18-3.11 (comp, 2 H, C14-H and C15-H) 
3.04-2.93 (comp, 3 H, C12-H, C14-H, and C17-H) 2.84-2.76 (m, 1 H, C15-H) 2.34 (dm, 
J = 16.0 Hz, 1 H, C13-H) 2.15- 2.09 (m, 1 H, C17-H) 2.01-1.94 (comp, 2 H, C13-H and 
C38-H) 1.77 (m, 1 H, C38-H) 1.69 (m, 1 H, C36-H) 1.55 (m, 1 H, C36-H) 0.99 (t, J = 7.5 
Hz, 3 H, C39-H3) 0.80 (t, J = 7.5 Hz, 3 H, C37-H3); 13C-NMR (125 MHz, CD3OD) δ 
141.6, 139.1, 138.8, 138.4, 129.5, 129.5, 129.3, 129.2, 129.1, 129.0, 128.9, 123.7 (C7), 
121.8 (C6), 117.8 (C5), 111.6 (C8), 107.3 (C3), 77.0 (C20 or C28), 74.9 (C20 or C28), 
74.5 (C18), 74.3 (C21 or C29), 74.0 (C21 or C29), 60.9 (C15), 59.4 (C16), 51.1 (C14), 
50.6 (C11), 50.1 (C12), 49.5 (C10), 39.9 (C17), 29.1 (C13), 23.6 (C36), 19.6 (C38), 11.4 














































(4S/R, 7R/S, 13cR/S, 14S/R)-tert-Butyl-8,8-bis((benzyloxy)methyl)-14-
hydroxy-2,3,5,6,7,8-hexahydro-1H-1,7-methanopyrrolo[1',2':1,2]azocino[4,3-
b]indole-9(13cH)-carboxylate. (4.56). (WLM7_181_2). A mixture of 3.25 (31 mg, 
0.051 mmol) in Et2O (0.5 mL) at room temperature was added lithium aluminum hydride 
(4 mg, 0.102 mmol) in one portion and the reaction was stirred at room temperature for 
four h. The reaction mixture was quenched with saturated aq Rochelle’s salt (2.0 mL) and 
allowed to stir at room temperature for 10 min. The reaction mixture was diluted with 
MeOH (4.0 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts 
were washed with H2O (10.0 mL), brine (10.0 mL), dried (Na2SO4), and conctrated in 
vacuo to afford a yellow solid. Subsequent purification by flash chromatography (basic 
alumina) eluting with CH2Cl2 : MeOH (100% → 19 : 1) afforded 28 mg (90%) 4.56 as a 
white solid: 1H-NMR (500 MHz, CDCl3) δ 12.45 (br, 1 H) 7.68 (d, J = 7.5 Hz, 1 H) 7.65 
(d, J = 9.0 Hz, 1 H) 7.34-7.20 (comp, 8 H) 7.16-7.14 (comp, 2 H) 7.07-7.05 (comp, 2 H) 
5.20 (app t, J = 5.0 Hz, 1 H) 4.65 (d, J = 9.5 Hz, 1 H) 4.51 (d, J = 12.0 Hz, 2 H) 4.44 (d, J 
= 11.0 Hz, 1 H) 4.36 (d, J = 12.0 Hz, 1 H) 4.28 (d, J = 9.5 Hz, 1 H) 4.09 (m, 1 H) 4.00 (d, 
J = 9.0 Hz, 1 H) 3.87 (m, 1 H) 3.84 (d, J = 9.0 Hz, 1 H) 3.24-3.20 (m, 1 H) 3.09 (app t, J 
= 12.0 Hz, 1 H) 2.88-2.81 (comp, 3 H) 2.52 (m, 1 H) 2.16 (m, 1 H) 2.07-2.03 (m, 1 H) 
1.88-1.83 (m, 1 H) 1.63 (s, 9 H); 13C-NMR (125 MHz, CDCl3) δ 151.2, 139.6, 136.9, 
136.551, 136.4, 128.5, 128.4, 128.1, 128.0, 128.0, 127.8, 127.5, 125.1, 122.9, 118.4, 
113.8, 110.5, 85.1, 80.8, 75.7, 75.1, 73.7, 73.4, 60.8, 49.9, 49.8, 49.2, 48.6, 46.8, 33.3, 





Assignments: 1H-NMR: δ 12.44 (br, 1 H, O38-H) 7.68 (d, J = 7.5 Hz, 1 H, C8-H) 
7.65 (d, J = 9.0 Hz, 1 H, C5-H) 7.34-7.20 (comp, 8 H) 7.16-7.14 (comp, 2 H) 7.07-7.05 
(comp, 2 H) 5.20 (app t, J = 5.0 Hz, 1 H, C16-H) 4.65 (d, J = 9.5 Hz, 1 H, C18-H or C19-
H or C20-H or C21-H) 4.51 (d, J = 12.0 Hz, 2 H, C18-H or C19-H or C20-H or C21-H) 
4.44 (d, J = 11.0 Hz, 1 H, C18-H or C19-H or C20-H or C21-H) 4.36 (d, J = 12.0 Hz, 1 
H, C18-H or C19-H or C20-H or C21-H) 4.28 (d, J = 9.5 Hz, 1 H, C18-H or C19-H or 
C20-H or C21-H) 4.09 (m, 1 H, C15-H) 4.00 (d, J = 9.0 Hz, 1 H, C18-H or C19-H or 
C20-H or C21-H) 3.87 (m, 1 H, C12-H) 3.84 (d, J = 9.0 Hz, 1 H, C18-H or C19-H or 
C20-H or C21-H) 3.24-3.20 (m, 1 H, C15-H) 3.09 (app t, J = 12.0 Hz, 1 H, C17-H) 2.88-
2.81 (comp, 3 H, C11-H, C13-H, C17-H2) 2.52 (m, 1 H, C14-H) 2.16 (m, 1 H, C14-H) 
2.07-2.03 (m, 1H, C34-H) 1.88-1.83 (m, 1H, C34-H) 1.63 (s, 9H, C37-CH3). 13C-NMR: 
δ 151.2 (C35), 139.6, 136.892, 136.6, 136.4, 128.6, 128.5, 128.1, 128.0, 128.0, 127.8, 
127.5, 125.1, 122.9, 118.4, 113.8, 110.5, 85.1 (C36), 80.8 (C12), 75.7 (C18 or C19 or 
C20 or C21), 75.1 (C18 or C19 or C20 or C21), 73.7 (C18 or C19 or C20 or C21), 73.4 
(C18 or C19 or C20 or C21), 60.8 (C16), 49.9 (C11 or C13), 49.8 (C11 or C13), 49.2 


















































(1R/S, 4R/S, 7R/S, 13cS/R, 14S/R)-8,8-Bis((benzyloxy)methyl)-
2,3,5,6,7,8,9,13c-octahydro-1H-1,7-methanopyrrolo[1',2':1,2]azocino[4,3-b]indol-14-
ol. (4.57). (WLM7_149_2). A 1.5 mL screw top vial charged with 4.56 (7 mg, 0.0115 
mmol), 40% aq NaOH (0.1 mL), and MeOH (1.0 mL) was stirred at room temperature 
for one week. The reaction mixture was quenched with saturated aq NH4Cl (0.5 mL) and 
extracted with CH2Cl2 (3 x 1.0 mL). The combined organic extracts were washed with 
H2O (1.0 mL), brine (1.0 mL), dried (Na2SO4), and concentrated in vacuo to afford a 
yellow oil. Subsequent purification by RP HPLC H2O : MeCN (90 : 10 → 5 : 95 over 30 
min) afforded 5.0 mg (85%) of 4.57 as a white solid. 1H-NMR (500 MHz, CD3OD) δ 
10.58 (br, 1 H) 7.58 (d, J = 8.0 Hz, 1 H) 7.39 (d, J = 8.5 Hz, 1 H) 7.31-7.23 (comp, 10 H) 
7.16 (td, J = 7.5, 1.0 Hz, 1 H) 7.10 (td, J = 7.5, 1.0 Hz, 1 H) 5.22 (d, J = 6.5 Hz, 1 H) 
4.60-4.53 (comp, 4H) 4.30 (d, J = 9.0 Hz, 1 H) 4.21 (d, J = 9.5 Hz, 1 H) 4.11 (d, J = 5.5 
Hz, 1 H) 4.06 (d, J = 9.0 Hz, 1 H) 3.76-3.71 (m, 1 H) 3.74 (d, J = 9.0 Hz, 1 H) 3.59-3.53 
(m, 1 H) 3.25 (td, J = 9.0, 3.5 Hz, 1 H) 2.98 (dm, J = 14.0 Hz, 1 H) 2.90 (t, J = 7.5 Hz, 1 
H) 2.80 (app t, J = 5.0 Hz, 1 H) 2.64 (m, 1 H) 2.22-2.15 (comp, 2 H) 2.07 (m, 1 H); 13C-
NMR (125 MHz, CD3OD) δ 142.9, 139.6, 139.5, 137.1, 129.4, 129.4, 129.0, 128.8, 
128.7, 128.6, 123.3, 121.0, 118.0, 112.3, 100.7, 82.3, 76.2, 74.5, 74.4, 73.5, 63.9, 51.6, 
50.1, 49.6, 48.2, 43.4, 33.2, 22.6; HRMS (ESI) m/z observed 509.28030 [C33H36N2O3 










Assignments: 1H-NMR (500 MHz, CD3OD) δ 10.58 (br, 1 H, N1-H) 7.58 (d, J = 
8.0 Hz, 1 H, C5-H) 7.39 (d, J = 8.5 Hz, 1 H, C8-H) 7.31-7.23 (comp, 10 H, C23-H, C24-
H, C25-H, C26-H, C27-H, C29-H, C30-H, C31-H, C32-H, C33-H) 7.16 (td, J = 7.5, 1.0 
Hz, 1 H, C7-H) 7.10 (td, J = 7.5, 1.0 Hz, 1 H, C6-H) 5.22 (d, J = 6.5 Hz, 1 H, C16-H) 
4.60-4.53 (comp, 4 H, C20-H2, C21-H2) 4.30 (d, J = 9.0 Hz, 1 H, C18-H or C19-H) 4.21 
(d, J = 9.5 Hz, 1 H, C18-H or C19-H) 4.11 (d, J = 5.5 Hz, 1 H, C12-H) 4.06 (d, J = 9.0 
Hz, 1 H, C18-H or C19-H) 3.76-3.71 (m, 1 H, C15-H) 3.74 (d, J = 9.0 Hz, 1 H, C18-H or 
C19-H) 3.59-3.53 (m, 1 H, C15-H) 3.25 (td, J = 9.0, 3.5 Hz, 1 H, C17-H) 2.98 (dm, J = 
14.0 Hz, 1 H, C17-H) 2.90 (t, J = 7.5 Hz, 1 H, C13-H) 2.80 (app t, J = 5.0 Hz, 1 H, C11-
H) 2.64 (m, 1 H, C14-H) 2.22-2.15 (comp, 2 H, C14-H, C34-H) 2.07 (m, 1 H, C34-H); 
13C-NMR (125 MHz, CD3OD) δ 142.9, 139.6, 139.5, 137.1, 129.4, 129.4, 129.0, 128.8, 
128.7, 128.6, 123.3 (C7), 121.0 (C6), 118.0 (C5), 112.3 (C8), 100.7 (C3), 82.3 (C12), 
76.2 (C18 or C19), 74.5 (C20 or C21), 74.4 (C20 or C21), 73.5 (C18 or C19), 63.9 (C16), 

















































1H-1,7-methanopyrrolo[1',2':1,2]azocino[4,3-b]indol-14-one (4.58). (WLM7_130_2). 
A 1.5 mL screw top vial charged with 3.25 (4 mg, mmol), 40% aq NaOH (0.1 mL), and 
MeOH (1.0 mL) was stirred at room temperature for one week. The reaction mixture was 
diluted with CH2Cl2 (2.0 mL), washed with H2O (1.0 mL), brine (1.0 mL), dried 
(Na2SO4), and concentrated in vacuo to afford a yellow oil. Subsequent purification by 
RP HPLC H2O : MeCN (90 : 10 → 5 : 95 over 30 min) afforded 2.0 mg (60%) of 4.58 as 
a yellow solid: 1H-NMR (500 MHz, CD3OD) δ 7.60 (d, J = 8.0 Hz, 1 H) 7.36 (dm, J = 
8.0 Hz, 1 H) 7.28-7.16 (comp, 10 H) 7.15 (td, J = 7.0, 1.0 Hz, 1 H) 7.08 (td, J = 7.0, 1.0 
Hz, 1 H) 4.91 (d, J = 5.5 Hz, 1 H) 4.59 (d, J = 12.0 Hz, 1H) 4.56 (d, J = 12.0 Hz, 1 H) 
4.44 (d, J = 12.0 Hz, 1 H) 4.39 (d, J = 12.0 Hz, 1 H) 4.09 (d, J = 9.0 Hz, 1 H) 3.82 (d, J = 
9.0 Hz, 1 H) 3.66 (d, J = 9.0 Hz, 1 H) 3.62 (d, J = 9.0 Hz, 1 H) 3.52-3.41 (m, 2 H) 3.28-
3.25 (m, 2 H) 3.16-3.15 (m, 1 H) 2.82 (m, 1 H) 2.61-2.53 (m, 1 H) 2.24-2.16 (m, 2 H) 
2.02-1.98 (m, 1 H) 13C-NMR (125 MHz, CD3OD) δ 215.3, 139.8, 139.4, 139.3, 137.1, 
129.4, 130.0, 128.9, 128.8, 128.6, 123.3, 120.7, 118.6, 112.1, 75.5, 74.6, 74.3, 72.5, 60.0, 
58.0, 55.6, 51.4, 49.6, 47.0, 31.7, 23.8; HRMS (ESI) m/z observed 507.26450 









































Assignments: 1H-NMR: δ 7.60 (d, J = 8.0 Hz, 1 H, C5-H) 7.36 (dm, J = 8.0 Hz, 1 
H, C8-H) 7.28-7.16 (comp, 10 H, C22-H, C23-H, C24-H, C25-H, C26-H, C27-H, C29-H, 
C30-H, C31-H, C32-H, C33-H) 7.15 (td, J = 7.0, 1.0 Hz, 1 H, C7-H) 7.08 (td, J = 7.0, 1.0 
Hz, 1 H, C6-H) 4.91 (d, J = 5.5 Hz, 1 H, C16-H) 4.59 (d, J = 12.0 Hz, 1 H, C20-H or 
C21-H) 4.56 (d, J = 12.0 Hz, 1 H, C20-H or C21-H) 4.44 (d, J = 12.0 Hz, 1 H, C20-H or 
C21-H) 4.39 (d, J = 12.0 Hz, 1 H, C20-H or C21-H) 4.09 (d, J = 9.0 Hz, 1 H, C19-H) 
3.82 (d, J = 9.0 Hz, 1 H, C19-H) 3.66 (d, J = 9.0 Hz, 1 H, C18-H) 3.62 (d, J = 9.0 Hz, 1 
H, C18-H) 3.52-3.41 (m, 2 H, C15-H) 3.28-3.25 (m, 2 H, C13-H and C17-H) 3.16-3.15 
(m, 1 H, C11-H) 2.82 (m, 1 H, C17-H) 2.61-2.53 (m, 1 H, C14-H) 2.24-2.16 (m, 2 H, 
C14-H and C34-H) 2.02-1.98 (m, 1 H, C34-H) 13C-NMR: δ 215.3 (C12), 139.8, 139.4, 
139.3, 137.1, 129.4, 130.0, 128.9, 128.8, 128.6, 123.3 (C7), 120.7 (C6), 118.6 (C5), 
112.1 (C8), 75.5 (C18), 74.6 (C20 or C21), 74.3 (C20 or C21), 72.5 (C19), 60.0 (C16), 
58.0 (C13), 55.6 (C11), 51.4 (C15), 49.6 (C17), 47.0 (C10), 31.7 (C14), 23.8 (C34). 
 
 
(1R/S, 4R/S, 7R/S, 13cS/R, 14S/R)-8,8-Bis((benzyloxy)methyl)-14-
(methoxymethoxy)-2,3,5,6,7,8,9,13c-octahydro-1H-1,7-
methanopyrrolo[1',2':1,2]azocino[4,3-b]indole. (4.59). (WLM7_215_2). To a mixture 
of 4.56 (4.0 mg, 0.00657 mmol) and N,N-diisopropylethylamine (4.25 mg, 0.0329 mmol) 
in dry CH2Cl2 (0.3 mL) at 0 °C was added MOM-Cl (0.0197 mmol, 17 µL, 1.18 M in 
CH2Cl2). After 5 h, the reaction was quench by the addition of saturated aq NaHCO3 (0.5 








mL). The combined organic extracts were washed with brine (1.0 mL), dried (Na2SO4), 
and concentrated in vacuo to afford a yellow oil that was purified by flash 
chromatography (basic Al2O3) eluting with CH2Cl2 : MeOH (95 : 5) to provide 4.3 mg 
(quant) of 4.59 as a white solid. 1H-NMR (500 MHz, CD3OD) δ 7.70 (d, J = 8.5 Hz, 1 H) 
7.67 (d, J = 8.0 Hz, 1 H) 7.39 (td, J = 7.0, 1.0 Hz, 1 H) 7.31 (td, J = 7.0, 1.0 Hz, 1 H) 
7.25-7.14 (comp, 10 H) 5.46 (d, J = 6.5 Hz, 1 H) 4.57-4.46 (comp, 4 H) 4.41 (d, J = 11.5 
Hz, 1 H) 4.34 (d, J = 9.0 Hz, 1 H) 4.27 (d, J = 9.5 Hz, 1 H) 4.21 (d, J = 7.0 Hz, 1 H) 4.12 
(d, J = 7.0 Hz, 1 H) 4.08 (dd, J = 5.5, 1.5 Hz, 1 H) 3.95-3.90 (m, 1 H) 3.94 (d, J = 9.5 Hz, 
1 H) 3.81 (dt, J = 13.0, 9.0 Hz, 1 H) 3.48 (s, 3 H) 3.34 (td, J = 14.0, 3.0 Hz, 1 H) 3.15 
(dm, 12.0 Hz, 1 H) 3.02 (m, 1 H) 2.97 (m, 1 H) 2.61 (m, 1 H) 2.23-2.15 (comp, 3 H) 1.60 
(s, 9 H); 13C-NMR (125 MHz, CD3OD) δ 152.3, 143.6, 139.2, 139.1, 137.9, 129.8, 129.4, 
129.4, 128.9, 128.8, 128.8, 128.6, 126.0, 124.0, 118.2, 115.1, 108.0, 90.8, 87.1, 81.3, 
77.1, 76.1, 74.2, 74.1, 67.7, 59.6, 56.5, 55.8, 51.1, 50.9, 47.8, 32.8, 28.2, 24.6; HRMS 
(ESI) m/z observed 653.35850 [C40H48N2O6 (M+H)+ requires 653.35850]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.70 (d, J = 8.5 Hz, 1 H, C8-H) 
7.67 (d, J = 8.0 Hz, 1 H, C5-H) 7.39 (td, J = 7.0, 1.0 Hz, 1 H, C7-H) 7.31 (td, J = 7.0, 1.0 
Hz, 1 H, C6-H) 7.25-7.14 (comp, 10 H, C23-H, C24-H, C25-H, C26-H, C27-H, C29-H, 

















































C18-H or C19-H or C20-H or C21-H) 4.41 (d, J = 11.5 Hz, 1 H, C18-H or C19-H or 
C20-H or C21-H) 4.34 (d, J = 9.0 Hz, 1 H, C18-H or C19-H or C20-H or C21-H) 4.27 (d, 
J = 9.5 Hz, 1 H C18-H or C19-H or C20-H or C21-H) 4.21 (d, J = 7.0 Hz, 1 H, C35-H) 
4.12 (d, J = 7.0 Hz, 1 H, C35-H) 4.08 (dd, J = 5.5, 1.5 Hz, 1 H, C12-H) 3.95-3.90 (m, 1 
H, C15-H) 3.94 (d, J = 9.5 Hz, 1 H, C18-H or C19-H or C20-H or C21-H) 3.81 (dt, J = 
13.0, 9.0 Hz, 1 H, C15-H) 3.48 (s, 3 H, C36-H3) 3.34 (td, J = 14.0, 3.0 Hz, 1 H, C17-H) 
3.15 (dm, 12.0 Hz, 1 H, C17-H) 3.02 (m, 1 H, C11-H) 2.97 (m, 1 H, C13-H) 2.61 (m, 1 
H, C14-H) 2.23-2.15 (comp, 3 H, C14-H and C34-H2) 1.60 (s, 9 H, C39-H3); 13C-NMR 
(125 MHz, CD3OD) δ 152.3 (C37), 143.6, 139.2, 139.1, 137.9, 129.8, 129.4, 129.4, 
128.9, 128.8, 128.8, 128.6, 126.0 (C7), 124.0 (C6), 118.2 (C5), 115.1 (C8), 108.0 (C3), 
90.8 (C35), 87.1 (C38), 81.3 (C12), 77.1 (C18 or C19 C20 or C21), 76.1 (C18 or C19 
C20 or C21), 74.2 (C18 or C19 C20 or C21), 74.1 (C18 or C19 C20 or C21), 67.7 (C16), 
59.6 (C36), 56.5 (C15), 55.8 (C17), 51.1 (C10), 50.9 (C13), 47.8 (C11), 32.8 (C14), 28.2 
(C39) 24.6 (C34). 
 
 
1,3-Bis(benzyloxy)-2-(5-chloro-1H-indol-2-yl)propan-2-yl acetate. (4.64a). 
(WLM7_244_2). A solution of n-BuLi (3.33 mL of 2.5 M in hexanes, 8.32 mmol) was 
added dropwise to a solution of 5-chloroindole (4.63a) (1.15 g, 7.57 mmol) in dry THF 
(40 mL) at –78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed 
through a short column of anhydrous CaSO4) was bubbled through the reaction for 15 
min. The reaction was stirred for 15 min, the bath was removed, and the reaction was 








cycles), and the reaction was evacuated for 30 sec, and then sparged with N2 for 20 min. 
The reaction was cooled to –78 °C, whereupon t-BuLi (4.62 mL of 1.8 M solution, 8.32 
mmol) was added dropwise. The reaction was stirred for 80 min and transferred via 
cannula to a solution of 1,3-dibenzyloxyacetone (3.17) (2.25 g, 8.32 mmol) in dry THF 
(20 mL) at –78 ºC. The reaction was stirred for 2.5 h, freshly distilled acetic anhydride 
(2.32 g, 22.7 mmol, 2.15 mL) was added dropwise, and the reaction was allowed to warm 
to room temperature over 7 h. Saturated aq NaHCO3 (30 mL) was added, and the reaction 
was stirred for 30 min, whereupon brine (25 mL) and EtOAc (25 mL) were added. The 
layers were separated, and the aqueous layer was extracted with EtOAc (2 x 25 mL). The 
combine organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (10 : 1 → 4 : 1) containing 1% NEt3 to give 1.41 g (40%) of 4.64a as a 
white solid: 1H-NMR (600 MHz, CD3CN) δ 9.61 (br, 1 H) 7.52 (d, J = 1.8 Hz, 1 H) 7.36 
(d, J = 9.0 Hz, 1 H) 7.33-7.26 (comp, 10 H) 7.10 (dd, J = 9.0, 1.8 Hz, 1 H) 6.37 (dd, J = 
1.8, 0.8 Hz, 1 H) 4.54 (d, J = 12.0 Hz, 2 H) 4.51 (d, J = 12.0 Hz, 2 H) 4.13 (d, J = 11.4 
Hz, 2 H) 4.11 (d, J = 11.4 Hz, 2 H) 2.03 (s, 3 H); 13C-NMR (150 MHz, CD3CN) δ 170.4, 
139.9, 139.2, 135.3, 129.8, 129.3, 128.7, 128.6, 125.3, 122.6, 120.4, 113.5, 100.2, 81.3, 





Assignments: 1H-NMR (600 MHz, CD3CN) δ 9.61 (br, 1 H, N1-H) 7.52 (d, J = 
1.8 Hz, 1 H, C5-H) 7.36 (d, J = 9.0 Hz, 1 H, C8-H) 7.33-7.26 (comp, 10 H, C16-H, C17-
H, C18-H, C19-H, C20-H, C22-H, C23-H, C24-H, C25-H, and C26-H) 7.10 (dd, J = 9.0, 
1.8 Hz, 1 H, C7-H) 6.37 (dd, J = 1.8, 0.8 Hz, 1 H, C3-H) 4.54 (d, J = 12.0 Hz, 2 H, C13-
H and C14-H) 4.51 (d, J = 12.0 Hz, 2 H, C13-H and C14-H) 4.13 (d, J = 11.4 Hz, 2 H, 
C11-H and C12-H) 4.11 (d, J = 11.4 Hz, 2 H, C11-H and C12-H) 2.03 (s, 3 H, C28-H3); 
13C-NMR (150 MHz, CD3CN) δ 170.4 (C27), 139.9, 139.2, 135.3, 129.8, 129.3, 128.7, 
128.6, 125.3, 122.6 (C7), 120.4 (C5), 113.5 (C8), 100.2 (C3), 81.3 (C10), 74.1 (C13 and 
C14), 71.3 (C11 and C12), 22.1 (C28). 
 
 
1,3-Bis(benzyloxy)-2-(6-chloro-1H-indol-2-yl)propan-2-yl acetate. (4.64b). 
(WLM8_73). A solution of n-BuLi (2.9 mL of 2.5 M solution in hexanes, 7.256 mmol) 
was added dropwise to a solution of 3.63b (1.00 g, 6.596 mmol) in dry THF (30 mL) at –
78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed through a short 
column of anhydrous CaSO4) was bubbled through the reaction for 15 min. The reaction 
was stirred for 15 min, the bath was removed, and the reaction was stirred for 1 h at room 








































was evacuated for 30 sec, and then sparged with N2 for 20 min. The reaction was cooled 
to –78 °C, whereupon t-BuLi (4.54 mL of 1.8 M solution in pentane, 7.256 mmol) was 
added dropwise. The reaction was stirred for 80 min and transferred via cannula to a 
solution of 3.17 (1.96 g, 7.256 mmol) in dry THF (30 mL) at –78 ºC. The reaction was 
stirred for 2.5 h, freshly distilled acetic anhydride (2.02 g, 19.79 mmol, 1.87 mL) was 
added dropwise, and the reaction was allowed to warm to room temperature over 7 h. 
Saturated aq NaHCO3 (50 mL) was added, and the reaction was stirred for 30 min, 
whereupon brine (50 mL) and Et2O (50 mL) were added. The layers were separated, and 
the aqueous layer was extracted with Et2O (2 x 50 mL). The combined organic layers 
were dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting 
yellow oil was purified by flash chromatography eluting with Hexanes : EtOAc (20:1 → 
10:1 → 4:1 → 1:1) containing 1% NEt3 to give 1.645 g (52%) of 4.64b as a white solid 
and 873 mg (31%) of 4.64c as a brown oil: 1H-NMR (600 MHz, CD3CN) δ 9.59 (br, 1 H) 
7.48 (d, J = 8.4 Hz, 1 H) 7.41 (d, J = 2.4 Hz, 1 H) 7.34-7.24 (comp, 10 H) 7.02 (dd, J = 
8.4, 1.8 Hz, 1 H) 6.41 (d, J = 6.41 Hz, 1 H) 4.53 (app d, 4 H) 4.12 (app d, 4 H) 2.03 (s, 3 
H); 13C-NMR (150 MHz, CD3CN) δ 170.5, 139.2, 139.2, 137.2, 129.3, 128.7, 128.6, 
127.9, 127.4, 122.4, 120.9, 111.8, 100.7, 81.3, 74.1, 71.3, 22.1; HRMS (ESI) m/z 




(WLM8_73). 1H-NMR (400 MHz, CD3CN) δ 9.54 (br, 1H), 7.47 (dt, J = 8.4, 0.7 Hz, 
1H), 7.45 – 7.39 (m, 1H), 7.30 (comp, 10H), 7.02 (dd, J = 8.3, 1.4 Hz, 1H), 6.38 (dd, J = 








NMR (100 MHz, CD3CN) δ 143.1, 139.3, 137.0, 129.3, 128.7, 128.5, 127.9, 127.2, 
122.1, 120.6, 118.3, 111.8, 99.5, 74.7, 74.1; HRMS (ESI) m/z observed 444.13530 





(WLM8_97_2). A solution of TMS-OTf (276 mg, 1.242 mmol, 0.225 mL) in dry CH2Cl2 
(1.0 mL) was added dropwise to a solution of 3.64a (480 mg, 1.035 mmol), 3.10 (400 
mg, 1.14 mmol), and 2,6-di(tert-butyl)-4-methylpyridine (425 mg, 2.07 mmol) in dry 
CH2Cl2 (4.0 mL) at –78 ºC. The reaction was stirred for 3 h at –78 ºC, whereupon a 
solution of TBAF•3H2O (980 mg) in CH2Cl2 (5.0 mL) was added dropwise. The bath was 
removed, and the reaction was stirred at room temperature for 1 h. Saturated aq NaHCO3 
(5.0 mL) was added, and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic extracts were washed with brine (25 mL), 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The resultant yellow 
oil was purified by flash chromatography eluting with Hexanes : EtOAc (10 : 1 → 4 : 1 
→ 2 : 1) containing 1% NEt3 to afford 425 mg (69%) of 4.65a as a yellow foam: 1H-
NMR (500 MHz, CD3CN, 70 °C) δ 9.68 (br, 1 H) 7.47 (d, J = 2.0 Hz, 1 H) 7.36-7.23 
(comp, 9 H) 7.17-7.15 (comp, 2 H) 7.12 (dd, 9.0, 2.0 Hz, 1 H) 6.00 (br, 1 H) 5.78 (app t, 
J = 3.5 Hz, 1 H) 5.31 (app d, J = 15.0 Hz, 1 H) 5.21 (app d, J = 7.5 Hz, 1 H) 4.63 (d, J = 
12.0 Hz, 2 H) 4.59 (d, J = 12.0 Hz, 2 H) 4.39 (d, J = 12.0 Hz, 1 H) 4.33 (d, J = 12.0 Hz, 1 









= 8.5 Hz, 1 H) 3.65 (d, J = 8.5 Hz, 1 H) 3.10 (dd, J = 6.0, 3.0 Hz, 1 H) 3.04 (dd, J = 18.5, 
9.5 Hz, 1 H) 3.01 (t, J = 13.0 Hz, 1 H) 2.87 (dd, J = 19.0, 3.0 Hz, 1 H) 2.04 (dm, J = 15.0 
Hz, 1 H) 1.78 (m, 1 H); 13C-NMR (125 MHz, 70 °C) δ 211.5, 156.0, 141.2, 139.4, 139.3, 
135.2, 134.8, 129.6, 129.5 129.4, 129.1, 129.0, 129.0, 128.9, 128.8, 128.7, 126.2, 123.2, 
117.7, 113.7, 110.9, 81.9, 76.0, 74.7, 74.6, 74.4, 71.9, 67.0, 58.3, 46.6, 46.0, 40.9, 28.8; 





(WLM8_83). A solution of TMS-OTf (370 mg, 1.67 mmol, 0.3 mL) in dry CH2Cl2 (2.0 
mL) was added dropwise to a solution of 4.64b (645 mg, 1.39 mmol), 3.10 (540 mg, 1.53 
mmol), and 2,6-di(tert-butyl)-4-methylpyridine (571 mg, 2.78 mmol) in dry CH2Cl2 (5.0 
mL) at –78 ºC. The reaction was stirred for 3 h at –78 ºC, whereupon a solution of 
TBAF•3H2O (1.32 g, 4.17 mmol) in CH2Cl2 (5 mL) was added dropwise. The bath was 
removed, and the reaction was stirred at room temperature for 1 h. Saturated aq NaHCO3 
(10 mL) was added, and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic extracts were washed with brine (30 mL), 
dried (Na2SO4), filtered, and concentrated under reduced pressure. The resultant yellow 
oil was purified by flash chromatography eluting with Hexanes : EtOAc (10 : 1 → 4 : 1) 
containing 1% NEt3 to afford 741 mg (89%) of 4.65b as a yellow foam: 1H-NMR (500 
MHz, CD3CN, 70 ºC) δ 9.69 (br, 1 H) 7.46 (d, J = 8.5 Hz, 1 H) 7.42 (d, J = 2.0 Hz, 1 H) 









7.06 (dd, J = 8.5, 1.5 Hz, 1 H) 6.00 (br, 1 H) 5.84 (app t, 1 H) 5.33 (br, 1 H) 5.21 (br, 1 
H) 4.65 (d, J = 12.0 Hz, 1 H) 4.63 (m, 2 H) 4.60 (d, J = 12.0 Hz, 1 H) 4.40 (d, J = 12.0 
Hz, 1 H) 4.35 (d, J = 12.0 Hz, 1 H) 4.00 (d, J = 9.5 Hz, 1 H) 3.95 (d, J = 14.5 Hz, 1 H) 
3.78 (d, J = 9.5 Hz, 1 H) 3.74 (d, J = 9.0 Hz, 1 H) 3.68 (d, J = 9.0 Hz, 1 H) 3.13 (dd, J = 
6.0, 3.0 Hz, 1 H) 2.90 (dd, J = 19.0, 4.0 Hz, 1 H) 3.02 (d, J = 13.0 Hz, 1 H) 2.89 (dd, J = 
19.0, 3.0 Hz, 1 H) 2.05 (dm, J = 15.5 Hz, 1 H) 1.80 (tm, J = 14.5 Hz, 1 H); 13C-NMR 
(125 MHz, CD3CN, 70 ºC) δ 211.5, 156.0, 140.4, 139.3, 139.2, 137.0, 134.7, 129.6, 
129.4, 129.0, 128.9, 128.8, 128.7, 128.6, 121.2, 119.9, 117.8, 112.1, 111.2, 75.9, 74.7, 
74.4, 73.3, 67.0, 58.2, 50.3, 46.5, 46.0, 40.8, 28.8; HRMS (ESI) m/z observed 599.23080 
[C35H35ClN2O5 (M+H)+ requires 599.23070]. 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 6,6-bis((benzyloxy)methyl)-10-chloro-12-hydroxy-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.66a). 
(WLM7_284_2). Lithium borohydride (17 mg, 0.79 mmol) was added to a solution of 
4.65a (95 mg, 0.159 mmol) in dry MeOH (1.6 mL) at 0 ºC. After 4 h, saturated aq 
Rochelle’s salt (2.0 mL) was added, and the reaction was stirred for 5 min. the reaction 
mixture was extracted with CH2Cl2 (3 x 10 mL), washed with brine (10 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure. Subsequent purification by 
flash chromatography eluting with Hexanes : EtOAc (3:1 → 1:1) afforded 77 mg (81%) 
of 4.66a as a white solid: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.58 (br, 1 H) 7.39-7.23 
(comp, 12 H) 7.07 (dd, J = 8.5, 2.0 Hz, 1 H) 6.03 (br, 1 H) 5.54 (d, J = 6.5 Hz, 1 H) 5.34 









J = 12.0 Hz, 1 H) 4.50 (d, J = 12.0 Hz, 1 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.27 (td, J = 9.0, 
1.5 Hz, 1 H) 4.06 (d, J = 9.0 Hz, 1 H) 4.06 (d, J = 9.0 Hz, 1 H) 3.99 (d, J = 9.0 Hz, 1 H) 
3.81 (dd, J = 10.0, 5.0 Hz, 1 H) 3.70 (d, J = 9.0 Hz, 1 H) 3.19 (br, 1 H) 2.97 (m, 1 H) 
2.66 (app t, J = 12.5 Hz, 1 H) 2.58 (app t, J = 5.0 Hz, 1 H) 2.04 (br, 1 H) 1.90-1.83 
(comp, 2 H) 1.80-1.72 (m, 1 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 156.3, 142.9, 
139.9, 139.7, 135.2, 135.1, 129.6, 129.5, 129.1, 128.9, 128.9, 128.8, 128.7, 126.0, 122.7, 
117.8, 117.4, 113.6, 113.4, 75.9, 74.6, 74.3, 74.3, 74.2, 66.7, 48.2, 47.9, 41.6; HRMS 
(ESI) m/z observed 623.22820 [C35H37ClN2O5 (M+Na)+ requires 623.22830]. 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 6,6-bis((benzyloxy)methyl)-9-chloro-12-hydroxy-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.66b). 
(WLM8_84). Lithium borohydride (38 mg, 1.75 mmol) was added to a solution of 4.65b 
(525 mg, 0.876 mmol) in dry MeOH (9.0 mL) at 0 ºC. After 4 h, saturated aq Rochelle’s 
salt (5.0 mL) was added, and the reaction was stirred for 5 min. the reaction mixture was 
extracted with CH2Cl2 (3 x 25 mL), washed with brine (50 mL), dried (Na2SO4), filtered, 
and concentrated under reduced pressure. The resulting yellow oil was purified by flash 
chromatography eluting with Hexanes : EtOAc (2 : 1 → 1 : 1) to give 481 mg (91%) of 
4.66b as a white solid: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.56 (br, 1 H) 7.39-7.34 
(comp, 6 H) 7.31-7.23 (comp, 6 H) 7.02 (dd, J = 8.5, 2.0 Hz, 1 H) 6.01 (br, 1 H) 5.57 (d, 
J = 6.5 Hz, 1 H) 5.33 (br, 1 H) 5.22 (br, 1 H) 4.67-4.64 (comp, 3 H) 4.60 (d, J = 12.0 Hz, 
1 H) 4.50 (d, J = 12.0 Hz, 1 H) 4.47 (d, J = 12.0 Hz, 1 H) 4.28 (m, 1 H) 4.06 (d, J = 8.5 









3.23 (d, J = 5.0 Hz, 1 H) 2.98 (m, 1 H) 2.66 (m, 1 H) 2.59 (m, 1 H) 1.89-1.83 (comp, 2 
H) 1.80-1.72 (m, 1 H); 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 156.3, 142.0, 139.8, 139.7, 
137.0, 135.1, 129.6, 129.5, 129.0, 128.9, 128.9, 128.7, 128.1, 126.4, 120.9, 119.6, 117.4, 
113.6, 112.0, 75.9, 74.6, 74.3, 74.3, 74.2, 66.7, 48.2, 48.2, 47.9, 41.6, 41.5, 31.2; HRMS 
(ESI) m/z observed 623.22840 [C35H37ClN2O5 (M+Na)+ requires 623.22830]. 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 6,6-bis((benzyloxy)methyl)-10-chloro-12-hydroxy-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.67a). 
(WLM7_286). A round bottom flask charged with Pd2(dba)3 (0.18 mg, 0.0002 mmol) and 
1,4-bis(diphenylphosphino)butane (0.17 mg, 0.0004 mmol) was placed under vacuum 
and backfilled with N2 three times. A second round bottom flask was charged with 4.66a 
(12 mg, 0.02 mmol) and 1,3-dimethylbarbituric acid (31 mg, 0.2 mmol) and placed under 
vacuum and backfilled with N2 three times. THF (0.2 mL) was then added to both flasks, 
and the mixtures were stirred at room temperature under N2 for 5 min. The Pd/ligand 
mixture was added via syringe to the flask containing 4.66a, and stirring was continued at 
room temperature until 4.66a was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (0.5 mL) extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (5 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (100% CH2Cl2 → 9:1 → 4:1) containing 









CD3OD) δ 7.55 (dd, J = 2.0, 0.5 Hz, 1H) 7.36 (dd, J = 8.5, 0.5 Hz, 1 H) 7.29-7.20 (comp, 
5 H) 7.20-7.16 (comp, 5 H) 7.12 (dd, J = 9.0, 2.0 Hz, 1 H) 5.15 (dd, J = 5.5, 1.5 Hz, 1 H) 
4.60 (d, J = 11.5 Hz, 1 H) 4.57 (d, J = 12.0 Hz, 1 H) 4.50 (d, J = 12.5 Hz, 1 H) 4.47 (d, J 
= 12.5 Hz, 1 H) 4.38 (td, J = 9.0, 2.0 Hz, 1 H) 4.19 (d, J = 9.5 Hz, 1 H) 3.99 (d, J = 9.5 
Hz, 1 H) 3.96 (d, J = 9.5 Hz, 1 H) 3.79 (d, J = 9.0 Hz, 1 H) 2.98-2.91 (comp, 2 H) 2.79-
2.73 (comp 2 H) 2.26 (dm, J = 15.5 Hz, 1 H) 2.09 (ddd, J = 15.0, 3.5, 1.5 Hz, 1 H) 1.89 
(m, 1 H); 13C-NMR (125 MHz, CD3OD) δ 143.8, 139.5, 139.5, 135.5, 129.4, 129.3, 
128.9, 128.9, 128.8, 128.6, 128.2, 126.7, 123.3, 117.7, 113.5, 106.8, 74.7, 74.6, 74.6, 
74.3, 73.6, 49.6, 47.0, 41.5, 40.1, 28.2; HRMS (ESI) m/z observed 539.20730 
[C31H33ClN2O3 (M+Na)+ requires 539.20720]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.55 (dd, J = 2.0, 0.5 Hz, 1H, C5-
H) 7.36 (dd, J = 8.5, 0.5 Hz, 1 H, C8-H) 7.29-7.20 (comp, 5 H) 7.20-7.16 (comp, 5 H) 
7.12 (dd, J = 9.0, 2.0 Hz, 1 H, C7-H) 5.15 (dd, J = 5.5, 1.5 Hz, 1 H, C16-H) 4.60 (d, J = 
11.5 Hz, 1 H, C21-H or C29-H) 4.57 (d, J = 12.0 Hz, 1 H, C21-H or C29-H) 4.50 (d, J = 
12.5 Hz, 1 H, C21-H or C29-H) 4.47 (d, J = 12.5 Hz, 1 H, C21-H or C29-H) 4.38 (td, J = 
9.0, 2.0 Hz, 1 H, C18-H) 4.19 (d, J = 9.5 Hz, 1 H, C20-H or C28-H) 3.99 (d, J = 9.5 Hz, 
1 H, C20-H or C28-H) 3.96 (d, J = 9.5 Hz, 1 H, C20-H or C28-H) 3.79 (d, J = 9.0 Hz, 1 

































C12-H and C14-H) 2.26 (dm, J = 15.5 Hz, 1 H, C13-H) 2.09 (ddd, J = 15.0, 3.5, 1.5 Hz, 
1 H, C14-H) 1.89 (m, 1 H, C13-H); 13C-NMR (125 MHz, CD3OD) δ 143.8, 139.5, 139.5, 
135.5, 129.4, 129.3, 128.9, 128.9, 128.8, 128.6, 128.2, 126.7, 123.3 (C7), 117.7 (C5), 
113.5 (C8), 106.8 (C3), 74.7 (C20 or C28), 74.6 (C18), 74.6 (C21 or C29), 74.3 (C21 or 




hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.67b). (WLM8_182). A round 
bottom flask charged with Pd2(dba)3 (1.1 mg, 0.00125 mmol) and 1,4-
bis(diphenylphosphino)butane (1.1 mg, 0.0025 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.66b (75 
mg, 0.125 mmol) and 1,3-dimethylbarbituric acid (195 mg, 1.25 mmol) and placed under 
vacuum and backfilled with N2 three times. THF (0.6 mL) was then added to both flasks, 
and the mixtures were stirred at room temperature under N2 for 5 min. The Pd/ligand 
mixture was added via syringe to the flask containing 4.66b, and stirring was continued at 
room temperature until 4.66b was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (2.0 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (2.0 mL) extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (98 : 2 → 95 : 5) containing 1% NEt3 









J = 8.5 Hz, 1 H) 7.33-7.25 (comp, 6 H) 7.20-7.16 (comp, 5 H) 6.98 (dd, J = 8.0, 2.0 Hz, 1 
H) 4.72 (d, J = 5.5 Hz, 1 H) 4.61 (d, J = 11.5 Hz, 1 H) 4.57 (d, J = 12.0 Hz, 1 H) 4.46 
(comp, 3 H) 4.17 (d, J = 9.0 Hz, 1 H) 4.00 (d, J = 9.5 Hz, 1 H) 3.97 (d, J = 9.5 Hz, 1 H) 
3.67 (d, J = 9.0 Hz, 1 H) 2.82 (ddd, J = 14.0, 9.0, 6.5 Hz, 1 H) 2.70-2.66 (comp, 2 H) 
2.54 (td, J = 14.0, 8.0 Hz, 1 H); 13C-NMR (125 MHz, CD3OD) δ 141.4, 139.7, 137.4, 
129.4, 129.3, 128.9, 128.9, 128.7, 128.5, 128.2, 126.1, 120.5, 119.4, 111.7, 111.6, 75.7, 
74.9, 74.5, 74.3, 73.4, 47.3, 42.8, 41.9, 30.8; HRMS (ESI) m/z observed 517.22540 




2,3,4,5,6,7-hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.68a). (WLM8_43). 
A mixture of 4.67a (5.5 mg, 0.0106 mmol) and 37% aq formaldehyde solution (3 mg, 
0.106 mmol, 8.5 µL) in CH2Cl2 (0.3 mL) was stirred for 5 min at room temperature 
whereupon sodium triacetoxyborohydride (11 mg, 0.0532 mmol) was added in one 
portion. Stirring was continued for 12 h at room temperature. The reaction was quenched 
with saturated aq Rochelle’s salt (0.5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by RP HPLC H2O : 
MeCN (10% MeCN → 95% MeCN over 30 min) afforded 1.9 mg (34%) of 4.48a as a 
white solid: 1H-NMR (500 MHz, CD3OD) δ 7.59 (d, J = 1.5 Hz, 1 H) 7.39 (dd, J = 9.0, 
0.5 Hz, 1 H) 7.31-7.24 (comp, 5 H) 7.20-7.16 (comp, 5 H) 7.15 (dd, J = 9.0, 2.0 Hz, 1 H) 









(app t, 2 H) 4.34 (td, J = 8.5, 2.0 Hz, 1 H) 4.18 (d, J = 9.5 Hz, 1 H) 3.99 (d, J = 9.5 Hz, 1 
H) 3.96 (d, J = 9.5 Hz, 1 H) 3.80 (d, J = 9.0 Hz, 1 H) 3.05-2.99 (comp, 2 H) 2.88 (td, J = 
14.0, 4.0 Hz, 1 H) 2.83 (s, 3 H) 2.75 (m, 1 H) 2.28 (dm, J = 16.5 Hz, 1 H) 2.08 (ddd, J = 
15.0, 8.5, 1.5 Hz, 1 H) 1.93 (tm, J = Hz, 1 H); 13C-NMR (125 MHz, CD3OD) δ 144.4, 
139.4, 139.4, 135.5, 129.6, 129.4, 129.3, 129.0, 128.9, 128.8, 128.7, 127.3, 123.5, 117.4, 
113.9, 104.5, 74.8, 74.6, 74.4, 74.3, 73.5, 60.4, 52.6, 49.9, 46.3, 45.8, 39.9, 28.6; HRMS 




hexahydro-1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.68b). (WLM8_90). A mixture 
of 4.67b (44 mg, 0.0807 mmol) and 37% aq formaldehyde solution (24 mg, 0.807 mmol, 
65 µL) in CH2Cl2 (0.8 mL) was stirred for 5 min at room temperature whereupon sodium 
triacetoxyborohydride (86 mg, 0.404 mmol) was added in one portion. Stirring was 
continued for 4 h at room temperature. The reaction was quenched with saturated aq 
Rochelle’s salt (1.0 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford 27 mg (60%) of 4.68b as a white solid: 1H-NMR (500 MHz, CD3OD) δ 
7.46 (d, J = 8.5 Hz, 1 H) 7.36 (dd, J = 4.0, 0.5 Hz, 1 H) 7.33-7.25 (comp, 5 H) 7.20-7.15 
(comp, 5 H) 7.02 (dd, J = 8.0, 2.0 Hz, 1 H) 4.62 (d, J = 12.0 Hz, 1 H) 4.58 (m, 1 H) 4.58 
(d, J = 12.0 Hz, 1 H) 4.47 (app t, 2 H) 4.39 (td, J = 9.0, 2.5 Hz, 1 H) 4.17 (d, J = 9.0 Hz, 
1 H) 4.00 (d, J = 9.0 Hz, 1 H) 3.96 (d, J = 9.5 Hz, 1 H) 3.70 (d, J = 9.0 Hz, 1 H) 2.91 









H) 2.44 (td, J = 13.5, 3.5 Hz, 1 H) 2.06 (m, 1 H) 1.94-1.83 (comp, 2 H); 13C-NMR (125 
MHz, CD3OD) δ 142.1, 139.6, 139.6, 137.2, 129.4, 129.3, 128.9, 128.9, 128.7, 128.6, 
128.3, 127.6, 121.1, 119.6, 111.9, 108.4, 75.3, 75.1, 74.6, 74.3, 73.4, 58.1, 52.2, 49.6, 




(1S/R, 5R/S)-2-Allyl 7-tert-butyl 6,6-bis((benzyloxy)methyl)-10-chloro-12-oxo-
3,4,5,6-tetrahydro-1H-1,5-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.69a). 
(WLM8_142). 4-dimethylaminopyridine (67 mg, 0.551 mmol) was added to a solution of 
4.65a (220 mg, 0.367 mmol) in a mixture of di-tert-butyl dicarbonate (1.0 ml) and 
toluene (0.8 mL), and the reaction was stirred for 5 h at room temperature. The reaction 
was partitioned between H2O (15 mL) and Et2O (15 mL). The layers were separated, and 
the organic layer was extracted with Et2O (2 x 20 mL). The combined organic extracts 
were washed with brine (20 mL), dried (Na2SO4), and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (10 : 1 → 6 : 1) to give 174 mg (68%) of 4.69a as a yellow foam: 1H 
NMR (500 MHz, CD3CN, 70 ºC) δ 7.77 (d, J = 8.9 Hz, 1H), 7.45 (d, J = 2.1 Hz, 1H), 
7.30 (dd, J = 8.9, 2.1 Hz, 1H), 7.25 (comp, 6H), 7.18 (comp, 4H), 6.02 (br, J = 24.8 Hz, 
1H), 5.76 (br, 1H), 5.18 (comp, 2H), 4.65 (comp, 2H), 4.51 (d, J = 9.2 Hz, 1H), 4.48 (d, J 
= 11.7 Hz, 1H), 4.43 (d, J = 11.8 Hz, 1H), 4.37 (d, J = 11.7 Hz, 1H), 4.30 (d, J = 11.8 Hz, 
1H), 4.09 (d, J = 9.7 Hz, 1H), 3.77 (comp, 3H), 3.22 (dd, J = 5.9, 3.1 Hz, 1H), 3.07 (dd, J 









15.3, 5.8, 2.9 Hz, 1H), 1.78 – 1.69 (m, 1H), 1.64 (s, 9H); 13C NMR (125 MHz, CD3CN, 
70 ºC) δ 211.3, 156.0, 152.2, 140.8, 139.4, 139.2, 136.2, 134.8, 130.1, 129.5, 129.4, 
129.1, 129.0, 128.8, 128.7, 128.7, 125.9, 123.3, 120.0, 118.7, 116.9, 87.1, 76.7, 74.6, 
74.3, 74.3, 67.1, 64.9, 50.4, 48.1, 46.4, 41.2, 29.9, 28.6; HRMS (ESI) m/z observed 
699.28300 [C40H43ClN2O7 (M+H)+ requires 699.28320]. 
 
 
(1S/R, 5R/S)-2-Allyl 7-tert-butyl 6,6-bis((benzyloxy)methyl)-9-chloro-12-oxo-
3,4,5,6-tetrahydro-1H-1,5-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.69b). 
(WLM8_196). 4-dimethylaminopyridine (43 mg, 0.351 mmol) was added to a solution of 
4.65b (140 mg, 0.234 mmol) in a mixture of di-tert-butyl dicarbonate (0.5 ml) and 
toluene (0.4 mL), and the reaction was stirred for 3 h at room temperature. The reaction 
was partitioned between H2O (15 mL) and Et2O (25 mL). The layers were separated, and 
the organic layer was extracted with Et2O (2 x 25 mL). The combined organic extracts 
were washed with brine (40 mL), dried (Na2SO4), and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (4 : 1) to give 128 mg (78%) of 4.69b as a yellow foam: 1H-NMR (500 
MHz, CD3CN, 70 ºC) δ 7.83 (d, J = 2.0 Hz, 1 H) 7.42 (d, J = 8.0 Hz, 1 H) 7.27-7.21 
(comp, 7H) 7.18-7.15 (comp, 4 H) 5.97 (br, 1 H) 5.77 (br, 1 H) 5.28 (br, 1 H) 5.20 (br, 1 
H) 4.61 (br, 2 H) 4.50 (d, J = 9.5 Hz, 1 H) 4.47 (d, J = 11.5 Hz, 1 H) 4.42 (d, J = 11.5 Hz, 
1 H) 4.36 (d, J = 11.5 Hz, 1 H) 4.29 (d, J = 11.5 Hz, 1 H) 4.09 (d, J = 10.0 Hz, 1 H) 3.79-
3.74 (m, 1 H) 3.76 (d, J = 9.0 Hz, 1 H) 3.73 (d, J = 9.5 Hz, 1 H) 3.20 (dd, J = 6.0, 3.0 Hz, 









(dm, J = 15.0 Hz, 1 H) 1.72  (tm, J = 12.5 Hz, 1 H) 1.64 (s, 9 H); 13C-NMR (125 MHz, 
CD3CN, 70 ºC) δ 211.4, 156.0, 152.1, 140.1, 139.4, 139.3, 138.0, 134.8, 131.4, 129.5, 
129.4, 129.1, 128.9, 128.8, 128.7, 127.6, 124.0, 120.5, 120.4, 115.6, 87.3, 76.6, 74.7, 
74.3, 74.3, 67.1, 65.1, 50.4, 48.0, 46.5, 41.1, 29.9, 28.6; HRMS (ESI) m/z observed 
721.26490 [C40H43ClN2O7 (M+Na)+ requires 721.26510]. 
 
 
(1S/R, 5R/S, 12R/S)-2-Allyl 7-tert-butyl 6,6-bis((benzyloxy)methyl)-10-chloro-
12-hydroxy-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. 
(4.70a). (WLM8_144). Lithium aluminum hydride (79 µL of a 1M solution in THF, 
0.079 mmol) was added to a solution of 4.69a (55 mg, 0.079 mmol) in dry THF (0.8 mL) 
and the reaction was stirred for 2 h at 0 ºC until starting material was consumed by TLC. 
Excess lithium aluminum hydride was quenched with saturated aq Rochelle’s Salt (1.0 
ml) and stirred for 15 min. The reaction mixture was extracted with CH2Cl2 (3 x 10 mL), 
and the combined organic extracts were washed with brine (15 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The resulting yellow oil was purified by flash 
chromatography eluting with Hexanes : EtOAc (4:1 → 1:1) to give 34 mg (62%) of 4.70a 
as a white solid: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 7.73 (d, J = 9.0 Hz, 1 H) 7.35 (d, 
J = 1.5 Hz, 1 H) 7.31-7.20 (comp, 9 H) 7.17-7.12 (comp, 2 H) 6.01 (br, 1 H) 5.55 (d, 1 H) 
5.22 (br, 2 H) 4.64 (br, 2 H) 4.55 (d, J = 12.0 Hz, 1 H) 4.52-4.49 (comp, 3 H) 4.46 (d, J = 
12.0 Hz, 1 H) 4.40 (d, J = 12.0 Hz, 1 H) 4.25 (d, J = 9.5 Hz, 1 H) 4.22 (br, 1 H) 3.75 (br, 
1 H) 3.70 (d, J = 9.5 Hz, 1 H) 3.64 (d, J = 5.0 Hz, 1 H) 2.89 (ddd, J = 14.0, 8.0, 6.5 Hz, 1 









13C-NMR (125 MHz, CD3CN, 70 ºC) δ 156.3, 152.3, 141.6, 139.7, 139.5, 136.2, 135.1, 
130.0, 129.5, 129.4, 129.1,  128.9, 128.8, 128.6, 128.4, 125.5, 122.5, 118.4, 116.8, 86.6, 
78.1, 75.8, 75.6, 74.2, 74.0, 66.8, 54.8, 51.2, 48.4, 42.0, 39.9, 32.0, 28.6; HRMS (ESI) 
m/z observed 723.28040 [C40H45ClN2O7 (M+Na)+ requires 723.28080]. 
 
 
(1S/R, 5R/S, 12R/S)-2-Allyl 7-tert-butyl 6,6-bis((benzyloxy)methyl)-9-chloro-
12-hydroxy-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. 
(4.70b). (WLM8_197). Lithium aluminum hydride (183 µL of a 1M solution in THF, 
0.183 mmol) was added to a solution of 4.69b (128 mg, 0.183 mmol) in dry THF (1.8 
mL) and the reaction was stirred for 2 h at 0 ºC until starting material was consumed by 
TLC. Excess lithium aluminum hydride was quenched with saturated aq Rochelle’s Salt 
(0.25 ml) and stirred for 15 min. The reaction mixture was extracted with CH2Cl2 (3 x 25 
mL), and the combined organic extracts were washed with brine (40 mL), dried 
(Na2SO4), and concentrated under reduced pressure. The resulting yellow oil was purified 
by flash chromatography eluting with Hexanes : EtOAc (3 : 1 → 2 : 1) to give 80 mg 
(63%) of 4.70b as a white solid: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 7.98 (d, J = 1.5 
Hz, 1 H) 7.34 (d, J = 8.5 Hz, 1 H) 7.31-7.25 (comp, 5 H) 7.23-7.19 (comp, 4 H) 7.14-
7.12 (comp, 2 H) 6.00 (br, 1 H) 5.58 (br, 1 H) 5.21 (br, 2 H) 4.63 (br, 2 H) 4.56-4.49 
(comp, 3 H) 4.46 (d, J = 11.5 Hz, 1 H) 4.40 (d, J = 12.0 Hz, 1 H) 4.26 (d, J = 10.0 Hz, 1 
H) 4.22 (dd, J = 17.5, 9.5 Hz, 1 H) 3.72 (br, 1 H) 3.69 (d, J = 10.0 Hz, 1 H) 3.63 (d, J = 
6.5 Hz, 1 H) 2.88 (m, 1 H) 2.82 (app t, 1 H) 2.48 (br, 1 H) 2.03 (m, 1 H) 1.81-1.73 









139.5, 138.1, 135.1, 131.1, 129.7, 129.5, 129.4, 129.1, 128.8, 128.6, 128.4, 127.4, 123.7, 
123.0, 120.9, 120.2, 115.4, 86.7, 78.2, 75.8, 75.5, 74.2, 74.0, 66.8, 54.9, 51.2, 48.5, 42.0, 




(1S/R, 5R/S, 12R/S)-tert-Butyl 6,6-bis((benzyloxy)methyl)-10-chloro-12-
hydroxy-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-7(2H)-carboxylate. 
(4.71a). (WLM8_145). A round bottom flask charged with Pd2(dba)3 (1.6 mg, 0.00178 
mmol) and 1,4-bis(diphenylphosphino)butane (1.5 mg, 0.00356 mmol) was placed under 
vacuum and backfilled with N2 three times. A second round bottom flask was charged 
with 4.70a (12.5 mg, 0.0178 mmol) and 1,3-dimethylbarbituric acid (28 mg, 0.178 mmol) 
and placed under vacuum and backfilled with N2 three times. THF (0.2 mL) was then 
added to both flasks, and the mixtures were stirred at room temperature under N2 for 5 
min. An aliquot of the Pd/ligand mixture (20 µL) was added via syringe to the flask 
containing 4.70a, and stirring was continued at room temperature until 4.70a was gone by 
TLC. The reaction was quenched with saturated aq NaHCO3 (0.1 mL) and stirred at room 
temperature for 15 min. The reaction mixture was diluted with H2O (0.5 mL) extracted 
with CH2Cl2 (3 x 10 mL). The combined organic extracts were washed with brine (10 
mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a brown oil. 
Subsequent purification by flash chromatography eluting with CH2Cl2 : MeOH (98 : 2) 
containing 1% NEt3 provided 9 mg (82%) of 4.71a as a white solid: 1H-NMR (500 MHz, 









7.13 (comp, 3 H) 7.09-7.07 (comp, 2 H) 4.75 (d, J = 6.0 Hz, 1 H) 4.55-4.38 (comp, 7 H) 
4.32 (d, J = 10.0 Hz, 1 H) 3.65 (d, J = 9.5 Hz, 1 H) 2.84 (m, 1 H) 2.77 (ddd, J = 14.0, 9.0, 
7.0 Hz, 1 H) 2.59 (dd, J = 13.5, 5.5 Hz, 1 H) 2.46 (td, J = 13.5, 4.0 Hz, 1 H) 2.12 (dd, J = 
13.0, 10.0 Hz, 1 H) 2.02 (dm, J = 14.5 Hz, 1 H) 1.76 (m, 1 H) 1.54 (s, 9 H); 13C-NMR 
(125 MHz, CD3OD) δ 152.3, 141.3, 139.6, 139.5, 136.3, 129.9, 129.3, 129.1, 129.0, 
128.8, 128.6, 128.2, 127.7, 125.3, 118.7, 116.4, 86.0, 78.1, 75.6, 75.1, 74.2, 73.6, 54.6, 
51.1, 44.1, 42.3, 41.4, 31.8, 28.2; HRMS (ESI) m/z observed 639.25890 [C36H41ClN2O5 
(M+Na)+ requires 639.25960]. 
 
tert-Butyl (1S/R, 5R/S, 12R/S)-6,6-bis((benzyloxy)methyl)-9-chloro-12-
hydroxy-1,2,3,4,5,6-hexahydro-7H-5,1-ethanoazocino[4,3-b]indole-7-carboxylate. 
(4.71b). (WLM8_198). A round bottom flask charged with Pd2(dba)3 (3.4 mg, 0.00371 
mmol) and 1,4-bis(diphenylphosphino)butane (3.2 mg, 0.00741 mmol) was placed under 
vacuum and backfilled with N2 three times. A second round bottom flask was charged 
with 4.70b (26 mg, 0.0371 mmol) and 1,3-dimethylbarbituric acid (58 mg, 0.371 mmol) 
and placed under vacuum and backfilled with N2 three times. THF (0.35 mL) was then 
added to both flasks, and the mixtures were stirred at room temperature under N2 for 5 
min. An aliquot of the Pd/ligand mixture (35 µL) was added via syringe to the flask 
containing 4.70b, and stirring was continued at room temperature until 4.70b was gone 
by TLC. The reaction was quenched with saturated aq NaHCO3 (1.0 mL) and stirred at 
room temperature for 15 min. The reaction mixture was diluted with H2O (5.0 mL) 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were washed with 









Subsequent purification by RPHPLC eluting with MeCN : H2O (10% MeCN → 90% 
MeCN over 45 min) containing 0.1% TFA provided 18.4 mg (81%) of 4.71b as a white 
solid and 1.5 mg (6%) of 4.71c as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.78 
(dd, J = 1.8, 0.5 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.29 (dd, J = 8.5, 1.8 Hz, 1H), 7.24 
(comp, 5H), 7.16 (comp, 3H), 7.07 (comp, J = 6.7, 2.8, 1.3 Hz, 2H), 5.29 (dd, J = 6.8, 1.1 
Hz, 1H), 4.52 (comp, 4H), 4.43 (comp, 3H), 4.37 (td, J = 9.1, 1.6 Hz, 1H), 3.67 (d, J = 
9.9 Hz, 1H), 2.93 (comp, 3H), 2.69 (td, J = 13.7, 4.5 Hz, 1H), 2.31 (ddd, J = 15.0, 9.5, 
1.3 Hz, 1H), 2.20 (dt, J = 15.8, 5.1 Hz, 1H), 1.97 – 1.86 (m, 1H), 1.60 (s, 9H); 13C-NMR 
(125 MHz, CD3OD) δ 151.7, 142.7, 139.5, 139.1, 137.9, 131.8, 129.3, 129.2, 129.1, 
128.7, 128.5, 127.8, 126.3, 124.0, 120.1, 116.4, 115.3, 87.1, 78.0, 74.5, 74.3, 74.1, 73.7, 
53.9, 51.3, 49.0, 42.0, 38.6, 29.2, 28.2; HRMS (ESI) m/z observed 617.27830 
[C36H41ClN2O5 (M+H)+ requires 617.27770]. 
 
 
tert-Butyl (1S/R, 5R/S, 12R/S)-2-allyl-6,6-bis((benzyloxy)methyl)-9-chloro-12-
hydroxy-1,2,3,4,5,6-hexahydro-7H-5,1-ethanoazocino[4,3-b]indole-7-carboxylate. 
(4.71c). (WLM8_198). 1H-NMR (500 MHz, CD3OD) δ 7.74 (s, 1H), 7.60 (d, J = 8.6 Hz, 
1H), 7.20 (comp, 11H), 6.00 (ddd, J = 17.2, 11.9, 5.5 Hz, 1H), 5.57 (d, J = 10.4 Hz, 1H), 
5.48 (d, J = 17.1 Hz, 1H), 5.27 (d, J = 6.1 Hz, 1H), 4.46 (comp, 8H), 3.98 (dd, J = 13.7, 
6.4 Hz, 1H), 3.66 (d, J = 10.1 Hz, 1H), 3.45 (dd, J = 13.3, 7.7 Hz, 1H), 3.10 (dd, J = 13.2, 
5.5 Hz, 1H), 3.06 – 2.95 (m, 1H), 2.96 – 2.85 (m, 1H), 2.79 (td, J = 14.4, 3.6 Hz, 1H), 
2.26 (comp, 2H), 2.01 – 1.81 (m, 1H), 1.61 (s, 9H); 13C-NMR (125 MHz, CD3OD) δ 









126.3, 124.4, 119.9, 115.5, 113.8, 87.4, 77.6, 74.5, 74.1, 74.1, 73.8, 62.1, 58.5, 53.1, 51.3, 




(1S/R, 5R/S, 12R/S)-allyl 6,6-bis((benzyloxy)methyl)-10-chloro-12-methoxy-7-
methyl-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. 
(4.72a). (WLM7_294_2). A mixture of 4.66a (20 mg, 0.033 mmol) and 60% NaH 
dispersion in mineral oil (13 mg, 0.33 mmol) in DMF (0.3 mL) at 0 °C under N2 was 
stirred for five min and methyl p-toluenesulfonate (31 mg, 0.17 mmol) was added in one 
portion. The reaction was allowed to warm slowly to room temperature overnight. The 
reaction was quenched with saturated aq NH4Cl (0.5 mL), diluted with H2O (0.5 mL), and 
extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were washed with 
brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. 
Purification by flash chromatography eluting with Hexanes : EtOAc (6 : 1) to provide 21 
mg (quant) of 4.72a as a clear oil: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 7.33-7.22 
(comp, 10 H) 7.19-7.12 (comp, 2 H) 7.11 (dd, J = 9.0, 2.0 Hz, 1 H) 6.03 (br, 1 H) 5.58 (d, 
J = 6.5 Hz, 1 H) 5.36 (br, 1 H) 5.22 (br, 1 H) 4.65 (br, 2 H) 4.52-4.47 (comp, 3 H) 4.41 
(d, J = 12.0 Hz, 1 H) 4.38 (d, J = 10.5 Hz, 1 H) 3.98-3.92 (comp, 3 H) 3.82-3.75 (m, 1 H) 
3.82 (s, 3 H) 3.77 (t, J = 8.5 Hz, 1 H) 3.31 (s, 3 H) 3.02-2.97 (comp, 2 H) 2.77 (m, 1 H) 
2.15 (dm, J = 14.5 Hz, 1 H) 1.78-1.70 (m, 2 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 
156.3, 142.7, 140.1, 139.5, 137.5, 135.2, 129.5, 129.5, 129.0, 128.9, 128.8, 128.7, 128.5, 









48.4, 47.1, 42.1, 34.0, 32.6; HRMS (ESI) m/z observed 651.25910 [C37H41ClN2O5 
(M+Na)+ requires 651.25960]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 7.33-7.22 (comp, 10 H) 
7.19-7.12 (comp, 2 H) 7.11 (dd, J = 9.0, 2.0 Hz, 1 H) 6.03 (br, 1 H, C37-H) 5.58 (d, J = 
6.5 Hz, 1 H, C16-H) 5.36 (br, 1 H, C38-H) 5.22 (br, 1 H, C38-H) 4.65 (br, 2 H, C36-H2) 
4.52-4.47 (comp, 3 H, C20-H2 or C28-H2) 4.41 (d, J = 12.0 Hz, 1 H, C20-H or C28-H) 
4.38 (d, J = 10.5 Hz, 1 H, C21-H or C29-H) 3.98-3.92 (comp, 3 H, C21-H2 or C29-H2) 
3.82-3.75 (m, 1 H, C14-H) 3.82 (s, 3 H, C1-H3) 3.77 (t, J = 8.5 Hz, 1 H, C18-H) 3.31 (s, 
3 H, C19-H3) 3.02-2.97 (comp, 2 H, C12-H, C17-H) 2.77 (m, 1 H, C14-H) 2.15 (dm, J = 
14.5 Hz, 1 H, C13-H) 1.78-1.70 (m, 2 H, C13-H, C17-H); 13C-NMR (125 MHz, CD3CN, 
70 °C) δ 156.3 (C15), 142.7, 140.1, 139.5, 137.5, 135.2, 129.5, 129.5, 129.0, 128.9, 
128.8, 128.7, 128.5, 126.0, 122.8 (C7), 117.6 (C5), 117.4, 115.3, 111.8 (C8), 86.3 (C18), 
77.9 (C20 or C28), 75.1 (C20 or C28), 74.2 (C21 or C29), 74.1 (C21 or C29), 66.7 (C36), 











































(1S/R, 5R/S, 12R/S)-allyl 6,6-bis((benzyloxy)methyl)-9-chloro-12-methoxy-7-
methyl-3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. 
(4.72b). (WLM8_85). A mixture of 4.66b (481 mg, 0.80 mmol) and 60% NaH 
dispersion in mineral oil (160 mg, 4.0 mmol) in DMF (8.0 mL) at 0 °C under N2 was 
stirred for five min and methyl p-toluenesulfonate (447 mg, 2.4 mmol) was added in one 
portion. The reaction was allowed to warm slowly to room temperature overnight. The 
reaction was quenched with saturated aq NH4Cl (5.0 mL), diluted with H2O (20 mL), and 
extracted with EtOAc (3 x 40 mL). The combined organic extracts were washed with 
brine (50 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. 
Purification by flash chromatography eluting with hexanes : EtOAc (4 : 1 to 2 : 1) to 
provide 473 mg (94%) of 4.72b as a clear oil: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 
7.34-7.19 (comp, 11 H) 7.18 (dd, J = 7.0, 2.0 Hz, 1 H) 7.02 (dd, J = 8.5, 1.5 Hz, 1 H) 
6.02 (br, 1 H) 5.61 (d, J = 6.5 Hz, 1 H) 5.34 (br, 1 H) 5.22 (br, 1 H) 4.64 (br, 2 H) 4.51 
(d, J = 12.0 Hz, 1 H) 4.49 (app t, J = 12.0 Hz, 2 H) 4.41 (d, J = 11.5 Hz, 1 H) 4.37 (d, J = 
10.5 Hz, 1 H) 3.97 (d, J = 9.5 Hz, 1 H) 3.94 (d, J = 9.5 Hz, 1 H) 3.92 (d, J = 10.5 Hz, 1 
H) 3.80 (s, 3 H) 3.77 (t, J = 10.0 Hz, 2 H) 3.30 (s, 3 H) 3.03-2.97 (comp, 2 H) 2.78 (m, 1 
H) (dm, J = 14.5 Hz, 1 H) 1.80-1.70 (comp, 2 H); 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 
156.3, 142.0, 140.1, 139.4, 139.4, 135.2, 129.5, 129.5, 129.0, 128.9, 128.8, 128.7, 128.5, 
126.2, 120.8, 119.5, 117.4, 115.8, 110.4, 86.3, 77.9, 75.1, 74.2, 74.0, 66.6, 57.5, 50.7, 
48.4, 47.1, 42.1, 38.8, 34.0, 32.7; HRMS (ESI) m/z observed 651.25980 [C37H41ClN2O5 













(WLM8_70). A round bottom flask charged with Pd2(dba)3 (1.1 mg, 0.00121 mmol) and 
1,4-bis(diphenylphosphino)butane (1.0 mg, 0.00242 mmol) was placed under vacuum 
and backfilled with N2 three times. A second round bottom flask was charged with 4.72a 
(76 mg, 0.121 mmol) and 1,3-dimethylbarbituric acid (189 mg, 0.121 mmol) and placed 
under vacuum and backfilled with N2 three times. THF (0.6 mL) was then added to both 
flasks, and the mixtures were stirred at room temperature under N2 for 5 min. The 
Pd/ligand mixture was added via syringe to the flask containing 4.72a, and stirring was 
continued at room temperature until 4.72a was gone by TLC. The reaction was quenched 
with saturated aq NaHCO3 (1.0 mL) and stirred at room temperature for 15 min. The 
reaction mixture was diluted with H2O (5.0 mL) extracted with CH2Cl2 (3 x 15 mL). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (98 : 2) containing 1% NEt3 provided 58 
mg (88%) of 4.73a as a white solid: 1H-NMR (600 MHz, CD3OD) δ 7.56 (d, J = 1.8 Hz, 
1 H) 7.36 (d, J = 9.0 Hz, 1 H) 7.31-7.30 (comp, 3 H) 7.28-7.26 (m, 1 H) 7.21-7.20 (comp, 
3 H) 7.18 (dd, J = 10.8, 2.4 Hz, 1 H) 7.12-7.10 (comp, 2 H) 5.21 (dd, J = 6.0, 1.5 Hz, 1 
H) 4.55 (d, J = 12.0 Hz, 1 H) 4.51 (comp, 2 H) 4.48 (d, J = 10.8 Hz, 1 H) 4.41 (d, J = 
12.0 Hz, 1 H) 4.01 (d, J = 9.0 Hz, 1 H) 3.88 (d, J = 9.0 Hz, 1 H) 3.86 (d, J = 10.8 Hz, 1 
H) 3.85 (td, J = 7.8, 1.8 Hz, 1 H) 3.80 (s, 3 H) 3.39 (s, 3 H) 3.16 (m, 1 H) 3.00-2.91 









13C-NMR (150 MHz, CD3OD) δ 143.3, 139.6, 138.9, 137.6, 129.4, 129.4, 128.9, 128.9, 
128.8, 128.7, 128.0, 127.0, 123.7, 117.7, 111.8, 109.3, 85.2, 78.6, 74.2, 74.2, 73.9, 57.9, 
50.6, 49.6, 45.6, 41.9, 38.2, 33.4, 29.3; HRMS (ESI) m/z observed 567.23740 
[C33H37ClN2O3 (M+Na)+ requires 567.23850]. 
 
 
Assignments: 1H-NMR (600 MHz, CD3OD) δ 7.56 (d, J = 1.8 Hz, 1 H, C5-H) 
7.36 (d, J = 9.0 Hz, 1 H, C8-H) 7.31-7.30 (comp, 3 H) 7.28-7.26 (m, 1 H) 7.21-7.20 
(comp, 3 H) 7.18 (dd, J = 10.8, 2.4 Hz, 1 H, C7-H) 7.12-7.10 (comp, 2 H) 5.21 (dd, J = 
6.0, 1.5 Hz, 1 H, C16-H) 4.55 (d, J = 12.0 Hz, 1 H, C21-H or C29-H) 4.51 (comp, 2 H, 
C21-H2 or C29-H2) 4.48 (d, J = 10.8 Hz, 1 H, C20-H or C28-H) 4.41 (d, J = 12.0 Hz, 1 
H, C21-H or C29-H) 4.01 (d, J = 9.0 Hz, 1 H, C20-H or C28-H) 3.88 (d, J = 9.0 Hz, 1 H, 
C20-H or C28-H) 3.86 (d, J = 10.8 Hz, 1 H, C20-H or C28-H) 3.85 (td, J = 7.8, 1.8 Hz, 1 
H, C18-H) 3.80 (s, 3 H, C1-H3) 3.39 (s, 3 H, C19-H3) 3.16 (m, 1 H, C12-H) 3.00-2.91 
(comp, 3 H, C14-H2, C17-H) 2.38 (dm, J = 15.6 Hz, 1 H, C13-H) 2.09 (dd, J = 14.4, 9.0 
Hz, 1 H, C17-H) 1.86 (m, 1 H, C13-H); 13C-NMR (150 MHz, CD3OD) δ 143.3 (C2), 
139.6 (C22 or C30), 138.9 (C22 or C30), 137.6 (C9), 129.4, 129.4, 128.9, 128.9, 128.8, 
128.7, 128.0 (C4), 127.0 (C6), 123.7 (C7), 117.7 (C5), 111.8 (C8), 109.3 (C3), 85.2 
(C18), 78.6 (C20 or C28), 74.2 (C21 or C29), 74.2 (C20 or C28), 73.9 (C21 or C29), 57.9 






































(WLM8_89). A round bottom flask charged with Pd2(dba)3 (1.6 mg, 0.00175 mmol) and 
1,4-bis(diphenylphosphino)butane (1.5 mg, 0.0035 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.72b (110 
mg, 0.175 mmol) and 1,3-dimethylbarbituric acid (273 mg, 1.75 mmol) and placed under 
vacuum and backfilled with N2 three times. THF (0.8 mL) was then added to both flasks, 
and the mixtures were stirred at room temperature under N2 for 5 min. The Pd/ligand 
mixture was added via syringe to the flask containing 4.72b, and stirring was continued at 
room temperature until 4.72b was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (20 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (20 mL) extracted with CH2Cl2 (3 x 20 mL). The combined 
organic extracts were washed with brine (30 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (99 : 1) containing 1% NEt3 provided 63 
mg (66%) of 4.73b as a white solid: 1H-NMR (500 MHz, CD3CN) δ 7.40 (d, J = 9.0 Hz, 
1 H) 7.32-7.16 (comp, 11 H) 6.97 (dd, J = 8.5, 2.0 Hz, 1 H) 4.57 (d, J = 6.0 Hz, 1 H) 4.48 
(d, J = 12.0 Hz, 1 H) 4.46 (comp, 2 H) 4.37 (d, J = 12.0 Hz, 1 H) 4.34 (d, J = 10.5 Hz, 1 
H) 3.96 (td, 1 H) 3.91 (d, J = 9.0 Hz, 1 H) 3.86 (d, J = 7.0 Hz, 1 H) 3.84 (d, J = 6.0 Hz, 1 
H) 3.76 (s, 3 H) 3.29 (s, 3 H) 2.90 (m, 1 H) 2.68 (ddd, J = 13.0, 8.5, 6.5 Hz, 1 H) 2.51-









13C-NMR (125 MHz, CD3CN) δ 140.7, 139.8, 139.3, 139.0, 129.2, 129.2, 128.7, 128.6, 
128.5, 128.4, 127.5, 126.0, 119.8, 119.6, 116.6, 109.8, 84.5, 78.1, 75.1, 73.8, 73.5, 57.2, 
50.1, 48.0, 46.5, 42.6, 42.1, 33.4, 33.3; HRMS (ESI) m/z observed 567.23900 





(WLM8_71). A mixture of 4.73a (58 mg, 0.106 mmol) and 37% aq formaldehyde 
solution (32 mg, 1.06 mmol, 86 µL) in CH2Cl2 (1.0 mL) was stirred for 5 min at room 
temperature and sodium triacetoxyborohydride (113 mg, 0.532 mmol) was added in one 
portion. Stirring was continued for 4 h at room temperature. The reaction was quenched 
with saturated aq Rochelle’s salt (0.5 mL) and extracted with CH2Cl2 (3 x 20 mL). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (98 : 2) containing 1% NEt3 afforded 56 
mg (94%) of 4.74a as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.45 (d, J = 2.0 Hz, 1 
H) 7.29-7.18 (comp, 9 H) 7.15-7.13 (comp, 2 H) 7.06 (dd, J = 9.0, 2.0 Hz, 1 H) 4.49 (d, J 
= 7.0 Hz, 1 H) 4.48 (app t, 2 H) 4.34-4.31 (comp, 2 H) 4.28 (d, J = 5.0 Hz, 1 H) 3.91 (d, J 
= 9.0 Hz, 1 H) 3.89 (td, J = 9.0, 2.0 Hz, 1 H) 3.83 (d, J = 10.5 Hz, 1 H) 3.77 (d, J = 9.0 
Hz, 1 H) 3.72 (s, 3 H) 3.32 (s, 3 H) 2.95 (m, 1 H) 2.82 (ddd, J = 14.0, 9.0, 6.5 Hz, 1 H) 
2.41 (td, J = 13.0, 4.0 Hz, 1 H) 2.35 (s, 3 H) 2.32 (dd, J = 13.0, 5.0 Hz, 1 H) 2.14 (dm, J 









139.2, 137.5, 130.3, 129.3, 129.3, 128.7, 128.7, 128.6, 128.6, 126.0, 122.5, 118.3, 112.7, 
111.2, 86.5, 78.6, 75.0, 74.1, 73.8, 57.4, 56.7, 52.5, 50.5, 47.8, 45.8, 40.5, 33.3, 31.7; 





(WLM8_90). A mixture of 4.73b (44 mg, 0.0807 mmol) and 37% aq formaldehyde 
solution (24 mg, 0.807 mmol, 65 µL) in CH2Cl2 (0.8 mL) was stirred for 5 min at room 
temperature and sodium triacetoxyborohydride (86 mg, 0.404 mmol) was added in one 
portion. Stirring was continued for 4 h at room temperature. The reaction was quenched 
with saturated aq Rochelle’s salt (0.5 mL) and extracted with CH2Cl2 (3 x 15 mL). The 
combined organic extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford 27 mg (60%) of 4.74b as a white solid: 1H-NMR (500 
MHz, CD3CN) δ 7.42 (d, J = 6.5 Hz, 1 H) 7.32-7.16 (comp, 11H) 7.00 (dd, J = 8.5, 2.0 
Hz, 1 H) 4.48-4.43 (comp, 3 H) 4.37 (d, J = 7.0 Hz, 1 H) 4.35 (d, J = 8.5 Hz, 1 H) 4.32 
(d, J = 5.5 Hz, 1 H) 3.92 (td, J = 10.0, 1.5 Hz, 1 H) 3.92 (d, J = 9.0 Hz, 1 H) 3.80 (d, J = 
10.0 Hz, 2 H) 3.75 (s, 3 H) 3.29 (s, 3 H) 2.92 (m, 1 H) 2.83 (ddd, J = 13.5, 9.0, 6.5 Hz, 1 
H) 2.38 (dd, J = 6.5, 1.5 Hz, 1 H) 2.35 (s, 3 H) 2.31 (td, J = 13.0, 4.0 Hz, 1 H) 2.11 (dm, J 
= 6.5 Hz, 1 H) 1.80 (m, 1 H) 1.69 (ddd, J = 13.5, 9.0, 1.5 Hz, 1 H); 13C-NMR (500 MHz, 
CD3CN) δ 141.0, 139.7, 139.0, 138.8, 129.3, 129.2, 128.9, 128.6, 128.6, 128.4, 127.7, 















(WLM8_190). A round bottom flask charged with Pd(PPh3)4 (1.1 mg, 0.000935 mmol) 
and 4.72a (12 mg, 0.19 mmol) was placed under vacuum and backfilled with N2 three 
times. THF (0.2 mL) was added and the mixture was stirred at room temperature over 
night. The reaction mixture was diluted with H2O (5.0 mL) and extracted with CH2Cl2 (3 
x 15 mL). The combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4), filtered, and concentrated in vacuo to afford a brown oil. Subsequent 
purification by RP HPLC H2O : MeCN (10% MeCN → 95% MeCN over 60 min) 
provided 4.9 mg (44%) of 4.75a as a white solid: 1H-NMR (500 MHz, CD3CN) δ 7.52 (d, 
J = 2.0 Hz, 1H), 7.32 (comp, 10H), 7.20 (dd, J = 8.8, 2.0 Hz, 1H), 7.18 – 7.12 (m, 2H), 
6.11 (ddt, J = 17.2, 10.6, 6.8 Hz, 1H), 5.49 (d, J = 10.5 Hz, 1H), 5.39 (d, J = 17.2 Hz, 
1H), 4.97 (d, J = 6.0 Hz, 1H), 4.49 (comp, 3H), 4.40 (d, J = 11.7 Hz, 1H), 4.00 (comp, J 
= 9.2 Hz, 2H), 3.83 (comp, 6H), 3.46 – 3.34 (m, 1H), 3.32 (s, 3H), 3.14 (comp, 3H), 2.90 
– 2.76 (m, 1H), 2.37 – 2.28 (m, 1H), 2.11 – 2.04 (m, 1H), 2.05 – 1.97 (m, 1H); 13C NMR 
(125 MHz, CD3CN) δ 144.0, 139.5, 138.7, 137.0, 129.6, 129.4, 129.3, 129.0, 129.0, 
128.8, 128.7, 128.5, 126.7, 124.5, 123.2, 117.5, 112.2, 107.9, 84.3, 78.5, 74.2, 74.0, 73.5, 
61.2, 57.8, 57.6, 55.3, 50.2, 44.6, 37.6, 33.8, 28.8; HRMS (ESI) m/z observed 585.28740 













(WLM8_88). A round bottom flask charged with Pd(PPh3)4 (1.2 mg, 0.00098 mmol) and 
4.72b (31 mg, 0.049 mmol) was placed under vacuum and backfilled with N2 three times. 
THF (0.5 mL) was added and the mixture was stirred at room temperature over night. 
The reaction mixture was diluted with H2O (5.0 mL) and extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a brown oil. Subsequent purification by 
PTLC eluting with CH2Cl2 : MeOH (99 : 1) containing 1% NEt3 provided 8.1 mg (28%) 
of 4.75b as a white solid: 1H-NMR (500 MHz, CD3CD) δ 7.45-7.44 (comp, 2 H) 7.36-
7.23 (comp, 8 H) 7.15-7.12 (comp, 3 H) 6.06 (m, 1 H) 5.47 (d, J = 10.0 Hz, 1 H) 5.39 (d, 
J = 18.0 Hz, 1 H) 5.01 (d, J = 5.0 Hz, 1 H) 4.51-4.44 (comp, 4 H) 4.39 (d, J = 11.5 Hz, 1 
H) 3.99 (d, J = 9.0 Hz, 1 H) 3.96 (td, J = 9.0, 2.0 Hz, 1 H) 3.83 (d, J = 9.0 Hz, 1 H) 3.79 
(s, 3 H) 3.79-3.77 (comp, 2 H) 3.36 (m, 1 H) 3.32 (s, 3 H) 3.16-3.07 (comp, 3 H) 2.78 (m, 
1H) 2.31 (dm, J = 16.0 Hz, 1 H) 2.02-1.97 (comp, 2 H); 13C-NMR (500 MHz, CD3CD) δ 
143.4, 139.5, 139.0, 138.6, 129.4, 129.3, 129.2, 129.0, 128.8, 128.8, 128.7, 128.5, 126.6, 
124.9, 121.7, 119.4, 110.7, 108.2, 84.2, 78.4, 74.1, 74.0, 73.5, 61.3, 57.9, 57.8, 50.2, 50.1, 














(WLM8_205). A screw top vial charged with Pd(OAc)2 (3.5 mg, 0.0156 mmol) and 
SPhos (16 mg, 0.0390 mmol) was placed under vacuum and backfilled with N2 three 
times, and toluene (0.1 mL) was added to the reaction vial. A second screw top vial 
charged with K3PO4 (7.6 mg, 0.0358 mmol), phenylboronic acid (4.4 mg, 0.0358 mmol), 
and 4.74a (10 mg, 0.0179 mmol) was placed under vacuum and backfilled with N2 three 
times, and toluene (0.15 mL) was added to the second reaction vial. Both vials were 
stirred for 30 min, and an aliquot (5.7 µL) of the Pd/ligand mixture was added to the vial 
containg 4.74a. The reaction was heated to 100 ºC for 24 h. The reaction mixture was 
cooled to rt, diluted with H2O (0.5 mL), and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a black oil. Subsequent purification by flash 
chromatography eluting with Hexanes : EtOAc (1 : 1 → 100% EtOAc) containing 1% 
NEt3 followed by further purification via RPHPLC eluting with MeCN : H2O (10% 
MeCN → 90% MeCN over 60 min) containing 0.1% TFA afforded 3.5 mg (33%) of 
4.76a as a white solid: 1H-NMR (600 MHz, CD3CN) δ 7.77 – 7.73 (m, 1H), 7.67 (comp, 
2H), 7.51 (dd, J = 8.6, 1.7 Hz, 1H), 7.44 (comp, 2H), 7.31 (comp, 10H), 7.17 (comp, 2H), 
5.07 (d, J = 6.0 Hz, 1H), 4.50 (comp, 4H), 4.41 (d, J = 11.7 Hz, 1H), 4.03 (d, J = 9.1 Hz, 
1H), 3.97 (td, J = 9.0, 1.5 Hz, 1H), 3.88 (d, J = 9.1 Hz, 1H), 3.85 (s, 3H), 3.80 (d, J = 
10.8 Hz, 1H), 3.33 (s, 3H), 3.17 (ddd, J = 15.2, 9.3, 6.2 Hz, 1H), 3.13 – 3.06 (m, 1H), 








MHz, CD3CN) δ 141.8, 141.8, 138.6, 137.7, 137.2, 133.6, 128.8, 128.4, 128.3, 128.0, 
127.8, 127.6, 127.5, 127.5, 127.1, 126.6, 121.8, 115.4, 110.1, 110.0, 83.4, 77.6, 73.3, 
73.0, 72.4, 58.2, 56.8, 51.5, 49.1, 45.1, 43.5, 36.4, 32.6, 28.1; HRMS (ESI) m/z observed 





b]indole. (4.76b). (WLM8_206). A screw top vial charged with Pd(OAc)2 (3.5 mg, 
0.0156 mmol) and SPhos (16 mg, 0.0390 mmol) was placed under vacuum and backfilled 
with N2 three times, and toluene (0.1 mL) was added to the reaction vial. A second screw 
top vial charged with K3PO4 (5.6 mg, 0.0264 mmol), 4-(trifluoromethyl)phenylboronic 
acid (5.0 mg, 0.0264 mmol), and 4.74a (7.4 mg, 0.0132 mmol) was placed under vacuum 
and backfilled with N2 three times, and toluene (0.13 mL) was added to the second 
reaction vial. Both vials were stirred for 30 min, and an aliquot (4.3 µL) of the Pd/ligand 
mixture was added to the vial containg 4.74a. The reaction was heated to 100 ºC for 24 h. 
The reaction mixture was cooled to rt, diluted with H2O (0.5 mL), and extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to afford a black oil. Subsequent 
purification by flash chromatography eluting with Hexanes : EtOAc (1 : 1 → 100% 
EtOAc) containing 1% NEt3 followed by further purification via RPHPLC eluting with 
MeCN : H2O (10% MeCN → 90% MeCN over 60 min) containing 0.1% TFA afforded 








3H), 7.73 (d, J = 8.1 Hz, 2H), 7.61 (dd, J = 8.6, 1.7 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 
7.26 (comp, 10H), 5.30 (d, J = 5.8 Hz, 1H), 4.58 (d, J = 11.6 Hz, 1H), 4.53 (comp, 3H), 
4.43 (d, J = 11.7 Hz, 1H), 4.08 (d, J = 7.0 Hz, 1H), 3.88 (comp, 6H), 3.43 (s, 3H), 3.29 – 
3.21 (m, 1H), 3.14 (comp, 3H), 2.89 (s, 3H), 2.47 – 2.30 (m, 1H), 2.15 (dd, J = 15.1, 8.5 
Hz, 1H), 2.02 – 1.85 (m, 1H); HRMS (ESI) m/z observed 669.32930 [C41H43F3N2O3 




(4.78). (WLM8_131). A solution of n-BuLi (1.86 mL of 2.5 M solution in hexanes, 4.66 
mmol) was added dropwise to a solution of 4.77 (500 mg, 4.23 mmol) in dry THF (18 
mL) at –78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed through a 
short column of anhydrous CaSO4) was bubbled through the reaction for 15 min. The 
reaction was stirred for 15 min, the bath was removed, and the reaction was stirred for 1 h 
at room temperature. Excess CO2 was removed via freeze-pump-thaw (3 cycles), and the 
reaction was evacuated for 30 sec, and then sparged with N2 for 30 min. The reaction was 
cooled to –78 °C, whereupon t-BuLi (2.59 mL of 1.8 M solution in pentane, 4.66 mmol) 
was added dropwise. The reaction was stirred for 2 h and transferred via cannula to a 
solution of 3.17 (1.26 g, 4.66 mmol) in dry THF (18 mL) at –78 ºC. The reaction was 
stirred for 3.5 h, freshly distilled acetic anhydride (1.295 g, 12.69 mmol, 1.2 mL) was 
added dropwise, and the reaction was allowed to warm to room temperature over 7 h. 
Saturated aq NaHCO3 (10 mL) was added, and the reaction was stirred for 30 min, 
whereupon brine (20 mL) and CH2Cl2 (40 mL) were added. The layers were separated, 






layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
resulting yellow oil was purified by flash chromatography eluting with Hexanes : EtOAc 
(4 : 1 → 2 : 1 → 100% EtOAc) containing 1% NEt3 to give 767 mg (42%) of 4.78 as a 
white solid: 1H-NMR (500 MHz, CD2Cl2) δ 12.92 (br, 1 H) 8.42 (td, J = 3.0, 1.5 Hz, 1 H) 
8.00 (dd, J = 8.0, 1.0 Hz, 1 H) 7.14 (dd, J = 4.0, 2.0 Hz, 1 H) 7.33-7.26 (comp, 10 H) 
6.55 (d, J = 2.0 Hz, 1 H) 4.63 (app s, 4 H) 4.40 (d, J = 9.0 Hz, 2 H) 4.35 (d, J = 9.0 Hz, 2 
H) 2.05 (s, 3 H); 13C-NMR (125 MHz, CD2Cl2) δ 169.8, 149.2, 142.6, 138.7, 138.4, 
129.3, 128.6, 128.1, 128.0, 121.1, 116.1, 98.6, 80.8, 74.0, 70.5, 22.0; HRMS (ESI) m/z 





(4.79). (WLMX_258). A solution of TMS-OTf (83 mg, 0.372 mmol, 67 µL) in dry 
CH2Cl2 (0.3 mL) was added dropwise to a solution of 3.10 (29 mg, 0.0818 mmol), 4.78 
(32 mg, 0.0734 mmol), and 2,6-di(tert-butyl)-4-methylpyridine (92 mg, 0.446 mmol) in 
dry CH2Cl2 (0.5 mL) at –78 ºC. The reaction was stirred for 3 h at –78 ºC, whereupon a 
solution of TBAF•3H2O (152 mg, 0.483 mmol) in CH2Cl2 (0.5 mL) was added dropwise. 
The bath was removed, and the reaction was stirred at room temperature for 1 h. 
Saturated aq NaHCO3 (0.5 mL) was added, and the layers were separated. The aqueous 
layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were 
washed with brine (15 mL), dried (Na2SO4), filtered, and concentrated under reduced 







Hexanes : EtOAc (4 : 1 → 1 : 1) containing 1% NEt3 to afford 33 mg (78 %) of 4.79 as a 
yellow foam: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.89 (br, 1H), 8.29 (dd, J = 4.7, 1.5 
Hz, 1H), 7.90 (dd, J = 8.0, 1.3 Hz, 1H), 7.40 (comp, 5H), 7.29 (comp, 3H), 7.26 – 7.18 
(m, 2H), 7.14 (dd, J = 7.9, 4.7 Hz, 1H), 6.05 (br, 1H), 5.86 (t, J = 3.6 Hz, 1H), 5.36 (d, J 
= 17.5 Hz, 1H), 5.26 (d, J = 10.7 Hz, 1H), 4.67 (comp, 4H), 4.45 (d, J = 11.9 Hz, 1H), 
4.40 (d, J = 11.8 Hz, 1H), 4.10 (dd, J = 9.4, 1.4 Hz, 1H), 3.98 (d, J = 14.8 Hz, 1H), 3.88 
(d, J = 9.4 Hz, 1H), 3.84 (d, J = 9.4 Hz, 1H), 3.75 (d, J = 9.4 Hz, 1H), 3.18 (dd, J = 5.9, 
2.9 Hz, 1H), 3.10 (comp, 2H), 2.95 (dd, J = 18.7, 3.0 Hz, 1H), 2.18 – 2.08 (m, 1H), 1.85 
(dddd, J = 15.6, 13.2, 4.8, 2.9 Hz, 1H). 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 211.9, 
156.5, 149.7, 145.3, 140.6, 139.9, 139.8, 135.3, 130.2, 129.9, 129.6, 129.5, 129.4, 129.3, 
127.4, 120.6, 118.2, 117.8, 110.6, 76.6, 75.2, 74.9, 74.0, 67.5, 59.1, 50.6, 47.3, 46.5, 41.4, 
29.4. HRMS (ESI) m/z observed 566.26440 [C34H35N3O5 (M+H)+ requires 566.26490]. 
 
Assigments: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.89 (br, 1H, N1-H), 8.29 
(dd, J = 4.7, 1.5 Hz, 1H, C7-H), 7.90 (dd, J = 8.0, 1.3 Hz, 1H, C5-H), 7.40 (comp, 5H, 
C24-H, C25-H, C26-H, C27-H, C28-H, C29-H, C30-H, C31-H, C32-H, or C33-H), 7.29 
(comp, 3H, C24-H, C25-H, C26-H, C27-H, C28-H, C29-H, C30-H, C31-H, C32-H, or 
C33-H), 7.26 – 7.18 (m, 2H, C24-H, C25-H, C26-H, C27-H, C28-H, C29-H, C30-H, 










































5.86 (t, J = 3.6 Hz, 1H, C14-H), 5.36 (d, J = 17.5 Hz, 1H, C36-H), 5.26 (d, J = 10.7 Hz, 
1H, C36-H), 4.67 (comp, 4H, C34-H2 and C20-H2 or C21-H2), 4.45 (d, J = 11.9 Hz, 1H, 
C20-H or C21-H), 4.40 (d, J = 11.8 Hz, 1H, C20-H or C21-H), 4.10 (dd, J = 9.4, 1.4 Hz, 
1H, C18-H or C19-H), 3.98 (d, J = 14.8 Hz, 1H, C16-H), 3.88 (d, J = 9.4 Hz, 1H, C18-H 
or C19-H), 3.84 (d, J = 9.4 Hz, 1H, C18-H or C19-H), 3.75 (d, J = 9.4 Hz, 1H, C18-H or 
C19-H), 3.18 (dd, J = 5.9, 2.9 Hz, 1H, C11-H), 3.10 (comp, 2H, C13-H and C16-H), 2.95 
(dd, J = 18.7, 3.0 Hz, 1H, C13-H), 2.18 – 2.08 (m, 1H, C17-H), 1.85 (dddd, J = 15.6, 
13.2, 4.8, 2.9 Hz, 1H, C17-H). 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 211.9 (C12), 156.5 
(C15), 149.7 (C9), 145.3 (C7), 140.6 (C2), 139.9 (C22 or C23), 139.8 (C22 or C23), 
135.3 (C35), 130.2 (C26 and C30 or C27 and C31), 129.9 (C26 and C30 or C27 and 
C31), 129.6 (C25 and C33 or C24 and C32), 129.5 (C28 or C29), 129.4 (C25 and C33 or 
C24 and C32), 129.3 (C28 or C29), 127.4 (C5), 120.6 (C4), 118.2 (C36), 117.8 (C6), 
110.6 (C3), 76.6 (C), 75.2 (C), 74.9 (C), 74.0 (C), 67.5 (C34), 59.1 (C11), 50.6 (C13), 
47.3 (C10), 46.5 (C14), 41.4 (C16), 29.4 (C17). 
 
 
Allyl (5S/R, 9R/S, 12R/S)-10,10-bis((benzyloxy)methyl)-12-hydroxy-
5,7,8,9,10,11-hexahydro-6H-9,5-ethanopyrido[3',2':4,5]pyrrolo[3,2-c]azocine-6-
carboxylate. (4.82). (WLM8_269). Lithium borohydride (24 mg, 1.092 mmol) was 
added to a solution of 4.79 (155 mg, 0.273 mmol) in dry MeOH (2.7 mL) at 0 ºC. After 4 
h, saturated aq Rochelle’s salt (1.0 mL) was added, and the reaction was stirred for 5 min. 
the reaction mixture was extracted with CH2Cl2 (3 x 20 mL), washed with brine (30 mL), 







purification by flash chromatography eluting with Hexanes : EtOAc (2:1 → 1:1) afforded 
50 mg (32%) of 4.82 as a white solid: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.72 (br, 
1H), 8.20 (dd, J = 4.7, 0.9 Hz, 1H), 7.77 (dd, J = 7.9, 1.0 Hz, 1H), 7.33 (comp, 13H), 
7.05 (ddd, J = 7.8, 4.7, 0.7 Hz, 1H), 6.03 (br, 1H), 5.58 (d, J = 6.6 Hz, 1H), 5.35 (d, J = 
17.9 Hz, 1H), 5.24 (d, J = 8.2 Hz, 1H), 4.64 (comp, 4H), 4.52 (d, J = 12.2 Hz, 1H), 4.50 
(d, J = 12.1 Hz, 1H), 4.29 (t, J = 9.3 Hz, 1H), 4.13 (d, J = 9.1 Hz, 1H), 4.10 (d, J = 9.6 
Hz, 1H), 4.04 (d, J = 9.5 Hz, 1H), 3.83 (d, J = 16.2 Hz, 1H), 3.76 (d, J = 9.2 Hz, 1H), 
2.99 (dt, J = 14.8, 7.5 Hz, 1H), 2.72 (t, J = 14.2 Hz, 1H), 2.62 (m, 1H), 1.89 (comp, 2H), 
1.84 – 1.73 (m, 1H); 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 156.3, 149.2, 144.2, 139.8, 
139.7, 135.2, 129.7, 129.5, 129.1, 129.0, 128.9, 128.7, 126.5, 119.8, 117.4, 117.1, 112.4, 
76.0, 74.7, 74.5, 74.3, 74.3, 66.7, 48.4, 48.2, 48.1, 41.7, 41.7, 31.3; HRMS (ESI) m/z 




5H-9,5-ethanopyrido[3',2':4,5]pyrrolo[3,2-c]azocin-12-ol. (4.83a). (WLM8_271). A 
round bottom flask charged with Pd2(dba)3 (2.4 mg, 0.00264 mmol) and 1,4-
bis(diphenylphosphino)butane (2.3 mg, 0.00528 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.82 (15 
mg, 0.0264 mmol) and 1,3-dimethylbarbituric acid (21 mg, 0.132 mmol) and placed 
under vacuum and backfilled with N2 three times. THF (.25 mL) was then added to both 
flasks, and the mixtures were stirred at room temperature under N2 for 5 min. An aliquot 







stirring was continued at room temperature until 4.82 was gone by TLC. The reaction 
was quenched with saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 
min. The reaction mixture was diluted with H2O (0.5 mL) extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a brown oil. Subsequent purification by 
RPHPLC eluting with MeCN : H2O (10% MeCN → 90% MeCN) containing 0.1% TFA 
provided 4.9 mg (38%) of 4.83a as a white solid and 1.6 mg (12%) of 4.83b: 1H-NMR 
(500 MHz, CD3OD) δ 8.27 (br, 1H), 8.06 (dd, J = 8.0, 1.4 Hz, 1H), 7.27 (comp, 11H), 
5.22 (dd, J = 6.5, 1.6 Hz, 1H), 4.63 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.5 Hz, 1H), 4.53 
(d, J = 12.1 Hz, 1H), 4.49 (d, J = 12.0 Hz, 1H), 4.41 (td, J = 8.9, 2.3 Hz, 1H), 4.19 (d, J = 
9.4 Hz, 1H), 4.05 (d, J = 9.4 Hz, 1H), 4.02 (d, J = 9.4 Hz, 1H), 3.91 (d, J = 9.4 Hz, 1H), 
2.99 (comp, 2H), 2.82 (comp, 2H), 2.34 – 2.26 (m, 1H), 2.13 (ddd, J = 15.0, 8.6, 1.6 Hz, 
1H), 1.99 – 1.86 (m, 1H); 13C-NMR (126 MHz, CD3OD) δ 143.9, 143.1, 139.3, 139.3, 
135.6, 129.4, 129.3, 129.0, 128.9, 128.8, 128.7, 120.9, 117.4, 111.4, 106.7, 74.6, 74.5, 
74.5, 74.4, 74.0, 54.8, 49.3, 47.3, 41.6, 40.1, 28.3; HRMS (ESI) m/z observed 506.24100 




5H-9,5-ethanopyrido[3',2':4,5]pyrrolo[3,2-c]azocin-12-ol. (4.83b). (WLM8_271). 1H-
NMR (600 MHz, CD3OD) δ 8.29 (br, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.25 (comp, 11H), 
6.02 (td, J = 17.1, 7.0 Hz, 1H), 5.58 (d, J = 10.3 Hz, 1H), 5.51 (d, J = 17.1 Hz, 1H), 5.18 







Hz, 1H), 4.49 (d, J = 12.1 Hz, 1H), 4.38 (t, J = 8.7 Hz, 1H), 4.19 (d, J = 9.5 Hz, 1H), 4.05 
(d, J = 9.3 Hz, 1H), 4.02 (d, J = 9.5 Hz, 1H), 3.93 (dd, J = 14.3, 7.4 Hz, 1H), 3.90 (d, J = 
9.5 Hz, 1H), 3.45 (dd, J = 13.6, 7.3 Hz, 1H), 3.20 – 3.11 (m, 1H), 3.01 (ddd, J = 15.2, 
9.2, 6.0 Hz, 1H), 2.92 – 2.82 (m, 1H), 2.82 – 2.75 (m, 1H), 2.35 (d, J = 16.0 Hz, 1H), 
2.14 (dd, J = 15.3, 8.0 Hz, 1H), 1.94 (t, J = 15.3 Hz, 1H); 13C-NMR (150 MHz, CD3OD) 
δ 144.5, 144.0, 139.3, 139.2, 136.1, 129.4, 129.3, 129.0, 129.0, 128.9, 128.7, 128.5, 
127.6, 126.2, 125.8, 117.9, 104.2, 74.8, 74.7, 74.4, 74.3, 74.0, 61.6, 58.8, 50.2, 49.7, 46.5, 
40.2, 28.4; HRMS (ESI) m/z observed 524.29020 [C33H37N3O3 (M+H)+ requires 
524.29080]. 
 
Allyl (1R/S, 5R/S, 6S/R, 8R/S)-7,7-bis((benzyloxy)methyl)-8-hydroxy-3'-oxo-4-
azaspiro[bicyclo[3.2.2]nonane-6,2'-indoline]-4-carboxylate (4.86a). (WLM8_86). 
70% meta-chloroperoxyacetic acid (5 mg, 0.0194 mmol) was added to a solution of 4.12 
(10 mg, 0.0176 mmol) and NaHCO3 (3 mg, 0.0352 mmol) in CH2Cl2 (0.3 mL) at rt. After 
45 min, the reaction was quenched with saturated aq NaHCO3 (2.5 mL) and extracted 
with CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4), filtered and concentrated in vacuo to afford a yellow solid. Subsequent 
purification by flash chromatography eluting with Hexanes : EtOAc (1 : 1) afforded 8 mg 
(80%) of 4.86a as a bright yellow solid: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 7.42 
(comp, 2H), 7.31 (comp, 5H), 7.18 (comp, 3H), 7.02 (comp, 2H), 6.80 (dt, J = 8.3, 0.8 
Hz, 1H), 6.71 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 5.85 (br, 1H), 5.69 (s, 1H), 5.19 (d, J = 17.0 








(comp, 3H), 4.20 (d, J = 11.8 Hz, 1H), 4.15 – 4.12 (m, 1H), 4.11 (d, J = 7.2 Hz, 1H), 4.08 
(d, J = 7.0 Hz, 1H), 3.85 (d, J = 9.4 Hz, 1H), 3.72 (d, J = 9.3 Hz, 1H), 3.69 (d, J = 9.4 Hz, 
1H), 3.14 (ddd, J = 14.2, 12.6, 5.6 Hz, 1H), 2.55 (dt, J = 16.3, 4.2 Hz, 1H), 2.36 (ddd, J = 
16.3, 9.9, 2.3 Hz, 1H), 2.31 – 2.20 (m, 1H), 2.18 (d, J = 7.3 Hz, 1H), 1.73 – 1.64 (m, 1H); 
13C-NMR (125 MHz, CD3CN, 70 ºC) δ 203.5, 161.2, 157.7, 140.3, 140.0, 137.9, 134.5, 
129.4, 129.1, 128.7, 128.6, 128.5, 128.2, 125.1, 121.6, 119.0, 117.8, 113.3, 74.3, 73.2, 
72.2, 72.1, 71.7, 68.0, 67.3, 56.9, 48.8, 42.2, 41.6, 31.1, 26.9. 
 
 
Allyl (1R/S, 5R/S, 6S/R, 8R/S)-7,7-bis((benzyloxy)methyl)-8-((tert-
butyldimethylsilyl)oxy)-3'-oxo-4-azaspiro[bicyclo[3.2.2]nonane-6,2'-indoline]-4-
carboxylate. (4.86b). (WLM8_261). 70% meta-chloroperoxyacetic acid (5.5 mg, 0.0226 
mmol) was added to a solution of 4.13 (14 mg, 0.0206 mmol) in toluene (0.2 mL) at rt. 
After 45 min, the reaction was quenched with saturated aq NaHCO3 (2.5 mL) and 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were washed with 
brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo to afford a yellow 
solid. Subsequent purification by flash chromatography eluting with Hexanes : EtOAc 
















2-(2-methoxypropan-2-yl)-1H-indole. (4.102). (WLM8_42). Silica gel 
imbedded with oxalic acid (570 mg silica prepared via dissolving 1 mmol oxalic acid 
onto 4 g silica gel) was added to a solution of 4.99 (250 mg, 1.43 mmol) in MeOH (14.3 
mL) at room temperature. After 1.5 h, the solvent was removed, and the reaction was 
diluted with CH2Cl2 (25 mL). The solution was washed with water (25 mL), brine (25 
mL), dried (Na2SO4), and concentrated under reduced pressure to afford a yellow oil. 
Subsequent purification by flash chromatography eluting with Hexanes : EtOAc (4 : 1) 
provided 203 mg (75%) of 4.102 as a white solid and 58 mg (23%) of 4.99 as a white 
solid: 1H-NMR (400 MHz, CD3CN) δ 9.32 (br, 1 H) 7.53 (dd, J = 7.2, 2.0 Hz, 1 H) 7.40 
(dd, J = 7.2, 2.0 Hz, 1 H) 7.13 (td, J = 7.2, 1.2 Hz, 1 H) 7.04 (td, J = 7.2, 1.2 Hz, 1 H) 
6.36 (dd, J = 2.2, 1.0 Hz, 1 H) 3.03 (s, 3 H) 1.59 (s, 6 H); 13C-NMR (100 MHz, CD3CN) 
δ 144.2, 137.4, 129.0, 122.4, 121.0, 120.2, 111.9, 100.4, 74.3, 51.0, 26.9. HRMS (CI) m/z 
observed 189.1154 [C12H15NO (M)+ requires 189.1154]. 
 
 
Assignments: 1H-NMR (400 MHz, CD3CN) δ 9.32 (br, 1 H, N1-H) 7.53 (dd, J = 
7.2, 2.0 Hz, 1 H, C5-H) 7.40 (dd, J = 7.2, 2.0 Hz, 1 H, C8-H) 7.13 (td, J = 7.2, 1.2 Hz, 1 
H, C7-H) 7.04 (td, J = 7.2, 1.2 Hz, 1 H, C6-H) 6.36 (dd, J = 2.2, 1.0 Hz, 1 H, C3-H) 3.03 
(s, 3 H, C13-H3) 1.59 (s, 6 H, C11-H3 and C12-H3); 13C-NMR (100 MHz, CD3CN) δ 
144.2, 137.4, 129.0, 122.4 (C7), 121.0 (C5), 120.2 (C6), 111.9 (C8), 100.4 (C3), 74.3 























ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.96). (WLM8_61). A solution of 
TMS-OTf (141 mg, 0.634 mmol, 115 µL) in dry CH2Cl2 (1.0 mL) was added dropwise to 
a solution of 4.99 (50 mg, 0.264 mmol), 3.10 (102 mg, 0.291 mmol), and 2,6-di(tert-
butyl)-4-methylpyridine (190 mg, 0.924 mmol) in a dry CH2Cl2 (1.0 mL) and MeCN (0.4 
mL) mixture at –78 ºC. The reaction was stirred for 4 h at –78 ºC, whereupon a solution 
of TBAF•3H2O (333 mg, 1.06 mmol) in CH2Cl2 (1.0 mL) was added dropwise. The bath 
was removed, and the reaction was stirred at room temperature for 1 h. Saturated aq 
NaHCO3 (5 mL) was added, and the layers were separated. The aqueous layer was 
extracted with CH2Cl2 (3 x 10). The combined organic extracts were washed with brine 
(20 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The resultant 
yellow oil was purified by flash chromatography eluting with Hexanes : EtOAc (5 : 1 to 3 
: 1 to 1 : 1) containing 1% NEt3 to provide 40 mg (43%) of 4.96 as a yellow foam: 1H-
NMR (500 MHz, CD3CN, 70 °C) δ 9.31 (br, 1 H) 7.45 (d, J = 8.0 Hz, 1 H) 7.37 (d, J = 
8.0 Hz, 1 H) 7.13 (td, J = 7.0, 1.0 Hz, 1 H) 7.06 (td, J = 7.5, 1.0 Hz, 1 H) 6.00 (br, 1 H) 
5.83 (t, J = 3.5 Hz, 1 H) 5.30 (br, 1 H) 5.22 (br, 1 H) 4.63 (br, 2 H) 3.96 (d, 14.5 Hz, 1 H) 
3.02 (dd, J = 14.0, 4.0 Hz, 1 H) 3.05 (t, J = 14.5 Hz, 1 H) 2.82 (dd, J = 19.0, 3.5 Hz, 1 H) 
2.68 (dd, J = 6.0, 3.0 Hz, 1 H) 2.14 (dm, J = 15.5 Hz, 1 H) 1.87 (tm, 1 H) 1.53 (s, 3 H) 
1.35 (s, 3 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 213.2, 156.1, 144.8, 136.9, 134.9, 
128.2, 123.0, 120.7, 118.6, 117.6, 111.9, 108.1, 66.9, 65.6, 50.0, 46.1, 40.4, 37.1, 32.2, 









Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.31 (br, 1 H, N1-H) 7.45 
(d, J = 8.0 Hz, 1 H, C5-H) 7.37 (d, J = 8.0 Hz, 1 H, C8-H) 7.13 (td, J = 7.0, 1.0 Hz, 1 H, 
C7-H) 7.06 (td, J = 7.5, 1.0 Hz, 1 H, C6-H) 6.00 (br, 1 H, C21-H) 5.83 (t, J = 3.5 Hz, 1 
H, C16-H) 5.30 (br, 1 H, C22a-H or C22b-H) 5.22 (br, 1 H, C22a-H or C22b-H) 4.63 (br, 2 
H, C15-H2) 3.96 (d, 14.5 Hz, 1 H, C13-H) 3.02 (dd, J = 14.0, 4.0 Hz, 1 H, C17-H) 3.05 (t, 
J = 14.5 Hz, 1 H, C13-H) 2.82 (dd, J = 19.0, 3.5 Hz, 1 H, C17-H) 2.68 (dd, J = 6.0, 3.0 
Hz, 1 H, C11-H) 2.14 (dm, J = 15.5 Hz, 1 H, C12-H) 1.87 (tm, 1 H, C12-H) 1.53 (s, 3 H, 
C19-H3 or C20-H3) 1.35 (s, 3 H, C19-H3 or C20-H3); 13C-NMR (125 MHz, CD3CN, 70 
°C) δ 213.2 (C18), 156.1 (C14), 144.8, 136.9, 134.9, 128.2, 123.0 (C7), 120.7 (C6), 118.6 
(C5), 117.6, 111.9 (C8), 108.1 (C3), 66.9 (C15), 65.6 (C11), 50.0 (C17), 46.1 (C16), 40.4 
(C13), 37.1 (C10), 32.2 (C19 or C20), 28.9 (C12), 28.1 (C19 or C20). 
 
 
(1S/R, 5R/S, 12R/S)-allyl 12-hydroxy-6,6-dimethyl-3,4,5,6-tetrahydro-1H-5,1-
ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.103). (WLM7_300). Lithium 
borohydride (3.6 mg, 0.165 mmol) was added to a solution of 4.96 (29 mg, 0.0823 mmol) 
in dry MeOH (0.8 mL) at 0 ºC. After 14 h, saturated aq Rochelle’s salt (0.5 mL) was 

































CH2Cl2 (3 x 5), washed with brine (10 mL), dried (Na2SO4), filtered, and concentrated 
under reduced pressure. The resulting yellow oil was purified by flash chromatography 
eluting with Hexanes : EtOAc (1 : 1) to give 17 mg (93%) of 4.103 as a white solid: 1H-
NMR (500 MHz, CD3CN, 70 °C) δ 9.12 (br, 1 H) 7.36-7.33 (comp, 2 H) 7.08 (td, J = 8.0, 
1.0 Hz, 1 H) 7.02 (td, J = 8.0, 1.0 Hz, 1 H) 6.03 (br, 1 H) 5.57 (d, J = 6.5 Hz, 1 H) 5.36 
(br, 1 H) 5.23 (br, 1 H) 4.66 (br, 2 H) 4.35 (app t, J = 9.0 Hz, 1 H) 3.80 (d, J = 7.5 Hz, 1 
H) 3.00 (m, 1 H) 2.74-2.68 (comp, 2 H) 2.10 (m, 1 H) 1.97 (m, 1 H) 1.89 (m, 1 H) 1.77 
(m, 1 H) 1.58 (s, 3 H) 1.50 (s, 3 H); 13C-NMR (500 MHz, CD3CN, 70 °C) δ 156.5, 146.7, 
136.8, 135.3, 128.0, 122.3, 120.5, 118.2, 117.3, 111.8, 111.0, 76.3, 66.6, 56.4, 48.4, 41.6, 




Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.12 (br, 1 H, N1-H) 7.36-
7.33 (comp, 2 H, C5-H and C8-H) 7.08 (td, J = 8.0, 1.0 Hz, 1 H, C7-H) 7.02 (td, J = 8.0, 
1.0 Hz, 1 H, C6-H) 6.03 (br, 1 H, C21-H) 5.57 (d, J = 6.5 Hz, 1 H, C16-H) 5.36 (br, 1 H, 
C22-H) 5.23 (br, 1 H, C22-H) 4.66 (br, 2 H, C15-H2) 4.35 (app t, J = 9.0 Hz, 1 H, C18-H) 
3.80 (d, J = 7.5 Hz, 1 H, C13-H) 3.00 (m, 1 H, C17-H) 2.74-2.68 (comp, 2 H, C13-H and 
O23-H) 2.10 (m, 1 H, C11-H) 1.97 (m, 1 H, C12-H) 1.89 (m, 1 H, C17-H) 1.77 (m, 1 H, 
C12-H) 1.58 (s, 3 H, C19-H3 or C20-H3) 1.50 (s, 3 H, C19-H3 or C20-H3); 13C-NMR (500 





























118.2 (C5), 117.3 (C22), 111.8 (C8), 111.0 (C3), 76.3 (C18), 66.6 (C15), 56.4 (C11), 




Allyl (1S/R, 5R/S, 12R/S)-12-methoxy-6,6,7-trimethyl-1,3,4,5,6,7-hexahydro-
2H-5,1-ethanoazocino[4,3-b]indole-2-carboxylate. (4.104). (WLM8_54). A mixture of 
4.103 (27 mg, 0.0762 mmol) and 60% NaH dispersion in mineral oil (30.5 mg, 0.762 
mmol) in DMF (0.75 mL) at 0 °C under N2 was stirred for five min and methyl p-
toluenesulfonate (71 mg, 0.381 mmol) was added in one portion. The reaction was 
allowed to warm slowly to room temperature overnight. The reaction was quenched with 
saturated aq NH4Cl (0.5 mL), diluted with H2O (5.0 mL), and extracted with CH2Cl2 (3 x 
10 mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a clear oil. Purification by flash 
chromatography eluting with Hexanes : EtOAc (4 : 1) to provide 22 mg (76%) of 4.104 
as a clear oil: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 7.37 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 
8.1 Hz, 1H), 7.17 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.06 (ddd, J = 7.9, 7.0, 1.0 Hz, 1H), 
6.05 (br, 1H), 5.64 (d, J = 6.7 Hz, 1H), 5.30 (comp, 2H), 4.67 (br, 2H), 3.89 (s, 3H), 3.83 
(td, J = 9.3, 1.5 Hz, 2H), 3.34 (s, 3H), 3.03 (dt, J = 14.5, 7.6 Hz, 1H), 2.73 (br, 1H), 2.37 
– 2.24 (m, 1H), 2.17 – 2.09 (m, 1H), 1.78 – 1.69 (m, 1H), 1.68 (s, 3H), 1.63 (s, 3H); 13C-
NMR (125 MHz, CD3CN, 70 ºC) δ 156.3, 146.7, 139.3, 135.2, 127.6, 122.6, 120.6, 
118.2, 117.4, 112.5, 110.2, 86.4, 66.6, 57.2, 54.3, 48.5, 41.2, 40.2, 34.1, 31.6, 29.0; 










5,1-ethanoazocino[4,3-b]indole. (4.105). (WLM8_41). A round bottom flask charged 
with Pd2(dba)3 (1.2 mg, 0.0013 mmol) and 1,4-bis(diphenylphosphino)butane (1.1 mg, 
0.0026 mmol) was placed under vacuum and backfilled with N2 three times. A second 
round bottom flask was charged with 4.104 (5 mg, 0.013 mmol) and 1,3-
dimethylbarbituric acid (20 mg, 0.13 mmol) and placed under vacuum and backfilled 
with N2 three times. THF (0.1 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. An aliquot of the Pd/ligand mixture (10 
µL) was added via syringe to the flask containing 4.104, and stirring was continued at 
room temperature until 4.104 was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (0.1 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (0.5 mL) extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with MeCN : H2O (10% MeCN → 90% MeCN) containing 0.1% 
TFA provided 3 mg (77%) of 4.105 as a white solid: 1H-NMR (600 MHz, CD3OD) δ 
7.54 (dt, J = 8.0, 1.0 Hz, 1H), 7.40 (dt, J = 8.3, 0.8 Hz, 1H), 7.22 (ddd, J = 8.3, 7.0, 1.1 
Hz, 1H), 7.13 (ddd, J = 7.9, 7.0, 0.9 Hz, 1H), 5.26 (dd, J = 6.3, 1.8 Hz, 1H), 3.96 (comp, 
4H), 3.41 (s, 3H), 3.03 (comp, 2H), 2.83 (td, J = 13.8, 3.6 Hz, 1H), 2.45 (comp, 2H), 2.16 
(ddd, J = 14.9, 8.6, 1.8 Hz, 1H), 1.94 – 1.82 (m, 1H), 1.74 (s, 3H), 1.68 (s, 3H); 13C-NMR 







52.5, 49.8, 40.8, 40.5, 38.0, 33.8, 30.9, 28.7, 28.5; HRMS (ESI) m/z observed 321.19320 




1H-5,1-ethanoazocino[4,3-b]indole. (4.106). (WLM8_55). A round bottom flask 
charged with Pd(PPh3)4 (3.3 mg, 0.00288 mmol) and 4.104 (22 mg, 0.0575 mmol) was 
placed under vacuum and backfilled with N2 three times. THF (0.5 mL) was added and 
the mixture was stirred at room temperature over night. The reaction mixture was diluted 
with H2O (5.0 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a brown oil. Subsequent purification by RP HPLC H2O : MeCN (10% 
MeCN → 95% MeCN over 60 min) provided 5.3 mg (27%) of 4.106 as a white solid: 1H-
NMR (600 MHz, CDCl3) δ 7.49 (dt, J = 7.9, 1.0 Hz, 1H), 7.26 (dt, J = 8.2, 0.9 Hz, 1H), 
7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.09 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.13 – 5.95 (m, 
1H), 5.31 (dq, J = 17.4, 1.9 Hz, 1H), 5.22 (dq, J = 10.3, 1.6 Hz, 1H), 4.41 (d, J = 6.4 Hz, 
1H), 4.03 (td, J = 9.0, 2.0 Hz, 1H), 3.89 (s, 3H), 3.36 (s, 3H), 3.31 (dd, J = 14.4, 6.5 Hz, 
1H), 3.06 (dd, J = 13.9, 5.1 Hz, 1H), 2.90 – 2.73 (m, 1H), 2.57 – 2.42 (m, 1H), 2.29 (td, J 
= 13.0, 3.8 Hz, 1H), 2.22 – 2.16 (m, 1H), 2.17 – 2.09 (m, 1H), 1.83 (ddd, J = 13.5, 9.0, 
1.5 Hz, 2H), 1.64 (s, 3H), 1.58 (s, 3H); 13C-NMR (150 MHz, CDCl3) δ 144.9, 137.9, 
137.7, 128.3, 121.2, 119.3, 118.3, 116.8, 109.9, 108.6, 85.6, 77.4, 77.2, 76.9, 62.1, 56.7, 
56.1, 52.9, 49.2, 40.3, 39.3, 33.3, 31.5, 31.5, 28.7; HRMS (ESI) m/z observed 339.24340 










Dimethylmethanamine. (4.107). (WLM9_83). Zinc chloride (4.7 mg, 0.0343 mmol) 
was added to a solution of 4.108 (8.5 mg, 0.0229 mmol), 36% aq formaldehyde (2.1 mg, 
0.0252 mmol, 2 µL), and 40% aq dimethylamine (25.8 mg, 0.229 mmol, 26 µL) in EtOH 
(0.23 mL). The reaction mixture was stirred at rt. After 36 h, the reaction was diluted 
with H2O (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts 
were washed with brine (5 mL), dried (Na2SO4), filtered, and concentrated in vacuo to 
afford a brown oil. Subsequent purification by flash chromatography eluting with 
Hexanes : EtOAc (10 : 1 → 100% EtOAc) containing 1% NEt3 afforded 5 mg (51%) of 
4.107 as a clear oil: 1H-NMR (500 MHz, CD3CN) δ 9.24 (br, 1H), 7.57 (ddt, J = 7.8, 1.4, 
0.7 Hz, 1H), 7.31 (comp, 11H), 7.07 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.00 (ddd, J = 8.0, 
7.0, 1.1 Hz, 1H), 4.57 – 4.49 (comp, 4H), 3.80 (comp, 4H), 3.63 (p, J = 5.8 Hz, 1H), 3.51 
(s, 2H), 2.14 (s, 6H); 13C-NMR (125 MHz, CD3CN) δ 139.7, 137.8, 136.5, 129.5, 129.3, 
128.6, 128.5, 121.9, 119.7, 119.6, 111.7, 110.2, 73.7, 70.9, 54.1, 45.5, 38.4; HRMS (ESI) 
m/z observed 429.25480 [C28H32N2O2 (M+H)+ requires 429.25370]. 
 
 
2-(1,3-bis(benzyloxy)propan-2-yl)-1H-Indole. (4.108). (WLM9_84). 











mmol) and 10% Pd/C (7.4 mg) in EtOH (0.65 mL) in a glass vial. The glass vial was 
sealed, and the reaction was stirred for 12 h at 80 ºC. The reaction mixture was cooled to 
rt, diluted with EtOAc (10 mL), and filtered through a pad of Celite® that was 
subsequently washed with EtOAc (3 x 5 mL). The combined organic extracts were 
washed with H2O (20 mL), brine (20 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a brown oil that was subsequently purified by flash chromatography 
eluting with Hexanes : EtOAc (8 : 1) to afford 26 mg (55%) of 4.108 as a clear oil: 1H-
NMR (400 MHz, CDCl3) δ 8.87 (br, 1H), 7.55 (dd, J = 7.8, 1.2 Hz, 1H), 7.33 (comp, 
11H), 7.13 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.07 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 6.33 – 
6.25 (m, 1H), 4.58 (comp, 4H), 3.87 (qd, J = 9.1, 5.7 Hz, 4H), 3.42 (p, J = 5.7 Hz, 1H); 
13C-NMR (100 MHz, CDCl3) δ 139.1, 138.2, 135.9, 128.6, 128.2, 127.9, 127.9, 121.3, 
120.1, 119.6, 110.8, 99.6, 73.6, 70.6, 39.7; HRMS (ESI) m/z observed 394.17800 
[C25H25NO2 (M+Na)+ requires 394.17780]. 
 
 
2-(1H-indol-2-yl)-1,3-Dimethoxypropan-2-yl acetate. (4.118a). 
(WLM7_239_2). A solution of n-BuLi (3.94 mL of 2.5 M solution in hexanes, 9.86 
mmol) was added dropwise to a solution of indole (3.18) (1.05 g, 8.96 mmol) in dry THF 
(25 mL) at –78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed 
through a short column of anhydrous CaSO4) was bubbled through the reaction for 15 
min. The reaction was stirred for 15 min, the bath was removed, and the reaction was 
stirred for 1 h at room temperature. Excess CO2 was removed via freeze-pump-thaw (3 
cycles), and the reaction was evacuated for 30 sec, and then sparged with N2 for 20 min. 







pentane, 9.86 mmol) was added dropwise. The reaction was stirred for 80 min and 
transferred via cannula to a solution of 4.117 (1.16 g, 9.86 mmol) in dry THF (25 mL) at 
–78 ºC. The reaction was stirred for 2.5 h, freshly distilled acetic anhydride (2.75 g, 26.89 
mmol, 2.54 mL) was added dropwise, and the reaction was allowed to warm to room 
temperature over 7 h. Saturated aq NaHCO3 (25 mL) was added, and the reaction was 
stirred for 30 min, whereupon brine (50 mL) and Et2O (50 mL) were added. The layers 
were separated, and the aqueous layer was extracted with Et2O (2 x 50 mL). The combine 
organic layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. 
The resulting yellow oil was purified by flash chromatography eluting with Hexanes : 
EtOAc (10:1 to 8:1 to 5:1 to 2:1) containing 1% NEt3 to give 1.25 g (50%) of 4.118a as a 
white solid: 1H-NMR (600 MHz, CD3CN) δ 9.44 (br, 1 H) 7.51 (dd, J = 7.8, 1.2 Hz, 1 H) 
7.39 (dd, J = 7.8, 1.2 Hz, 1 H) 7.11 (td, J = 7.2, 1.2 Hz, 1 H) 7.02 (td, J = 7.2, 1.2 Hz, 1 
H) 6.38 (dd, J = 2.4, 0.6 Hz, 1 H) 4.01 (d, J = 9.6 Hz, 2 H) 3.98 (d, J = 9.6 Hz, 2 H) 3.35 
(s, 6 H) 2.03 (s, 3 H); 13C-NMR (150 MHz, CD3CN) δ 170.5, 138.1, 136.9, 128.7, 122.6, 
121.1, 120.4, 112.1, 100.4, 81.3, 73.7, 59.8, 22.1; HRMS (CI) m/z observed 277.1314 
[C15H19NO4 (M)+ requires 277.1314]. 
 
 
Assignments: 1H-NMR (600 MHz, CD3CN) δ 9.44 (br, 1 H, N1-H) 7.51 (dd, J = 
7.8, 1.2 Hz, 1 H, C5-H) 7.39 (dd, J = 7.8, 1.2 Hz, 1 H, C8-H) 7.11 (td, J = 7.2, 1.2 Hz, 1 
H, C7-H) 7.02 (td, J = 7.2, 1.2 Hz, 1 H, C6-H) 6.38 (dd, J = 2.4, 0.6 Hz, 1 H, C3-H) 4.01 


























(s, 6 H, C13-H3 and C14-H3) 2.03 (s, 3 H, C16-H3); 13C-NMR (150 MHz, CD3CN) δ 
170.5 (C15), 138.1, 136.9, 128.7, 122.6 (C7), 121.1 (C5), 120.4 (C6), 112.1 (C8), 100.4 
(C3), 81.3 (C10), 73.7 (C11 and C12), 59.8 (C13 and C14), 22.1 (C16). 
 
 
2-(1H-indol-2-yl)-1,3-Diphenoxypropan-2-yl acetate. (4.118b). (WLM8_107). 
A solution of n-BuLi (1.88 mL of 2.5 M solution in hexanes, 4.695 mmol) was added 
dropwise to a solution of indole (3.18) (500 mg, 4.268 mmol) in dry THF (20 mL) at –78 
°C. The reaction was stirred for 30 min, and dried CO2 gas (passed through a short 
column of anhydrous CaSO4) was bubbled through the reaction for 15 min. The reaction 
was stirred for 15 min, the bath was removed, and the reaction was stirred for 1 h at room 
temperature. Excess CO2 was removed via freeze-pump-thaw (3 cycles), and the reaction 
was evacuated for 30 sec, and then sparged with N2 for 20 min. The reaction was cooled 
to –78 °C, whereupon t-BuLi (2.61 mL of 1.8 M solution in pentane, 4.695 mmol) was 
added dropwise. The reaction was stirred for 80 min and transferred via cannula to a 
solution of 4.115a (1.14 g, 4.695 mmol) in dry THF (20 mL) at –78 ºC. The reaction was 
stirred for 2.5 h, freshly distilled acetic anhydride (1.31 g, 12.8 mmol, 1.21 mL) was 
added dropwise, and the reaction was allowed to warm to room temperature over 7 h. 
Saturated aq NaHCO3 (30 mL) was added, and the reaction was stirred for 30 min, 
whereupon brine (50 mL) and Et2O (50 mL) were added. The layers were separated, and 
the aqueous layer was extracted with Et2O (2 x 50 mL). The combined organic layers 
were dried (Na2SO4), filtered, and concentrated under reduced pressure. The resulting 
yellow oil was purified by flash chromatography eluting with Hexanes : EtOAc (8 : 1) 







MHz, CD3CN) δ 9.67 (br, 1 H) 7.55 (d, J = 8.5 Hz, 1 H) 7.43 (dd, J = 8.0, 1.0 Hz, 1 H) 
7.29-7.24 (comp, 4 H) 7.15 (dt, J = 7.0, 1.5 Hz, 1 H) 7.05 (dt, J = 7.0, 1.0 Hz, 1 H) 6.98-
6.93 (comp, 6 H) 6.59 (dd, J = 2.0, 0.5 Hz, 1 H) 4.80 (d, J = 10.0 Hz, 2 H) 4.77 (d, J = 
10.0 Hz, 2 H) 2.07 (s, 3 H); 13C-NMR (500 MHz, CD3CN) δ 170.6, 159.5, 137.1, 136.8, 
130.5, 128.7, 123.0, 122.3, 121.3, 120.6, 115.8, 112.2, 101.0, 80.7, 69.2, 22.0; HRMS 
(ESI) m/z observed 424.15170 [C25H23NO4 (M+Na)+ requires 424.15190]. 
 
 
1,3-Bis(4-chlorophenoxy)-2-(1H-indol-2-yl)propan-2-yl acetate. (4.118c). 
(WLM8_122). A solution of n-BuLi (1.94 mL of 2.5 M solution in hexanes, 4.977 
mmol) was added dropwise to a solution of indole (3.18) (530 mg, 4.524 mmol) in dry 
THF (23 mL) at –78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed 
through a short column of anhydrous CaSO4) was bubbled through the reaction for 15 
min. The reaction was stirred for 15 min, the bath was removed, and the reaction was 
stirred for 1 h at room temperature. Excess CO2 was removed via freeze-pump-thaw (3 
cycles), and the reaction was evacuated for 30 sec, and then sparged with N2 for 20 min. 
The reaction was cooled to –78 °C, whereupon t-BuLi (2.77 mL of 1.8 M solution in 
pentane, 4.977 mmol) was added dropwise. The reaction was stirred for 80 min and 
transferred via cannula to a solution of 4.115b (1.55 g, 4.977 mmol) in dry THF (23 mL) 
at –78 ºC. The reaction was stirred for 2.5 h, freshly distilled acetic anhydride (1.385 g, 
13.57 mmol, 1.28 mL) was added dropwise, and the reaction was allowed to warm to 
room temperature over 7 h. Saturated aq NaHCO3 (40 mL) was added, and the reaction 







layers were separated, and the aqueous layer was extracted with Et2O (2 x 60 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (4 : 1) containing 1% NEt3 to give 413 mg (19%) of 4.118c as a white 
solid: 1H-NMR (500 MHz, CD3CN) δ 9.63 (br, 1 H) 7.54 (dd, J =8.0, 1.0 Hz, 1 H) 7.42 
(dd, J = 8.0, 1.0 Hz, 1 H) 7.24 (d, J = 9.0 Hz, 4 H) 7.15 (td, J = Hz, 1 H) 7.05 (td, J = 7.5, 
1.0 Hz, 1 H) 6.93 (d, J = 9.0 Hz, 4 H) 6.57 (dd, J = 2.5, 1.0 Hz, 1 H); 13C-NMR (125 
MHz, CD3CN) δ 171.2, 158.9, 137.7, 137.0, 130.9, 129.3, 127.3, 123.7, 122.0, 121.3, 
118.1, 112.8, 101.7, 81.1, 70.3, 22.6; HRMS (ESI) m/z observed 492.07400 
[C25H21Cl2NO4 (M+Na)+ requires 492.07400]. 
 
 
2-(1H-indol-2-yl)-1,3-Bis(4-methoxyphenoxy)propan-2-yl acetate. (4.118d). 
(WLM8_175). A solution of n-BuLi (3.76 mL of 2.5 M solution in hexanes, 9.390 
mmol) was added dropwise to a solution of indole (3.18) (1.00 g, 8.536 mmol) in dry 
THF (25 mL) at –78 °C. The reaction was stirred for 30 min, and dried CO2 gas (passed 
through a short column of anhydrous CaSO4) was bubbled through the reaction for 15 
min. The reaction was stirred for 15 min, the bath was removed, and the reaction was 
stirred for 1 h at room temperature. Excess CO2 was removed via freeze-pump-thaw (3 
cycles), and the reaction was evacuated for 30 sec, and then sparged with N2 for 20 min. 
The reaction was cooled to –78 °C, whereupon t-BuLi (5.22 mL of 1.8 M solution in 
pentane, 9.390 mmol) was added dropwise. The reaction was stirred for 80 min and 







at –78 ºC. The reaction was stirred for 2.5 h, freshly distilled acetic anhydride (2.61 g, 
25.61 mmol, 2.42 mL) was added dropwise, and the reaction was allowed to warm to 
room temperature over 7 h. Saturated aq NaHCO3 (50 mL) was added, and the reaction 
was stirred for 30 min, whereupon brine (50 mL) and Et2O (50 mL) were added. The 
layers were separated, and the aqueous layer was extracted with Et2O (2 x 50 mL). The 
combined organic layers were dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (9:1 → 4:1 → 3:2) containing 1% NEt3 to give 3.071 g (78%) of 
4.118d as a white solid: 1H-NMR (600 MHz, CD3CN) δ 9.72 (br, 1 H) 7.61 (d, J = 8.4 
Hz, 1 H) 7.49 (d, J = 8.4 Hz, 1 H) 7.20 (td, J = 6.6, 1.2 Hz, 1 H) 7.10 (td, J = 6.6, 1.2 Hz, 
1 H) 6.94 (d, J = 9.0 Hz, 4 H) 6.86 (d, J = 9.0 Hz, 4 H) 6.64 (d, J = 2.4 Hz, 1 H) 4.79 (d, 
J = 9.6 Hz, 2 H) 4.76 (d, J = 10.2 Hz, 1 H) 3.73 (s, 6 H) 2.11 (s, 3 H); 13C-NMR (150 
MHz, CD3CN) δ 170.7, 155.3, 153.6, 137.1, 136.9, 128.7, 123.0, 121.4, 120.6, 117.0, 
115.6, 112.2, 101.1, 80.9, 70.1, 56.2, 22.1; HRMS (ESI) m/z observed 484.17230 




ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.119a). (WLM8_44). A solution of 
TMS-OTf (867 mg, 3.9 mmol, 0.71 mL) in dry CH2Cl2 (3.9 mL) was added dropwise to a 
solution of 4.118a (900 mg, 3.25 mmol), 3.10 (1.25 g, 3.57 mmol), and 2,6-di(tert-butyl)-
4-methylpyridine (1.35 g, 6.5 mmol) in dry CH2Cl2 (12.0 mL) at –78 ºC. The reaction 








in CH2Cl2 (12.0 mL) was added dropwise. The bath was removed, and the reaction was 
stirred at room temperature for 1 h. Saturated aq NaHCO3 (5 mL) was added, and the 
layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The 
combined organic extracts were washed with brine (100 mL), dried (Na2SO4), filtered, 
and concentrated under reduced pressure. The resultant yellow oil was purified by flash 
chromatography eluting with Hexanes : EtOAc (4:1 → 3:1 → 1:1) containing 1% NEt3 to 
provide 1.08 g (81%) of 4.119a as a yellow foam: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 
9.56 (br, 1 H) 7.49 (d, J = 7.5 Hz, 1 H) 7.43 (d, J = 8.0 Hz, 1 H) 7.15 (td, J = 7.5, 1.0 Hz, 
1 H) 7.08 (td, 7.5, 1.0 Hz, 1 H) 6.01 (br, 1 H) 5.87 (app t, J = 3.5 Hz, 1 H) 5.33 (br, 1 H) 
5.22 (d, J = 8.0 Hz, 1 H) 4.64 (br, 2 H) 4.00-3.96 (m, 1 H) 3.85 (d, J = 9.5 Hz, 1 H) 3.65 
(d, J = 9.0 Hz, 1 H) 3.60 (d, J = 9.0 Hz, 1 H) 3.51 (d, J = 9.0 Hz, 1 H) 3.40 (s, 3 H) 3.18 
(s, 3 H) 3.11-3.02 (comp, 3 H) 2.92 (dd, J = 8.5, 3.0 Hz, 1 H)  2.04 (dm, J = 15.5 Hz, 1 
H) 1.79 (tdd, J = 14.5, 4.5, 2.5 Hz, 1 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 211.7, 
156.1, 139.6, 136.8, 134.9, 127.9, 123.2, 120.8, 118.6, 117.7, 112.3, 110.8, 78.2, 75.9, 
66.9, 59.9, 59.4, 58.5, 46.3, 46.2, 40.8, 28.9; HRMS (ESI) m/z observed 435.18930 
[C23H28N2O5 (M+Na)+ requires 435.18900]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.56 (br, 1 H, N1-H) 7.49 
(d, J = 7.5 Hz, 1 H, C5-H) 7.43 (d, J = 8.0 Hz, 1 H, C8-H) 7.15 (td, J = 7.5, 1.0 Hz, 1 H, 



































H, C16-H) 5.33 (br, 1 H, C24-H or C25-H) 5.22 (d, J = 8.0 Hz, 1 H, C24-H or C25-H) 
4.64 (br, 2 H, C15-H2) 4.00-3.96 (m, 1 H, C13-H) 3.85 (d, J = 9.5 Hz, 1 H, C19-H or 
C20-H) 3.65 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.60 (d, J = 9.0 Hz, 1 H, C19-H or 
C20-H) 3.51 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.40 (s, 3 H, C21-H3 or C22-H3) 3.18 
(s, 3 H, C21-H3 or C22-H3) 3.11-3.02 (comp, 3 H, C11-H, C13-H, and C17-H) 2.92 (dd, J 
= 8.5, 3.0 Hz, 1 H, C17-H) 2.04 (dm, J = 15.5 Hz, 1 H, C12-H) 1.79 (tdd, J = 14.5, 4.5, 
2.5 Hz, 1 H, C12-H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 211.7 (C18), 156.1 (C14), 
139.6, 136.8, 134.9, 127.9, 123.2 (C7), 120.8 (C6), 118.6 (C5), 117.7, 112.3 (C8), 110.8 
(C3), 78.2 (C19 or C20), 75.9 (C19 or C20), 66.9 (C15), 59.9 (C21 or C22), 59.4 (C21 or 




ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.119b). (WLM8_117). A solution of 
TMS-OTf (373 mg, 1.54 mmol, 0.304 mL) in dry CH2Cl2 (1.0 mL) was added dropwise 
to a solution of 4.118b (562 mg, 1.40 mmol), 3.10 (541 mg, 1.54 mmol), and 2,6-di(tert-
butyl)-4-methylpyridine (575 mg, 2.80 mmol) in dry CH2Cl2 (6.0 mL) at –78 ºC. The 
reaction was stirred for 3 h at –78 ºC, whereupon a solution of TBAF•3H2O (1.325 mg, 
4.20 mmol) in CH2Cl2 (7.0 mL) was added dropwise. The bath was removed, and the 
reaction was stirred at room temperature for 1 h. Saturated aq NaHCO3 (10 mL) was 
added, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (3 x 
30 mL). The combined organic extracts were washed with brine (20 mL), dried (Na2SO4), 








by flash chromatography eluting with Hexanes : EtOAc (4 : 1) containing 1% NEt3 to 
afford 562 mg (75%) of 4.118b as a yellow foam: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 
9.67 (br, 1 H) 7.55 (d, J = 8.0 Hz, 1 Hz) 7.45 (dm, J = 8.5 Hz, 1 Hz) 7.34-7.30 (comp, 2 
H) 7.24-7.17 (comp, 3 Hz) 7.11 (td, J = 7.5, 1.0 Hz, 1 H) 7.08 (dm, J = 9.0 Hz, 2 H) 7.00 
(dt, J = 7.0, 1.0 Hz, 1 H) 6.92 (dt, J = 7.5, 1.0 Hz, 1 H) 6.86 (dm, J = 8.0 Hz, 2 H) 6.01 
(br, 1 H) 5.97 (t, J = 3.5 Hz, 1 H) 5.35 (br, 1 H) 5.22 (br, 1 H) 4.68-4.66 (comp, 3 H) 4.40 
(d, J = 9.5 Hz, 1 H) 4.37 (d, J = 9.0 Hz, 1 H) 4.29 (d, J = 9.5 Hz, 1 H) 4.05 (m, 1 H) 3.41 
(dd,  J = 6.0, 2.5 Hz, 1 H) 3.20 (dd, J = 19.0, 4.0 Hz, 1 H) 3.20 (m, 1 H) 3.09 (dd,  J = 
19.0, 3.0 Hz, 1 H) 2.20 (dm, J = 15.5 Hz, 1 H) 1.96-1.88 (comp, 2 H); 13C-NMR (125 
MHz, CD3CN, 70 ºC) δ 211.6, 159.9, 159.7, 156.1, 137.8, 137.1, 134.9, 130.8, 130.7, 
127.9, 123.6, 122.9, 122.6, 121.0, 118.9, 117.7, 116.5, 116.1, 112.4, 111.7, 73.8, 71.3, 
67.0, 58.2, 50.4, 46.2, 46.2, 41.0, 29.0; HRMS (ESI) m/z observed 559.22140 





(WLM8_132). A solution of TMS-OTf (72 mg, 0.324 mmol, 59 µL) in dry CH2Cl2 (0.4 
mL) was added dropwise to a solution of 4.118c (127 mg, 0.27 mmol), 3.10 (104 mg, 
0.297 mmol), and 2,6-di(tert-butyl)-4-methylpyridine (111 mg, 0.54 mmol) in dry 
CH2Cl2 (1.0 mL) at –78 ºC. The reaction was stirred for 3 h at –78 ºC, whereupon a 
solution of TBAF•3H2O (256 mg, 0.81 mmol) in CH2Cl2 (2.0 mL) was added dropwise. 








Saturated aq NaHCO3 (2.0 mL) was added, and the layers were separated. The aqueous 
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were 
washed with brine (25 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The resultant yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (10 : 1 → 4 : 1) containing 1% NEt3 to afford 73 mg (44%) of 4.119c 
as a yellow foam: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.63 (br, 1 H) 7.54 (d, J = 7.5 
Hz, 1 H) 7.45 (d, J = 8.5 Hz, 1 H) 7.31 (d, J = 9.5 Hz, 2 H) 7.22-7.17 (comp, 3 H) 7.11 (t, 
J = 7.5 Hz, 1 H) 7.05 (d, J = 9.0 Hz, 2 H) 6.83 (d, J = 9.0 Hz, 2 H) 6.02 (br, 1 H) 5.95 
(app t, 1 H) 5.33 (br, 1 H) 5.22 (br, 1 H) 4.63 (br, 2 H) 4.62 (d, J = 9.5 Hz, 1 H) 4.37 (d, J 
= 10.0 Hz, 1 H) 4.26 (d, J = 9.5 Hz, 1 H) 4.26 (d, J = 9.5 Hz, 1 H) 4.03 (app d, J = 15.5 
Hz, 1 H) 3.37 (dd, J = 5.5, 3.0 Hz, 1 H) 3.22-3.14 (m, 1 H) 3.18 (dd, J = 19.0, 4.0 Hz, 1 
H) 3.05 (dd, J = 19.0, 3.0 Hz, 1 H) 2.17 (dm, J = 15.5 Hz, 1 H) 1.91-1.88 (m, 1 H); 13C-
NMR (125 MHz, CD3CN, 70 ºC) δ 211.6, 158.6, 158.4, 156.1, 137.3, 137.1 134.9, 130.5, 
130.5, 127.8, 127.4, 127.1, 123.7, 121.0, 118.9, 118.2, 117.7, 112.4, 111.8, 74.0, 71.5, 
67.0, 58.0, 50.3, 46.1, 46.1, 41.0, 28.8; HRMS (ESI) m/z observed 627.10000 





(WLM8_199). A solution of TMS-OTf (115 mg, 0.517 mmol, 94 µL) in dry CH2Cl2 (0.5 
mL) was added dropwise to a solution of 3.10 (167 mg, 0.474 mmol), 4.118d (199 mg, 








CH2Cl2 (2.2 mL) at –78 ºC. The reaction was stirred for 3 h at –78 ºC, whereupon a 
solution of TBAF•3H2O (408 mg, 1.293 mmol) in CH2Cl2 (3.0 mL) was added dropwise. 
The bath was removed, and the reaction was stirred at room temperature for 1 h. 
Saturated aq NaHCO3 (10 mL) was added, and the layers were separated. The aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL). The combined organic extracts were 
washed with brine (25 mL), dried (Na2SO4), filtered, and concentrated under reduced 
pressure. The resultant yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (10 : 1 → 4 : 1 → 2 : 1) containing 1% NEt3 to afford 178 mg (69 %) 
of 4.119d as a yellow foam: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.67 (br, 1 H), 7.54 
(dd, J = 8.0, 1.0 Hz, 1 H), 7.45 (dt, J = 8.2, 1.0 Hz, 1 H), 7.17 (ddd, J = 8.2, 7.0, 1.2 Hz, 1 
H), 7.11 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H), 7.02 (d, J = 9.2 Hz, 2 H), 6.88 (d, J = 9.2 Hz, 2 
H), 6.78 (d, J = 0.6 Hz, 4 H), 6.02 (br, 1 H) 5.97 (t, J = 3.5 Hz, 1 H), 5.33 (d, J = 16.8 Hz, 
1 H), 5.22 (d, J = 10.0 Hz, 1 H), 4.65 (br, 2 H), 4.59 (d, J = 9.5 Hz, 1 H), 4.32 (d, J = 9.6 
Hz, 1 H), 4.29 (d, J = 9.3 Hz, 1 H), 4.21 (d, J = 9.3 Hz, 1 H), 4.03 (d, J = 14.6 Hz, 1 H), 
3.74 (s, 3 H), 3.69 (s, 3 H), 3.37 (dd, J = 5.8, 2.7 Hz, 1 H), 3.19 (dd, J = 18.9, 4.3 Hz, 2 
H), 3.07 (dd, J = 18.8, 3.2 Hz, 1 H), 2.18 (ddt, J = 15.7, 5.7, 2.8 Hz, 1 H), 1.89 (ddd, J = 
15.8, 4.9, 2.6 Hz, 1 H). 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 211.60, 156.14, 156.10, 
155.90, 153.97, 153.84, 138.02, 137.04, 134.88, 127.84, 123.57, 120.97, 118.85, 117.70, 
117.26, 116.17, 116.05, 112.38, 111.58, 74.64, 72.21, 67.02, 61.11, 58.14, 56.69, 56.62, 
50.40, 46.22, 41.01, 28.96. HRMS (ESI) m/z observed 619.24180 [C35H36N2O7 (M+Na)+ 
requires 619.24150].  
 402 
 
Assignment: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.67 (br, 1 H, N1-H), 7.54 
(dd, J = 8.0, 1.0 Hz, 1 H, C5-H), 7.45 (dt, J = 8.2, 1.0 Hz, 1 H, C8-H), 7.17 (ddd, J = 8.2, 
7.0, 1.2 Hz, 1 H, C7-H), 7.11 (ddd, J = 8.0, 7.0, 1.1 Hz, 1 H, C6-H), 7.02 (d, J = 9.2 Hz, 2 
H, C22-H and C30-H or C23-H and C31-H), 6.88 (d, J = 9.2 Hz, 2 H, C22-H and C30-H 
or C23-H and C31-H), 6.78 (d, J = 0.6 Hz, 4 H, C24-H and C25-H and C28-H and C29-
H), 6.02 (br, 1 H, C35-H) 5.97 (t, J = 3.5 Hz, 1 H, C14-H), 5.33 (d, J = 16.8 Hz, 1 H, 
C36-H), 5.22 (d, J = 10.0 Hz, 1 H, C36-H), 4.65 (br, 2 H, C34-H), 4.59 (d, J = 9.5 Hz, 1 
H, C18-H or C19-H), 4.32 (d, J = 9.6 Hz, 1 H, C18-H or C19-H), 4.29 (d, J = 9.3 Hz, 1 
H, C18-H or C19-H), 4.21 (d, J = 9.3 Hz, 1 H, C18-H or C19-H), 4.03 (d, J = 14.6 Hz, 1 
H, C16), 3.74 (s, 3 H, C32-H3 or C33-H3), 3.69 (s, 3 H, C32-H3 or C33-H3), 3.37 (dd, J = 
5.8, 2.7 Hz, 1 H, C11), 3.19 (dd, J = 18.9, 4.3 Hz, 2 H, C13-H and C16-H), 3.07 (dd, J = 
18.8, 3.2 Hz, 1 H, C13-H), 2.18 (ddt, J = 15.7, 5.7, 2.8 Hz, 1 H, C17-H), 1.89 (ddd, J = 
15.8, 4.9, 2.6 Hz, 1 H, C17-H). 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 211.60 (C15), 
156.14 (C20 or C21), 156.10 (C15), 155.90 (C20 or C21), 153.97 (C26 or C27), 153.84 
(C26 or C27), 138.02 (C2 or C9), 137.04 (C2 or C9), 134.88 (C36), 127.84 (C4), 123.57 
(C7), 120.97 (C6), 118.85 (C5), 117.70 (C30 and C22 or C31 and C23), 117.26 (C30 and 














































C25 and C29), 112.38 (C8), 111.58 (C3), 74.64 (C18 or C19), 72.21 (C18 or C19), 67.02 
(C34), 61.11 (C10), 58.14 (C11), 56.69 (C32 or C33), 56.62 (C32 or C33), 50.40 (C13), 
46.22 (C14), 41.01 (C16), 28.96 (C17). 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 12-hydroxy-6,6-bis(methoxymethyl)-3,4,5,6-
tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.120a). 
(WLM7_246_2). Lithium borohydride (29 mg, 1.31 mmol) was added to a solution of 
4.119a (108 mg, 0.262 mmol) in dry MeOH (1.3 mL) at 0 ºC. After 14 h, saturated aq 
Rochelle’s salt (1.0 mL) was added, and the reaction was stirred for 5 min. the reaction 
mixture was extracted with CH2Cl2 (3 x 5 mL), washed with brine (10 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The resulting yellow oil was 
purified by flash chromatography eluting with Hexanes : EtOAc (1:1 to 100% EtOAc) to 
give 44 mg (40%) of 4.120a as a white solid and 30 mg of recovered 4.119a: 1H-NMR 
(500 MHz, CD3CN, 70 °C) δ 9.50 (br, 1 H) 7.39 (d, J = 8.5 Hz, 2 H) 7.11 (td, J = 7.0, 1.0 
Hz, 1 H) 7.03 (td, J = 7.5, 0.5 Hz, 1 H) 6.03 (br, 1 H) 5.60 (d, J = 7.0 Hz, 1 H) 5.34 (br, 1 
H) 5.23 (br, 1 H) 4.65 (br, 2 H) 4.26 (t, J = 9.0 Hz, 1 H) 3.89-3.81 (comp, 4 H) 3.54 (d, J 
= 9.0 Hz, 1 H) 3.45 (s, 3 H) 3.29 (s, 3 H) 3.00 (m, 1 H) 2.70 (m, 1 H) 2.50 (m, 1 H) 1.90-
1.85 (comp, 2 H) 1.81-1.73 (m, 1 H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 156.4, 
141.1, 136.8, 135.3, 127.6, 122.7, 120.5, 117.4, 113.3, 112.2, 77.0, 76.4, 76.1, 66.6, 59.8, 
59.4, 48.3, 48.2, 47.9, 41.6, 31.3; HRMS (ESI) m/z observed 437.20460 [C23H30N2O5 










Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 9.50 (br, 1 H, N1-H) 7.39 
(d, J = 8.5 Hz, 2 H, C5-H and C8-H) 7.11 (td, J = 7.0, 1.0 Hz, 1 H, C7-H) 7.03 (td, J = 
7.5, 0.5 Hz, 1 H, C6-H) 6.03 (br, 1 H, C23-H) 5.60 (d, J = 7.0 Hz, 1 H, C16-H) 5.34 (br, 
1 H, C24a-H or C24b-H) 5.23 (br, 1 H, C24-H or C25-H) 4.65 (br, 2 H, C25-H2) 4.26 (t, 
J = 9.0 Hz, 1 H, C18-H) 3.89-3.81 (comp, 4 H, C19-H, C20-H2, and C13-H) 3.54 (d, J = 
9.0 Hz, 1 H, C19-H) 3.45 (s, 3 H, C21-H3 or C22-H3) 3.29 (s, 3 H, C21-H3 or C22-H3) 
3.00 (m, 1 H, C17-H) 2.70 (m, 1 H, C13-H) 2.50 (m, 1 H, C11-H) 1.90-1.85 (comp, 2 H, 
C12-H and C17-H) 1.81-1.73 (m, 1 H, C12-H); 13C-NMR (125 MHz, CD3CN, 70 °C) δ 
156.4 (C14), 141.1, 136.8, 135.3, 127.6, 122.7 (C7), 120.5 (C6), 117.4, 113.3 (C3), 112.2 
(C5 or C8), 77.0 (C19 or C20), 76.4 (C19 or C20), 76.1 (C18), 66.6 (C15), 59.8 (C21 or 
C22), 59.4 (C21 or C22), 48.3 (C16), 48.2 (C10), 47.9 (C11), 41.6 (C13), 31.3 (C12). 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 12-hydroxy-6,6-bis(phenoxymethyl)-3,4,5,6-
tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.120b). 
(WLM8_123). Lithium borohydride (24 mg, 1.07 mmol) was added to a solution of 
4.119b (287 mg, 0.535 mmol) in dry MeOH (5.4 mL) at 0 ºC. After 12 h, saturated aq 










































mixture was extracted with CH2Cl2 (3 x 20 mL), washed with brine (25 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The resulting yellow oil was 
purified by flash chromatography eluting with Hexanes : EtOAc (3:1 to 1:1) to give 108 
mg (38%) of 4.120b as a white solid and 158 mg (55%) of recovered 4.119b as a white 
solid: 1H-NMR (500 MHz, CD3OD, 70º C) δ 9.57 (br, 1 H) 7.44 (d, J = 8.0 Hz, 1 H) 7.43 
(d, J = 8.0 Hz, 1 H) 7.31- 7.28 (comp, 2 H) 7.24-7.20 (comp, 2 H) 7.14 (dt, J = 7.0, 1.0 
Hz, 1 H) 7.08-7.04 (comp, 3 H) 6.97 (t, J = 7.0 Hz, 1 H) 6.94 (dd, J =  8.0, 1.0 Hz, 2 H) 
6.89 (t,  J = 7.0 Hz, 1 H) 6.04 (br, 1 H) 5.67 (d,  J = 6.0 Hz, 1 H) 5.37 (br, 1 H) 5.23 (br, 
1 H) 4.78 (d, J = 9.0 Hz, 1 H) 4.67 (br, 2 H) 4.65 (d, J = 8.5 Hz, 1 H) 4.55 (d, J = 8.5 Hz, 
1 H) 4.45 (t, J = 8.0 Hz, 1 H) 4.34 (d, J = 8.5 Hz, 1 H) 3.88 (m, 1 H) 3.08 (m, 1 H) 3.01 
(d, J = 1.0 Hz, 1 H) 2.91 (m, 1 H) 2.81 (m, 1 H) 2.00-1.84 (comp, 3 H). 13C-NMR (125 
MHz, CD3OD, 70 ºC) δ 160.4, 160.2, 156.4, 139.5, 137.0, 135.2, 130.8, 130.6, 127.4, 
123.0, 122.6, 122.2, 120.7, 118.5, 117.4, 116.5, 116.3, 114.0, 112.3, 75.9, 72.1, 71.4, 
66.7, 48.4, 48.0, 47.6, 41.8, 31.2, 30.5. HRMS (ESI) m/z observed 561.23620 
[C33H34N2O5 (M+Na)+ requires 561.23600]. 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 6,6-bis((4-chlorophenoxy)methyl)-12-hydroxy-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.120c). 
(WLM8_180). Lithium borohydride (10.2 mg, 0.469 mmol) was added to a solution of 
4.119c (71 mg, 0.117 mmol) in dry MeOH (2.4 mL) at 0 ºC. After 12 h, saturated aq 
Rochelle’s salt (3.0 mL) was added, and the reaction was stirred for 5 min. the reaction 








(Na2SO4), filtered, and concentrated under reduced pressure. The resulting yellow oil was 
purified by flash chromatography eluting with Hexanes : EtOAc (2 : 1 → 1:1) to give 55 
mg (77%) of 4.120c as a white solid: 1H-NMR (500 MHz, (CD3)2SO, 70 ºC) δ 10.88 (br, 
1H), 7.42 (d, J = 8.7 Hz, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 9.0 Hz, 2H), 7.25 (d, 
J = 9.0 Hz, 2H), 7.12 – 7.07 (m, 1H), 7.07 (d, J = 9.0 Hz, 2H), 7.00 (td, J = 8.0, 0.9 Hz, 
1H), 6.95 (d, J = 9.0 Hz, 2H), 6.22 (br, 1H), 5.56 (d, J = 6.5 Hz, 1H), 5.30 (br, 2H), 4.94 
(d, J = 8.8 Hz, 2H), 4.62 (br, 2H), 4.53 (d, J = 9.6 Hz, 1H), 4.43 (dd, J = 9.7, 1.3 Hz, 1H), 
4.35 (comp, 2H), 3.88 – 3.70 (m, 1H), 3.06 – 2.91 (m, 1H), 2.89 – 2.81 (m, 1H), 2.67 (d, 
J = 39.7 Hz, 1H), 1.84 (comp, 3H); 13C-NMR (125 MHz, (CD3)2SO, 70 ºC) δ 157.4, 
157.2, 135.1, 133.5, 128.9, 128.7, 125.4, 124.6, 124.1, 120.9, 118.7, 116.6, 116.4, 116.3, 
111.4, 110.9, 73.2, 71.1, 68.9, 64.8, 46.3, 45.4. HRMS (ESI) m/z observed 629.15810 





(WLM8_200). Lithium borohydride (6.5 mg, 0.298 mmol) was added to a solution of 
4.119d (89 mg, 0.149 mmol) in dry MeOH (1.5 mL) at 0 ºC. After 12 h, saturated aq 
Rochelle’s salt (5 mL) was added, and the reaction was stirred for 5 min. the reaction 
mixture was extracted with CH2Cl2 (3 x 20 mL), washed with brine (25 mL), dried 
(Na2SO4), filtered, and concentrated under reduced pressure. The resulting yellow oil was 
purified by flash chromatography eluting with Hexanes : EtOAc (2 : 1 → 1 : 1) to give 70 








1H), 7.47 – 7.38 (m, 2H), 7.13 (td, J = 7.4, 1.2 Hz, 1H), 7.06 (td, J = 7.3, 0.9 Hz, 1H), 
6.98 (d, J = 9.2 Hz, 2H), 6.89 – 6.82 (comp, 4H), 6.79 (d, J = 9.2 Hz, 2H), 6.04 (br, 1H), 
5.67 (d, J = 6.5 Hz, 1H), 5.36 (br, 1H), 5.23 (br, 1H), 4.72 (d, J = 9.3 Hz, 1H), 4.67 (br, 
2H), 4.58 (d, J = 9.4 Hz, 1H), 4.50 (d, J = 9.4 Hz, 1H), 4.43 (td, J = 9.0, 1.9 Hz, 1H), 
4.26 (d, J = 9.2 Hz, 1H), 3.96 – 3.84 (m, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 3.13 – 3.01 (m, 
1H), 2.91 – 2.70 (comp, 2H), 2.04 – 1.96 (comp, 2H), 1.89 – 1.84 (m, 1H). 13C-NMR 
(125 MHz, CD3CN, 70 ºC) δ 156.4, 155.9, 155.6, 154.5, 154.3, 139.7, 137.0, 135.2, 
127.5, 123.0, 120.7, 118.5, 117.7, 117.4, 116.1, 116.0, 113.8, 112.2, 75.9, 73.0, 72.3, 
66.7, 56.7, 56.6, 48.4, 48.1, 47.5, 41.8, 41.7, 31.2. HRMS (ESI) m/z observed 621.25690 
[C35H38N2O7 (M+Na)+ requires 621.25710]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3CN, 70 ºC) δ 9.59 (br, 1H, N1-H), 7.47 – 
7.38 (comp, 2H, C5-H and C8-H), 7.13 (td, J = 7.4, 1.2 Hz, 1H, C7-H) 7.06 (td, J = 7.3, 
0.9 Hz, 1H, C6-H), 6.98 (d, J = 9.2 Hz, 2H, C22-H and C30-H or C23-H and C31-H), 
6.89 – 6.82 (comp, 4H, C22-H, C23-H, C24-H, C25-H, C28-H, C29-H, C30-H, or C31-
H), 6.79 (d, J = 9.2 Hz, 2H, C24-H and C28-H or C25-H and C29-H), 6.04 (br, 1H, C35-
















































J = 9.3 Hz, 1H, C18-H or C19-H), 4.67 (br, 2H, C34-H2), 4.58 (d, J = 9.4 Hz, 1H, C18-H 
or C19-H), 4.50 (d, J = 9.4 Hz, 1H, C18-H or C19-H), 4.43 (td, J = 9.0, 1.9 Hz, 1H, C13-
H), 4.26 (d, J = 9.2 Hz, 1H, C18-H or C19-H), 3.96 – 3.84 (m, 1H, C16-H), 3.74 (s, 3H, 
C32-H3 or C33-H3), 3.69 (s, 3H, C32-H3 or C33-H3), 3.13 – 3.01 (m, 1H, C13-H), 2.91 – 
2.70 (comp, 2H, C11-H, C16-H), 2.04 – 1.96 (comp, 2H, C13-H and C17-H), 1.89 – 1.84 
(m, 1H, C17-H). 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 156.4 (C15), 155.9 (C20 or 
C21), 155.6 (C20 or C21), 154.5 (C26 or C27), 154.3 (C26 or C27), 139.7 (C35), 137.0 
(C9), 135.2 (C2), 127.5 (C4), 123.0 (C7), 120.7 (C6), 118.5 (C5), 117.7 (C30 and C22 or 
C31 and C23), 117.4 (C30 and C22 or C31 and C23), 116.1 (C28 and C24 or C29 and 
C25), 116.0 (C28 and C24 or C29 and C25), 113.8 (C3), 112.2 (C8), 75.9 (C12), 73.0 
(C18 or C19), 72.3 (C18 or C19), 66.7 (C34), 56.7 (C32 or C33), 56.6 (C32 or C33), 48.4 




ethanoazocino[4,3-b]indol-12-ol. (4.121a). (WLM7_251_2). A round bottom flask 
charged with Pd2(dba)3 (1.0 mg, 0.00106 mmol) and 1,4-bis(diphenylphosphino)butane 
(0.9 mg, 0.00212 mmol) was placed under vacuum and backfilled with N2 three times. A 
second round bottom flask was charged with 4.120a (44 mg, 0.106 mmol) and 1,3-
dimethylbarbituric acid (165 mg, 1.06 mmol) and placed under vacuum and backfilled 
with N2 three times. THF (0.5 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. The Pd/ligand mixture was added via 








until 4.120a was gone by TLC. The reaction was quenched with saturated aq NaHCO3 
(0.3 mL) and stirred at room temperature for 15 min. The reaction mixture was diluted 
with H2O (3.0 mL) extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts 
were washed with brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo to 
afford a brown oil. Subsequent purification by flash chromatography eluting with 
CH2Cl2/MeOH (100% CH2Cl2 to 95:5) containing 1% NEt3 to provide 23 mg (66%) of 
4.121a as a white solid: 1H-NMR (500 MHz, CD3OD) δ 10.67 (br, 1 H) 7.53 (d, J = 8.0 
Hz, 1 H) 7.39 (d, J = 8.0 Hz, 1 H) 7.13 (td, J = 8.0, 1.0 Hz, 1 H) 7.07 (td, J = 8.0, 1.0 Hz, 
1 H) 5.21 (d, J = 5.0 Hz, 1 H) 4.42 (td, J = 9.0, 2.0 Hz, 1 H) 3.98 (d, J = 9.5 Hz, 1 H) 
3.87 (d, J = 9.5 Hz, 1 H) 3.83 (d, J = 9.5 Hz, 1 H) 3.67 (d, J = 9.5 Hz, 1 H) 3.41 (s, 3 H) 
3.30 (s, 3 H) 3.04-2.97 (comp, 2 H) 2.84 (td, J = 9.0, 4.0 Hz, 1 H) 2.72 (m, 1 H) 2.26 
(dm, J = 15.0 Hz, 1 H) 2.16 (ddd, J = 15.0, 4.0, 1.0 Hz, 1 H) 1.92 (tm, 1 H); 13C-NMR 
(125 MHz, CD3OD) δ 141.9, 137.1, 127.0, 123.1, 120.8, 117.9, 112.2, 106.8, 77.3, 76.4, 
74.8, 59.4, 59.2, 49.8, 49.6, 46.9, 41.5, 40.4, 28.3; HRMS (ESI) m/z observed 353.18360 
[C19H26N2O3 (M+Na)+ requires 353.18360]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 10.67 (br, 1 H, N1-H) 7.53 (d, J = 
8.0 Hz, 1 H, C5-H) 7.39 (d, J = 8.0 Hz, 1 H, C8-H) 7.13 (td, J = 8.0, 1.0 Hz, 1 H, C7-H) 
7.07 (td, J = 8.0, 1.0 Hz, 1 H, C6-H) 5.21 (d, J = 5.0 Hz, 1 H, C16-H) 4.42 (td, J = 9.0, 
2.0 Hz, 1 H, C18-H) 3.98 (d, J = 9.5 Hz, 1 H, C19-H or C20-H) 3.87 (d, J = 9.5 Hz, 1 H, 



























C19-H or C20-H) 3.41 (s, 3 H, C21-H3 or C22-H3) 3.30 (s, 3 H, C22-H3 or C22-H3) 3.04-
2.97 (comp, 2 H, C13-H and C17-H) 2.84 (td, J = 9.0, 4.0 Hz, 1 H, C13-H) 2.72 (m, 1 H, 
C11-H) 2.26 (dm, J = 15.0 Hz, 1 H, C12-H) 2.16 (ddd, J = 15.0, 4.0, 1.0 Hz, 1 H, C17-H) 
1.92 (tm, 1 H, C12-H); 13C-NMR (125 MHz, CD3OD) δ 141.9, 137.1, 127.0, 123.1 (C7), 
120.8 (C6), 117.9 (C5), 112.2 (C8), 106.8 (C3), 77.3 (C19 or C20), 76.4 (C19 or C20), 
74.8 (C18), 59.4 (C21 or C22), 59.2 (C21 or C22), 49.8 (C16), 49.6 (C10), 46.9 (C11), 




ethanoazocino[4,3-b]indol-12-ol. (4.121b). (WLM8_126). A round bottom flask 
charged with Pd2(dba)3 (2.7 mg, 0.00297 mmol) and 1,4-bis(diphenylphosphino)butane 
(2.5 mg, 0.00594 mmol) was placed under vacuum and backfilled with N2 three times. A 
second round bottom flask was charged with 4.120b (16 mg, 0.0297 mmol) and 1,3-
dimethylbarbituric acid (46 mg, 0.297 mmol) and placed under vacuum and backfilled 
with N2 three times. THF (0.3 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. The Pd/ligand mixture (30 µL) was 
added via syringe to the flask containing 4.120b, and stirring was continued at room 
temperature until 4.120b was gone by TLC. The reaction was quenched with saturated aq 
NaHCO3 (0.5 mL) and stirred at room temperature for 15 min. The reaction mixture was 
diluted with H2O (2.0 mL) extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (15 mL), dried (Na2SO4), filtered, and concentrated in 








with CH2Cl2 : MeOH (96 : 4 → 90 : 10) containing 1% NEt3 provided 11.5 mg (85%) of 
4.121b as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.56 (dt, J = 7.9, 1.0 Hz, 1H), 
7.41 (dt, J = 8.1, 0.9 Hz, 1H), 7.27 (d, J = 7.1 Hz, 1H), 7.25 (d, J = 7.7 Hz, 1H), 7.19 (d, J 
= 7.1 Hz, 1H), 7.17 (d, J = 7.5 Hz, 1H), 7.12 (dd, J = 7.1, 1.2 Hz, 1H), 7.05 (td, J = 7.8, 
0.9 Hz, 1H), 7.00 (comp, 2H), 6.96 – 6.91 (m, 3H), 6.91 – 6.80 (m, 1H), 5.00 (dd, J = 
6.7, 1.4 Hz, 1H), 4.94 (d, J = 9.5 Hz, 1H), 4.63 (dd, J = 9.0, 2.2 Hz, 1H), 4.57 (comp, 
2H), 4.35 (d, J = 9.4 Hz, 1H), 3.00 (comp, 2H), 2.84 (comp, 2H), 2.16 (comp, 2H), 1.99 – 
1.88 (m, 1H); 13C-NMR (125 MHz, CD3OD) δ 160.4, 160.2, 139.6, 137.3, 130.5, 130.3, 
127.2, 122.8, 122.3, 122.0, 120.4, 118.3, 116.1, 116.0, 112.0, 110.5, 75.4, 72.9, 70.8, 
48.8, 48.3, 47.2, 42.1, 41.9, 30.0; HRMS (ESI) m/z observed 477.21490 [C29H30N2O3 




1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.121c). (WLM8_137). A 1 mL vial charged 
with Pd2(dba)3 (1.8 mg, 0.00198 mmol) and 1,4-bis(diphenylphosphino)butane (1.7 mg, 
0.00396 mmol) was placed under vacuum and backfilled with N2 three times. A second 
round bottom flask was charged with 4.120c (12 mg, 0.0198 mmol) and 1,3-
dimethylbarbituric acid (31 mg, 0.198 mmol) and placed under vacuum and backfilled 
with N2 three times. THF (0.2 mL) was then added to both flasks, and the mixtures were 
stirred at room temperature under N2 for 5 min. An aliquot of the Pd/ligand mixture (20 
µL) was added via syringe to the flask containing 4.120c, and stirring was continued at 








saturated aq NaHCO3 (0.2 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (1.0 mL) extracted with CH2Cl2 (3 x 10 mL). The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (95 : 5) containing 1% NEt3 provided 6 mg 
(58%) of 4.121c as a white solid: 1H-NMR (500 MHz, CD3OD) δ 7.59 (d, J = 8.0 Hz, 1 
H) 7.42 (d, J = 8.0 Hz, 1 H) 7.25 (d, J = 9.0 Hz, 2 H) 7.19-7.15 (comp, 3 H) 7.11 (td, J = 
7.5 Hz, 1 H) 6.97 (d, J = 9.0 Hz, 2 H) 6.90 (d, J = 9.0 Hz, 2 H) 5.31 (d, J = 5.5 Hz, 1 H) 
4.87 (d, J = 10.0 Hz, 1 H) 4.57-4.52 (comp, 3 H) 4.46 (d, J = 9.5 Hz, 1 H) 3.11-3.04 
(comp, 3 H) 2.97 (td, J = 13.5, 4.0 Hz, 1 H) 2.31 (dm, J = 16.0 Hz, 1 H) 2.27 (dd, J = 
15.0, 10.0 Hz, 1 H) 2.04 (tm, J = 17.0 Hz, 1 H); 13C-NMR (125 MHz, CD3OD) δ 158.9, 
158.7, 140.1, 137.4, 130.5, 130.2, 127.4, 127.0, 127.0, 123.5, 121.0, 118.2, 117.5, 117.5, 
112.3, 107.6, 74.6, 73.1, 71.6, 49.8, 49.6, 47.0, 41.6, 40.3, 28.1; HRMS (ESI) m/z 




1,5-ethanoazocino[4,3-b]indol-12-ol. (4.121d). (WLM9_80). A round bottom flask 
charged with Pd2(dba)3 (3.4 mg, 0.00367 mmol) and 1,4-bis(diphenylphosphino)butane 
(3.1 mg, 0.00734 mmol) was placed under vacuum and backfilled with N2 three times. A 
second round bottom flask was charged with 4.120d (22 mg, 0.367 mmol) and 1,3-
dimethylbarbituric acid (57 mg, 0.367 mmol) and placed under vacuum and backfilled 








stirred at room temperature under N2 for 5 min. A 30 µL aliquot of the Pd/ligand mixture 
was added via syringe to the flask containing 4.120d, and stirring was continued at room 
temperature until 4.120d was gone by TLC. The reaction was quenched with saturated aq 
NaHCO3 (5 mL) and stirred at room temperature for 15 min. The reaction mixture was 
diluted with H2O (5 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a brown oil. Subsequent purification by flash chromatography eluting 
with CH2Cl2 : MeOH (95 : 5 → 90 : 10) containing 1% NEt3 followed by RP HPLC H2O 
: MeCN (75 : 25 → 90 : 10 over 30 min) provided 11.5 mg (61%) of 4.121d as a white 
solid. 1H-NMR (500 MHz, CD3OD) δ 7.58 (d, J = 7.9 Hz, 1H), 7.43 (dt, J = 8.1, 0.9 Hz, 
1H), 7.14 (td, J = 7.7, 1.0 Hz, 1H), 7.08 (td, J = 7.4, 1.1 Hz, 1H), 6.96 (d, J = 9.0 Hz, 
2H), 6.88 (d, J = 9.1 Hz, 2H), 6.85 (d, J = 9.0 Hz, 2H), 6.77 (d, J = 9.1 Hz, 2H), 5.06 (d, 
J = 6.3 Hz, 1H), 4.90 (d, J = 9.7 Hz, 1H), 4.66 – 4.58 (m, 1H), 4.52 (app s, 2H), 4.30 (d, J 
= 9.4 Hz, 1H), 3.75 (s, 3H), 3.71 (s, 3H), 3.07 – 2.96 (comp, 2H), 2.96 – 2.78 (comp, 
2H), 2.28 – 2.15 (comp, 2H), 2.01 – 1.92 (m, 1H). 13C-NMR (125 MHz, CD3OD) δ 
154.3, 154.1, 153.1, 152.9, 138.4, 135.8, 125.7, 121.4, 118.9, 116.8, 115.8, 115.6, 114.2, 
114.0, 110.6, 73.8, 72.4, 70.2, 54.6, 54.5, 48.1, 45.9, 45.5, 40.3, 40.3, 28.2. HRMS (ESI) 




Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.58 (d, J = 7.9 Hz, 1H, C5-H), 
7.43 (dt, J = 8.1, 0.9 Hz, 1H, C8-H), 7.14 (td, J = 7.7, 1.0 Hz, 1H, C7-H), 7.08 (td, J = 
7.4, 1.1 Hz, 1H, C6-H), 6.96 (d, J = 9.0 Hz, 2H, C22-H and C30-H or C23-H and C31-
H), 6.88 (d, J = 9.1 Hz, 2H, C22-H and C30-H or C23-H and C31-H), 6.85 (d, J = 9.0 Hz, 
2H, C24-H and C28-H or C25-H and C29-H), 6.77 (d, J = 9.1 Hz, 2H, C24-H and C28-H 
or C25-H and C29-H), 5.06 (d, J = 6.3 Hz, 1H, C14-H), 4.90 (d, J = 9.7 Hz, 1H, C18-H 
or C19-H), 4.63 (td, J = 9.0, 1.8 Hz, 1H, C12-H), 4.52 (app s, 2H, C18-H and C19-H), 
4.30 (d, J = 9.4 Hz, 1H, C18-H or C19-H), 3.75 (s, 3H, C32-H3 or C33-H3), 3.71 (s, 3H, 
C32-H3 or C33-H3), 3.07 – 2.96 (comp, 2H, C11-H and C13-H), 2.96 – 2.78 (comp, 2H, 
C16-H2), 2.28 – 2.15 (comp, 2H, C13-H and C17-H), 2.01 – 1.92 (m, 1H, C17-H). 13C-
NMR (125 MHz, CD3OD) δ 154.3 (C20 or C21), 154.1 (C20 or C21), 153.1 (C26 or 
C27), 152.9 (C26 or C27), 138.4 (C9), 135.8 (C2), 125.7 (C4), 121.4 (C7), 118.9 (C6), 
116.8 (C5), 115.8 (C22 and C30 or C23 and C31), 115.6 (C22 and C30 or C23 and C31), 
114.2 (C24 and C28 or C25 and C29), 114.0 (C24 and C28 or C25 and C29), 110.6 (C8), 
108.4 (C3), 73.8 (C12), 72.4 (C18 or C19), 70.2 (C18 or C19), 54.6 (C32 or C33), 54.5 












































1H-5,1-ethanoazocino[4,3-b]indol-12-ol. (4.122a). (WLM7_265_2). A mixture of 
4.121a (4.0 mg, 0.012 mmol) and 37% aq formaldehyde solution (3.6 mg, 0.12 mmol, 10 
µL) in CH2Cl2 (0.3 mL) was stirred for 5 min at room temperature whereupon sodium 
triacetoxyborohydride (10 mg, 0.048 mmol) was added in one portion. Stirring was 
continued for 14 h at room temperature. The reaction was quenched with saturated aq 
Rochelle’s salt (0.5 mL) and extracted with CH2Cl2 (3 x 2 mL). The combined organic 
extracts were washed with brine (3 mL), dried (Na2SO4), filtered, and concentrated in 
vacuo to afford a brown oil. Subsequent purification by RP HPLC H2O/MeCN (90 : 10 to 
5 : 95 over 30 min) afforded 4.0 mg (95%) of 4.122a as a white solid. 1H-NMR (500 
MHz, CD3OD) δ 10.82 (br, 1 H) 7.55 (d, J = 8.0 Hz, 1 H) 7.42 (d, J = 8.0 Hz, 1 H) 7.15 
(td, J = 7.0, 1.0 Hz, 1 H) 7.11 (td, J = 7.0, 1.0 Hz, 1 H) 5.12 (d, J = 5.0 Hz, 1 H) 4.37 (td, 
J = 9.5, 3.0 Hz, 1 H) 3.96 (d, J = 9.0 Hz, 1 H) 3.88 (d, J = 9.0 Hz, 1 H) 3.84 (d, J = 9.0 
Hz, 1 H) 3.70 (d, J = 9.0 Hz, 1 H) 3.40 (s, 3 H) 3.30 (s, 3 H) 3.12-3.05 (comp, 2 H) 2.95 
(td, J = 13.5, 4.0 Hz, 1 H) 2.86 (s, 3 H) 2.70 (m, 1 H) 2.28 (dm, 16.0 Hz, 1 H) 2.15 (ddd, 
J = 15.0, 8.0, 2.0 Hz, 1 H) 1.96 (tm, 1 H); 13C-NMR (125 MHz, CD3OD) δ 142.6, 137.1, 
128.4, 123.2, 121.4, 117.8, 112.5, 104.5, 77.4, 76.6, 74.6, 60.6, 59.4, 59.2, 52.6, 49.7, 











Assignments: 1H-NMR (500 MHz, CD3OD) δ 10.82 (br, 1 H, N1-H) 7.55 (d, J = 
8.0 Hz, 1 H, C5-H) 7.42 (d, J = 8.0 Hz, 1 H, C8-H) 7.15 (td, J = 7.0, 1.0 Hz, 1 H, C7-H) 
7.11 (td, J = 7.0, 1.0 Hz, 1 H, C6-H) 5.12 (d, J = 5.0 Hz, 1 H, C16-H) 4.37 (td, J = 9.5, 
3.0 Hz, 1 H, C18-H) 3.96 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.88 (d, J = 9.0 Hz, 1 H, 
C19-H or C20-H) 3.84 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.70 (d, J = 9.0 Hz, 1 H, 
C19-H or C20-H) 3.40 (s, 3 H, C21-H3 or C22-H3) 3.30 (s, 3 H, C21-H3 or C22-H3) 3.12-
3.05 (comp, 2 H, C13-H and C17-H) 2.95 (td, J = 13.5, 4.0 Hz, 1 H, C13-H) 2.86 (s, 3 H, 
C14-H3) 2.70 (m, 1 H, C11-H) 2.28 (dm, 16.0 Hz, 1 H, C12-H) 2.15 (ddd, J = 15.0, 8.0, 
2.0 Hz, 1 H, C17-H) 1.96 (tm, 1 H, C12-H); 13C-NMR (125 MHz, CD3OD) δ 142.6, 
137.1, 128.4, 123.2 (C7), 121.4 (C6), 117.8 (C5), 112.5 (C8), 104.5 (C3), 77.4 (C19 or 
C20), 76.6 (C19 or C20), 74.6 (C18), 60.6 (C16), 59.4 (C21 or C22), 59.2 (C21 or C22), 
52.6 (C13), 49.7 (C10), 46.3 (C11), 45.8 (C14), 40.1 (C17), 28.7 (C12).  
 
 
(1S/R, 5R/S)-2-Allyl 7-tert-butyl 6,6-bis(methoxymethyl)-12-oxo-3,4,5,6-
tetrahydro-1H-1,5-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.123a). 
(WLM7_259_2). 4-dimethylaminopyridine (136 mg, 1.12 mmol) was added to a solution 
of 4.119a (307 mg, 0.744 mmol) in a mixture of di-tert-butyl dicarbonate (1.5 ml) and 

































was partitioned between H2O (25.0 mL) and Et2O (25.0 mL). The layers were separated, 
and the organic layer was extracted with Et2O (2 x 25 mL). The combined organic 
extracts were washed with brine (40 mL), dried (Na2SO4), and concentrated under 
reduced pressure. The resulting yellow oil was purified by flash chromatography eluting 
with Hexanes : EtOAc (10 : 1 → 4 : 1 → 100% EtOAc) containing 1% NEt3 to give 232 
mg (63%) of 4.123a as a yellow foam and 94 mg (31%) of unreacted starting material 
4.119a: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 7.84 (dd, J = 9.0, 1.0 Hz, 1 H) 7.53 (d, J = 
8.0 Hz, 1 H) 7.38 (td, J = 7.5, 1.0 Hz, 1 H) 7.29 (td, J = 7.5, 1.0 Hz, 1 H) 6.15 (br, 1 H) 
5.89 (br, 1 H) 5.27 (br, 2 H) 4.69 (br, 2 H) 4.42 (d, J = 9.0 Hz, 1 H) 4.00 (d, J = 9.5 Hz, 1 
H) 3.95-3.92 (m, 1 H) 3.60 (d, J = 9.5 Hz, 1 H) 3.60 (d, J = 9.5 Hz, 1 H) 3.32 (s, 3 H) 
3.17 (s, 3 H) 3.16-3.11 (comp, 2 H) 3.03 (dd, J = 13.5, 4.5 Hz, 1 H) 2.88 (m, 1 H) 2.18 
(dm, J = 15.0 Hz, 1 H) 1.83-1.76 (m, 1 H) 1.79 (s, 9 H); 13C-NMR (125 MHz, CD3CN, 70 
°C) δ 211.4, 156.0, 152.8, 139.0, 137.7, 134.8, 128.7, 125.9, 123.5, 120.1, 119.1, 115.1, 
109.6, 86.6, 84.2, 78.7, 76.7, 67.0, 64.7, 59.5, 58.9, 49.9, 49.0, 46.5, 43.7, 41.1, 30.0, 
28.7; HRMS (ESI) m/z observed 535.24110 [C20H28N2O3 (M+Na)+ requires 535.24150]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3CN, 70 °C) δ 7.84 (dd, J = 9.0, 1.0 Hz, 1 
H, C8-H) 7.53 (d, J = 8.0 Hz, 1 H, C5-H) 7.38 (td, J = 7.5, 1.0 Hz, 1 H, C7-H) 7.29 (td, J 









































C24a-H and C24b-H) 4.69 (br, 2 H, C15-H2) 4.42 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 
4.00 (d, J = 9.5 Hz, 1 H, C19-H or C20-H) 3.95-3.92 (m, 1 H, C13-H) 3.60 (d, J = 9.5 
Hz, 1 H, C19-H or C20-H) 3.60 (d, J = 9.5 Hz, 1 H, C19-H or C20-H) 3.32 (s, 3 H, C21-
H3 or C22-H3) 3.17 (s, 3 H, C21-H3 or C22-H3) 3.16-3.11 (comp, 2 H, C11-H and C17-H) 
3.03 (dd, J = 13.5, 4.5 Hz, 1 H, C17-H) 2.88 (m, 1 H, C13-H) 2.18 (dm, J = 15.0 Hz, 1 H, 
C12-H) 1.83-1.76 (m, 1 H, C12-H) 1.79 (s, 9 H, C26-H3); 13C-NMR (125 MHz, CD3CN, 
70 °C) δ 211.4 (C18), 156.0 (C14), 152.8 (C1), 139.0, 137.7, 134.8, 128.7, 125.9 (C7), 
123.5 (C6), 120.1, 119.1 (C5), 115.1 (C8), 109.6 (C3), 86.6 (C25), 78.7 (C19 or C20), 
76.7 (C19 or C20), 67.0 (C15), 64.7 (C11), 59.5 (C21 or C22), 58.9 (C21 or C22), 49.9 
(C13), 46.5 (C16), 43.7 (C10), 41.1 (C13), 30.0 (C12), 28.7 (C26). 
 
 
(1S/R, 5R/S)-2-allyl 7-tert-butyl 12-oxo-6,6-bis(phenoxymethyl)-3,4,5,6-
tetrahydro-1H-1,5-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.123b). 
(WLM8_120). 4-dimethylaminopyridine (54 mg, 0.442 mmol) was added to a solution of 
4.119b (158 mg, 0.294 mmol) in a mixture of di-tert-butyl dicarbonate (0.6 ml) and 
toluene (0.4 mL), and the reaction was stirred for 5 h at room temperature. The reaction 
was partitioned between H2O (10 mL) and Et2O (25 mL). The layers were separated, and 
the organic layer was extracted with Et2O (2 x 25 mL). The combined organic extracts 
were washed with brine (25 mL), dried (Na2SO4), and concentrated under reduced 
pressure. The resulting yellow oil was purified by flash chromatography eluting with 
Hexanes : EtOAc (4 : 1) to give 75 mg (40%) of 4.123b as a yellow foam and 73 mg 








8.0 Hz, 1 H) 7.57 (d, J = 7.5 Hz, 1 H) 7.37 (td, J = 7.0, 1.5 Hz, 1 H) 7.31-7.22 (comp, 5 
H) 6.99-6.92 (comp, 2 H) 6.87-6.81 (comp, 4 H) 5.99 (comp, 2 H) 5.43-5.20 (comp, 2 H) 
4.95 (d, J = 9.0 Hz, 1 H) 4.74 (d, J = 10.0 Hz, 1 H) 4.65 (comp, 2 H) 4.51 (d, J = 9.0 Hz, 
1 H) 4.38 (d, J = 10.0 Hz, 1 H) 3.97 (d, J = 13.0 Hz, 1 H) 3.44 (dd, J = 6.0, 3.0 Hz, 1 H) 
2.95 (dd, J = 18.5, 2.0 Hz, 1 H) 3.13 (dd, J = 18.5, 5.0 Hz, 1 H) 3.09 (m, 1 H) 2.16 (dm, J 
= 15.5 Hz, 1 H) 1.84 (tm, J = 14.0 Hz, 1 H) 1.45 (s, 9 H); 13C-NMR (500 MHz, CD3CN, 
70 ºC) δ 211.3, 159.6, 159.5, 156.1, 152.9, 137.8, 137.8, 134.8, 130.7, 130.7, 128.8, 
126.4, 123.8, 122.7, 122.6, 121.2, 119.4, 116.0, 115.9, 115.6, 86.8, 74.2, 72.7, 67.1, 65.1, 
49.4, 48.5, 46.5, 41.2, 30.1, 28.4; HRMS (ESI) m/z observed 659.27270 [C38H40N2O7 
(M+Na)+ requires 659.27280]. 
 
 
(1S/R, 5R/S, 12R/S)-2-allyl 7-tert-butyl 12-hydroxy-6,6-bis(methoxymethyl)-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.124a). 
(WLM7_289_2). Lithium aluminum hydride (7.3 mg, 0.191 mmol) was added to a 
solution of 4.123a (24.5 mg, 0.0478 mmol) in dry THF (0.5 mL) and the reaction was 
stirred for 2 h at 0 ºC until starting material was consumed by TLC. Excess lithium 
aluminum hydride was quenched with saturated aq Rochelle’s Salt (0.3 ml) and stirred 
for 15 min. The reaction mixture was extracted with CH2Cl2 (3 x 10 mL), and the 
combined organic extracts were washed with brine (20 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The resulting yellow oil was purified by flash 
chromatography eluting with CH2Cl2 : MeOH (100% CH2Cl2 → 96 : 3) to give 14 mg 








Hz, 1 H) 7.37 (d, J = 8.0 Hz, 1 H) 7.29 (td, J = 8.0, 1.0 Hz, 1 H) 7.19 (td, J = 7.5, 0.5 Hz, 
1 H) 6.02 (br, 1 H) 5.60 (br, 1 H) 5.36 (br, 1 H) 5.25 (br, 1 H) 4.67 (br, 2 H) 4.27 (s, 2 H) 
4.22 (m, 1 H) 4.06 (d, J = 12.0 Hz, 1 H) 3.81 (br, 1 H) 3.60 (d, J = 7.0 Hz, 1 H) 4.47 (d, J 
= 10.0 Hz, 1 H) 3.30 (s, 3 H) 3.23 (s, 3 H) 2.92 (m, 1 H) 2.72 (m, 1 H) 2.50 (br, 1 H) 1.97 
(comp, 2 H) 1.84-1.76 (m, 1 H) 1.73 (s, 9 H); 13C-NMR (125 MHz, CD3CN) δ 156.3, 
152.8, 137.4, 135.1, 128.5, 125.6, 123.3, 122.7, 122.6, 118.3, 115.0, 86.1, 80.2, 77.5, 
75.8, 59.3, 59.1, 54.5, 50.7, 42.0, 28.7; HRMS (ESI) m/z observed 537.25690 
[C28H38N2O7 (M+Na)+ requires 537.25710]. 
 
 
(1S/R, 5R/S, 12R/S)-2-Allyl 7-tert-butyl 12-hydroxy-6,6-bis(phenoxymethyl)-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2,7-dicarboxylate. (4.124b). 
(WLM8_124). Lithium aluminum hydride (132 µL of a 1M solution in THF, 0.132 
mmol) was added to a solution of 4.123b (42 mg, 0.066 mmol) in dry THF (0.65 mL) and 
the reaction was stirred for 2 h at 0 ºC until starting material was consumed by TLC. 
Excess lithium aluminum hydride was quenched with saturated aq Rochelle’s Salt (1.0 
ml) and stirred for 15 min. The reaction mixture was extracted with CH2Cl2 (3 x 10 mL), 
and the combined organic extracts were washed with brine (20 mL), dried (Na2SO4), and 
concentrated under reduced pressure. The resulting yellow oil was purified by flash 
chromatography eluting with Hexanes : EtOAc (4 : 1 → 2 : 1) to give 26 mg (62%) of 
4.124b as a yellow foam: 1H-NMR (500 MHz, (CD3)2SO, 70 ºC) δ 7.75 (dt, J = 8.4, 0.8 
Hz, 1H), 7.43 (d, J = 7.4 Hz, 1H), 7.35 (ddd, J = 8.4, 7.1, 1.3 Hz, 1H), 7.27 (comp, 5H), 








5.18 (m, 2H), 5.15 (d, J = 8.1 Hz, 1H), 4.90 (comp, 2H), 4.66 (comp, J = 3.7 Hz, 2H), 
4.25 (comp, 2H), 3.82 (d, J = 14.2 Hz, 1H), 3.10 – 3.04 (m, 1H), 2.99 – 2.84 (m, 1H), 
2.82 – 2.62 (m, 1H), 2.14 – 1.97 (m, 1H), 1.95 – 1.85 (m, 1H), 1.85 – 1.73 (m, 1H), 1.33 
(s, 9H); 13C-NMR (125 MHz, CD3CN, 70 ºC) δ 159.3, 158.5, 155.4, 151.8, 137.8 136.8, 
134.1, 129.6, 129.6, 127.5, 124.9, 122.4, 122.4, 121.2, 121.0, 118.1, 115.2, 114.9, 114.4, 
85.143, 75.3, 74.7, 71.1, 65.8, 53.1, 49.4, 47.5, 41.1, 29.5, 27.3; HRMS (ESI) m/z 
observed 661.28840 [C38H42N2O7 (M+Na)+ requires 661.28840]. 
 
 
(1S/R, 5R/S, 12R/S)-tert-Butyl 12-hydroxy-6,6-bis(methoxymethyl)-3,4,5,6-
tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-7(2H)-carboxylate. (4.125a). 
(WLM7_290_2). A round bottom flask charged with Pd2(dba)3 (0.5 mg, 0.000534 mmol) 
and 1,4-bis(diphenylphosphino)butane (0.5 mg, 0.00107 mmol) was placed under 
vacuum and backfilled with N2 three times. A second round bottom flask was charged 
with 4.124a (5.5 mg, 0.0107 mmol) and 1,3-dimethylbarbituric acid (17 mg, 0.107 mmol) 
and placed under vacuum and backfilled with N2 three times. THF (0.2 mL) was then 
added to both flasks, and the mixtures were stirred at room temperature under N2 for 5 
min. The Pd/ligand mixture was added via syringe to the flask containing 4.124a, and 
stirring was continued at room temperature until 4.124a was gone by TLC. The reaction 
was quenched with saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 
min. The reaction mixture was diluted with H2O (1.0 mL) extracted with CH2Cl2 (3 x 5 
mL). The combined organic extracts were washed with brine (5 mL), dried (Na2SO4), 








HPLC H2O/MeCN (10% MeCN to 95% MeCN over 30 min) to provide 4.5 mg (98%) of 
4.125a as a white solid: 1H-NMR (600 MHz, CD3OD) δ 7.73 (d, J = 8.2 Hz, 1 H) 7.59 (d, 
J = 7.8 Hz, 1 H) 7.33 (td, J = 7.8, 1.2 Hz, 1 H) (td, J = 7.8, 0.6 Hz, 1 H) 5.30 (d, J = 6.0 
Hz, 1 H) 4.41 (d, J = 8.4 Hz, 1 H) 4.39 (td, J = 9.0, 1.2 Hz, 1 H) 4.28 (d, J = 10.2 Hz, 1 
H) 4.15 (d, J = 8.4 Hz, 1 H) 3.41 (d, J = 10.2 Hz, 1 H) 3.30 (s, 3 H) 3.24 (s, 3 H) 3.01 
(dd, J = 13.2, 5.4 Hz, 1 H) 2.95 (m, 1 H) 2.91 (m, 1 H) 2.71 (td, J = 13.8, 4.8 Hz, 1 H) 
2.28-2.02 (comp, 2 H) 1.95 (m, 1 H) 1.75 (s, 9 H); 13C-NMR (150 MHz, CD3OD) δ 
152.5, 141.4, 137.7, 127.5, 125.9, 123.4, 118.7, 115.9, 115.0, 86.4, 80.4, 76.4, 74.5, 59.1, 
58.7, 53.1, 50.9, 49.6, 42.0, 38.6, 29.1, 28.4; HRMS (ESI) m/z observed 431.25580 
[C24H34N2O5 (M+H)+ requires 431.25400]. 
 
 
Assignments: 1H-NMR (600 MHz, CD3OD) δ 7.73 (d, J = 8.2 Hz, 1 H, C5-H) 
7.59 (d, J = 7.8 Hz, 1 H, C8-H) 7.33 (td, J = 7.8, 1.2 Hz, 1 H, C7-H) (td, J = 7.8, 0.6 Hz, 
1 H, C6-H) 5.30 (d, J = 6.0 Hz, 1 H, C16-H) 4.41 (d, J = 8.4 Hz, 1 H, C19-H or C20-H) 
4.39 (td, J = 9.0, 1.2 Hz, 1 H, C18-H) 4.28 (d, J = 10.2 Hz, 1 H, C19-H or C20-H) 4.15 
(d, J = 8.4 Hz, 1 H, C19-H or C20-H) 3.41 (d, J = 10.2 Hz, 1 H, O15-H) 3.30 (s, 3 H, 
C21-H3 or C22-H3) 3.24 (s, 3 H, C21-H3 or C22-H3) 3.01 (dd, J = 13.2, 5.4 Hz, 1 H, C13-
H) 2.95 (m, 1 H, C17-H) 2.91 (m, 1 H, C11-H) 2.71 (td, J = 13.8, 4.8 Hz, 1 H, C13-H) 




































13C-NMR (150 MHz, CD3OD) δ 152.5 (C1), 141.4, 137.7, 127.5, 125.9 (C7), 123.4 (C6), 
118.7 (C8), 115.9 (C3), 115.0 (C5), 86.4 (C23), 80.4 (C19 or C20), 76.4 (C19 or C20), 
74.5 (C18), 59.1 (C21 or C22), 58.7 (C21 or C22), 53.1 (C11), 50.9 (C10), 49.6 (C16), 
42.0 (C13), 38.6 (C17), 29.1 (C12), 28.4 (C24). 
 
 
(1S/R, 5R/S, 12R/S)-tert-Butyl 12-hydroxy-6,6-bis(phenoxymethyl)-3,4,5,6-
tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-7(2H)-carboxylate. (4.125b). 
(WLM8_125). A round bottom flask charged with Pd2(dba)3 (1.2 mg, 0.00133 mmol) and 
1,4-bis(diphenylphosphino)butane (1.2 mg, 0.0027 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.124b (17 
mg, 0.027 mmol) and 1,3-dimethylbarbituric acid (42 mg, 0.27 mmol) and placed under 
vacuum and backfilled with N2 three times. THF (0.2 mL) was then added to both flasks, 
and the mixtures were stirred at room temperature under N2 for 5 min. The Pd/ligand 
mixture was added via syringe to the flask containing 4.124b, and stirring was continued 
at room temperature until 4.124b was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (2.0 mL) extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by preparative TLC 
eluting with CH2Cl2 : MeOH (98 : 2) containing 1% NEt3 provided 5.0 mg (34%) of 
4.125b as a white solid: 1H-NMR (600 MHz, CD3OD) δ 7.74 (d, J = 8.4 Hz, 1 H) 7.63 (d, 








6.89 (tm, J = 7.2 Hz, 2 H) 6.72 (dm, J = 7.8 Hz, 2 H) 5.32 (d, J = 8.4 Hz, 1 H) 4.95 (d, J 
= 9.6 Hz, 1 H) 4.83 (m, 1 H) 4.80 (d, J = 8.4 Hz, 1 H) 4.59 (td, J = 9.6, 1.2 Hz, 1 H) 4.24 
(d, J = 9.6 Hz, 1 H) 3.10 (m, 1 H) 2.83 (m, 1 H) 2.67 (dd, J = 9.6, 2.4 Hz, 2 H) (ddd, J = 
13.8, 9.6,  1.2 Hz, 1 H) 2.01 (dm, J = 14.4 Hz, 1 H) 1.83 (m, 1 H) 1.30 (s, 9 H); 13C-NMR 
(150 MHz, CD3OD) δ 160.4, 159.6, 152.9, 138.3, 137.9, 130.4, 130.3, 128.5, 125.4, 
122.9, 122.6, 122.0, 121.6, 119.2, 116.0, 115.5, 115.0, 85.5, 76.3, 75.5, 71.6, 53.8, 50.3, 




(1S/R, 5R/S, 12R/S)-Allyl 12-methoxy-6,6-bis(methoxymethyl)-7-methyl-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.126a). 
(WLM7_263_2). A mixture of 4.120a (46 mg, 0.11 mmol) and 60% NaH dispersion in 
mineral oil (22 mg, 0.56 mmol) in DMF (1.1 mL) at 0 °C under N2 was stirred for five 
min and methyl p-toluenesulfonate (207 mg, 1.11 mmol) was added in one portion. The 
reaction was allowed to warm slowly to room temperature overnight. The reaction was 
quenched with saturated aq NH4Cl (1.0 mL), diluted with H2O (5 mL), and extracted with 
EtOAc (3 x 15 mL). The combined organic extracts were washed with brine (25 mL), 
dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. Purification by 
flash chromatography eluting with Hexanes : EtOAc (4 : 1 to 2 : 1) to provide 48 mg 
(quant) of 4.126a as a clear oil: 1H-NMR (500 MHz, CD3CN) δ 7.37 (d, J = 8.0 Hz, 1 H) 
7.33 (d, J = 8.0 Hz, 1 H) 7.17 (td, J = 8.0, 1.0 Hz, 1 H) 7.05 (td, J = 8.0, 1.5 Hz, 1 H) 6.04 








10.5 Hz, 1 H) 3.89 (s, 3 H) 3.80 (comp, 3 H) 3.76 (td, J = 9.0, 1.0 Hz, 1 H) 3.66 (d, J = 
10.5 Hz, 1 H) 3.34 (s, 3 H) 3.28 (s, 3 H) 3.27 (s, 3 H) 3.02 (m, 1 H) 2.92 (m, 1 H) 2.81 
(m, 1 H) 2.08 (dm, J = 14.5 Hz, 1 H) 1.81 (app t, J = 12.5 Hz, 1 H) 1.73 (m, 1 H); 13C-
NMR (125 MHz, CD3CN) δ 156.3, 140.8, 138.9, 135.3, 127.5, 122.8, 120.5, 117.3, 
115.4, 110.3, 86.4, 80.5, 77.4, 66.6, 61.1, 59.0, 59.0, 57.3, 50.4, 48.5, 46.7, 42.1, 33.5; 
HRMS (ESI) m/z observed 465.23580 [C25H34N2O5 (M+Na)+ requires 465.23600]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3CN) δ 7.37 (d, J = 8.0 Hz, 1 H, C5-H) 
7.33 (d, J = 8.0 Hz, 1 H, C8-H) 7.17 (td, J = 8.0, 1.0 Hz, 1 H, C7-H) 7.05 (td, J = 8.0, 1.5 
Hz, 1 H, C6-H) 6.04 (br, 1 H, C15-H) 5.65 (d, J = 7.0 Hz, 1 H, C16-H) 5.25 (br, 1 H, 
C23-H) 5.23 (br, 1 H, C23-H) 4.66 (br, 2 H, C14-H2) 4.25 (d, J = 10.5 Hz, 1 H, C19-H or 
C20-H) 3.89 (s, 3 H, C1-H3) 3.80 (comp, 3 H, C19-H, C20-H, and C13-H) 3.76 (td, J = 
9.0, 1.0 Hz, 1 H, C18-H) 3.66 (d, J = 10.5 Hz, 1 H, C19-H or C20-H) 3.34 (s, 3 H, C24-
H3) 3.28 (s, 3 H, C21-H3 or C22-H3) 3.27 (s, 3 H, C21-H or C22-H3) 3.02 (m, 1 H, C17-
H) 2.92 (m, 1 H, C11-H) 2.81 (m, 1 H, C13-H) 2.08 (dm, J = 14.5 Hz, 1 H, C12-H) 1.81 
(app t, J = 12.5 Hz, 1 H, C17-H) 1.73 (m, 1 H, C12-H); 13C-NMR (125 MHz, CD3CN) δ 
156.3 (C25), 140.8, 138.9, 135.3, 127.5, 122.8 (C7), 120.5 (C6), 118.2 (5), 117.3, 115.4 



































(C17), 59.0 (C21 or C22), 59.0 (C21 or C22), 57.3 (C24), 50.4 (C10), 48.5 (C16), 46.7 
(C11), 42.1 (C13), 33.5 (C1) 32.7 (C12). 
 
 
(1S/R, 5R/S, 12R/S)-Allyl 12-methoxy-7-methyl-6,6-bis(phenoxymethyl)-
3,4,5,6-tetrahydro-1H-5,1-ethanoazocino[4,3-b]indole-2(7H)-carboxylate. (4.126b). 
(WLM8_189). A mixture of 4.120b (39 mg, 0.0725 mmol) and 60% NaH dispersion in 
mineral oil (29 mg, 0.725 mmol) in dry DMF (0.7 mL) at 0 °C under N2 was stirred for 
five min and methyl p-toluenesulfonate (67 mg, 0.362 mmol) was added in one portion. 
The reaction was allowed to warm slowly to room temperature overnight. The reaction 
was quenched with saturated aq NH4Cl (0.5 mL), diluted with H2O (2.0 mL), and 
extracted with CH2Cl2 (3 x 15 mL). The combined organic extracts were washed with 
brine (10 mL), dried (Na2SO4), filtered, and concentrated in vacuo to afford a clear oil. 
Purification by flash chromatography eluting with Hexanes : EtOAc (10 : 1) to provide 
45.5 mg (99%) of 4.126b as a clear oil: 1H-NMR (500 MHz, CD3CD) δ 7.64 (d, J = 8.0 
Hz, 1 H) 7.47 (d, J = 8.0 Hz, 1 H) 7.31-7.21 (comp, 6 H) 6.97-6.92 (comp, 4 H) 6.88 (d, J 
= 8.5 Hz, 1 H) 6.15 (m, 1 H) 5.64-5.59 (comp, 2 H) 5.35 (d, J = 6.0 Hz, 1 H) 5.19 (d, J = 
11.0 Hz, 1 H) 4.73 (d, J = 9.0 Hz, 1 H) 4.53 (d, J = 11.0 Hz, 1 H) 4.42 (d, J = 9.0 Hz, 1 
H) 4.07 (dd, J = 13.5, 6.5Hz, 1 H) 3.95 (td, J = 7.5 Hz, 1 H) 3.92 (s, 3 H) 3.61 (dd, J = 
14.0, 8.0 Hz, 1 H) 3.43 (m, 1 H) 3.34-3.26 (m, 1 H) 3.21-3.12 (comp, 2 H) 3.18 (s, 3 H) 
2.41 (dm, J = 15.5 Hz, 1 H) 2.24 (dd, J = 15.0, 8.0 Hz, 1 H) 2.05 (m, 1 H); 13C-NMR (500 
MHz, CD3CD) δ 159.7, 159.1, 141.0, 139.5, 130.8, 130.5, 128.9, 128.4, 125.9, 124.1, 








50.5, 50.0, 44.7, 38.4, 33.3, 29.3; HRMS (ESI) m/z observed 589.26750 [C35H38N2O5 




hexahydro-1H-5,1-ethanoazocino[4,3-b]indole. (4.127a). (WLM7_269_2). A round 
bottom flask charged with Pd2(dba)3 (0.6 mg, 0.00066 mmol) and 1,4-
bis(diphenylphosphino)butane (0.55 mg, 0.00131 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.126a (29 
mg, 0.066 mmol) and 1,3-dimethylbarbituric acid (103 mg, 0.66 mmol) and placed under 
vacuum and backfilled with N2 three times. THF (0.3 mL) was then added to both flasks, 
and the mixtures were stirred at room temperature under N2 for 5 min. The Pd/ligand 
mixture was added via syringe to the flask containing 4.126a, and stirring was continued 
at room temperature until 4.126a was gone by TLC. The reaction was quenched with 
saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 min. The reaction 
mixture was diluted with H2O (0.5 mL) extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (100% CH2Cl2 to 100 : 1) containing 1% 
NEt3 to provide 20 mg (85%) of 4.127a as a white solid:  1H-NMR (500 MHz, CD3OD) δ 
7.54 (d, J = 8.0 Hz, 1 H) 7.39 (d, J = 8.0 Hz, 1 H) 7.22 (td, J = 7.5, 1.0 Hz, 1 H) 7.11 (td, 
J = 7.5, 1.0 Hz, 1 H) 5.26 (dd, J = 6.5, 1.0 Hz, 1 H) 4.38 (d, J = 11.0 Hz, 1 H) 3.92 (s, 3 








(d, J = 11.0 Hz, 1 H) 3.43 (s, 3 H) 3.30 (s, 3 H) 3.29 (s, 3 H) 3.11 (m, 1 H) 3.04-2.98 
(comp, 3 H) 3.34 (dm, J = 15.5 Hz, 1 H) 2.10 (ddd, J = 15.0, 9.0, 2.0 Hz, 1 H) 1.94-1.86 
(m, 1 H); 13C-NMR (125 MHz, CD3OD) δ 141.5, 139.2, 127.0, 123.5, 121.1, 118.0, 
110.4, 109.4, 85.3, 81.2, 76.5, 58.8, 58.8, 57.7, 50.3, 49.6, 45.3, 41.9, 38.4, 33.0, 29.4; 
HRMS (ESI) m/z observed 381.21510 [C21H30N2O3 (M+Na)+ requires 381.21490]. 
 
 
Assignments: 1H-NMR (500 MHz, CD3OD) δ 7.54 (d, J = 8.0 Hz, 1 H, C5-H) 
7.39 (d, J = 8.0 Hz, 1 H, C8-H) 7.22 (td, J = 7.5, 1.0 Hz, 1 H, C7-H) 7.11 (td, J = 7.5, 1.0 
Hz, 1 H, C6-H) 5.26 (dd, J = 6.5, 1.0 Hz, 1 H, C16-H) 4.38 (d, J = 11.0 Hz, 1 H, C19-H 
or C20-H) 3.92 (s, 3 H, C1-H3) 3.87 (td, J = 9.0, 2.0 Hz, 1 H, C18-H) 3.85 (d, J = 9.0 Hz, 
1 H, C19-H or C20-H) 3.76 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.62 (d, J = 11.0 Hz, 1 
H, C19-H or C20-H) 3.43 (s, 3 H, C15-H3) 3.30 (s, 3 H, C21-H3 or C22-H3) 3.29 (s, 3 H, 
C21-H3 or C22-H3) 3.11 (m, 1 H, C11-H) 3.04-2.98 (comp, 3 H, C13-H2, C17-H) 3.34 
(dm, J = 15.5 Hz, 1 H, C12-H) 2.10 (ddd, J = 15.0, 9.0, 2.0 Hz, 1 H, C17-H) 1.94-1.86 
(m, 1 H, C12-H); 13C-NMR (125 MHz, CD3OD) δ 141.5, 139.2, 127.0, 123.5 (C7), 121.1 
(C6), 118.0 (C5), 110.4 (C8), 109.4 (C3), 85.3 (C18), 81.2 (C19 or C20), 76.5 (C19 or 
C20), 58.8 (C21 or C22), 58.8 (C21 or C22), 57.7 (C15), 50.3 (C10), 49.6 (C16), 45.3 
































hexahydro-1H-5,1-ethanoazocino[4,3-b]indole (4.127b). (WLM8_191). A round 
bottom flask charged with Pd2(dba)3 (0.73 mg, 0.000794 mmol) and 1,4-
bis(diphenylphosphino)butane (0.68 mg, 0.00159 mmol) was placed under vacuum and 
backfilled with N2 three times. A second round bottom flask was charged with 4.126b (45 
mg, 0.0794 mmol) and 1,3-dimethylbarbituric acid (124 mg, 0.794 mmol) and placed 
under vacuum and backfilled with N2 three times. THF (0.4 mL) was then added to both 
flasks, and the mixtures were stirred at room temperature under N2 for 5 min. The 
Pd/ligand mixture was added via syringe to the flask containing 4.126b, and stirring was 
continued at room temperature until 4.126b was gone by TLC. The reaction was 
quenched with saturated aq NaHCO3 (0.5 mL) and stirred at room temperature for 15 
min. The reaction mixture was diluted with H2O (5 mL) extracted with CH2Cl2 (3 x 10 
mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4), 
filtered, and concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with CH2Cl2 : MeOH (99 : 1) containing 1% NEt3 followed by 
RP HPLC eluting with H2O : MeCN (10% MeCN → 90% MeCN over 60 min) provided 
25 mg (66%) of 4.127b as a white solid and 7.5 mg (18%) of 4.127c as a white solid: 1H-
NMR (500 MHz, CD3OD) δ 7.65 (d, J = 9.0 Hz, 1 H) 7.40 (d, J = 9.0 Hz, 1 H) 7.28-7.24 
(comp, 5 H) 7.17 (dt, J = 7.5, 1.0 Hz, 1 H) 6.96-6.91 (comp, 4 H) 6.82 (dd, J = 8.5, 1.0 
Hz, 1 H) 5.39 (d, J = 5.5 Hz, 1 H) 5.14 (d, J = 10.5 Hz, 1 H) 4.70 (d, J = 9.0 Hz, 1 H) 
4.53 (d, J = 11.0 Hz, 1 H) 4.42 (d, J = 9.0 Hz, 1 H) 3.94 (dt, J = 9.0, 1.5 Hz, 1 H) 3.87 (s, 








(dm, J = 16.0 Hz, 1 H) 2.20 (ddd, J = 14.0, 8.5, 2.0 Hz, 1 H) 2.00 (tm, 1 H). 13C-NMR 
(125 MHz, CD3OD) δ 159.8, 159.1, 140.1, 139.5, 130.8, 130.5, 127.1, 123.9, 122.7, 
122.1, 121.4, 118.4, 115.6, 115.4, 110.5, 110.4, 85.0, 76.2, 71.7, 57.8, 49.9, 45.3, 41.8, 





2,3,4,5,6,7-hexahydro-1H-5,1-ethanoazocino[4,3-b]indole. (4.127c). (WLM8_143). A 
round bottom flask charged with Pd(PPh3)4 (0.12 mg, 0.000106 mmol) and 4.126b (6 mg, 
0.0106 mmol) was placed under vacuum and backfilled with N2 three times. THF (0.1 
mL) was added and the mixture was stirred at room temperature over night. The reaction 
mixture was diluted with H2O (1.0 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by RP HPLC H2O : 
MeCN (10% MeCN → 95% MeCN over 60 min) provided 3 mg (55%) of 4.127c as a 
white solid: 1H-NMR (500 MHz, CD3OD) δ 7.65 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 8.3 Hz, 
1H), 7.28 (comp, 6H), 6.96 (comp, 4H), 6.89 (d, J = 8.1 Hz, 2H), 6.15 (ddd, J = 17.1, 
10.3, 5.6 Hz, 1H), 5.64 (d, J = 6.6 Hz, 1H), 5.61 (d, J = 13.3 Hz, 1H), 5.36 (d, J = 5.9 Hz, 
1H), 5.24 – 5.17 (m, 1H), 4.73 (dd, J = 9.1, 1.4 Hz, 1H), 4.54 (d, J = 11.0 Hz, 1H), 4.43 
(d, J = 9.0 Hz, 1H), 4.08 (dd, J = 13.6, 6.6 Hz, 1H), 4.00 – 3.93 (m, 1H), 3.92 (s, 3H), 
3.62 (dd, J = 14.0, 7.5 Hz, 1H), 3.47 – 3.42 (m, 1H), 3.30 – 3.26 (m, 1H), 3.19 (comp, 








NMR (125 MHz, CD3OD) δ 159.7, 159.1, 141.0, 139.5, 130.8, 130.5, 128.9, 128.4, 
125.9, 124.1, 122.8, 122.1, 122.0, 118.1, 115.5, 115.5, 111.0, 108.4, 84.7, 76.4, 71.6, 
61.7, 59.1, 57.9, 50.5, 50.0, 44.7, 38.4, 33.3, 29.3; HRMS (ESI) m/z observed 523.29600 




2,3,4,5,6,7-hexahydro-1H-5,1-ethanoazocino[4,3-b]indole. (4.128a). (WLM7_281_2). 
A mixture of 4.127a (6.3 mg, 0.018 mmol) and 37% aq formaldehyde solution (14 mg, 
0.18 mmol, 14 µL) in CH2Cl2 (0.2 mL) was stirred for 5 min at room temperature 
whereupon sodium triacetoxyborohydride (19 mg, 0.088 mmol) was added in one 
portion. Stirring was continued for 4 h at room temperature. The reaction was quenched 
with saturated aq Rochelle’s salt (0.5 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford 6.5 mg (quant) of 4.128a as a white solid: 1H-NMR (500 
MHz, CDCl3) δ 7.45 (d, J = 8.0 Hz, 1 H) 7.35 (d, J = 8.0 Hz, 1 H) 7.26 (td, J = 8.0, 1.0 
Hz, 1 H) 7.17 (td, J = 8.0, 1.0 Hz, 1 H) 4.72 (d, J = 5.0 Hz, 1 H) 4.31 (d, J = 10.5 Hz, 1 
H) 4.20 (t, J = 9.0 Hz, 1 H) 3.91 (s, 3 H) 3.86 (d, J = 9.0 Hz, 1 H) 3.66 (d, J = 9.0 Hz, 1 
H) 3.57 (d, J = 10.5 Hz, 1 H) 3.41 (s, 3 H) 3.41-3.39 (m, 1 H) 3.28 (s, 6 H) 2.98 (m, 1 H) 
2.90 (m, 1 H) 2.86 (m, 1 H) 2.72 (s, 3 H) 2.30-2.22 (m, 1 H) 2.15-2.11 (m, 1 H) 1.95 (dd, 
J = 13.0, 8.5 Hz, 1 H); 13C-NMR (125 MHz, CDCl3) δ 140.3, 137.6, 127.1, 122.2, 120.3, 












Assignments: 1H-NMR (500 MHz, CDCl3) δ 7.45 (d, J = 8.0 Hz, 1 H, C5-H) 7.35 
(d, J = 8.0 Hz, 1 H, C8-H) 7.26 (td, J = 8.0, 1.0 Hz, 1 H, C7-H) 7.17 (td, J = 8.0, 1.0 Hz, 
1 H, C6-H) 4.72 (d, J = 5.0 Hz, 1 H, C16-H) 4.31 (d, J = 10.5 Hz, 1 H, C19-H or C20-H) 
4.20 (t, J = 9.0 Hz, 1 H, C18-H) 3.91 (s, 3 H, C1-H3) 3.86 (d, J = 9.0 Hz, 1 H, C19-H or 
C20-H) 3.66 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.57 (d, J = 10.5 Hz, 1 H, C19-H or 
C20-H) 3.41 (s, 3 H, C15-H3) 3.41-3.39 (m, 1 H, C17-H) 3.28 (s, 6 H, C21-H3 and C22-
H3) 2.98 (m, 1 H, C11-H) 2.90 (m, 1 H, C13-H) 2.86 (m, 1 H, C13-H) 2.72 (s, 3 H, C14-
H3) 2.30-2.22 (m, 1 H, C12-H) 2.15-2.11 (m, 1 H, C12-H) 1.95 (dd, J = 13.0, 8.5 Hz, 1 
H, C17-H); 13C-NMR (125 MHz, CDCl3) δ 140.3, 137.6, 127.1, 122.2 (C7), 120.3 (C6), 
117.1 (C5), 109.4 (C8), 108.1 (C3), 83.6 (C18), 80.5 (C19 or C20), 76.0 (C19 or C20), 
58.6 (C21 or C22), 58.4 (C21 or C22), 57.9 (C16), 57.1 (C15), 51.4 (C13), 49.0 (C10), 







































round bottom flask charged with Pd(PPh3)4 (0.5 mg, 0.00407 mmol) and 4.127a (18 mg, 
0.0407 mmol) was placed under vacuum and backfilled with N2 three times. THF (0.4 
mL) was added and the mixture was stirred at room temperature over night. The reaction 
mixture was diluted with H2O (2.0 mL) and extracted with CH2Cl2 (3 x 5 mL). The 
combined organic extracts were washed with brine (10 mL), dried (Na2SO4), filtered, and 
concentrated in vacuo to afford a brown oil. Subsequent purification by flash 
chromatography eluting with Hexanes : EtOAc (1 : 1) containing 1% NEt3 to provide 
14.5 mg (90%) of 4.129 as a white solid: 1H-NMR (500 MHz, CDCl3) δ 7.50 (d, J = 7.5 
Hz, 1 H) 7.29 (d, J = 8.0 Hz, 1 H) 7.19 (td, J = 8.0, 1.0 Hz, 1 H) 7.07 (td, J = 8.0, 1.0 Hz, 
1 H) 6.06 (m, 1 H)  (dd, J = 7.0, 1.0 Hz, 1 H) 5.22 (dd, J = 10.0, 1.0 Hz, 1 H) 4.46 (d, J = 
6.0 Hz, 1 H) 4.23 (d, J = 10.5 Hz, 1 H) 4.00 (td, J = 9.0, 1.5 Hz, 1 H) 3.89 (s, 3 H) 3.79 
(d, J = 9.0 Hz, 1 H) 3.64 (d, J = 9.0 Hz, 1 H) 3.61 (d, J = 10.5 Hz, 1 H) 3.39 (s, 3 H) 
3.36-3.25 (m, 1 H) 3.29 (s, 3 H) 3.27 (s, 3 H) 3.07 (dd, J = 14.0, 5.5 Hz, 1 H) 2.88 (m, 1 
H) 2.82 (m, 1 H) 2.52 (dd, J = 12.0, 6.0 Hz, 1 H) 2.11-2.06 (m, 1 H) 1.86-1.79 (m, 1 H) 
1.81 (ddd, J = 13.5, 4.5, 1.0 Hz, 1 H); 13C-NMR (125 MHz, CDCl3) 138.5, 137.3, 128.1, 
121.3, 119.0, 118.1, 108.7, 85.3, 80.4, 76.5, 61.9, 58.5, 58.3, 56.7, 52.7, 50.0, 48.8, 44.8, 



































Assignments: 1H-NMR (500 MHz, CDCl3) δ 7.50 (d, J = 7.5 Hz, 1 H, C5-H) 7.29 
(d, J = 8.0 Hz, 1 H, C8-H) 7.19 (td, J = 8.0, 1.0 Hz, 1 H, C7-H) 7.07 (td, J = 8.0, 1.0 Hz, 
1 H, C6-H) 6.06 (m, 1 H, C15-H)  (dd, J = 17.0, 1.5 Hz, 1 H, C23a-H) 5.22 (dd, J = 10.0, 
1.0 Hz, 1 H, C23b-H) 4.46 (d, J = 6.0 Hz, 1 H, C16-H) 4.23 (d, J = 10.5 Hz, 1 H, C19-H 
or C20-H) 4.00 (td, J = 9.0, 1.5 Hz, 1 H, C18-H) 3.89 (s, 3 H, C1-H3) 3.79 (d, J = 9.0 Hz, 
1 H, C19-H or C20-H) 3.64 (d, J = 9.0 Hz, 1 H, C19-H or C20-H) 3.61 (d, J = 10.5 Hz, 1 
H, C19-H or C20-H) 3.39 (s, 3 H, C24-H3) 3.36-3.25 (m, 1 H, C14-H) 3.29 (s, 3 H, C21-
H3) 3.27 (s, 3 H, C22-H3) 3.07 (dd, J = 14.0, 5.5 Hz, 1 H, C14-H3) 2.88 (m, 1 H, C11-H) 
2.82 (m, 1 H, C17-H) 2.52 (dd, J = 12.0, 6.0 Hz, 1 H, C13-H) 2.11-2.06 (m, 1 H, C13-H) 
1.86-1.79 (m, 1 H, C12-H or C17-H) 1.81 (ddd, J = 13.5, 4.5, 1.0 Hz, 1 H, C12-H or 
C17-H); 13C-NMR (125 MHz, CDCl3) 138.5, 137.3, 128.1, 121.3 (C7), 119.0 (C6), 118.1 
(C5), 108.7 (C8), 85.3 (C18), 80.4 (C19 or C20), 76.5 (C19 or C20), 61.9 (C14), 58.5 
(C21 or C22), 58.3 (C21 or C22), 56.7 (C24), 52.7 (C16), 50.0 (C13), 48.8 (C10), 44.8 











Chapter 6:  Crystallography Data 
Note: All crystallography data was collected by Dr. Vincent Lynch at the 
University of Texas at Austin. 
6.1 CRYSTALLOGRAPHY DATA FOR COMPOUND 2.14 
View of 2.14 showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  











X-ray Experimental for C23H23NO4S: Crystals grew as highly intergrown clusters 
by slow cooling in MeOH.  The data crystal was cut from a cluster of crystals and had 
approximate dimensions; 0.15 x 0.08 x 0.06 mm. The data were collected on a Rigaku 
SCX-Mini diffractometer with a Mercury CCD using a graphite monochromator with 
MoKα radiation (λ = 0.71075Å). A total of 1080 frames of data were collected using ω-
scans with a scan range of 0.5° and a counting time of 30 seconds per frame. The data 
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were collected at 153 K using a Rigaku XStream low temperature device. Details of 
crystal data, data collection and structure refinement are listed in Table 6.1. Data 
reduction were performed using the Rigaku Americas Corporation’s Crystal Clear 
version 1.40.301 The structure was solved by direct methods using SIR97302 and refined by 
full-matrix least-squares on F2 with anisotropic displacement parameters for the non-H 
atoms using SHELXL-97.303 Structure analysis was aided by use of the programs 
PLATON98304 and WinGX.305 The hydrogen atoms on carbon were calculated in ideal 
positions with isotropic displacement parameters set to 1.2xUeq of the attached atom 
(1.5xUeq for methyl hydrogen atoms). The function, Σw(|Fo|2 - |Fc|2)2, was minimized, 
where w = 1/[(σ(Fo))2 + (0.0657*P)2 + (0.5409*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) 
refined to 0.178, with R(F) equal to 0.0751 and a goodness of fit, S, = 1.06. Definitions 
used for calculating R(F), Rw(F2) and the goodness of fit, S, are given below.
306 The data 
were checked for secondary extinction effects but no correction was necessary. Neutral 
atom scattering factors and values used to calculate the linear absorption coefficient are 
from the International Tables for X-ray Crystallography (1992).307 All figures were 
generated using SHELXTL/PC.308 Tables of positional and thermal parameters, bond 










Table 6.1.  Crystal Data and Structure Refinement for 2.14. 
Empirical formula    C23 H23 N O4 S 
Formula weight    409.48 
Temperature     153(2) K 
Wavelength     0.71075 Å 
Crystal system    Monoclinic 
Space group     P21/c 
Unit cell dimensions   a = 13.644(3) Å α= 90°. 
     b = 11.362(3) Å β= 106.798(5)°. 
    c = 13.569(3) Å γ = 90°. 
Volume    2013.7(8) Å3 
Z     4 
Density (calculated)   1.351 Mg/m3 
Absorption coefficient  0.191 mm-1 
F(000)     864 
Crystal size    0.15 x 0.08 x 0.06 mm 
Theta range for data collection 2.38 to 25.00°. 
Index ranges    -16<=h<=16, -13<=k<=13, -16<=l<=16 
Reflections collected   17158 
Independent reflections  3544 [R(int) = 0.1577] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction   None 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3544 / 174 / 264 
Goodness-of-fit on F2   1.057 
Final R indices    [I>2sigma(I)] R1 = 0.0751, wR2 = 0.1512 
R indices (all data)   R1 = 0.1310, wR2 = 0.1777 
Largest diff. peak and hole  0.316 and -0.370 e.Å-3 
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Table 6.2.  Atomic Coordinates  (x 104) and Equivalent Isotropic Displacement 
Parameters (Å2 x 103) for 2.14 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________ 
      x     y    z   U(eq) 
________________________________________________________________________ 
C1  7215(3) 744(3)  9295(3)  24(1) 
C2  6658(3) -105(4) 8613(3)  28(1) 
C3  6984(3) -454(4) 7783(3)  31(1) 
C4  7872(3) 10(4)  7633(3)  31(1) 
C5  8431(3) 830(4)  8328(3)  29(1) 
C6  8116(3) 1221(4) 9166(3)  25(1) 
C7  8798(3) 2093(4) 9927(3)  28(1) 
C8  8385(3) 2369(4) 10860(4)  36(1) 
C9  7728(3) 1388(4) 11091(3)  34(1) 
C10  8810(4) 3226(4) 9348(4)  40(1) 
C11  9655(4) 3698(4) 9219(4)  49(1) 
C12  10664(4) 3157(4) 9624(4)  42(1) 
C13  10687(3) 2049(4) 10177(3)  33(1) 
C14  9848(3) 1570(4) 10319(3)  28(1) 
C15  7856(4) -571(5) 11758(5)  62(2) 
C16  8617(4) -1434(4) 12306(4)  55(2) 
C17  5889(3) 3161(4) 9543(3)  25(1) 
C18  5789(3) 3344(4) 8508(3)  27(1) 
C19  5927(3) 4473(4) 8172(3)  26(1) 
C20  6194(3) 5414(4) 8863(3)  27(1) 
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Table 6.2., cont. 
C21  6297(3) 5206(4) 9899(3)  30(1) 
C22  6134(3) 4093(4) 10246(3)  27(1) 
C23  6356(3) 6629(4) 8494(4)  36(1) 
N1  6877(2) 1075(3) 10175(2)  25(1) 
O1  5024(2) 1120(3) 9188(2)  31(1) 
O2  5602(2) 1826(3) 10995(2)  33(1) 
O3  8360(2) 399(3)  11426(2)  34(1) 
O4  11444(3) 3608(3) 9502(3)  59(1) 



















Table 6.3.   Bond lengths [Å] and angles [°] for  2.14. 
Lengths: 
C1-C6   1.401(6) 
C1-C2   1.399(6) 
C1-N1   1.448(5) 
C2-C3   1.382(6) 
C2-H2   0.95 
C3-C4   1.390(6) 
C3-H3   0.95 
C4-C5   1.386(6) 
C4-H4   0.95 
C5-C6   1.399(6) 
C5-H5   0.95 
C6-C7   1.535(6) 
C7-C14   1.499(6) 
C7-C10   1.510(6) 
C7-C8   1.559(6) 
C8-C9   1.519(6) 
C8-H8A   0.99 
C8-H8B   0.99 
C9-O3   1.410(5) 
C9-N1   1.478(5) 
C9-H9   1.00 
C10-C11   1.328(7) 
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Table 6.3., cont. 
C10-H10   0.95 
C11-C12   1.463(7) 
C11-H11   0.95 
C12-O4   1.235(5) 
C12-C13   1.461(6) 
C13-C14   1.331(6) 
C13-H13   0.95 
C14-H14   0.95 
C15-O3   1.438(6) 
C15-C16   1.465(7) 
C15-H15A   0.99 
C15-H15B   0.99 
C16-H16A   0.98 
C16-H16B   0.98 
C16-H16C   0.98 
C17-C18   1.388(6) 
C17-C22   1.400(6) 
C17-S1   1.757(4) 
C18-C19   1.392(6) 
C18-H18   0.95 
C19-C20   1.400(6) 
C19-H19   0.95 
C20-C21   1.391(6) 
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Table 6.3., cont. 
C20-C23   1.507(6) 
C21-C22   1.390(6) 
C21-H21   0.95 
C22-H22   0.95 
C23-H23A   0.98 
C23-H23B   0.98 
C23-H23C   0.98 
N1-S1    1.658(3) 
O1-S1    1.426(3) 
O2-S1    1.444(3)
Angles: 
C6-C1-C2  120.8(4) 
C6-C1-N1  120.2(4) 
C2-C1-N1  118.9(4) 
C3-C2-C1  119.8(4) 
C3-C2-H2  120.1 
C1-C2-H2  120.1 
C2-C3-C4  120.6(4) 
C2-C3-H3  119.7 
C4-C3-H3  119.7 
C5-C4-C3  119.1(4) 
C5-C4-H4  120.4 
C3-C4-H4  120.4 
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Table 6.3., cont. 
C4-C5-C6  121.9(4) 
C4-C5-H5  119.0 
C6-C5-H5  119.0 
C1-C6-C5  117.8(4) 
C1-C6-C7  123.3(4) 
C5-C6-C7  118.9(4) 
C14-C7-C10  111.7(4) 
C14-C7-C6  108.3(3) 
C10-C7-C6  107.2(4) 
C14-C7-C8  108.9(3) 
C10-C7-C8  108.2(4) 
C6-C7-C8  112.6(3) 
C9-C8-C7  113.2(4) 
C9-C8-H8A  108.9 
C7-C8-H8A  108.9 
C9-C8-H8B  108.9 
C7-C8-H8B  108.9 
H8A-C8-H8B  107.8 
O3-C9-N1  109.7(3) 
O3-C9-C8  108.0(3) 
N1-C9-C8  111.7(4) 
O3-C9-H9  109.1 
N1-C9-H9  109.1 
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Table 6.3., cont. 
C8-C9-H9  109.1 
C11-C10-C7  123.6(4) 
C11-C10-H10  118.2 
C7-C10-H10  118.2 
C10-C11-C12  122.6(5) 
C10-C11-H11  118.7 
C12-C11-H11  118.7 
O4-C12-C11  122.0(5) 
O4-C12-C13  122.4(5) 
C11-C12-C13  115.7(4) 
C14-C13-C12  122.4(4) 
C14-C13-H13  118.8 
C12-C13-H13  118.8 
C13-C14-C7  124.1(4) 
C13-C14-H14  118.0 
C7-C14-H14  118.0 















C18-C17-C22  120.7(4) 
C18-C17-S1  119.8(3) 
C22-C17-S1  119.5(3) 
C17-C18-C19  119.1(4) 
C17-C18-H18  120.4 
C19-C18-H18  120.4 
C18-C19-C20  121.2(4) 
C18-C19-H19  119.4 
C20-C19-H19  119.4 
C21-C20-C19  118.5(4) 
C21-C20-C23  120.6(4) 
C19-C20-C23  120.8(4) 
C20-C21-C22  121.2(4) 
C20-C21-H21  119.4 
C22-C21-H21  119.4 
C21-C22-C17  119.2(4) 
C21-C22-H22  120.4 
C17-C22-H22  120.4 
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C1-N1-C9  113.3(3) 
C1-N1-S1  119.4(3) 
C9-N1-S1  119.1(3) 
C9-O3-C15  114.1(3) 
O1-S1-O2  119.70(18) 
O1-S1-N1  107.81(17) 
O2-S1-N1  105.46(17) 
O1-S1-C17  108.03(19) 










Table 6.4.   Anisotropic Displacement parameters  (Å2x 103) for 2.14 
The anisotropic displacement factor exponent takes the form:  -2π2[h2 a*2 U11 + ...  + 2 h k 
a* b* U12]. 
______________________________________________________________________________________    
 U11  U22   U33  U23  U13  U12 
_______________________________________________________________________  
C1 26(2)   23(2)  23(2)   3(2)  9(2)   4(2) 
C2 22(2)   32(2)  28(3)   1(2)  4(2)   -3(2) 
C3 31(2)   30(2)  27(3)   -6(2)  3(2)   0(2) 
C4 33(2)   37(3)  24(3)   0(2)  9(2)   5(2) 
C5 26(2)   35(3)  28(3)   7(2)  11(2)   1(2) 
C6 23(2)   27(2)  25(2)   1(2)  6(2)   3(2) 
C7 23(2)   26(2)  35(3)   -1(2)  7(2)   1(2) 
C8 29(2)   40(3)  40(3)   -11(2)  10(2)   1(2) 
C9 29(2)   45(3)  25(3)   -2(2)  5(2)   7(2) 
C10 32(3)   30(3)  50(3)   6(2)  -1(2)   1(2) 
C11 48(3)   39(3)  51(3)   17(2)  -1(2)   -7(3) 
C12 36(3)   49(3)  39(3)   3(2)  7(2)   -10(2) 
C13 24(2)   44(3)  28(3)   -1(2)  4(2)   -2(2) 
C14 28(2)   31(2)  24(2)   -2(2)  5(2)   3(2) 
C15 48(3)   72(4)  74(4)   38(3)  32(3)   10(3) 
C16 66(4)   46(3)  53(4)   3(3)  19(3)   6(3) 
C17 19(2)   28(2)  31(3)   2(2)  10(2)   1(2) 
C18 23(2)   32(2)  23(2)   -6(2)  5(2)   -1(2) 
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Table 6.4., cont. 
C19 25(2)   30(2)  20(2)   2(2)  5(2)   0(2) 
C20 23(2)   27(2)  32(3)   2(2)  9(2)   1(2) 
C21 28(2)   30(2)  30(3)   -4(2)  5(2)   3(2) 
C22 30(2)   34(3)  18(2)   0(2)  9(2)   0(2) 
C23 36(3)   33(3)  38(3)   7(2)  12(2)   4(2) 
N1 24(2)   32(2)  20(2)   -2(2)  9(2)   1(2) 
O1 24(2)   35(2)  33(2)   1(1)  5(1)   -5(1) 
O2 33(2)   45(2)  28(2)   4(1)  18(1)   3(2) 
O3 28(2)   45(2)  29(2)   8(1)  9(1)   5(2) 
O4 40(2)   72(3)  64(3)   11(2)  12(2)   -24(2) 












Table 6.5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
103) for 2.14. 
___________________________________________________________________________________________________________________________________________________________________________ 
    x       y      z    U(eq) 
___________________________________________________________________________________________________________________________________________________________________________ 
H2  6059   -440   8720   33 
H3  6596   -1017   7312   37 
H4  8093   -231   7061   37 
H5  9045   1134   8232   35 
H8A  8972   2509   11477   44 
H8B  7975   3101   10716   44 
H9  7440   1648   11655   40 
H10  8179   3623   9061   48 
H11  9601   4416   8848   59 
H13  11323   1656   10445   39 
H14  9918   853   10693   34 
H15A  7371   -947   11154   74 
H15B  7463   -280   12218   74 
H16A  8965   -1770   11832   82 
H16B  8275   -2064   12575   82 
H16C  9121   -1047   12879   82 
H18  5628   2707   8034   32 
H19  5839   4606   7461   31 
H21  6483   5836   10377   36 
H22  6188   3966   10952   32 
H23A  5949   7198   8752   54 
H23B  6142   6643   7740   54 
H23C  7083   6837   8751   54 
_______________________________________________________________________  
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Table 6.6.  Torsion angles [°] for 2.14. 
C6-C1-C2-C3  -1.9(6) 
N1-C1-C2-C3  -178.3(4) 
C1-C2-C3-C4  1.5(6) 
C2-C3-C4-C5  0.1(6) 
C3-C4-C5-C6  -1.3(6) 
C2-C1-C6-C5  0.7(6) 
N1-C1-C6-C5  177.1(3) 
C2-C1-C6-C7  -175.9(4) 
N1-C1-C6-C7  0.5(6) 
C4-C5-C6-C1  0.9(6) 





C1-C6-C7-C8  0.9(6) 
C5-C6-C7-C8  -175.6(4) 
C14-C7-C8-C9 -94.5(4) 
C10-C7-C8-C9 143.9(4) 
C6-C7-C8-C9  25.6(5) 
C7-C8-C9-O3  66.3(5) 
C7-C8-C9-N1  -54.5(5) 
C14-C7-C10-C11 -0.7(7) 
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C6-C1-N1-C9  -29.3(5) 
C2-C1-N1-C9  147.1(4) 
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Table 6.6., cont. 
C6-C1-N1-S1  119.0(4) 
C2-C1-N1-S1  -64.6(4) 
O3-C9-N1-C1  -63.5(4) 
C8-C9-N1-C1  56.2(5) 
O3-C9-N1-S1  148.1(3) 




C1-N1-S1-O1  45.0(3) 
C9-N1-S1-O1  -168.5(3) 
C1-N1-S1-O2  174.0(3) 











6.2 CRYSTALLOGRAPHIC DATA FOR 2.33G 
View of 2.33g showing the atom labeling scheme. Displacement ellipsoids are 
scaled to the 50% probability level. 
Figure 6.2. X-ray Structure of 2.33g 
 
X-ray Experimental for C24H25NO5S:  Crystals grew as long colorless laths by 
slow cooling from MeOH. The data crystal was cut from a larger crystal and had 
approximate dimensions; 0.58 x 0.08 x 0.02 mm. The data were collected on a Rigaku 
SCX-Mini diffractometer with a Mercury 2 CCD using a graphite monochromator with 
MoKα radiation (λ = 0.71075Å). A total of 360 frames of data were collected using ω-
scans with a scan range of 1° and a counting time of 120 seconds per frame. The data 
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were collected at 163 K using a Rigaku XStream low temperature device. Details of 
crystal data, data collection and structure refinement are listed in Table 6.7. Data 
reduction were performed using the Rigaku Americas Corporation’s Crystal Clear 
version 1.40.301 The structure was solved by direct methods using SIR97302 and refined by 
full-matrix least-squares on F2 with anisotropic displacement parameters for the non-H 
atoms using SHELXL-97.303 Structure analysis was aided by use of the programs 
PLATON98304 and WinGX.305 The hydrogen atoms on carbon were calculated in ideal 
positions with isotropic displacement parameters set to 1.2xUeq of the attached atom 
(1.5xUeq for methyl hydrogen atoms). The function, Σw(|Fo|2 - |Fc|2)2, was minimized, 
where w = 1/[(σ(Fo))2 + (0.0542*P)2 + (1.9824*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) 
refined to 0.223, with R(F) equal to 0.0979 and a goodness of fit, S, = 1.15. Definitions 
used for calculating R(F), Rw(F2) and the goodness of fit, S, are given below.
306 The data 
were checked for secondary extinction effects but no correction was necessary. Neutral 
atom scattering factors and values used to calculate the linear absorption coefficient are 
from the International Tables for X-ray Crystallography (1992).307 All figures were 
generated using SHELXTL/PC.308 Tables of positional and thermal parameters, bond 










Table 6.7.  Crystal data and structure refinement for 2.33g 
Empirical formula    C24 H25 N O5 S 
Formula weight    439.51 
Temperature     163(2) K 
Wavelength     0.71073 Å 
Crystal system    Monoclinic 
Space group     P21/c 
Unit cell dimensions   a = 12.624(6) Å α= 90°. 
    b = 6.874(3) Å β= 101.420(13)°. 
     c = 25.203(11) Å γ = 90°. 
Volume    2143.8(17) Å3 
Z     4 
Density (calculated)   1.362 Mg/m3 
Absorption coefficient  0.188 mm-1 
F(000)     928 
Crystal size    0.58 x 0.08 x 0.02 mm 
Theta range for data collection 1.65 to 25.00°. 
Index ranges    -15<=h<=15, -7<=k<=8, -29<=l<=29 
Reflections collected   11784 
Independent reflections  3758 [R(int) = 0.1360] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission  1.00 and 0.808 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3758 / 0 / 283 
Goodness-of-fit on F2   1.152 
Final R indices [I>2sigma(I)]  R1 = 0.0979, wR2 = 0.1819 
R indices (all data)   R1 = 0.1799, wR2 = 0.2233 
Largest diff. peak and hole  0.359 and -0.455 e.Å-3 
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Table 6.8.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for 2.33g.  
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
_______________________________________________________________________  
    x      y      z              U(eq) 
_______________________________________________________________________ 
C1  3645(5)  9055(8)  496(2)   30(2) 
C2  3353(5)  11031(9)  663(2)   35(2) 
C3  2811(4)  11003(8)  1162(2)  29(1) 
C4  3362(4)  9536(8)  1579(2)  29(1) 
C5  3092(5)  9535(9)  2097(2)  34(2) 
C6  3572(5)  8265(9)  2489(2)  35(2) 
C7  4360(5)  6964(9)  2384(2)  32(2) 
C8  4633(5)  6905(9)  1884(2)  28(1) 
C9  4137(4)  8179(8)  1475(2)  26(1) 
C10  1624(5)  10463(9)  1007(2)  36(2) 
C11  821(5)   11663(9)  1071(3)  36(2) 
C12  1016(5)  13652(9)  1296(3)  40(2) 
C13  2154(5)  14209(9)  1462(3)  38(2) 
C14  2951(5)  13004(9)  1407(2)  37(2) 
C15  2871(5)  6153(9)  67(3)   40(2) 
C16  1790(6)  5221(9)  -135(3)  52(2) 
C17  -541(5)  9312(9)  726(3)   51(2) 
C18  6577(5)  8420(9)  1248(2)  33(2) 
C19  6704(5)  10327(10)  1136(3)  40(2) 
C20  7556(5)  11416(9)  1437(2)  39(2) 
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Table 6.8., cont. 
C21  8265(5)  10516(11)  1863(3)  45(2) 
C22  8129(6)  8597(12)  1960(3)  61(2) 
C23  7278(5)  7504(11)  1653(3)  54(2) 
C24  9174(6)  11680(12)  2201(3)  64(2) 
N1  4414(4)  8109(7)  946(2)   29(1) 
O1  5605(3)  5119(6)  1016(2)  38(1) 
O2  5560(3)  7482(6)  278(2)   40(1) 
O3  2706(3)  7925(6)  332(2)   38(1) 
O4  -253(3)  11237(6)  931(2)   45(1) 
O5  285(4)   14719(6)  1352(2)  54(1) 















Table 6.9.   Bond lengths [Å] and angles [°] for  2.33g. 
Lengths: 
C1-O3    1.409(7) 
C1-N1   1.488(7) 
C1-C2   1.489(8) 
C1-H1   1.00 
C2-C3   1.546(8) 
C2-H2A   0.99 
C2-H2B   0.99 
C3-C14   1.504(8) 
C3-C10   1.518(8) 
C3-C4   1.522(8) 
C4-C5   1.412(8) 
C4-C9   1.413(8) 
C5-C6   1.368(8) 
C5-H5   0.95 
C6-C7   1.402(8) 
C6-H6   0.95 
C7-C8   1.370(8) 
C7-H7   0.95 
C8-C9   1.403(8) 
C8-H8   0.95 
C9-N1   1.445(7) 
C10-C11   1.341(8) 
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Table 6.9., cont. 
C10-H10   0.95 
C11-O4   1.363(7) 
C11-C12   1.482(9) 
C12-O5   1.209(7) 
C12-C13   1.465(8) 
C13-C14   1.330(8) 
C13-H13   0.95 
C14-H14   0.95 
C15-O3   1.424(7) 
C15-C16   1.502(8) 
C15-H15A   0.99 
C15-H15B   0.99 
C16-H16A   0.98 
C16-H16B   0.98 
C16-H16C   0.98 
C17-O4   1.441(7) 
C17-H17A   0.98 
C17-H17B   0.98 
C17-H17C   0.98 
C18-C19   1.357(8) 
C18-C23   1.365(8) 
C18-S1   1.760(6) 
C19-C20   1.403(8) 
C19-H19   0.95 
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Table 6.9., cont. 
C20-C21   1.398(9) 
C20-H20   0.95 
C21-C22   1.359(10) 
C21-C24   1.516(9) 
C22-C23   1.410(9) 
C22-H22   0.95 
C23-H23   0.95 
C24-H24A   0.98 
C24-H24B   0.98 
C24-H24C   0.98 
N1-S1    1.643(5) 
O1-S1    1.436(4) 
O2-S1    1.435(4) 
Angles: 
O3-C1-N1  111.6(5) 
O3-C1-C2  110.2(5) 
N1-C1-C2  110.1(5) 
O3-C1-H1  108.3 
N1-C1-H1  108.3 
C2-C1-H1  108.3 
C1-C2-C3  113.1(5) 
C1-C2-H2A  109.0 
C3-C2-H2A  109.0 
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Table 6.9., cont. 
C1-C2-H2B  109.0 
C3-C2-H2B  109.0 
H2A-C2-H2B  107.8 
C14-C3-C10  111.1(5) 
C14-C3-C4  108.7(5) 
C10-C3-C4  108.0(5) 
C14-C3-C2  106.8(5) 
C10-C3-C2  111.5(5) 
C4-C3-C2  110.8(5) 
C5-C4-C9  118.4(5) 
C5-C4-C3  118.5(5) 
C9-C4-C3  123.1(5) 
C6-C5-C4  121.0(6) 
C6-C5-H5  119.5 
C4-C5-H5  119.5 
C5-C6-C7  119.9(6) 
C5-C6-H6  120.0 
C7-C6-H6  120.0 
C8-C7-C6  120.7(6) 
C8-C7-H7  119.7 
C6-C7-H7  119.7 
C7-C8-C9  120.0(5) 
C7-C8-H8  120.0 
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Table 6.9., cont. 
C9-C8-H8  120.0 
C8-C9-C4  119.9(5) 
C8-C9-N1  120.2(5) 
C4-C9-N1  119.8(5) 
C11-C10-C3  123.3(6) 
C11-C10-H10  118.3 
C3-C10-H10  118.3 
C10-C11-O4  125.0(6) 
C10-C11-C12  122.8(6) 
O4-C11-C12  112.2(5) 
O5-C12-C13  122.4(6) 
O5-C12-C11  122.1(6) 
C13-C12-C11  115.4(6) 
C14-C13-C12  121.8(6) 
C14-C13-H13  119.1 
C12-C13-H13  119.1 
C13-C14-C3  125.6(6) 
C13-C14-H14  117.2 
C3-C14-H14  117.2 





















C19-C18-C23  121.0(6) 
C19-C18-S1  118.6(5) 
C23-C18-S1  120.3(5) 
C18-C19-C20  120.8(6) 
C18-C19-H19  119.6 
C20-C19-H19  119.6 
C21-C20-C19  119.0(6) 
C21-C20-H20  120.5 
C19-C20-H20  120.5 
C22-C21-C20  118.9(6) 
C22-C21-C24  121.3(7) 
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Table 6.9., cont. 
C20-C21-C24  119.8(7) 
C21-C22-C23  121.8(7) 
C21-C22-H22  119.1 
C23-C22-H22  119.1 
C18-C23-C22  118.4(7) 
C18-C23-H23  120.8 







C9-N1-C1  116.5(4) 
C9-N1-S1  122.9(4) 
C1-N1-S1  120.5(4) 
C1-O3-C15  114.7(5) 
C11-O4-C17  117.2(5) 
O2-S1-O1  118.1(3) 
O2-S1-N1  106.1(3) 
O1-S1-N1  110.4(3) 
O2-S1-C18  109.0(3) 
O1-S1-C18  107.9(3) 
N1-S1-C18  104.6(3)
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Table 6.10.   Anisotropic displacement parameters  (Å2x 103) for 2.33g  
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
_______________________________________________________________________  
U11  U22   U33  U23  U13  U12 
_______________________________________________________________________  
C1 28(3)   30(3)  31(3)   7(3)  1(3)   1(3) 
C2 44(4)   32(4)  28(4)   2(3)  5(3)   1(3) 
C3 25(3)   28(3)  32(4)   -1(3)  5(3)   4(3) 
C4 24(3)   26(3)  33(4)   -3(3)  -1(3)   -4(3) 
C5 42(4)   38(4)  24(3)   2(3)  15(3)   1(3) 
C6 42(4)   36(4)  28(4)   -5(3)  12(3)   -2(3) 
C7 32(4)   30(3)  30(4)   11(3)  -2(3)   4(3) 
C8 29(3)   31(3)  23(3)   2(3)  0(3)   4(3) 
C9 21(3)   28(3)  30(3)   -6(3)  3(3)   -7(3) 
C10 28(4)   38(4)  37(4)   0(3)  -2(3)   -1(3) 
C11 22(3)   41(4)  43(4)   3(3)  2(3)   2(3) 
C12 34(4)   40(4)  44(4)   -2(4)  7(3)   4(3) 
C13 42(4)   28(4)  42(4)   -4(3)  -1(3)   -7(3) 
C14 40(4)   35(4)  35(4)   0(3)  3(3)   -2(3) 
C15 41(4)   26(3)  50(4)   -13(3)  1(3)   1(3) 
C16 53(5)   36(4)  58(5)   -8(4)  -9(4)   -7(4) 
C17 34(4)   39(4)  78(6)   -9(4)  7(4)   -9(3) 
C18 27(3)   39(4)  32(4)   0(3)  6(3)   0(3) 
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Table 6.10., cont. 
C19 37(4)   46(4)  37(4)   10(4)  7(3)   0(3) 
C20 40(4)   34(4)  42(4)   0(3)  9(3)   -7(3) 
C21 32(4)   63(5)  39(4)   6(4)  2(3)   -6(4) 
C22 35(4)   81(6)  61(5)   19(5)  -6(4)   -9(4) 
C23 36(4)   59(5)  62(5)   19(4)  -2(4)   -4(4) 
C24 41(5)   84(6)  63(5)   -10(5)  -1(4)   -21(4) 
N1 27(3)   31(3)  28(3)   -1(2)  4(2)   4(2) 
O1 41(3)   23(2)  52(3)   3(2)  13(2)   6(2) 
O2 42(3)   53(3)  26(2)   -1(2)  11(2)   5(2) 
O3 38(3)   34(2)  37(2)   -7(2)  -2(2)   2(2) 
O4 24(2)   43(3)  65(3)   -4(3)  2(2)   1(2) 
O5 41(3)   36(3)  85(4)   -2(3)  10(3)   11(2) 












Table 6.11.  Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for 2.33g 
_______________________________________________________________________  
    x     y    z           U(eq) 
_______________________________________________________________________  
H1   4010  9198  181  37 
H2A   2856  11649  357  42 
H2B   4016  11836  747  42 
H5   2568  10430  2173  40 
H6   3372  8265  2833  42 
H7   4707  6113  2661  38 
H8   5159  6002  1815  34 
H10   1441  9211  857  43 
H13   2328  15463  1612  46 
H14   3669  13445  1535  45 
H15A   3336  5270  323  48 
H15B   3233  6416  -240  48 
H16A   1458  4887  174  78 
H16B   1885  4037  -337  78 
H16C   1321  6131  -373  78 
H17A   -291  9125  385  77 
H17B   -1327  9159  662  77  
H17C   -199  8344  991  77 
H19   6210  10932  851  48 
H20   7650  12744  1352  47 
H22   8620  7975  2244  73 
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Table 6.11., cont. 
H23   7196  6162  1726  64 
H24A   9055  11781  2573  96 
H24B   9190  12986  2047  96 






















Table 6.12. Torsion angles [°] for 2.33g 
O3-C1-C2-C3   63.5(6) 
N1-C1-C2-C3   -60.0(6) 
C1-C2-C3-C14  158.9(5) 
C1-C2-C3-C10  -79.7(6) 
C1-C2-C3-C4   40.6(7) 
C14-C3-C4-C5  52.8(7) 
C10-C3-C4-C5  -67.8(7) 
C2-C3-C4-C5   169.8(5) 
C14-C3-C4-C9  -126.8(6) 
C10-C3-C4-C9  112.6(6) 
C2-C3-C4-C9   -9.8(8) 
C9-C4-C5-C6   0.5(9) 
C3-C4-C5-C6   -179.2(5) 
C4-C5-C6-C7   1.2(9) 
C5-C6-C7-C8   -2.0(9) 
C6-C7-C8-C9   1.1(9) 
C7-C8-C9-C4   0.6(8) 
C7-C8-C9-N1   -179.3(5) 
C5-C4-C9-C8   -1.4(8) 
C3-C4-C9-C8   178.3(5) 
C5-C4-C9-N1   178.6(5) 
C3-C4-C9-N1   -1.8(8) 
C14-C3-C10-C11  1.7(9) 
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Table 6.12., cont. 
C4-C3-C10-C11  120.9(7) 
C2-C3-C10-C11  -117.2(7) 
C3-C10-C11-O4  179.3(5) 
C3-C10-C11-C12  0.6(10) 
C10-C11-C12-O5  -179.9(7) 
O4-C11-C12-O5  1.2(9) 
C10-C11-C12-C13  -1.9(10) 
O4-C11-C12-C13  179.3(5) 
O5-C12-C13-C14  178.6(7) 
C11-C12-C13-C14  0.6(10) 
C12-C13-C14-C3  2.1(11) 
C10-C3-C14-C13  -3.1(9) 
C4-C3-C14-C13  -121.8(7) 
C2-C3-C14-C13  118.6(7) 
C23-C18-C19-C20  -0.6(10) 
S1-C18-C19-C20  -176.9(5) 
C18-C19-C20-C21  -1.2(10) 
C19-C20-C21-C22  2.3(10) 
C19-C20-C21-C24  -178.5(6) 
C20-C21-C22-C23  -1.6(12) 
C24-C21-C22-C23  179.2(7) 
C19-C18-C23-C22  1.3(10) 
S1-C18-C23-C22  177.6(5) 
C21-C22-C23-C18  -0.2(12) 
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Table 6.12., cont. 
C8-C9-N1-C1   162.4(5) 
C4-C9-N1-C1   -17.5(7) 
C8-C9-N1-S1   -19.3(7) 
C4-C9-N1-S1   160.7(4) 
O3-C1-N1-C9   -74.9(6) 
C2-C1-N1-C9   47.9(6) 
O3-C1-N1-S1   106.8(5) 
C2-C1-N1-S1   -130.4(5) 
N1-C1-O3-C15  -68.8(6) 
C2-C1-O3-C15  168.5(5) 
C16-C15-O3-C1  -174.1(5) 
C10-C11-O4-C17  3.4(10) 
C12-C11-O4-C17  -177.8(5) 
C9-N1-S1-O2   -174.8(4) 
C1-N1-S1-O2   3.4(5) 
C9-N1-S1-O1   56.1(5) 
C1-N1-S1-O1   -125.7(4) 
C9-N1-S1-C18  -59.7(5) 
C1-N1-S1-C18  118.5(4) 
C19-C18-S1-O2  47.5(6) 
C23-C18-S1-O2  -128.8(5) 
C19-C18-S1-O1  176.8(5) 
C23-C18-S1-O1  0.5(6) 
C19-C18-S1-N1  -65.7(6) 
C23-C18-S1-N1  118.0(6)
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6.3 CRYSTALLOGRAPHY DATA FOR COMPOUND 2.81 
View of 2.81 showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  The diastereomer shown has an R, S, R 
configuration at C7, C9 and C14, respectively. 
Figure 6.3.  X-ray Structure of 2.81 
 
 
View of 2.81 showing the atom labeling scheme.  Displacement ellipsoids are 
scaled to the 50% probability level.  The diastereomer shown has an R, R, R 
configuration at C7, C9a and C14, respectively.  The hydrogen atom on O9a was not 




Figure 6.4. X-ray Structure of 2.81 
 
 
View of 2.81 showing the overlap of the two diastereomers found in the crystal.  
The diastereomers are present in a 4:1 ratio.  The major component is composed of atoms 









Figure 6.5. X-ray Structure of 2.81 
 
X-ray Experimental for C21H21NO5S:  Crystals grew as colorless prisms by slow 
cooling from MeOH.  The data crystal was cut from a cluster of crystals and had 
approximate dimensions; 0.24 x 0.22 x 0.20 mm.  The data were collected on a Rigaku 
SCX-Mini diffractometer with a Mercury 2 CCD using a graphite monochromator with 
MoKα radiation (λ = 0.71075Å).  A total of 1080 frames of data were collected using ω-
scans with a scan range of 0.5° and a counting time of 25 seconds per frame.  The data 
were collected at 153 K using a Rigaku XStream low temperature device.  Details of 
crystal data, data collection and structure refinement are listed in Table 6.13. Data 
reduction were performed using the Rigaku Americas Corporation’s Crystal Clear 
version 1.40.301 The structure was solved by direct methods using SIR97302 and refined by 
full-matrix least-squares on F2 with anisotropic displacement parameters for the non-H 
atoms using SHELXL-97.303 Structure analysis was aided by use of the programs 
PLATON98304 and WinGX.305 The hydrogen atoms on carbon were calculated in ideal 
positions with isotropic displacement parameters set to 1.2xUeq of the attached atom 
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(1.5xUeq for methyl hydrogen atoms). The hydrogen atom on O9 was observed in a ∆F 
map and refined with an isotropic displacement parameter.   
 The crystal was a racemic twin. In addition, the molecule appeared to be 
disordered. The apparent disorder was due to the presence of a small amount of a 
different diastereomer at C9. The chiral carbon atoms in the molecule are C7, C9 and 
C14, which are R, S, R in the major component in the refinement model.  Inversion at C9 
yields the R, R, R diastereomer in a 4:1 ratio. This ratio was determined by refining the 
site occupancy factors for the two components. No hydrogen atom for the minor hydroxyl 
oxygen atom, O9a, was included in the final refinement model. 
The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + 
(0.0589*P)2 + (0.8331*P)] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.140, with R(F) 
equal to 0.0610 and a goodness of fit, S, = 1.10. Definitions used for calculating R(F), 
Rw(F2) and the goodness of fit, S, are given below.
306 The data were corrected for 
secondary extinction effects. The correction takes the form:  Fcorr = kFc/[1  +  (4.9(8)x10-
6)* Fc2 λ3/(sin2θ)]0.25 where k is the overall scale factor. Neutral atom scattering factors 
and values used to calculate the linear absorption coefficient are from the International 
Tables for X-ray Crystallography (1992).307 All figures were generated using 
SHELXTL/PC.308 Tables of positional and thermal parameters, bond lengths and angles, 







Table 6.13.  Crystal data and structure refinement for 2.81. 
Empirical formula     C21 H21 N O5 S 
Formula weight     399.45 
Temperature      153(2) K 
Wavelength      0.71075 Å 
Crystal system     Tetragonal 
Space group      P41212 
Unit cell dimensions    a = 10.487(7) Å α= 90°. 
     b = 10.487(7) Å β= 90°. 
     c = 35.25(4) Å  γ = 90°. 
Volume     3877(6) Å3 
Z      8 
Density (calculated)    1.369 Mg/m3 
Absorption coefficient   0.200 mm-1 
F(000)      1680 
Crystal size     0.24 x 0.22 x 0.20 mm 
Theta range for data collection  2.26 to 27.50°. 
Index ranges     -13<=h<=13, -13<=k<=13, -45<=l<=45 
Reflections collected    38992 
Independent reflections   4461 [R(int) = 0.1205] 
Completeness to theta = 27.50°  99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission   1.00 and 0.774 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   4461 / 30 / 274 
Goodness-of-fit on F2    1.105 
Final R indices [I>2sigma(I)]   R1 = 0.0610, wR2 = 0.1342 
R indices (all data)    R1 = 0.0720, wR2 = 0.1398 
Absolute structure parameter   0.50(11) 
Extinction coefficient    4.9(8)x10-6 
Largest diff. peak and hole   0.209 and -0.280 e.Å-3 
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Table 6.14.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for 2.81  
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
                  x                  y       z   U(eq)                
C1  -474(3)  2892(3)  617(1)   33(1) 
C2  -717(3)  1754(3)  426(1)   38(1) 
C3  -1142(3)  1861(4)  53(1)   51(1) 
C4  -1342(3)  3044(5)  -116(1)  61(1) 
C5  -1135(3)  4155(4)  87(1)   52(1) 
C6  -700(3)  4072(3)  453(1)   40(1) 
C7  -503(3)  5135(3)  740(1)   40(1) 
C10  -1816(3)  5625(3)  881(1)   44(1) 
C11  -2368(3)  4906(3)  1216(1)  41(1) 
C12  -1473(3)  4821(3)  1544(1)  37(1) 
C13  -69(3)   4935(3)  1451(1)  40(1) 
C14  247(3)   4454(3)  1057(1)  34(1) 
C15  2408(3)  2303(3)  890(1)   34(1) 
C16  2554(3)  1658(3)  552(1)   37(1) 
C17  3582(3)  1926(3)  323(1)   46(1) 
C18  4474(3)  2838(4)  423(1)   54(1) 
C19  4314(3)  3475(3)  766(1)   56(1) 
C20  3295(3)  3221(3)  1001(1)  43(1)  
C21  5600(4)  3106(5)  172(2)   85(2) 
N1  -44(2)   3052(2)  1001(1)  29(1) 
O1  -1365(3)  7812(4)  389(1)   54(1) 
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Table 6.14., cont. 
O2  -1543(3)  6956(3)  1005(1)  37(1) 
C8  190(4)   6381(4)  620(1)   39(1) 
C9  -717(4)  7459(4)  722(1)   39(1) 
O1A  -770(11)  8403(9)  608(3)   41 
O2A  -1890(12)  6735(13)  873(3)   41 
C8A  -170(16)  6246(14)  471(5)   41 
C9A  -1249(14)  7183(11)  541(4)   41 
O3  -1825(2)  4652(2)  1867(1)  50(1) 
O4  1318(2)  2449(2)  1545(1)  50(1) 
O5  582(2)   793(2)   1099(1)  42(1) 














Table 6.15.   Bond lengths [Å] and angles [°] for 2.81 
Lengths: 
C1-C6    1.386(4) 
C1-C2    1.394(4) 
C1-N1    1.437(4) 
C2-C3    1.392(5) 
C2-H2    0.95 
C3-C4    1.392(6) 
C3-H3    0.95 
C4-C5    1.383(6) 
C4-H4    0.95 
C5-C6    1.373(5) 
C5-H5    0.95 
C6-C7    1.519(5) 
C7-C8A    1.541(18) 
C7-C14    1.542(4) 
C7-C10    1.551(4) 
C7-C8    1.554(5) 
C10-O2A    1.167(14) 
C10-O2    1.491(5) 
C10-C11    1.517(4) 
C10-H10    1.00 
C11-C12    1.490(5) 
C11-H11A    0.99 
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Table 6.15., cont. 
C11-H11B    0.99 
C12-O3    1.213(4) 
C12-C13    1.513(4) 
C13-C14    1.515(4) 
C13-H13A    0.99 
C13-H13B    0.99 
C14-N1    1.514(4) 
C14-H14    1.00 
C15-C16    1.380(4) 
C15-C20    1.395(4) 
C15-S1    1.751(3) 
C16-C17    1.375(5) 
C16-H16    0.95 
C17-C18    1.384(5) 
C17-H17    0.95 
C18-C19    1.391(5) 
C18-C21    1.501(5) 
C19-C20    1.377(5) 
C19-H19    0.95 
C20-H20    0.95 
C21-H21A    0.98 
C21-H21B    0.98 
C21-H21C    0.98 
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Table 6.15., Cont. 
N1-S1     1.659(3) 
O1-C9     1.405(5) 
O1-H1O    0.72(5) 
O2-C9    1.424(4) 
C8-C9    1.520(5) 
C8-H8A    0.99 
C8-H8B    0.99 
C9-H9A    1.00 
O1A-C9A    1.394(10) 
O1A-H1O    1.26(5) 
O2A-C9A    1.428(10) 
C8A-C9A    1.519(10) 
C8A-H8AA    0.99 
C8A-H8AB    0.99 
C9A-H1O    1.43(5) 
C9A-H9AA    1.00 
O4-S1     1.420(3) 
O5-S1     1.430(2)
Angles: 
C6-C1-C2   122.1(3) 
C6-C1-N1   110.0(3) 
C2-C1-N1   127.8(3) 
C3-C2-C1   116.5(3) 
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Table 6.15., Cont. 
C3-C2-H2   121.8 
C1-C2-H2   121.8 
C4-C3-C2   121.6(3) 
C4-C3-H3   119.2 
C2-C3-H3   119.2 
C5-C4-C3   120.5(3) 
C5-C4-H4   119.8 
C3-C4-H4   119.8 
C6-C5-C4   118.9(3) 
C6-C5-H5   120.5 
C4-C5-H5   120.5 
C5-C6-C1   120.4(3) 
C5-C6-C7   128.7(3) 
C1-C6-C7   110.8(3) 
C6-C7-C8A   100.2(7) 
C6-C7-C14   102.2(2) 
C8A-C7-C14   132.8(7) 
C6-C7-C10   109.7(3) 
C8A-C7-C10   98.5(5) 
C14-C7-C10   111.9(3) 
C6-C7-C8   120.1(3) 
C14-C7-C8   110.3(3) 
C10-C7-C8   102.9(3) 
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Table 6.15., Cont. 
O2A-C10-C11  119.3(6) 
O2-C10-C11   108.1(3) 
O2A-C10-C7   112.5(6) 
O2-C10-C7   103.5(3) 
C11-C10-C7   115.1(3) 
O2A-C10-H10  86.1 
O2-C10-H10   110.0 
C11-C10-H10   110.0 
C7-C10-H10   110.0 
C12-C11-C10   113.1(3) 
C12-C11-H11A  108.9 
C10-C11-H11A  108.9 
C12-C11-H11B  108.9 
C10-C11-H11B  108.9 
H11A-C11-H11B  107.8 
O3-C12-C11   123.1(3) 
O3-C12-C13   120.8(3) 
C11-C12-C13   116.1(3) 
C12-C13-C14   112.6(3) 
C12-C13-H13A  109.1 
C14-C13-H13A  109.1 
C12-C13-H13B  109.1 
C14-C13-H13B  109.1 
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Table 6.15., Cont. 
H13A-C13-H13B  107.8 
N1-C14-C13   113.5(2) 
N1-C14-C7   104.7(2) 
C13-C14-C7   113.5(3) 
N1-C14-H14   108.3 
C13-C14-H14   108.3 
C7-C14-H14   108.3 
C16-C15-C20   120.3(3) 
C16-C15-S1   120.1(2) 
C20-C15-S1   119.4(2) 
C17-C16-C15   119.6(3) 
C17-C16-H16   120.2 
C15-C16-H16   120.2 
C16-C17-C18   121.4(3) 
C16-C17-H17   119.3 
C18-C17-H17   119.3 
C17-C18-C19   118.1(3) 
C17-C18-C21   120.7(4) 
C19-C18-C21   121.1(4) 
C20-C19-C18   121.5(3) 
C20-C19-H19   119.2 
C18-C19-H19   119.2 
C19-C20-C15   118.9(3) 
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Table 6.15., Cont. 
C19-C20-H20   120.5 
C15-C20-H20   120.5 
C18-C21-H21A  109.5 
C18-C21-H21B  109.5 
H21A-C21-H21B  109.5 
C18-C21-H21C  109.5 
H21A-C21-H21C  109.5 
H21B-C21-H21C  109.5 
C1-N1-C14   107.4(2) 
C1-N1-S1   118.57(19) 
C14-N1-S1   115.32(18) 
C9-O1-H1O   114(4) 
C9-O2-C10   105.0(3) 
C9-C8-C7   105.6(3) 
C9-C8-H8A   110.6 
C7-C8-H8A   110.6 
C9-C8-H8B   110.6 
C7-C8-H8B   110.6 
H8A-C8-H8B   108.8 
O1-C9-O2   112.9(3) 
O1-C9-C8   107.6(3) 
O2-C9-C8   105.7(3) 
O1-C9-H9A   110.2 
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Table 6.15., Cont. 
O2-C9-H9A   110.2 
C8-C9-H9A   110.2 
C10-O2A-C9A  108.5(10) 
C9A-C8A-C7   102.7(10) 
C9A-C8A-H8AA  111.2 
C7-C8A-H8AA  111.2 
C9A-C8A-H8AB  111.2 
C7-C8A-H8AB  111.2 
H8AA-C8A-H8AB  109.1 
O1A-C9A-O2A  109.5(10) 
O1A-C9A-C8A  110.7(11) 
O2A-C9A-C8A  105.7(11) 
O1A-C9A-H9AA  110.3 
O2A-C9A-H9AA  110.3 
C8A-C9A-H9AA  110.3 
O4-S1-O5   119.80(15) 
O4-S1-N1   106.67(13) 
O5-S1-N1   106.69(13) 
O4-S1-C15   108.53(16) 
O5-S1-C15   108.69(14) 




Table 6.16.   Anisotropic displacement parameters  (Å2x 103) for 2.81. 
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
_______________________________________________________________________  
U11  U22   U33  U23  U13  U12 
_______________________________________________________________________  
C1 25(1)   42(2)  32(1)   5(1)  0(1)   0(1) 
C2 29(2)   47(2)  37(2)   -4(1)  1(1)   -2(1) 
C3 28(2)   88(3)  38(2)   -11(2)  4(1)   -9(2) 
C4 31(2)   120(4)  32(2)   14(2)  2(1)   6(2) 
C5 37(2)   76(3)  43(2)   19(2)  9(2)   12(2) 
C6 26(2)   53(2)  40(2)   13(2)  7(1)   6(1) 
C7 35(2)   34(2)  50(2)   10(1)  14(1)   9(1) 
C10 37(2)   42(2)  54(2)   13(2)  12(2)   11(1) 
C11 29(2)   43(2)  52(2)   7(2)  9(1)   3(1) 
C12 39(2)   24(1)  49(2)   -2(1)  5(1)   -1(1) 
C13 38(2)   28(2)  53(2)   -8(1)  0(1)   1(1) 
C14 26(1)   27(1)  50(2)   1(1)  2(1)   0(1) 
C15 27(1)   31(2)  42(2)   -8(1)  -6(1)   5(1) 
C16 30(1)   35(2)  47(2)   -7(1)  -4(1)   5(1) 
C17 39(2)   44(2)  55(2)   -10(2)  -2(2)   9(1) 
C18 34(2)   45(2)  82(3)   -7(2)  8(2)   8(2) 
C19 29(2)   39(2)  99(3)   -20(2)  -3(2)   0(1) 
C20 29(2)   37(2)  63(2)   -15(2)  -8(1)   5(1) 
C21 43(2)   80(3)  133(4)   -11(3)  33(3)   -8(2) 
N1 28(1)   27(1)  31(1)   1(1)  -2(1)   3(1) 
 488 
Table 6.16., Cont. 
O1 57(2)   61(2)  45(2)   21(2)  6(2)   27(2) 
O2 37(2)   31(1)  41(2)   3(1)  3(1)   6(1) 
C8 33(2)   33(2)  52(2)   13(2)  5(2)   0(2) 
C9 42(2)   32(2)  43(2)   15(2)  2(2)   2(2) 
O3 54(2)   52(2)  46(1)   -3(1)  10(1)   -10(1) 
O4 61(2)   59(2)  31(1)   -5(1)  -13(1)   16(1) 
O5 51(1)   26(1)  48(1)   7(1)  -1(1)   -1(1) 















Table 6.17.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for 2.81 
_______________________________________________________________________  
 x   y   z   U(eq) 
_______________________________________________________________________   
H2  -598  947  543  45 
H3  -1298  1109  -90  62 
H4  -1624  3089  -371  73 
H5  -1291  4963  -26  62 
H10  -2441  5631  667  53 
H11A  -3159  5337  1300  49 
H11B  -2598  4033  1134  49 
H13A  429  4443  1639  47 
H13B  190  5840  1471  47 
H14  1178  4590  1011  41 
H16  1948  1033  477  45 
H17  3681  1476  91  55 
H19  4922  4100  840  67 
H20  3199  3665  1234  52 
H21A  5899  3979  216  128 
H21B  5348  3012  -94  128 
H21C  6286  2504  230  128 
H8A  1006  6473  759  47 
H8B  370  6379  345  47 
H9A  -229  8202  825  47 
H1O  -1770(50) 8360(50) 412(13) 44(14) 
H8AA  666  6625  536  41 
H8AB  -154  5962  203  41 
H9AA  -1846  7194  320  41 
_______________________________________________________________________ 
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Table 6.18.  Torsion angles [°] for 2.81 
C6-C1-C2-C3    3.0(4) 
N1-C1-C2-C3    179.3(3) 
C1-C2-C3-C4    -1.5(5) 
C2-C3-C4-C5    -0.7(5) 
C3-C4-C5-C6    1.5(5) 
C4-C5-C6-C1    -0.1(5) 
C4-C5-C6-C7    -174.6(3) 
C2-C1-C6-C5    -2.3(4) 
N1-C1-C6-C5    -179.2(3) 
C2-C1-C6-C7    173.2(3) 
N1-C1-C6-C7    -3.7(3) 
C5-C6-C7-C8A   -30.7(7) 
C1-C6-C7-C8A   154.3(6) 
C5-C6-C7-C14   -168.9(3) 
C1-C6-C7-C14   16.1(3) 
C5-C6-C7-C10   72.2(4) 
C1-C6-C7-C10   -102.7(3) 
C5-C6-C7-C8    -46.5(5) 
C1-C6-C7-C8    138.5(3) 
C6-C7-C10-O2A   -131.6(7) 
C8A-C7-C10-O2A   -27.5(10) 
C14-C7-C10-O2A   115.7(8) 
C8-C7-C10-O2A   -2.7(8) 
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Table 6.18., Cont. 
C6-C7-C10-O2   -155.0(2) 
C8A-C7-C10-O2   -50.9(7) 
C14-C7-C10-O2   92.3(3) 
C8-C7-C10-O2   -26.1(3) 
C6-C7-C10-C11   87.3(4) 
C8A-C7-C10-C11   -168.6(7) 
C14-C7-C10-C11   -25.4(4) 
C8-C7-C10-C11   -143.8(3) 
O2A-C10-C11-C12   -84.9(9) 
O2-C10-C11-C12   -61.7(3) 
C7-C10-C11-C12   53.4(4) 
C10-C11-C12-O3   156.7(3) 
C10-C11-C12-C13   -24.3(4) 
O3-C12-C13-C14   149.6(3) 
C11-C12-C13-C14   -29.3(4) 
C12-C13-C14-N1   -62.0(3) 
C12-C13-C14-C7   57.4(3) 
C6-C7-C14-N1   -21.5(3) 
C8A-C7-C14-N1   -138.1(7) 
C10-C7-C14-N1   95.8(3) 
C8-C7-C14-N1   -150.3(3) 
C6-C7-C14-C13   -145.8(2) 
C8A-C7-C14-C13   97.7(8) 
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Table 6.18., Cont. 
C10-C7-C14-C13  -28.5(4) 
C8-C7-C14-C13  85.4(3) 
C20-C15-C16-C17  0.0(5) 
S1-C15-C16-C17  175.5(2) 
C15-C16-C17-C18  -0.4(5) 
C16-C17-C18-C19  0.6(5) 
C16-C17-C18-C21  179.2(4) 
C17-C18-C19-C20  -0.4(5) 
C21-C18-C19-C20  -179.0(4) 
C18-C19-C20-C15  0.0(5) 
C16-C15-C20-C19  0.2(5) 
S1-C15-C20-C19  -175.3(3) 
C6-C1-N1-C14  -10.9(3) 
C2-C1-N1-C14  172.4(3) 
C6-C1-N1-S1   -143.8(2) 
C2-C1-N1-S1   39.6(4) 
C13-C14-N1-C1  144.8(3) 
C7-C14-N1-C1  20.5(3) 
C13-C14-N1-S1  -80.5(3) 
C7-C14-N1-S1  155.16(18) 
O2A-C10-O2-C9  -73.7(14) 
C11-C10-O2-C9  164.0(3) 
C7-C10-O2-C9  41.5(3) 
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Table 6.18., Cont. 
C6-C7-C8-C9   125.4(3) 
C8A-C7-C8-C9  85.5(12) 
C14-C7-C8-C9  -116.3(3) 
C10-C7-C8-C9  3.2(4) 
C10-O2-C9-O1  77.6(4) 
C10-O2-C9-C8  -39.7(4) 
C7-C8-C9-O1   -98.7(4) 
C7-C8-C9-O2   22.1(4) 
O2-C10-O2A-C9A  109.9(18) 
C11-C10-O2A-C9A  177.1(8) 
C7-C10-O2A-C9A  37.8(12) 
C6-C7-C8A-C9A  117.5(10) 
C14-C7-C8A-C9A  -125.1(9) 
C10-C7-C8A-C9A  5.6(11) 
C8-C7-C8A-C9A  -96.8(15) 
C10-O2A-C9A-O1A  -150.9(12) 
C10-O2A-C9A-C8A  -31.6(15) 
C7-C8A-C9A-O1A  130.7(12) 
C7-C8A-C9A-O2A  12.1(14) 
C1-N1-S1-O4   178.4(2) 
C14-N1-S1-O4  49.1(2) 
C1-N1-S1-O5   -52.4(2) 
C14-N1-S1-O5  178.23(19) 
C1-N1-S1-C15  63.1(2) 
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Table 6.18., Cont. 
C14-N1-S1-C15  -66.2(2) 
C16-C15-S1-O4  159.9(2) 
C20-C15-S1-O4  -24.6(3) 
C16-C15-S1-O5  28.1(3) 
C20-C15-S1-O5  -156.4(2) 
C16-C15-S1-N1  -86.1(3) 
C20-C15-S1-N1  89.5(3)
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Table 6.19.  Hydrogen bonds for 2.81  [Å and °] 
_______________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_______________________________________________________________________  
 O1-H1O...O3#1 0.72(5) 2.14(5) 2.840(5) 162(5) 
_______________________________________________________________________  





















6.4 CRYSTALLOGRAPHY DATA FOR COMPOUND 4.86B 
View of 4.86b showing the atom labeling scheme. Displacement ellipsoids are 
scaled to the 50% probability level.  











View of 4.86b showing the atom labeling scheme. Displacement ellipsoids are 
scaled to the 50% probability level.  
Figure 6.7. X-ray Structure of 4.86b 
 
 
X-ray Experimental for complex C41H52N2O6Si:  Crystals grew as long, colorless 
needles by cooling slowly in Hexanes. The data crystal had approximate dimensions; 
0.41 x 0.03 x 0.02 mm. The data were collected on an Agilent Technologies SuperNova 
Dual Source diffractometer using a µ-focus Cu Kα radiation source (λ = 1.5418Å) with 
collimating mirror monochromators.  A total of 1037 frames of data were collected using 
ω-scans with a scan range of 1° and a counting time of 16 seconds per frame with a 
detector offset of +/- 40.8° and 50 seconds per frame with a detector offset of +/- 108.3°. 
The data were collected at 100 K using an Oxford Cryostream low temperature device. 
Details of crystal data, data collection and structure refinement are listed in Table 1. Data 
collection, unit cell refinement and data reduction were performed using Agilent 
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Technologies CrysAlisPro V 1.171.37.31.301 The structure was solved by direct methods 
using SuperFlip302 and refined by full-matrix least-squares on F2 with anisotropic 
displacement parameters for the non-H atoms using SHELXL-2014/7.303 Structure 
analysis was aided by use of the programs PLATON98304 and WinGX.305 The hydrogen 
atoms were calculated in ideal positions with isotropic displacement parameters set to 
1.2xUeq of the attached atom (1.5xUeq for methyl hydrogen atoms). The hydrogen atoms 
on nitrogen were observed in a ∆F map and refined with isotropic displacement 
parameters. 
There are two molecules in the asymmetric unit. The ethylene group on one 
molecule was disordered about two positions. The disorder was modeled by assigning the 
variable x to the site occupancy for the atoms of one orientation, C81 and C82, and (1-x) 
the site occupancy for the atoms in the alternate orientation, C81a and C82a. The 
geometry for the two groups was restrained to be equivalent throughout the refinement 
process. A common isotropic displacement parameter was refined while refining the 
variable x. In this way, the site occupancy for the major component refined to 55(1)%.    
The function, Σw(|Fo|2 - |Fc|2)2, was minimized, where w = 1/[(σ(Fo))2 + 
(0.0456*P)2] and P = (|Fo|2 + 2|Fc|2)/3.  Rw(F2) refined to 0.182, with R(F) equal to 
0.0697 and a goodness of fit, S, = 1.00.  Definitions used for calculating R(F), Rw(F2) 
and the goodness of fit, S, are given below.306  The data were checked for secondary 
extinction effects but no correction was necessary.  Neutral atom scattering factors and 
values used to calculate the linear absorption coefficient are from the International Tables 
for X-ray Crystallography (1992).307 All figures were generated using SHELXTL/PC.308 
Tables of positional and thermal parameters, bond lengths and angles, torsion angles and 
figures are found elsewhere.   
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 Table 6.20.  Crystal data and structure refinement for 4.86b 
Empirical formula    C41 H52 N2 O6 Si 
Formula weight    696.93 
Temperature     100(2) K 
Wavelength     1.54184 Å 
Crystal system     triclinic 
Space group      P -1 
Unit cell dimensions    a = 14.6462(12) Å α= 78.522(6)°. 
     b = 17.2261(10) Å β= 66.733(7)°. 
     c = 18.0845(13) Å γ = 67.941(7)°. 
Volume     3877.9(6) Å3 
Z      4 
Density (calculated)    1.194 Mg/m3 
Absorption coefficient   0.914 mm-1 
F(000)      1496 
Crystal size     0.410 x 0.030 x 0.020 mm3 
Theta range for data collection  2.664 to 74.239°. 
Index ranges     -13<=h<=17, -14<=k<=21, -22<=l<=22 
Reflections collected    23896 
Independent reflections   15018 [R(int) = 0.0774] 
Completeness to theta = 67.684°  98.8 %  
Absorption correction    Semi-empirical from equivalents 
Max. and min. transmission   1.00 and 0.647 
Refinement method    Full-matrix least-squares on F2 
Data / restraints / parameters   15018 / 36 / 939 
Goodness-of-fit on F2    1.003 
Final R indices     [I>2sigma(I)] R1 = 0.0697, wR2 = 0.1456 
R indices (all data)    R1 = 0.1283, wR2 = 0.1820 
Extinction coefficient    n/a 
Largest diff. peak and hole   0.586 and -0.491 e.Å-3 
 500 
 Table 6.21.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x103) for 4.86b 
U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor.  
 x  y  z  U(eq) 
C1 2214(3) 5973(2) 6750(2) 21(1) 
C2 1013(3) 6262(2) 6854(2) 24(1) 
C3 907(3)  5668(2) 6451(2) 25(1) 
C4 12(3)  5616(2) 6380(2) 28(1) 
C5 152(3)  4986(3) 5933(3) 34(1) 
C6 1156(3) 4429(3) 5569(2) 32(1) 
C7 2049(3) 4465(2) 5640(2) 28(1) 
C8 1904(3) 5093(2) 6106(2) 23(1) 
C9 2644(3) 6681(2) 6206(2) 22(1) 
C10 4428(3) 6482(2) 6243(2) 26(1) 
C11 4180(3) 6118(2) 7119(2) 26(1) 
C12 2999(3) 6364(2) 7636(2) 23(1) 
C13 2413(3) 5797(2) 7573(2) 22(1) 
C14 2473(3) 7299(2) 7460(2) 24(1) 
C15 2252(3) 7460(2) 6669(2) 25(1) 
C16 3055(3) 4861(2) 7647(2) 24(1) 
C17 3869(3) 3863(2) 8490(2) 31(1) 
C18 4460(3) 3802(2) 9029(2) 28(1) 
C19 5021(3) 4344(3) 8877(3) 34(1) 
C20 5590(3) 4281(3) 9349(3) 40(1) 
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Table 6.21., Cont. 
C21 5603(3) 3669(3) 9986(3) 37(1) 
C22 5055(3) 3129(3) 10132(3) 37(1) 
C23 4476(3) 3196(2) 9658(2) 31(1) 
C24 1384(3) 5954(2) 8299(2) 25(1) 
C25 -161(3) 5626(3) 8884(2) 30(1) 
C26 -705(3) 5019(2) 8925(2) 27(1) 
C27 -349(3) 4494(2) 8308(2) 29(1) 
C28 -902(3) 3970(2) 8345(2) 29(1) 
C29 -1805(3) 3975(2) 9000(2) 31(1) 
C30 -2164(3) 4496(2) 9627(2) 31(1) 
C31 -1608(3) 5015(2) 9579(2) 30(1) 
C32 2244(4) 7744(3) 9318(3) 40(1) 
C33 1569(3) 9254(2) 8236(3) 35(1) 
C34 -99(3)  8442(3) 9436(2) 32(1) 
C35 -804(3) 8758(3) 8920(3) 48(1) 
C36 -236(4) 7616(3) 9904(3) 46(1) 
C37 -441(4) 9097(3) 10039(3) 43(1) 
C38 4310(3) 6126(2) 5065(2) 25(1) 
C39 4075(3) 5864(3) 3919(2) 31(1) 
C40 3230(4) 5746(3) 3747(3) 38(1) 
C41 3011(4) 6071(3) 3093(3) 40(1) 
C42 7427(3) 1065(2) 6592(2) 23(1) 
C43 6918(3) 1744(2) 7231(2) 26(1) 
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Table 6.21., Cont. 
C44 7733(3) 1664(2) 7547(2) 25(1) 
C45 7684(3) 2078(2) 8158(2) 31(1) 
C46 8594(3) 1875(3) 8326(2) 34(1) 
C47 9517(3) 1271(3) 7899(3) 34(1) 
C48 9575(3) 853(2)  7290(2) 29(1) 
C49 8654(3) 1061(2) 7119(2) 24(1) 
C50 7314(3) 1552(2) 5783(2) 25(1) 
C51 8063(3) 461(2)  4767(2) 27(1) 
C52 7693(3) -187(2) 5421(2) 25(1) 
C53 6680(3) 174(2)  6140(2) 23(1) 
C54 6897(3) 348(2)  6858(2) 20(1) 
C55 5922(3) 937(2)  5848(2) 27(1) 
C56 6232(3) 1728(2) 5746(2) 29(1) 
C57 7632(3) -471(2) 7138(2) 23(1) 
C58 7793(3) -1891(2) 7542(2) 29(1) 
C59 7465(3) -2585(2) 7448(2) 26(1) 
C60 7231(4) -2584(3) 6772(3) 39(1) 
C61 6960(4) -3238(3) 6675(3) 51(1) 
C62 6926(4) -3900(3) 7253(3) 47(1) 
C63 7157(4) -3905(3) 7921(3) 43(1) 
C64 7420(3) -3249(3) 8021(3) 34(1) 
C65 5856(3) 600(2)  7577(2) 24(1) 
C66 5190(3) 983(2)  8912(2) 26(1) 
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Table 6.21., Cont. 
C67 5480(3) 921(2)  9645(2) 24(1) 
C68 6522(3) 706(3)  9580(2) 32(1) 
C69 6762(3) 672(3)  10265(3) 36(1) 
C70 5971(3) 851(3)  11004(2) 34(1) 
C71 4925(3) 1065(2) 11074(2) 31(1) 
C72 4693(3) 1090(2) 10397(2) 29(1) 
C73 3466(5) 469(3)  6142(3) 60(2) 
C74 3866(4) 2092(3) 5294(3) 51(1) 
C75 2758(3) 1972(3) 7157(3) 36(1) 
C76 2709(4) 1354(3) 7909(3) 48(1) 
C77 1667(4) 2336(4) 7074(3) 58(1) 
C78 3061(4) 2692(3) 7270(3) 48(1) 
C79 9089(3) 1291(2) 4731(2) 28(1) 
C80 9973(3) 2215(3) 4712(3) 48(1) 
C81 9687(9) 2874(6) 5321(7) 46(2) 
C82 10023(11) 2731(12) 5933(11) 55(3) 
C81A 10239(11) 2587(9) 5168(9) 63(3) 
C82A 9702(13) 2821(14) 5866(14) 54(4) 
N1 2648(2) 5225(2) 6296(2) 23(1) 
N2 3805(2) 6361(2) 5840(2) 24(1) 
N3 8523(2) 763(2)  6532(2) 26(1) 
N4 8174(3) 1121(2) 5080(2) 29(1) 
O1 337(2)  6895(2) 7169(2) 30(1) 
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Table 6.21., Cont. 
O2 3337(2) 4728(2) 8343(2) 27(1) 
O3 872(2)  5388(2) 8313(2) 25(1) 
O4 1507(2) 7642(2) 8097(2) 24(1) 
O5 3615(2) 6170(2) 4724(2) 28(1) 
O6 5253(2) 5900(2) 4713(2) 31(1) 
O7 6048(2) 2271(2) 7372(2) 28(1) 
O8 7194(2) -1115(2) 7255(2) 24(1) 
O9 6099(2) 596(2)  8266(2) 25(1) 
O10 4879(2) 1078(2) 6406(2) 32(1) 
O11 9868(2) 891(2)  4207(2) 32(1) 
O12 9028(2) 1993(2) 5005(2) 35(1) 
Si1 1312(1) 8264(1) 8766(1) 26(1) 
Si2 3767(1) 1399(1) 6242(1) 29(1) 
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 Table 6.22. Bond lengths [Å] and angles [°] for 4.86b. 
Bond Lengths: 
C1-N1  1.459(4) 
C1-C9  1.569(5) 
C1-C13  1.579(5) 
C1-C2  1.579(5) 
C2-O1  1.218(4) 
C2-C3  1.452(5) 
C3-C8  1.393(5) 
C3-C4  1.404(5) 
C4-C5  1.386(5) 
C4-H4  0.95 
C5-C6  1.394(6) 
C5-H5  0.95 
C6-C7  1.387(5) 
C6-H6  0.95 
C7-C8  1.406(5) 
C7-H7  0.95 
C8-N1  1.368(5) 
C9-N2  1.477(4) 
C9-C15  1.523(5) 
C9-H9  1.00 
C10-N2  1.462(5) 
C10-C11  1.535(5) 
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Table 6.22., Cont. 
C10-H10A  0.99 
C10-H10B  0.99 
C11-C12  1.541(5) 
C11-H11A  0.99 
C11-H11B  0.99 
C12-C14  1.532(5) 
C12-C13  1.567(5) 
C12-H12  1.00 
C13-C24  1.529(5) 
C13-C16  1.542(5) 
C14-O4  1.425(4) 
C14-C15  1.540(5) 
C14-H14  1.00 
C15-H15A  0.99 
C15-H15B  0.99 
C16-O2  1.424(4) 
C16-H16A  0.99 
C16-H16B  0.99 
C17-O2  1.426(4) 
C17-C18  1.506(5) 
C17-H17A  0.99 
C17-H17B  0.99 
C18-C23  1.383(6) 
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Table 6.22., Cont. 
C18-C19  1.385(6) 
C19-C20  1.376(6) 
C19-H19  0.95 
C20-C21  1.398(6) 
C20-H20  0.95 
C21-C22  1.370(6) 
C21-H21  0.95 
C22-C23  1.389(6) 
C22-H22  0.95 
C23-H23  0.95 
C24-O3  1.427(4) 
C24-H24A  0.99 
C24-H24B  0.99 
C25-O3  1.412(4) 
C25-C26  1.511(5) 
C25-H25A  0.99 
C25-H25B  0.99 
C26-C31  1.383(5) 
C26-C27  1.387(5) 
C27-C28  1.398(5) 
C27-H27  0.95 
C28-C29  1.382(5) 
C28-H28  0.95 
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Table 6.22., Cont. 
C29-C30  1.395(5) 
C29-H29  0.95 
C30-C31  1.390(5) 
C30-H30  0.95 
C31-H31  0.95 
C32-Si1  1.862(5) 
C32-H32A  0.98 
C32-H32B  0.98 
C32-H32C  0.98 
C33-Si1  1.875(4) 
C33-H33A  0.98 
C33-H33B  0.98 
C33-H33C  0.98 
C34-C37  1.532(5) 
C34-C35  1.539(6) 
C34-C36  1.544(6) 
C34-Si1  1.877(4) 
C35-H35A  0.98 
C35-H35B  0.98 
C35-H35C  0.98 
C36-H36A  0.98 
C36-H36B  0.98 
C36-H36C  0.98 
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Table 6.22., Cont. 
C37-H37A  0.98 
C37-H37B  0.98 
C37-H37C  0.98 
C38-O6  1.210(4) 
C38-O5  1.358(5) 
C38-N2  1.364(5) 
C39-O5  1.454(4) 
C39-C40  1.480(6) 
C39-H39A  0.99 
C39-H39B  0.99 
C40-C41  1.309(6) 
C40-H40  0.95 
C41-H41A  0.95 
C41-H41B  0.95 
C42-N3  1.455(5) 
C42-C43  1.568(5) 
C42-C50  1.572(5) 
C42-C54  1.598(5) 
C43-O7  1.217(5) 
C43-C44  1.468(5) 
C44-C49  1.393(5) 
C44-C45  1.396(5) 
C45-C46  1.386(6) 
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Table 6.22., Cont. 
C45-H45  0.95 
C46-C47  1.394(6) 
C46-H46  0.95 
C47-C48  1.393(5) 
C47-H47  0.95 
C48-C49  1.401(5) 
C48-H48  0.95 
C49-N3  1.370(5) 
C50-N4  1.471(4) 
C50-C56  1.523(5) 
C50-H50  1.00 
C51-N4  1.452(4) 
C51-C52  1.536(5) 
C51-H51A  0.99 
C51-H51B  0.99 
C52-C53  1.545(5) 
C52-H52A  0.99 
C52-H52B  0.99 
C53-C55  1.526(5) 
C53-C54  1.558(5) 
C53-H53  1.00 
C54-C65  1.538(4) 
C54-C57  1.554(5) 
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Table 6.22., Cont. 
C55-O10  1.419(4) 
C55-C56  1.547(5) 
C55-H55  1.00 
C56-H56A  0.99 
C56-H56B  0.99 
C57-O8  1.422(4) 
C57-H57A  0.99 
C57-H57B  0.99 
C58-O8  1.424(5) 
C58-C59  1.504(5) 
C58-H58A  0.99 
C58-H58B  0.99 
C59-C64  1.385(6) 
C59-C60  1.395(6) 
C60-C61  1.388(6) 
C60-H60  0.95 
C61-C62  1.387(7) 
C61-H61  0.95 
C62-C63  1.374(7) 
C62-H62  0.95 
C63-C64  1.387(6) 
C63-H63  0.95 
C64-H64  0.95 
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Table 6.22., Cont. 
C65-O9  1.424(4) 
C65-H65A  0.99 
C65-H65B  0.99 
C66-O9  1.413(4) 
C66-C67  1.517(5) 
C66-H66A  0.99 
C66-H66B  0.99 
C67-C68  1.389(5) 
C67-C72  1.390(5) 
C68-C69  1.401(6) 
C68-H68  0.95 
C69-C70  1.377(6) 
C69-H69  0.95 
C70-C71  1.393(6) 
C70-H70  0.95 
C71-C72  1.382(6) 
C71-H71  0.95 
C72-H72  0.95 
C73-Si2  1.871(5) 
C73-H73A  0.98 
C73-H73B  0.98 
C73-H73C  0.98 
C74-Si2  1.873(5) 
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C74-H74A  0.98 
C74-H74B  0.98 
C74-H74C  0.98 
C75-C78  1.538(6) 
C75-C77  1.538(6) 
C75-C76  1.547(6) 
C75-Si2  1.876(4) 
C76-H76A  0.98 
C76-H76B  0.98 
C76-H76C  0.98 
C77-H77A  0.98 
C77-H77B  0.98 
C77-H77C  0.98 
C78-H78A  0.98 
C78-H78B  0.98 
C78-H78C  0.98 
C79-O11  1.220(5) 
C79-N4  1.354(5) 
C79-O12  1.356(5) 
C80-C81A  1.376(14) 
C80-O12  1.442(5) 
C80-C81  1.566(11) 
C80-H80C  0.9600 
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C80-H80D  0.9599 
C80-H80A  0.9600 
C80-H80B  0.9599 
C81-C82  1.325(18) 
C81-H81  0.95 
C82-H82A  0.95 
C82-H82B  0.95 
C81A-C82A  1.25(3) 
C81A-H81A  0.95 
C82A-H82C  0.95 
C82A-H82D  0.95 
N1-H1N  0.90(4) 
N3-H2N  0.87(4) 
O4-Si1  1.644(2) 































C3-C8-C7  120.6(3) 
N2-C9-C15  112.2(3) 
N2-C9-C1  110.8(3) 
C15-C9-C1  111.6(3) 
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N2-C9-H9  107.4 
C15-C9-H9  107.4 
C1-C9-H9  107.4 












C14-C12-C11  108.7(3) 
C14-C12-C13  113.2(3) 
C11-C12-C13  115.3(3) 
C14-C12-H12  106.4 
C11-C12-H12  106.4 
C13-C12-H12  106.4 
C24-C13-C16  106.7(3) 
C24-C13-C12  107.2(3) 
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C16-C13-C12  110.6(3) 
C24-C13-C1  111.9(3) 
C16-C13-C1  108.2(3) 
C12-C13-C1  112.2(3) 
O4-C14-C12  111.7(3) 
O4-C14-C15  108.5(3) 
C12-C14-C15  111.8(3) 
O4-C14-H14  108.2 
C12-C14-H14  108.2 
C15-C14-H14  108.2 
C9-C15-C14  114.7(3) 
C9-C15-H15A 108.6 
C14-C15-H15A 108.6 
C9-C15-H15B  108.6 
C14-C15-H15B 108.6 
H15A-C15-H15B 107.6 






O2-C17-C18  108.2(3) 
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C23-C18-C19  119.6(4) 
C23-C18-C17  120.9(3) 
C19-C18-C17  119.4(4) 
C20-C19-C18  120.2(4) 
C20-C19-H19  119.9 
C18-C19-H19  119.9 
C19-C20-C21  120.0(4) 
C19-C20-H20  120.0 
C21-C20-H20  120.0 
C22-C21-C20  119.7(4) 
C22-C21-H21  120.1 
C20-C21-H21  120.1 
C21-C22-C23  120.1(4) 
C21-C22-H22  119.9 
C23-C22-H22  119.9 
C18-C23-C22  120.3(4) 
C18-C23-H23  119.9 
C22-C23-H23  119.9 
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C31-C26-C27  119.3(3) 
C31-C26-C25  119.0(3) 
C27-C26-C25  121.7(3) 
C26-C27-C28  120.2(4) 
C26-C27-H27  119.9 
C28-C27-H27  119.9 
C29-C28-C27  119.9(4) 
C29-C28-H28  120.1 
C27-C28-H28  120.1 
C28-C29-C30  120.2(4) 
C28-C29-H29  119.9 
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C30-C29-H29  119.9 
C31-C30-C29  119.1(4) 
C31-C30-H30  120.4 
C29-C30-H30  120.4 
C26-C31-C30  121.2(4) 
C26-C31-H31  119.4 













C37-C34-C35  109.3(4) 
C37-C34-C36  109.0(3) 
C35-C34-C36  108.7(4) 
C37-C34-Si1  109.9(3) 
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C35-C34-Si1  109.6(3) 



















O6-C38-O5  123.1(3) 
O6-C38-N2  125.7(4) 
O5-C38-N2  111.2(3) 
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C41-C40-C39  122.7(4) 
C41-C40-H40  118.7 




N3-C42-C43  101.6(3) 
N3-C42-C50  110.3(3) 
C43-C42-C50  106.2(3) 
N3-C42-C54  113.7(3) 
C43-C42-C54  112.9(3) 
C50-C42-C54  111.4(3) 
O7-C43-C44  128.0(3) 
O7-C43-C42  125.4(4) 
C44-C43-C42  106.4(3) 
C49-C44-C45  122.0(4) 
C49-C44-C43  107.6(3) 
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C45-C44-C43  130.4(4) 
C46-C45-C44  117.6(4) 
C46-C45-H45  121.2 
C44-C45-H45  121.2 
C45-C46-C47  120.5(4) 
C45-C46-H46  119.8 
C47-C46-H46  119.8 
C48-C47-C46  122.4(4) 
C48-C47-H47  118.8 
C46-C47-H47  118.8 
C47-C48-C49  117.1(4) 
C47-C48-H48  121.5 
C49-C48-H48  121.5 
N3-C49-C44  111.6(3) 
N3-C49-C48  127.9(3) 
C44-C49-C48  120.4(3) 
N4-C50-C56  112.5(3) 
N4-C50-C42  111.1(3) 
C56-C50-C42  112.6(3) 
N4-C50-H50  106.7 
C56-C50-H50  106.7 
C42-C50-H50  106.7 
N4-C51-C52  113.5(3) 
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C55-C53-C52  109.9(3) 
C55-C53-C54  113.3(3) 
C52-C53-C54  113.3(3) 
C55-C53-H53  106.6 
C52-C53-H53  106.6 
C54-C53-H53  106.6 
C65-C54-C57  106.6(3) 
C65-C54-C53  109.2(3) 
C57-C54-C53  109.7(3) 
C65-C54-C42  111.1(3) 
C57-C54-C42  110.0(3) 
C53-C54-C42  110.2(3) 
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O10-C55-C53  110.0(3) 
O10-C55-C56  109.5(3) 
C53-C55-C56  110.7(3) 
O10-C55-H55  108.8 
C53-C55-H55  108.8 
C56-C55-H55  108.8 



















Table 6.22., Cont. 
H58A-C58-H58B 108.3 
C64-C59-C60  118.8(4) 
C64-C59-C58  120.5(4) 
C60-C59-C58  120.6(3) 
C61-C60-C59  120.5(4) 
C61-C60-H60  119.8 
C59-C60-H60  119.8 
C62-C61-C60  119.9(5) 
C62-C61-H61  120.1 
C60-C61-H61  120.1 
C63-C62-C61  119.9(4) 
C63-C62-H62  120.0 
C61-C62-H62  120.0 
C62-C63-C64  120.3(4) 
C62-C63-H63  119.9 
C64-C63-H63  119.9 
C59-C64-C63  120.6(4) 
C59-C64-H64  119.7 
C63-C64-H64  119.7 
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C54-C65-H65B 110.1 
H65A-C65-H65B 108.4 






C68-C67-C72  118.9(4) 
C68-C67-C66  121.3(3) 
C72-C67-C66  119.8(3) 
C67-C68-C69  119.9(4) 
C67-C68-H68  120.0 
C69-C68-H68  120.0 
C70-C69-C68  120.4(4) 
C70-C69-H69  119.8 
C68-C69-H69  119.8 
C69-C70-C71  120.0(4) 
C69-C70-H70  120.0 
C71-C70-H70  120.0 
C72-C71-C70  119.4(4) 
C72-C71-H71  120.3 
C70-C71-H71  120.3 
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C71-C72-C67  121.4(4) 
C71-C72-H72  119.3 













C78-C75-C77  109.0(4) 
C78-C75-C76  108.6(4) 
C77-C75-C76  109.3(4) 
C78-C75-Si2  110.4(3) 
C77-C75-Si2  110.5(3) 






















O11-C79-N4  125.1(4) 
O11-C79-O12  123.1(3) 
N4-C79-O12  111.8(3) 
C81A-C80-O12 123.6(8) 






















C82-C81-C80  125.6(12) 
C82-C81-H81  117.2 













C8-N1-C1  112.0(3) 
C8-N1-H1N  118(2) 
C1-N1-H1N  126(2) 
C38-N2-C10  117.5(3) 
C38-N2-C9  122.0(3) 
C10-N2-C9  118.9(3) 
C49-N3-C42  111.8(3) 
C49-N3-H2N  125(3) 
C42-N3-H2N  121(3) 
C79-N4-C51  118.3(3) 
C79-N4-C50  122.6(3) 
C51-N4-C50  119.0(3) 
C16-O2-C17  111.5(3) 
C25-O3-C24  109.7(3) 
C14-O4-Si1  126.1(2) 
C38-O5-C39  115.7(3) 
C57-O8-C58  112.0(3) 
C66-O9-C65  111.7(3) 
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C55-O10-Si2  129.7(2) 
C79-O12-C80  117.1(3) 
O4-Si1-C32  109.88(18) 
O4-Si1-C33  109.37(16) 
C32-Si1-C33  108.0(2) 
O4-Si1-C34  103.72(15) 
C32-Si1-C34  112.7(2) 
C33-Si1-C34  113.10(19) 
O10-Si2-C73  109.4(2) 
O10-Si2-C74  110.16(19) 
C73-Si2-C74  109.3(3) 
O10-Si2-C75  104.80(17) 





 Table 6.23.  Anisotropic displacement parameters  (Å2x 103) for 4.86b.   
The anisotropic displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k 
a* b* U12 ] 
U11  U22   U33  U23  U13  U12 
_______________________________________________________________________ 
  
C1 21(2)   18(2)  20(2)   -9(1)  -2(1)   -6(1) 
C2 21(2)   26(2)  22(2)   -5(1)  -3(1)   -7(1) 
C3 26(2)   26(2)  22(2)   -2(1)  -4(2)   -13(2) 
C4 26(2)   32(2)  27(2)   -1(2)  -7(2)   -13(2) 
C5 40(2)   33(2)  36(2)   -2(2)  -16(2)   -18(2) 
C6 43(2)   30(2)  30(2)   -7(2)  -14(2)   -17(2)  
C7 31(2)   27(2)  25(2)   -8(2)  -4(2)   -12(2) 
C8 26(2)   24(2)  19(2)   -2(1)  -3(1)   -13(2) 
C9 21(2)   19(2)  21(2)   -4(1)  -2(1)   -6(1) 
C10 23(2)   26(2)  26(2)   -10(2)  1(2)   -10(1) 
C11 23(2)   28(2)  24(2)   -7(2)  -2(1)   -10(2) 
C12 23(2)   25(2)  20(2)   -9(1)  -2(1)   -9(1) 
C13 21(2)   20(2)  21(2)   -9(1)  -1(1)   -6(1) 
C14 23(2)   21(2)  24(2)   -6(1)  1(1)   -11(1) 
C15 24(2)   22(2)  23(2)   -10(1)  0(1)   -6(1) 
C16 23(2)   23(2)  23(2)   -6(1)  -4(1)   -7(1) 
C17 35(2)   23(2)  35(2)   -5(2)  -14(2)   -6(2) 
C18 28(2)   23(2)  30(2)   -8(2)  -6(2)   -5(2) 
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C19 31(2)   29(2)  35(2)   1(2)  -7(2)   -10(2) 
C20 34(2)   39(2)  51(3)   0(2)  -17(2)   -16(2) 
C21 35(2)   38(2)  42(2)   -2(2)  -18(2)  -12(2) 
C22 43(2)   30(2)  37(2)   3(2)  -17(2)   -11(2) 
C23 35(2)   21(2)  36(2)   -4(2)  -10(2)   -8(2) 
C24 25(2)   25(2)  25(2)   -10(1)  -2(2)   -12(2) 
C25 25(2)   34(2)  25(2)   -13(2)  6(2)   -14(2) 
C26 28(2)   24(2)  26(2)   -4(2)  -2(2)   -11(2) 
C27 27(2)   28(2)  24(2)   -7(2)  2(2)   -11(2) 
C28 29(2)   22(2)  34(2)   -9(2)  -5(2)   -9(2) 
C29 25(2)   26(2)  39(2)   -7(2)  -6(2)   -10(2) 
C30 25(2)   26(2)  35(2)   -5(2)  1(2)   -11(2) 
C31 26(2)   31(2)  29(2)   -10(2)  -2(2)   -9(2) 
C32 46(3)   44(3)  38(2)   -2(2)  -17(2)   -20(2) 
C33 39(2)   27(2)  36(2)   -7(2)  -6(2)   -13(2) 
C34 30(2)   31(2)  27(2)   -15(2)  3(2)   -10(2) 
C35 29(2)   57(3)  51(3)   -21(2)  -4(2)   -8(2) 
C36 47(3)   38(2)  43(3)   -18(2)  9(2)   -21(2) 
C37 43(2)   38(2)  38(2)   -22(2)  6(2)   -15(2) 
C38 25(2)   18(2)  23(2)   -6(1)  2(2)   -8(1) 
C39 35(2)   31(2)  21(2)   -9(2)  1(2)   -10(2) 
C40 45(2)   37(2)  28(2)   -7(2)  -3(2)   -18(2) 
C41 48(3)   31(2)  43(3)   -10(2)  -14(2)   -12(2) 
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C42 20(2)   26(2)  21(2)   -11(1)  3(1)   -11(1) 
C43 29(2)   20(2)  22(2)   -6(1)  3(2)   -11(2) 
C44 29(2)   18(2)  24(2)   -7(1)  -1(2)   -10(1) 
C45 42(2)   22(2)  27(2)   -8(2)  -4(2)   -13(2) 
C46 46(2)   29(2)  30(2)   -7(2)  -12(2)   -15(2) 
C47 42(2)   29(2)  37(2)   -4(2)  -15(2)   -15(2) 
C48 30(2)   23(2)  29(2)   -7(2)  -2(2)   -11(2) 
C49 28(2)   19(2)  24(2)   -3(1)  -3(2)   -12(1) 
C50 26(2)   23(2)  18(2)   -8(1)  3(1)   -7(1) 
C51 25(2)   27(2)  25(2)   -12(2)  2(2)   -9(2) 
C52 27(2)   22(2)  24(2)   -9(1)  -1(2)   -9(1) 
C53 21(2)   24(2)  23(2)   -8(1)  -1(1)   -10(1) 
C54 21(2)   17(2)  20(2)   -3(1)  -1(1)   -8(1) 
C55 23(2)   30(2)  21(2)   -4(2)  -3(2)   -6(2) 
C56 29(2)   24(2)  24(2)   -4(2)  -2(2)   -6(2) 
C57 24(2)   20(2)  24(2)   -5(1)  -2(1)   -11(1) 
C58 29(2)   24(2)  31(2)   -3(2)  -5(2)   -10(2) 
C59 26(2)   18(2)  27(2)   -1(1)  -5(2)   -4(1)  
C60 53(3)   27(2)  42(2)   -1(2)  -22(2)   -14(2) 
C61 62(3)   35(3)  70(4)   -10(2)  -34(3)   -15(2) 
C62 45(3)   27(2)  73(4)   -9(2)  -19(2)   -16(2) 
C63 39(2)   31(2)  52(3)   2(2)  -6(2)   -16(2) 
C64 36(2)   31(2)  32(2)   1(2)  -7(2)   -14(2) 
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C65 25(2)   24(2)  18(2)   -4(1)  0(1)   -9(1) 
C66 22(2)   25(2)  21(2)   -6(1)  3(1)   -8(1) 
C67 26(2)   16(2)  22(2)   -5(1)  1(1)   -7(1) 
C68 31(2)   33(2)  24(2)   -5(2)  -1(2)   -11(2) 
C69 30(2)   39(2)  36(2)   -8(2)  -6(2)   -10(2) 
C70 41(2)   31(2)  28(2)   -6(2)  -7(2)   -12(2) 
C71 40(2)   25(2)  21(2)   -5(2)  3(2)   -14(2) 
C72 29(2)   26(2)  25(2)   -5(2)  1(2)   -11(2) 
C73 81(4)   56(3)  56(3)   -13(3)  -19(3)   -38(3) 
C74 38(2)   62(3)  34(3)   8(2)  -7(2)   -7(2) 
C75 22(2)   37(2)  36(2)   -7(2)  -2(2)   -4(2) 
C76 41(2)   43(3)  38(3)   -6(2)  7(2)   -12(2) 
C77 28(2)   60(3)  69(4)   -2(3)  -8(2)   -7(2) 
C78 49(3)   34(2)  46(3)   -15(2)  -2(2)   -8(2) 
C79 28(2)   29(2)  24(2)   -4(2)  -4(2)   -9(2) 
C80 32(2)   29(2)  85(4)   -14(2)  -19(2)   -11(2) 
C81 53(5)   39(5)  55(5)   -11(4)  -26(5)   -14(4) 
C82 58(8)   58(7)  58(6)   -7(5)  -40(6)   -6(7)  
C81A 43(6)   68(7)  75(6)   -30(6)  -24(6)   -1(5) 
C82A 39(7)   68(7)  56(7)   -18(6)  -37(7)   11(7) 
N1 21(2)   22(2)  25(2)   -14(1)  -1(1)   -6(1) 
N2 22(1)   24(2)  20(2)   -6(1)  2(1)   -7(1) 
N3 22(2)   22(2)  26(2)   -14(1)  4(1)   -8(1) 
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N4 32(2)   29(2)  22(2)   -12(1)  4(1)   -16(1) 
O1 21(1)   31(1)  29(1)   -12(1)  -2(1)   -2(1) 
O2 31(1)   20(1)  29(1)   -6(1)  -11(1)   -5(1) 
O3 20(1)   25(1)  27(1)   -11(1)  2(1)   -11(1) 
O4 22(1)   22(1)  26(1)   -12(1)  2(1)   -8(1) 
O5 27(1)   29(1)  20(1)   -10(1)  1(1)   -6(1) 
O6 26(1)   27(1)  28(1)   -9(1)  4(1)   -7(1) 
O7 28(1)   21(1)  26(1)   -9(1)  3(1)   -6(1) 
O8 23(1)   18(1)  30(1)   -3(1)  -6(1)   -9(1) 
O9 23(1)   26(1)  19(1)   -8(1)  1(1)   -6(1) 
O10 18(1)   42(2)  25(1)   -4(1)  -1(1)   -6(1) 
O11 23(1)   28(1)  39(2)   -11(1)  0(1)   -7(1) 
O12 44(2)   34(2)  28(2)   -10(1)  1(1)   -25(1) 
Si1 28(1)   23(1)  24(1)   -9(1)  -3(1)   -9(1) 
Si2 24(1)   32(1)  27(1)   -6(1)  -4(1)   -8(1) 
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 Table 6.24.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 
10 3) for 4.86b 
  x   y   z   U(eq) 
_______________________________________________________________________ 
H4  -668  6000  6629  34 
H5  -439  4933  5876  41 
H6  1232  4008  5259  38 
H7  2727  4082  5385  33 
H9  2362  6845  5756  26 
H10A  4296  7091  6236  32 
H10B  5185  6215  5937  32 
H11A  4539  6306  7377  31 
H11B  4479  5498  7116  31 
H12  2953  6301  8211  27 
H14  2961  7603  7406  29 
H15A  1483  7718  6794  30   
H15B  2586  7870  6315  30 
H16A  2630  4508  7702  28 
H16B  3696  4709  7160  28 
H17A  4365  3606  7974  37 
H17B  3354  3561  8753  37 
H19  5013  4761  8446  40 
H20  5975  4653  9242  48 
H21  5990  3629  10316  45 
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H22  5070  2707  10559  44 
H23  4090  2825  9765  38 
H24A  1533  5868  8803  30 
H24B  920  6540  8260  30 
H25A  -566  6198  8732  36 
H25B  -136  5636  9421  36 
H27  273  4490  7859  34 
H28  -657  3612  7921  35 
H29  -2183  3621  9024  37 
H30  -2781  4496  10080  38 
H31  -1852  5374  10002  36 
H32A  2135  7217  9590  60 
H32B  2118  8115  9720  60 
H32C  2969  7627  8936  60 
H33A  2310  9120  7884  53 
H33B  1414  9638  8636  53 
H33C  1119  9520  7912  53 
H35A  -602  8332  8546  72 
H35B  -717  9279  8614  72 
H35C  -1541  8863  9272  72 
H36A  -979  7714  10238  69 
H36B  190  7419  10251  69 
H36C  -6  7191  9522  69 
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Table 6.24., Cont. 
H37A  -1151  9143  10424  65 
H37B  -440  9642  9750  65 
H37C  50  8925  10331  65 
H39A  4656  5326  3894  37 
H39B  4360  6275  3518  37 
H40  2830  5421  4125  45 
H41A  3401  6398  2707  48 
H41B  2462  5980  3006  48 
H45  7050  2486  8448  37 
H46  8590  2149  8735  41 
H47  10129  1140  8029  41 
H48  10210  444  7002  35 
H50  7388  2109  5769  30 
H51A  8750  168  4366  33 
H51B  7552  718  4485  33 
H52A  8267  -513  5631  30 
H52B  7577  -583  5166  30 
H53  6330  -264  6344  28 
H55  5953  827  5315  32 
H56A  6216  2024  5220  34 
H56B  5698  2110  6173  34 
H57A  8348  -622  6725  28 
H57B  7679  -393  7648  28 
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Table 6.24., Cont. 
H58A  7671  -1865  8117  35 
H58B  8553  -2001  7231  35 
H60  7256  -2132  6374  46 
H61  6798  -3232  6214  61 
H62  6744  -4350  7188  56 
H63  7136  -4360  8316  52 
H64  7570  -3255  8488  41 
H65A  5399  1166  7463  28 
H65B  5478  197  7674  28 
H66A  4660  704  9043  31 
H66B  4880  1581  8754  31 
H68  7071  582  9072  38 
H69  7475  525  10220  44 
H70  6138  828  11466  41 
H71  4376  1194  11581  38 
H72  3980  1224  10448  35 
H73A  3993  186  5655  90 
H73B  2765  655  6104  90  
H73C  3481  79  6616  90 
H74A  4049  2569  5337  77 
H74B  3188  2298  5214  77 
H74C  4412  1772  4834  77 
H76A  3415  1085  7937  71 
 
 542 
Table 6.24., Cont. 
H76B  2442  925  7872  71 
H76C  2237  1661  8395  71 
H77A  1140  2593  7574  86 
H77B  1486  1885  6971  86 
H77C  1681  2762  6624  86 
H78A  2526  2988  7748  72 
H78B  3105  3085  6794  72 
H78C  3745  2464  7340  72 
H80C  10552  1709  4536  57 
H80D  9955  2580  4237  57 
H80A  10576  1739  4727  57 
H80B  10100   2464  4172  57 
H81  9234  3423  5246  55 
H82A  10477  2191  6030  66 
H82B  9809  3169  6274  66 
H81A  10901  2674  4926  75 
H82C  9034  2749  6136  65 
H82D  9962  3072  6128  65 
H1N  3330(30) 4990(20) 6000(20) 12(9) 
H2N  8980(30) 330(30) 6250(20) 25(10) 
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 Table 6.25.  Torsion angles [°] for 4.86b. 
________________________________________________________________  
N1-C1-C2-O1   -176.3(4) 
C9-C1-C2-O1   -61.5(5) 
C13-C1-C2-O1  61.6(5) 
N1-C1-C2-C3   -0.7(4) 
C9-C1-C2-C3   114.1(3) 
C13-C1-C2-C3  -122.8(3) 
O1-C2-C3-C8   173.5(4) 
C1-C2-C3-C8   -1.9(4) 
O1-C2-C3-C4   -6.6(7) 
C1-C2-C3-C4   177.9(4) 
C8-C3-C4-C5   -1.9(6) 
C2-C3-C4-C5   178.3(4) 
C3-C4-C5-C6   -0.2(6) 
C4-C5-C6-C7   1.0(6) 
C5-C6-C7-C8   0.3(6) 
C4-C3-C8-N1   -175.7(3) 
C2-C3-C8-N1   4.2(4) 
C4-C3-C8-C7   3.3(6) 
C2-C3-C8-C7   -176.9(3) 
C6-C7-C8-N1   176.4(4) 
C6-C7-C8-C3   -2.4(6) 
N1-C1-C9-N2   -51.5(4) 
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Table 6.25., Cont. 
C13-C1-C9-N2  74.9(3) 
C2-C1-C9-N2   -160.6(3) 
N1-C1-C9-C15  -177.2(3) 
C13-C1-C9-C15  -50.8(4) 
C2-C1-C9-C15  73.7(4) 
N2-C10-C11-C12  -48.9(4) 
C10-C11-C12-C14  -43.0(4) 
C10-C11-C12-C13  85.2(4) 
C14-C12-C13-C24  -71.5(4) 
C11-C12-C13-C24  162.6(3) 
C14-C12-C13-C16  172.7(3) 
C11-C12-C13-C16  46.8(4) 
C14-C12-C13-C1  51.7(4)  
C11-C12-C13-C1  -74.2(4) 
N1-C1-C13-C24  -115.6(3) 
C9-C1-C13-C24  119.9(3) 
C2-C1-C13-C24  -0.4(4) 
N1-C1-C13-C16  1.6(4) 
C9-C1-C13-C16  -122.9(3) 
C2-C1-C13-C16  116.9(3) 
N1-C1-C13-C12  123.9(3) 
C9-C1-C13-C12  -0.6(4) 
C2-C1-C13-C12  -120.9(3) 
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Table 6.25., Cont. 
C11-C12-C14-O4  -158.8(3) 
C13-C12-C14-O4  71.8(4) 
C11-C12-C14-C15  79.3(3) 
C13-C12-C14-C15  -50.0(4) 
N2-C9-C15-C14  -70.9(4) 
C1-C9-C15-C14  54.1(4) 
O4-C14-C15-C9  -126.7(3) 
C12-C14-C15-C9  -3.0(4) 
C24-C13-C16-O2  -66.2(3) 
C12-C13-C16-O2  50.0(4) 
C1-C13-C16-O2  173.3(3) 
O2-C17-C18-C23  138.3(4) 
O2-C17-C18-C19  -43.6(5) 
C23-C18-C19-C20  0.0(6) 
C17-C18-C19-C20  -178.1(4) 
C18-C19-C20-C21  -0.1(7) 
C19-C20-C21-C22  0.7(7) 
C20-C21-C22-C23  -1.0(7) 
C19-C18-C23-C22  -0.3(6) 
C17-C18-C23-C22  177.8(4) 
C21-C22-C23-C18  0.8(6) 
C16-C13-C24-O3  -55.7(4) 
C12-C13-C24-O3  -174.1(3) 
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Table 6.25., Cont. 
C1-C13-C24-O3  62.5(4) 
O3-C25-C26-C31  163.9(4) 
O3-C25-C26-C27  -19.2(6) 
C31-C26-C27-C28  0.4(6) 
C25-C26-C27-C28  -176.6(4) 
C26-C27-C28-C29  -0.1(6) 
C27-C28-C29-C30  -0.4(6) 
C28-C29-C30-C31  0.6(7) 
C27-C26-C31-C30  -0.1(7) 
C25-C26-C31-C30  177.0(4) 
C29-C30-C31-C26  -0.4(7) 
O5-C39-C40-C41  127.9(4) 
N3-C42-C43-O7  166.2(3) 
C50-C42-C43-O7  50.7(4) 
C54-C42-C43-O7  -71.6(5) 
N3-C42-C43-C44  -8.2(4) 
C50-C42-C43-C44  -123.6(3) 
C54-C42-C43-C44  114.0(3) 
O7-C43-C44-C49  -170.1(4) 
C42-C43-C44-C49  4.1(4) 
O7-C43-C44-C45  9.9(7) 
C42-C43-C44-C45  -175.9(4) 
C49-C44-C45-C46  0.4(6) 
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Table 6.25., Cont. 
C43-C44-C45-C46  -179.6(4) 
C44-C45-C46-C47  -0.5(6) 
C45-C46-C47-C48  0.4(6) 
C46-C47-C48-C49  -0.2(6) 
C45-C44-C49-N3  -177.8(3) 
C43-C44-C49-N3  2.2(4) 
C45-C44-C49-C48  -0.3(6) 
C43-C44-C49-C48  179.8(3) 
C47-C48-C49-N3  177.3(4) 
C47-C48-C49-C44  0.2(5) 
N3-C42-C50-N4  41.2(4) 
C43-C42-C50-N4  150.6(3) 
C54-C42-C50-N4  -86.1(3) 
N3-C42-C50-C56  168.4(3) 
C43-C42-C50-C56  -82.3(3) 
C54-C42-C50-C56  41.1(4) 
N4-C51-C52-C53  53.2(5) 
C51-C52-C53-C55  35.5(4) 
C51-C52-C53-C54  -92.3(4) 
C55-C53-C54-C65  61.0(4) 
C52-C53-C54-C65  -173.1(3) 
C55-C53-C54-C57  177.5(3) 
C52-C53-C54-C57  -56.6(4) 
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Table 6.25., Cont. 
C55-C53-C54-C42  -61.3(4) 
C52-C53-C54-C42  64.7(4) 
N3-C42-C54-C65  128.3(3) 
C43-C42-C54-C65  13.1(4) 
C50-C42-C54-C65  -106.3(3) 
N3-C42-C54-C57  10.4(4) 
C43-C42-C54-C57  -104.8(3) 
C50-C42-C54-C57  135.8(3) 
N3-C42-C54-C53  -110.6(3) 
C43-C42-C54-C53  134.2(3) 
C50-C42-C54-C53  14.8(4) 
C52-C53-C55-O10  158.0(3) 
C54-C53-C55-O10  -74.2(4) 
C52-C53-C55-C56  -80.8(4) 
C54-C53-C55-C56  47.0(4) 
N4-C50-C56-C55  69.1(4) 
C42-C50-C56-C55  -57.3(4) 
O10-C55-C56-C50  133.5(3) 
C53-C55-C56-C50  12.0(4) 
C65-C54-C57-O8  67.6(3) 
C53-C54-C57-O8  -50.5(3) 
C42-C54-C57-O8  -171.8(3) 
O8-C58-C59-C64  -143.4(4) 
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Table 6.25., Cont. 
O8-C58-C59-C60  38.4(5) 
C64-C59-C60-C61  -0.2(7) 
C58-C59-C60-C61  178.0(4) 
C59-C60-C61-C62  -0.3(8) 
C60-C61-C62-C63  0.3(8) 
C61-C62-C63-C64  0.2(7) 
C60-C59-C64-C63  0.7(6) 
C58-C59-C64-C63  -177.5(4) 
C62-C63-C64-C59  -0.7(7) 
C57-C54-C65-O9  50.5(3) 
C53-C54-C65-O9  168.9(3) 
C42-C54-C65-O9  -69.4(4) 
O9-C66-C67-C68  14.8(5) 
O9-C66-C67-C72  -165.9(3) 
C72-C67-C68-C69  -0.8(6) 
C66-C67-C68-C69  178.5(3) 
C67-C68-C69-C70  0.0(6) 
C68-C69-C70-C71  0.1(6) 
C69-C70-C71-C72  0.5(6) 
C70-C71-C72-C67  -1.3(6) 
C68-C67-C72-C71  1.4(6) 
C66-C67-C72-C71  -177.9(3) 
O12-C80-C81-C82  102.5(13) 
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Table 6.25., Cont. 
O12-C80-C81A-C82A -4(2) 
C3-C8-N1-C1   -4.8(4) 
C7-C8-N1-C1   176.3(4) 
C9-C1-N1-C8   -109.0(3) 
C13-C1-N1-C8  125.6(3) 
C2-C1-N1-C8   3.3(4) 
O6-C38-N2-C10  10.4(5) 
O5-C38-N2-C10  -169.9(3) 
O6-C38-N2-C9  176.0(3) 
O5-C38-N2-C9  -4.4(5) 
C11-C10-N2-C38  -137.6(3) 
C11-C10-N2-C9  56.3(4) 
C15-C9-N2-C38  -134.7(3) 
C1-C9-N2-C38  100.0(4) 
C15-C9-N2-C10  30.7(4) 
C1-C9-N2-C10  -94.7(4) 
C44-C49-N3-C42  -8.3(4) 
C48-C49-N3-C42  174.4(4) 
C43-C42-N3-C49  10.0(4) 
C50-C42-N3-C49  122.3(3) 
C54-C42-N3-C49  -111.7(3) 
O11-C79-N4-C51  -5.7(6) 
O12-C79-N4-C51  171.3(3) 
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Table 6.25., Cont. 
O11-C79-N4-C50  171.4(4) 
O12-C79-N4-C50  -11.5(6) 
C52-C51-N4-C79  129.0(4) 
C52-C51-N4-C50  -48.3(5) 
C56-C50-N4-C79  142.3(4) 
C42-C50-N4-C79  -90.4(4) 
C56-C50-N4-C51  -40.6(5) 
C42-C50-N4-C51  86.7(4) 
C13-C16-O2-C17  175.7(3) 
C18-C17-O2-C16  160.7(3) 
C26-C25-O3-C24  -178.3(3) 
C13-C24-O3-C25  -169.1(3) 
C12-C14-O4-Si1  105.8(3) 
C15-C14-O4-Si1  -130.5(3) 
O6-C38-O5-C39  4.7(5) 
N2-C38-O5-C39  -175.0(3) 
C40-C39-O5-C38  164.8(3) 
C54-C57-O8-C58  -177.9(3) 
C59-C58-O8-C57  -165.5(3) 
C67-C66-O9-C65  176.9(3) 
C54-C65-O9-C66  167.8(3) 
C53-C55-O10-Si2  -142.9(3) 
C56-C55-O10-Si2  95.2(4) 
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Table 6.25., Cont. 
O11-C79-O12-C80  -6.2(6) 
N4-C79-O12-C80  176.7(4) 
C81A-C80-O12-C79  -145.6(9) 
C81-C80-O12-C79  -165.1(5) 
C14-O4-Si1-C32  -57.3(3) 
C14-O4-Si1-C33  61.0(3) 
C14-O4-Si1-C34  -178.0(3) 
C37-C34-Si1-O4  -173.5(3) 
C35-C34-Si1-O4  -53.4(3) 
C36-C34-Si1-O4  66.3(3) 
C37-C34-Si1-C32  67.7(4) 
C35-C34-Si1-C32  -172.2(3) 
C36-C34-Si1-C32  -52.5(3) 
C37-C34-Si1-C33  -55.1(4) 
C35-C34-Si1-C33  65.0(3)  
C36-C34-Si1-C33  -175.4(3) 
C55-O10-Si2-C73  90.6(4) 
C55-O10-Si2-C74  -29.5(4) 
C55-O10-Si2-C75  -150.4(3) 
C78-C75-Si2-O10  57.6(4) 
C77-C75-Si2-O10  178.2(3) 
C76-C75-Si2-O10  -61.6(3) 
C78-C75-Si2-C73  175.5(4) 
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Table 6.25., Cont. 
C77-C75-Si2-C73  -63.8(4) 
C76-C75-Si2-C73  56.3(4) 
C78-C75-Si2-C74  -61.9(4) 
C77-C75-Si2-C74  58.7(4) 
C76-C75-Si2-C74  178.8(3)
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Table 6.26.  Hydrogen bonds for 4.86b [Å and °] 
D-H...A  d(D-H) d(H...A) d(D...A) <(DHA) 
 N1-H1N...O6#1 0.90(4)  2.15(4)  3.007(4) 160(3) 
 N3-H2N...O11#2 0.87(4)  2.21(4)  3.073(4) 168(4) 
Symmetry transformations used to generate equivalent atoms:  
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